-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
influence _ _ O
of _ _ O
prior _ _ B-Intervention
use _ _ I-Intervention
of _ _ I-Intervention
carbamazepine _ _ I-Intervention
(CBZ) _ _ I-Intervention
and _ _ I-Intervention
other _ _ I-Intervention
antiepileptic _ _ I-Intervention
drugs _ _ I-Intervention
(AEDs) _ _ I-Intervention
with _ _ I-Intervention
a _ _ I-Intervention
putatively _ _ I-Intervention
similar _ _ I-Intervention
mechanism _ _ I-Intervention
of _ _ I-Intervention
action _ _ I-Intervention
(inhibition _ _ I-Intervention
of _ _ I-Intervention
voltage-gated _ _ I-Intervention
sodium _ _ I-Intervention
channels; _ _ I-Intervention
VGSCs) _ _ I-Intervention
on _ _ O
seizure _ _ O
outcomes _ _ O
and _ _ O
tolerability _ _ O
when _ _ O
converting _ _ B-Intervention
to _ _ I-Intervention
eslicarbazepine _ _ I-Intervention
acetate _ _ I-Intervention
(ESL), _ _ I-Intervention
using _ _ O
data _ _ O
pooled _ _ O
from _ _ O
2 _ _ O
controlled _ _ O
conversion-to-ESL _ _ B-Intervention
monotherapy _ _ I-Intervention
trials _ _ O
(studies: _ _ O
093-045, _ _ O
093-046). _ _ O
Adults _ _ B-Patient
with _ _ I-Patient
treatment-resistant _ _ I-Patient
focal _ _ I-Patient
(partial-onset) _ _ I-Patient
seizures _ _ I-Patient
were _ _ O
randomized _ _ O
2:1 _ _ O
to _ _ O
ESL _ _ B-Intervention
1600 _ _ I-Intervention
or _ _ I-Intervention
1200 _ _ I-Intervention
mg _ _ I-Intervention
once _ _ I-Intervention
daily. _ _ I-Intervention
The _ _ O
primary _ _ O
efficacy _ _ O
endpoint _ _ O
was _ _ O
study _ _ O
exit _ _ O
(meeting _ _ O
predefined _ _ O
exit _ _ O
criteria _ _ O
related _ _ O
to _ _ O
worsening _ _ O
seizure _ _ O
control) _ _ O
versus _ _ O
an _ _ B-Control
historical _ _ I-Control
control _ _ I-Control
group. _ _ I-Control
Other _ _ O
endpoints _ _ O
included _ _ O
change _ _ O
in _ _ O
seizure _ _ O
frequency, _ _ O
responder _ _ O
rate, _ _ O
and _ _ O
tolerability. _ _ O
Endpoints _ _ O
were _ _ O
analyzed _ _ O
for _ _ O
subgroups _ _ O
of _ _ O
patients _ _ O
who _ _ O
received _ _ O
CBZ _ _ B-Intervention
(or _ _ I-Intervention
any _ _ I-Intervention
VGSC _ _ I-Intervention
inhibitor _ _ I-Intervention
[VGSCi]) _ _ I-Intervention
during _ _ O
baseline _ _ O
versus _ _ O
those _ _ O
who _ _ O
received _ _ O
other _ _ B-Control
AEDs. _ _ I-Control
Of _ _ O
365 _ _ O
patients _ _ O
in _ _ O
the _ _ O
studies, _ _ O
332 _ _ O
were _ _ O
evaluable _ _ O
for _ _ O
efficacy. _ _ O
The _ _ B-Outcome
higher _ _ I-Outcome
risk _ _ I-Outcome
of _ _ I-Outcome
study _ _ I-Outcome
exit _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
subgroups _ _ I-Outcome
that _ _ I-Outcome
received _ _ I-Outcome
CBZ _ _ I-Outcome
(or _ _ I-Outcome
any _ _ I-Outcome
VGSCi) _ _ I-Outcome
during _ _ I-Outcome
baseline, _ _ I-Outcome
versus _ _ I-Outcome
other _ _ I-Outcome
AEDs, _ _ I-Outcome
was _ _ I-Outcome
not _ _ I-Outcome
statistically _ _ I-Outcome
significant _ _ I-Outcome
(hazard _ _ I-Outcome
ratios _ _ I-Outcome
were _ _ I-Outcome
1.49 _ _ I-Outcome
for _ _ I-Outcome
+CBZ _ _ I-Outcome
vs _ _ I-Outcome
-CBZ _ _ I-Outcome
[P _ _ I-Outcome
= _ _ I-Outcome
.10] _ _ I-Outcome
and _ _ I-Outcome
1.27 _ _ I-Outcome
for _ _ I-Outcome
+VGSCi _ _ I-Outcome
vs. _ _ I-Outcome
-VGSCi _ _ I-Outcome
[P _ _ I-Outcome
= _ _ I-Outcome
.33]). _ _ I-Outcome
Reductions _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
and _ _ O
responder _ _ O
rates _ _ O
were _ _ O
lower _ _ O
in _ _ O
patients _ _ O
who _ _ O
converted _ _ O
from _ _ O
CBZ _ _ O
or _ _ O
other _ _ O
VGSCi _ _ O
compared _ _ O
with _ _ O
those _ _ O
who _ _ O
converted _ _ O
from _ _ O
other _ _ O
AEDs. _ _ O
There _ _ O
were _ _ O
no _ _ O
notable _ _ O
differences _ _ O
in _ _ O
overall _ _ O
tolerability _ _ O
between _ _ O
subgroups, _ _ O
but _ _ O
the _ _ O
incidence _ _ O
of _ _ O
some _ _ O
adverse _ _ O
events _ _ O
(eg, _ _ O
dizziness, _ _ O
somnolence, _ _ O
nausea) _ _ O
differed _ _ O
between _ _ O
subgroups _ _ O
and/or _ _ O
between _ _ O
treatment _ _ O
periods. _ _ O
Baseline _ _ O
use _ _ O
of _ _ O
CBZ _ _ O
or _ _ O
other _ _ O
major _ _ O
putative _ _ O
VGSC _ _ O
inhibitors _ _ O
did _ _ O
not _ _ O
appear _ _ O
to _ _ O
significantly _ _ O
increase _ _ O
the _ _ O
risk _ _ O
of _ _ O
study _ _ O
exit _ _ O
due _ _ O
to _ _ O
worsening _ _ O
seizure _ _ O
control, _ _ O
or _ _ O
to _ _ O
increase _ _ O
the _ _ O
frequency _ _ O
of _ _ O
side _ _ O
effects _ _ O
when _ _ O
converting _ _ O
to _ _ O
ESL _ _ O
monotherapy. _ _ O
However, _ _ O
bigger _ _ O
improvements _ _ O
in _ _ O
efficacy _ _ O
may _ _ O
be _ _ O
possible _ _ O
in _ _ O
patients _ _ O
converting _ _ O
to _ _ O
ESL _ _ O
monotherapy _ _ O
from _ _ O
an _ _ O
AED _ _ O
regimen _ _ O
that _ _ O
does _ _ O
not _ _ O
include _ _ O
a _ _ O
VGSC _ _ O
inhibitor. _ _ O


-DOCSTART- -X- -X- O

Electrical _ _ O
stimulation _ _ O
used _ _ O
for _ _ O
brain _ _ O
mapping _ _ O
in _ _ O
the _ _ O
postero-superior _ _ O
insula _ _ O
can _ _ O
evoke _ _ O
pain. _ _ O
The _ _ O
effects _ _ O
of _ _ O
prolonged _ _ O
high _ _ O
frequency _ _ O
insular _ _ O
stimulation _ _ O
on _ _ O
pain _ _ O
thresholds _ _ O
are _ _ O
unknown. _ _ O
Prolonged _ _ O
high _ _ O
frequency _ _ O
insular _ _ O
stimulation, _ _ O
by _ _ O
virtue _ _ O
of _ _ O
its _ _ O
inhibitory _ _ O
properties _ _ O
on _ _ O
networks, _ _ O
could _ _ O
decrease _ _ O
thermal _ _ O
nociception. _ _ O
Epileptic _ _ B-Patient
subjects _ _ I-Patient
had _ _ O
electrodes _ _ O
implanted _ _ O
in _ _ O
the _ _ O
insular _ _ O
cortex _ _ O
for _ _ O
the _ _ O
purpose _ _ O
of _ _ O
epileptic _ _ O
focus _ _ O
resection. _ _ O
Thermal _ _ O
and _ _ O
pressure _ _ O
nociceptive _ _ O
thresholds _ _ O
were _ _ O
tested _ _ O
bilaterally _ _ O
on _ _ O
the _ _ O
forearm _ _ O
on _ _ O
two _ _ O
consecutive _ _ O
days. _ _ O
Randomly _ _ O
assigned _ _ O
double-blind _ _ O
high _ _ B-Intervention
frequency _ _ I-Intervention
(150 _ _ I-Intervention
Hz) _ _ I-Intervention
insular _ _ I-Intervention
stimulation _ _ I-Intervention
took _ _ O
place _ _ O
for _ _ O
10 _ _ O
min _ _ O
before _ _ O
pain _ _ O
testing _ _ O
either _ _ O
on _ _ O
the _ _ O
first _ _ O
day _ _ O
or _ _ O
on _ _ O
the _ _ O
second _ _ O
day. _ _ O
Six _ _ O
subjects _ _ B-Patient
(three _ _ I-Patient
females; _ _ I-Patient
mean _ _ I-Patient
age _ _ I-Patient
of _ _ I-Patient
35 _ _ I-Patient
years) _ _ I-Patient
were _ _ O
included. _ _ O
Insular _ _ O
stimulation _ _ O
increased _ _ O
heat _ _ O
pain _ _ O
threshold _ _ O
on _ _ O
the _ _ O
ipsilateral _ _ O
(p _ _ O
= _ _ O
0.003; _ _ O
n _ _ O
= _ _ O
6) _ _ O
and _ _ O
contralateral _ _ O
sides _ _ O
(p _ _ O
= _ _ O
0.047; _ _ O
n _ _ O
= _ _ O
6). _ _ O
Differences _ _ O
in _ _ O
cold _ _ O
pain _ _ O
threshold _ _ O
did _ _ O
not _ _ O
reach _ _ O
statistical _ _ O
significance _ _ O
(ipsilateral: _ _ O
p _ _ O
= _ _ O
0.341, _ _ O
contralateral: _ _ O
p _ _ O
= _ _ O
0.143; _ _ O
n _ _ O
= _ _ O
6), _ _ O
but _ _ O
one _ _ O
subject _ _ O
had _ _ O
a _ _ O
profound _ _ O
decrease _ _ O
in _ _ O
both _ _ O
heat _ _ O
and _ _ O
cold _ _ O
pain _ _ O
responses. _ _ O
Pressure _ _ O
pain _ _ O
threshold _ _ O
was _ _ O
not _ _ O
modified _ _ O
by _ _ O
insular _ _ O
stimulation _ _ O
(ipsilateral: _ _ O
p _ _ O
= _ _ O
0.1123; _ _ O
contralateral: _ _ O
p _ _ O
= _ _ O
0.1192; _ _ O
n _ _ O
= _ _ O
6). _ _ O
Two _ _ O
of _ _ O
the _ _ O
three _ _ O
subjects _ _ O
who _ _ O
had _ _ O
a _ _ O
postero-superior _ _ O
operculo-insulectomy _ _ O
developed _ _ O
central _ _ O
pain _ _ O
with _ _ O
contralateral _ _ O
thermal _ _ O
nociceptive _ _ O
deficit. _ _ O
High _ _ O
frequency _ _ O
inhibitory _ _ O
postero-superior _ _ O
insular _ _ O
stimulation _ _ O
may _ _ O
have _ _ O
the _ _ O
potential _ _ O
to _ _ O
decrease _ _ O
thermal _ _ O
nociception. _ _ O
Together _ _ O
with _ _ O
previous _ _ O
studies, _ _ O
our _ _ O
data _ _ O
support _ _ O
the _ _ O
notion _ _ O
that _ _ O
the _ _ O
integrity _ _ O
of _ _ O
this _ _ O
brain _ _ O
region _ _ O
is _ _ O
necessary _ _ O
for _ _ O
thermal _ _ O
but _ _ O
not _ _ O
pressure _ _ O
nociceptive _ _ O
processing. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
assess _ _ O
the _ _ O
comparative _ _ O
effectiveness, _ _ O
efficacy, _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
lamotrigine _ _ B-Intervention
(LTG) _ _ I-Intervention
and _ _ O
sustained-release _ _ B-Control
carbamazepine _ _ I-Control
(CBZ) _ _ I-Control
in _ _ O
the _ _ O
treatment _ _ O
of _ _ O
newly _ _ B-Patient
diagnosed _ _ I-Patient
epilepsy _ _ I-Patient
in _ _ I-Patient
the _ _ I-Patient
elderly. _ _ I-Patient
Patients _ _ O
aged _ _ O
65 _ _ O
years _ _ O
or _ _ O
older, _ _ O
who _ _ O
had _ _ O
experienced _ _ O
at _ _ O
least _ _ O
two _ _ O
unprovoked _ _ O
partial _ _ O
and/or _ _ O
generalized _ _ O
tonic-clonic _ _ O
seizures, _ _ O
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
LTG _ _ O
(n=93) _ _ O
or _ _ O
CBZ _ _ O
(n=92) _ _ O
according _ _ O
to _ _ O
a _ _ O
multicenter _ _ O
double-blind, _ _ O
parallel-group _ _ O
design. _ _ O
Trial _ _ O
duration _ _ O
was _ _ O
40 _ _ O
weeks _ _ O
and _ _ O
included _ _ O
a _ _ O
4-week _ _ O
dose _ _ O
escalation _ _ O
followed _ _ O
by _ _ O
a _ _ O
maintenance _ _ O
phase _ _ O
during _ _ O
which _ _ O
dosages _ _ O
could _ _ O
be _ _ O
adjusted _ _ O
according _ _ O
to _ _ O
response. _ _ O
Initial, _ _ O
maintenance _ _ O
and _ _ O
maximum _ _ O
dosages _ _ O
were _ _ O
25 _ _ O
mg, _ _ O
100 _ _ O
mg, _ _ O
and _ _ O
500 _ _ O
mg _ _ O
per _ _ O
day _ _ O
for _ _ O
LTG, _ _ O
and _ _ O
100 _ _ O
mg, _ _ O
400 _ _ O
mg, _ _ O
and _ _ O
2,000 _ _ O
mg _ _ O
per _ _ O
day _ _ O
for _ _ O
CBZ, _ _ O
respectively. _ _ O
The _ _ O
primary _ _ O
end _ _ O
point _ _ O
was _ _ O
retention _ _ O
in _ _ O
the _ _ O
trial. _ _ O
In _ _ O
the _ _ O
LTG _ _ O
group, _ _ O
68 _ _ O
patients _ _ O
(73%) _ _ O
completed _ _ O
the _ _ O
40-week _ _ O
study _ _ O
period _ _ O
compared _ _ O
with _ _ O
61 _ _ O
(67%) _ _ O
in _ _ O
the _ _ O
CBZ _ _ O
group, _ _ O
a _ _ O
nonsignificant _ _ O
difference. _ _ O
Time _ _ O
to _ _ O
withdrawal _ _ O
from _ _ O
any _ _ O
cause _ _ O
did _ _ O
not _ _ O
differ _ _ O
between _ _ O
groups _ _ O
(p=0.34). _ _ O
The _ _ O
number _ _ O
of _ _ O
subjects _ _ O
who _ _ O
completed _ _ O
the _ _ O
40-week _ _ O
period _ _ O
and _ _ O
were _ _ O
seizure _ _ O
free _ _ O
in _ _ O
the _ _ O
last _ _ O
20 _ _ O
weeks _ _ O
was _ _ O
48 _ _ O
(52%) _ _ O
in _ _ O
the _ _ O
LTG _ _ O
group _ _ O
and _ _ O
52 _ _ O
(57%) _ _ O
in _ _ O
the _ _ O
CBZ _ _ O
group. _ _ O
Adverse _ _ O
events _ _ O
leading _ _ O
to _ _ O
withdrawal _ _ O
occurred _ _ O
in _ _ O
13 _ _ O
(14%) _ _ O
subjects _ _ O
in _ _ O
the _ _ O
LTG _ _ O
group _ _ O
and _ _ O
23 _ _ O
(25%) _ _ O
subjects _ _ O
in _ _ O
the _ _ O
CBZ _ _ O
group. _ _ O
LTG _ _ O
and _ _ O
CBZ _ _ O
showed _ _ O
comparable _ _ O
effectiveness, _ _ O
with _ _ O
a _ _ O
trend _ _ O
for _ _ O
higher _ _ O
seizure-free _ _ O
rates _ _ O
for _ _ O
CBZ _ _ O
and _ _ O
better _ _ O
tolerability _ _ O
for _ _ O
LTG. _ _ O
Differences _ _ O
in _ _ O
outcome _ _ O
compared _ _ O
with _ _ O
previous _ _ O
trials _ _ O
may _ _ O
be _ _ O
related _ _ O
to _ _ O
different _ _ O
dosing _ _ O
rates _ _ O
and _ _ O
use _ _ O
of _ _ O
a _ _ O
sustained-release _ _ O
formulation _ _ O
for _ _ O
CBZ. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
compare _ _ O
the _ _ O
outcomes _ _ O
of _ _ O
adrenocorticotrophic _ _ B-Intervention
hormone _ _ I-Intervention
(ACTH) _ _ I-Intervention
and _ _ O
Prednisolone _ _ B-Control
therapy _ _ I-Control
in _ _ O
children _ _ B-Patient
with _ _ I-Patient
West _ _ I-Patient
syndrome. _ _ I-Patient
The _ _ O
study _ _ O
was _ _ O
done _ _ O
at _ _ O
a _ _ O
tertiary _ _ O
health _ _ O
centre _ _ O
for _ _ O
children. _ _ O
The _ _ O
pediatric _ _ O
neurologist _ _ O
at _ _ O
the _ _ O
centre _ _ O
enrolled _ _ O
children _ _ O
into _ _ O
the _ _ O
study _ _ O
based _ _ O
on _ _ O
the _ _ O
inclusion _ _ O
and _ _ O
exclusion _ _ O
criteria. _ _ O
They _ _ O
were _ _ O
evaluated _ _ O
in _ _ O
detail, _ _ O
classified _ _ O
according _ _ O
to _ _ O
etiologic _ _ O
type _ _ O
and _ _ O
then, _ _ O
randomly _ _ O
assigned _ _ O
into _ _ O
two _ _ O
treatment _ _ O
groups, _ _ O
either _ _ O
ACTH _ _ B-Intervention
or _ _ O
Prednisolone. _ _ B-Control
They _ _ O
were _ _ O
followed _ _ O
at _ _ O
regular _ _ O
intervals _ _ O
till _ _ O
6 _ _ O
mo. _ _ O
There _ _ B-Outcome
was _ _ I-Outcome
no _ _ I-Outcome
difference _ _ I-Outcome
between _ _ I-Outcome
ACTH _ _ I-Outcome
and _ _ I-Outcome
Prednisolone _ _ I-Outcome
groups _ _ I-Outcome
with _ _ I-Outcome
respect _ _ I-Outcome
to _ _ I-Outcome
all _ _ I-Outcome
the _ _ I-Outcome
outcomes _ _ I-Outcome
measured. _ _ I-Outcome
Cessation _ _ O
of _ _ O
spasms _ _ O
was _ _ O
achieved _ _ O
in _ _ O
6/15 _ _ O
(40%) _ _ O
in _ _ O
Prednisolone _ _ O
group _ _ O
and _ _ O
9/18 _ _ O
(50%) _ _ O
in _ _ O
ACTH _ _ O
group _ _ O
(p _ _ O
= _ _ O
0.3906). _ _ O
The _ _ O
average _ _ O
time _ _ O
for _ _ O
achieving _ _ O
cessation _ _ O
was _ _ O
6.9 _ _ O
and _ _ O
8 _ _ O
d _ _ O
in _ _ O
ACTH _ _ O
and _ _ O
Prednisolone _ _ O
groups _ _ O
respectively _ _ O
(p _ _ O
= _ _ O
0.7902). _ _ O
The _ _ O
relapse _ _ O
rates _ _ O
were _ _ O
18.18 _ _ O
and _ _ O
50% _ _ O
in _ _ O
ACTH _ _ O
and _ _ O
Prednisolone _ _ O
groups _ _ O
respectively _ _ O
(p _ _ O
= _ _ O
0.28). _ _ O
The _ _ O
side-effects _ _ O
profile, _ _ O
subsequent _ _ O
epilepsy _ _ O
rates _ _ O
and _ _ O
improvement _ _ O
in _ _ O
milestones _ _ O
were _ _ O
similar _ _ O
in _ _ O
both _ _ O
the _ _ O
treatment _ _ O
groups. _ _ O
There _ _ O
is _ _ O
no _ _ O
significant _ _ O
difference _ _ O
in _ _ O
children _ _ O
treated _ _ O
with _ _ O
ACTH _ _ O
and _ _ O
Prednisolone. _ _ O
Study _ _ O
results _ _ O
cannot _ _ O
be _ _ O
generalized _ _ O
due _ _ O
to _ _ O
small _ _ O
sample _ _ O
size. _ _ O
However, _ _ O
Prednisolone _ _ O
can _ _ O
be _ _ O
a _ _ O
suitable _ _ O
alternative _ _ O
to _ _ O
ACTH _ _ O
in _ _ O
resource _ _ O
poor _ _ O
settings. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
assess _ _ O
the _ _ O
effect _ _ O
of _ _ O
brivaracetam _ _ B-Intervention
(BRV) _ _ I-Intervention
on _ _ O
steady-state _ _ O
plasma _ _ O
concentrations _ _ O
of _ _ O
commonly _ _ O
prescribed _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs). _ _ O
Data _ _ O
were _ _ O
pooled _ _ O
from _ _ O
five _ _ O
randomized, _ _ O
double-blind, _ _ O
placebo-controlled _ _ B-Control
efficacy _ _ O
studies _ _ O
(NCT00175929, _ _ O
NCT00175825, _ _ O
NCT00490035, _ _ O
NCT00464269, _ _ O
and _ _ O
NCT01261325) _ _ O
in _ _ O
which _ _ O
adults _ _ B-Patient
with _ _ I-Patient
refractory _ _ I-Patient
epilepsy, _ _ I-Patient
and _ _ I-Patient
receiving _ _ I-Patient
stable _ _ I-Patient
doses _ _ I-Patient
of _ _ I-Patient
1-2 _ _ I-Patient
AEDs, _ _ I-Patient
initiated _ _ O
adjunctive _ _ B-Intervention
treatment _ _ I-Intervention
with _ _ I-Intervention
BRV _ _ I-Intervention
(or _ _ O
placebo) _ _ B-Control
for _ _ I-Control
up _ _ I-Control
to _ _ I-Control
12 _ _ I-Control
weeks, _ _ I-Control
following _ _ O
a _ _ O
4-8 _ _ O
week _ _ O
baseline _ _ O
period. _ _ O
Concentrations _ _ O
of _ _ O
carbamazepine, _ _ O
carbamazepine _ _ O
epoxide, _ _ O
clobazam, _ _ O
clonazepam, _ _ O
lacosamide, _ _ O
lamotrigine, _ _ O
levetiracetam, _ _ O
oxcarbazepine _ _ O
(MHD), _ _ O
phenobarbital, _ _ O
phenytoin, _ _ O
pregabalin, _ _ O
topiramate, _ _ O
valproic _ _ O
acid _ _ O
and _ _ O
zonisamide, _ _ O
were _ _ O
measured _ _ O
during _ _ O
baseline _ _ O
and _ _ O
during _ _ O
BRV _ _ O
or _ _ O
placebo _ _ O
evaluation _ _ O
periods. _ _ O
Log-transformed _ _ O
data _ _ O
for _ _ O
patients _ _ O
receiving _ _ O
BRV _ _ O
dosages _ _ O
of _ _ O
50-200 _ _ O
mg/day _ _ O
(or _ _ O
placebo) _ _ O
were _ _ O
evaluated _ _ O
using _ _ O
repeated _ _ O
measures _ _ O
analysis _ _ O
of _ _ O
covariance. _ _ O
Geometric _ _ O
least-squares _ _ O
means _ _ O
ratios _ _ O
of _ _ O
respective _ _ O
AED _ _ O
concentrations _ _ O
(treatment _ _ O
vs _ _ O
baseline) _ _ O
and _ _ O
their _ _ O
90% _ _ O
confidence _ _ O
intervals _ _ O
(CIs) _ _ O
were _ _ O
calculated. _ _ O
Relevant _ _ O
interaction _ _ O
of _ _ O
BRV _ _ O
on _ _ O
the _ _ O
respective _ _ O
AED _ _ O
was _ _ O
inferred _ _ O
if _ _ O
CIs _ _ O
were _ _ O
entirely _ _ O
outside _ _ O
of _ _ O
0.80-1.25 _ _ O
limits. _ _ O
Within _ _ O
the _ _ O
population _ _ O
for _ _ O
analysis _ _ O
(n _ _ O
= _ _ O
1402), _ _ O
relevant _ _ O
interaction _ _ O
was _ _ O
observed _ _ O
for _ _ O
carbamazepine _ _ O
epoxide _ _ O
alone _ _ O
which _ _ O
increased _ _ O
up _ _ O
to _ _ O
2-fold _ _ O
from _ _ O
baseline _ _ O
due _ _ O
to _ _ O
inhibition _ _ O
of _ _ O
epoxide _ _ O
hydrolase _ _ O
by _ _ O
BRV, _ _ O
and _ _ O
the _ _ O
effect _ _ O
size _ _ O
was _ _ O
not _ _ O
influenced _ _ O
by _ _ O
concomitant _ _ O
valproic _ _ O
acid. _ _ O
Relevant _ _ O
interaction _ _ O
was _ _ O
not _ _ O
observed _ _ O
for _ _ O
other _ _ O
AEDs. _ _ O
In _ _ O
adults _ _ O
with _ _ O
focal _ _ O
seizures, _ _ O
adjunctive _ _ O
BRV _ _ O
treatment _ _ O
does _ _ O
not _ _ O
affect _ _ O
plasma _ _ O
concentrations _ _ O
of _ _ O
the _ _ O
evaluated _ _ O
AEDs _ _ O
but _ _ O
increases _ _ O
carbamazepine _ _ O
epoxide _ _ O
metabolite. _ _ O
Carbamazepine _ _ O
dose _ _ O
reduction _ _ O
should _ _ O
be _ _ O
considered _ _ O
if _ _ O
tolerability _ _ O
issues _ _ O
arise. _ _ O


-DOCSTART- -X- -X- O

Caregivers _ _ B-Patient
of _ _ I-Patient
children _ _ I-Patient
with _ _ I-Patient
both _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
learning _ _ I-Patient
problems _ _ I-Patient
need _ _ O
assistance _ _ O
to _ _ O
manage _ _ O
their _ _ O
child's _ _ O
complex _ _ O
medical _ _ O
and _ _ O
mental _ _ O
health _ _ O
problems. _ _ O
We _ _ O
tested _ _ O
the _ _ B-Intervention
cognitive _ _ I-Intervention
behavioral _ _ I-Intervention
intervention _ _ I-Intervention
Creating _ _ I-Intervention
Avenues _ _ I-Intervention
for _ _ I-Intervention
Parent _ _ I-Intervention
Partnership _ _ I-Intervention
(CAPP) _ _ I-Intervention
which _ _ O
was _ _ O
designed _ _ O
to _ _ O
help _ _ O
caregivers _ _ B-Patient
develop _ _ O
knowledge _ _ O
as _ _ O
well _ _ O
as _ _ O
the _ _ O
confidence _ _ O
and _ _ O
skills _ _ O
to _ _ O
manage _ _ O
their _ _ O
child's _ _ O
condition. _ _ O
The _ _ B-Intervention
CAPP _ _ I-Intervention
intervention _ _ I-Intervention
consisted _ _ I-Intervention
of _ _ I-Intervention
a _ _ I-Intervention
one-day _ _ I-Intervention
cognitive _ _ I-Intervention
behavioral _ _ I-Intervention
program _ _ I-Intervention
and _ _ I-Intervention
three _ _ I-Intervention
follow-up _ _ I-Intervention
group _ _ I-Intervention
sessions. _ _ I-Intervention
The _ _ O
sample _ _ O
comprised _ _ O
31 _ _ O
primary _ _ B-Patient
caregivers. _ _ I-Patient
Caregivers _ _ B-Patient
reported _ _ B-Outcome
that _ _ I-Outcome
the _ _ I-Outcome
program _ _ I-Outcome
was _ _ I-Outcome
useful _ _ I-Outcome
(mean _ _ I-Outcome
= _ _ I-Outcome
3.66 _ _ I-Outcome
on _ _ I-Outcome
a _ _ I-Outcome
4-point _ _ I-Outcome
scale), _ _ I-Outcome
acceptable _ _ I-Outcome
(mean _ _ I-Outcome
= _ _ I-Outcome
4.28 _ _ I-Outcome
on _ _ I-Outcome
a _ _ I-Outcome
5-point _ _ I-Outcome
scale), _ _ I-Outcome
and _ _ I-Outcome
pretty _ _ I-Outcome
easy _ _ I-Outcome
(mean _ _ I-Outcome
= _ _ I-Outcome
1.97 _ _ I-Outcome
on _ _ I-Outcome
a _ _ I-Outcome
4-point _ _ I-Outcome
scale). _ _ I-Outcome
Effect _ _ O
sizes _ _ O
were _ _ O
small _ _ O
to _ _ O
medium _ _ O
in _ _ O
paired _ _ O
t _ _ O
tests _ _ O
(comparison _ _ O
of _ _ O
intervention _ _ O
to _ _ O
control) _ _ O
and _ _ O
paired _ _ O
analysis _ _ O
of _ _ O
key _ _ O
variables _ _ O
in _ _ O
the _ _ O
pre- _ _ O
and _ _ O
post-tests. _ _ O
The _ _ O
CAPP _ _ O
program _ _ O
shows _ _ O
promise _ _ O
in _ _ O
helping _ _ O
caregivers _ _ O
build _ _ O
skills _ _ O
to _ _ O
manage _ _ O
their _ _ O
child's _ _ O
condition. _ _ O


-DOCSTART- -X- -X- O

Epileptiform _ _ B-Patient
discharges _ _ I-Patient
(ED) _ _ I-Patient
can _ _ O
occur _ _ O
during _ _ O
sevoflurane _ _ O
induction, _ _ O
especially _ _ O
in _ _ O
young _ _ B-Patient
female _ _ I-Patient
patients _ _ I-Patient
and _ _ O
when _ _ O
high _ _ O
alveolar _ _ O
concentrations _ _ O
are _ _ O
used. _ _ O
The _ _ O
aim _ _ O
of _ _ O
this _ _ O
study _ _ O
was _ _ O
to _ _ O
evaluate _ _ O
whether _ _ O
low _ _ B-Intervention
sevoflurane _ _ I-Intervention
concentration _ _ I-Intervention
reduces _ _ O
the _ _ O
occurrence _ _ O
of _ _ O
ED _ _ B-Patient
in _ _ I-Patient
female _ _ I-Patient
patients. _ _ I-Patient
Thirty-four _ _ O
female _ _ B-Patient
patients _ _ I-Patient
scheduled _ _ I-Patient
for _ _ I-Patient
minor _ _ I-Patient
gynecological _ _ I-Patient
surgery _ _ I-Patient
were _ _ O
prospectively _ _ O
included _ _ O
and _ _ O
randomized _ _ O
in _ _ O
two _ _ O
groups. _ _ O
In _ _ B-Control
group _ _ I-Control
A, _ _ I-Control
anesthesia _ _ I-Control
was _ _ I-Control
induced _ _ I-Control
with _ _ I-Control
sevoflurane _ _ I-Control
inspired _ _ I-Control
8% _ _ I-Control
manually _ _ I-Control
set _ _ I-Control
via _ _ I-Control
the _ _ I-Control
circuit _ _ I-Control
of _ _ I-Control
the _ _ I-Control
Zeus(®) _ _ I-Control
(Dräger _ _ I-Control
Medical, _ _ I-Control
Lübeck, _ _ I-Control
Germany) _ _ I-Control
anesthesia _ _ I-Control
workstation _ _ I-Control
(fresh _ _ I-Control
gas _ _ I-Control
flow _ _ I-Control
8L.min(-1)) _ _ I-Control
for _ _ I-Control
2min _ _ I-Control
and _ _ I-Control
then _ _ I-Control
2.5%. _ _ I-Control
In _ _ B-Intervention
group _ _ I-Intervention
B, _ _ I-Intervention
induction _ _ I-Intervention
was _ _ I-Intervention
performed _ _ I-Intervention
by _ _ I-Intervention
target-controlled _ _ I-Intervention
inhalation _ _ I-Intervention
with _ _ I-Intervention
a _ _ I-Intervention
target _ _ I-Intervention
end-tidal _ _ I-Intervention
concentration _ _ I-Intervention
of _ _ I-Intervention
sevoflurane _ _ I-Intervention
set _ _ I-Intervention
at _ _ I-Intervention
2.5% _ _ I-Intervention
(fresh _ _ I-Intervention
gas _ _ I-Intervention
flow _ _ I-Intervention
in _ _ I-Intervention
auto-control _ _ I-Intervention
mode). _ _ I-Intervention
Electroencephalogram _ _ O
(EEG) _ _ O
was _ _ O
recorded _ _ O
in _ _ O
the _ _ O
operating _ _ O
room _ _ O
throughout _ _ O
induction _ _ O
till _ _ O
two _ _ O
min _ _ O
after _ _ O
intubation _ _ O
and _ _ O
analyzed _ _ O
off-line _ _ O
by _ _ O
a _ _ O
neurophysiologist _ _ O
blinded _ _ O
to _ _ O
the _ _ O
randomization. _ _ O
ED _ _ B-Outcome
occurred _ _ I-Outcome
in _ _ I-Outcome
five _ _ I-Outcome
patients _ _ I-Outcome
(15%): _ _ I-Outcome
one _ _ I-Outcome
in _ _ I-Outcome
group _ _ I-Outcome
A _ _ I-Outcome
and _ _ I-Outcome
four _ _ I-Outcome
in _ _ I-Outcome
group _ _ I-Outcome
B _ _ I-Outcome
(P>0.05). _ _ I-Outcome
ED _ _ B-Outcome
occurred _ _ I-Outcome
with _ _ I-Outcome
a _ _ I-Outcome
median _ _ I-Outcome
delay _ _ I-Outcome
of _ _ I-Outcome
303 _ _ I-Outcome
s _ _ I-Outcome
[25-75 _ _ I-Outcome
interquartiles: _ _ I-Outcome
135-418] _ _ I-Outcome
and _ _ I-Outcome
the _ _ I-Outcome
median _ _ I-Outcome
duration _ _ I-Outcome
of _ _ I-Outcome
ED _ _ I-Outcome
episode _ _ I-Outcome
was _ _ I-Outcome
13 _ _ I-Outcome
s _ _ I-Outcome
[3-78]. _ _ I-Outcome
Fifteen _ _ O
patients _ _ O
had _ _ O
abnormal _ _ O
movements _ _ O
without _ _ O
simultaneous _ _ O
EEG _ _ O
abnormality. _ _ O
Induction _ _ B-Intervention
of _ _ I-Intervention
anesthesia _ _ I-Intervention
with _ _ I-Intervention
low _ _ I-Intervention
target _ _ I-Intervention
concentration _ _ I-Intervention
of _ _ I-Intervention
sevoflurane _ _ I-Intervention
(2.5%) _ _ I-Intervention
fails _ _ O
to _ _ O
totally _ _ O
prevent _ _ O
the _ _ O
occurrence _ _ O
of _ _ O
ED _ _ B-Patient
in _ _ I-Patient
young _ _ I-Patient
female _ _ I-Patient
patients _ _ I-Patient
and _ _ O
should _ _ O
be _ _ O
used _ _ O
carefully _ _ O
in _ _ O
this _ _ O
population. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
whether _ _ O
use _ _ O
of _ _ O
a _ _ B-Intervention
bisphosphonate _ _ I-Intervention
(risedronate) _ _ I-Intervention
in _ _ I-Intervention
addition _ _ I-Intervention
to _ _ I-Intervention
calcium _ _ I-Intervention
and _ _ I-Intervention
vitamin _ _ I-Intervention
D _ _ I-Intervention
in _ _ O
male _ _ B-Patient
veterans _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
who _ _ I-Patient
were _ _ I-Patient
taking _ _ I-Patient
antiepileptic _ _ I-Patient
drugs _ _ I-Patient
(AEDs) _ _ I-Patient
long _ _ I-Patient
term _ _ I-Patient
can _ _ O
prevent _ _ O
the _ _ O
loss _ _ O
of _ _ O
bone _ _ O
mass _ _ O
(BMD, _ _ B-Outcome
bone _ _ I-Outcome
mineral _ _ I-Outcome
density) _ _ I-Outcome
associated _ _ O
with _ _ O
AED _ _ O
use _ _ O
compared _ _ O
to _ _ O
patients _ _ O
who _ _ O
were _ _ O
treated _ _ O
with _ _ O
a _ _ B-Control
placebo _ _ I-Control
plus _ _ I-Control
calcium _ _ I-Control
and _ _ I-Control
vitamin _ _ I-Control
D. _ _ I-Control
As _ _ O
a _ _ O
secondary _ _ O
end _ _ O
point _ _ O
we _ _ O
studied _ _ O
the _ _ O
incidence _ _ O
of _ _ O
new _ _ O
morphometric _ _ O
vertebral _ _ O
and _ _ O
nonvertebral _ _ O
fractures. _ _ O
Antiepileptic _ _ O
drug _ _ O
and _ _ O
osteoporosis _ _ O
prevention _ _ O
trial _ _ O
(ADOPT) _ _ O
was _ _ O
designed _ _ O
as _ _ O
a _ _ O
prospective _ _ O
2-year _ _ O
double-blind, _ _ O
randomized _ _ O
placebo _ _ B-Control
controlled _ _ I-Control
study _ _ O
involving _ _ O
80 _ _ O
male _ _ B-Patient
veterans _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
who _ _ I-Patient
were _ _ I-Patient
being _ _ I-Patient
treated _ _ I-Patient
with _ _ I-Patient
AEDs _ _ I-Patient
such _ _ I-Patient
as _ _ I-Patient
phenytoin, _ _ I-Patient
phenobarbital, _ _ I-Patient
sodium _ _ I-Patient
valproate, _ _ I-Patient
or _ _ I-Patient
carbamazepine _ _ I-Patient
for _ _ I-Patient
a _ _ I-Patient
minimum _ _ I-Patient
of _ _ I-Patient
2 _ _ I-Patient
years. _ _ I-Patient
All _ _ O
enrolled _ _ O
participants _ _ O
received _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
supplementation, _ _ O
and _ _ O
were _ _ O
randomized _ _ O
to _ _ O
risedronate _ _ B-Intervention
or _ _ O
matching _ _ B-Control
placebo. _ _ I-Control
Total _ _ O
body, _ _ O
bilateral _ _ O
proximal _ _ O
femora, _ _ O
and _ _ O
anteroposterior _ _ O
(AP) _ _ O
lumbar _ _ O
spine _ _ O
BMDs _ _ O
in _ _ O
addition _ _ O
to _ _ O
morphometric _ _ O
lateral _ _ O
vertebral _ _ O
assessments _ _ O
(LVAs) _ _ O
were _ _ O
evaluated _ _ O
by _ _ O
a _ _ O
dual _ _ O
energy _ _ O
x-ray _ _ O
absorptiometry _ _ O
(DXA) _ _ O
instrument. _ _ O
Comparisons _ _ O
of _ _ O
BMDs _ _ O
were _ _ O
made _ _ O
between _ _ O
baseline, _ _ O
1 _ _ O
year, _ _ O
and _ _ O
after _ _ O
2 _ _ O
years _ _ O
of _ _ O
enrollment _ _ O
in _ _ O
the _ _ O
study. _ _ O
The _ _ O
incidence _ _ O
of _ _ O
new _ _ O
vertebral _ _ O
and _ _ O
nonvertebral _ _ O
fractures _ _ O
was _ _ O
secondary _ _ O
end _ _ O
point. _ _ O
Of _ _ O
the _ _ O
80 _ _ O
patients _ _ O
initially _ _ O
enrolled _ _ O
in _ _ O
the _ _ O
study, _ _ O
53 _ _ O
patients _ _ O
completed _ _ O
the _ _ O
study. _ _ O
Baseline _ _ O
characteristics _ _ O
of _ _ O
the _ _ O
two _ _ O
groups _ _ O
were _ _ O
similar. _ _ O
At _ _ B-Outcome
the _ _ I-Outcome
end _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
study, _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
placebo _ _ I-Outcome
plus _ _ I-Outcome
calcium _ _ I-Outcome
and _ _ I-Outcome
vitamin _ _ I-Outcome
D _ _ I-Outcome
group, _ _ I-Outcome
we _ _ I-Outcome
observed _ _ I-Outcome
a _ _ I-Outcome
significant _ _ I-Outcome
improvement _ _ I-Outcome
in _ _ I-Outcome
BMD _ _ I-Outcome
at _ _ I-Outcome
any _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
evaluated _ _ I-Outcome
sites _ _ I-Outcome
when _ _ I-Outcome
compared _ _ I-Outcome
to _ _ I-Outcome
their _ _ I-Outcome
baseline _ _ I-Outcome
scans _ _ I-Outcome
in _ _ I-Outcome
69% _ _ I-Outcome
(18/26) _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
participants. _ _ I-Outcome
In _ _ O
the _ _ O
risedronate _ _ O
plus _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
group, _ _ O
we _ _ O
observed _ _ O
significant _ _ O
improvement _ _ O
of _ _ O
BMDs _ _ O
in _ _ O
70% _ _ O
(19/27) _ _ O
of _ _ O
the _ _ O
participants. _ _ O
At _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
study, _ _ O
the _ _ O
risedronate _ _ O
group _ _ O
experienced _ _ O
a _ _ O
significant _ _ O
increase _ _ O
of _ _ O
BMD _ _ O
at _ _ O
the _ _ O
lumbar _ _ O
spine _ _ O
L1-4 _ _ O
(1.267-1.332 _ _ O
g/cm(2)), _ _ O
which _ _ O
was _ _ O
significantly _ _ O
larger _ _ O
than _ _ O
that _ _ O
seen _ _ O
in _ _ O
the _ _ O
placebo _ _ O
group) _ _ O
(1.229 _ _ O
g/cm(2) _ _ O
vs. _ _ O
1.245 _ _ O
g/cm(2) _ _ O
; _ _ O
p _ _ O
= _ _ O
0.0066).There _ _ O
were _ _ O
nonsignificant _ _ O
differences _ _ O
between _ _ O
the _ _ O
two _ _ O
groups _ _ O
regarding _ _ O
changes _ _ O
of _ _ O
total _ _ O
body _ _ O
BMD _ _ O
or _ _ O
at _ _ O
the _ _ O
proximal _ _ O
bilateral _ _ O
femora. _ _ O
Five _ _ O
new _ _ O
vertebral _ _ O
fractures _ _ O
and _ _ O
one _ _ O
nonvertebral _ _ O
fracture _ _ O
were _ _ O
observed _ _ O
only _ _ O
in _ _ O
the _ _ O
placebo _ _ O
group. _ _ O
Calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
supplementation _ _ O
or _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
supplementation _ _ O
in _ _ O
addition _ _ O
to _ _ O
risedronate _ _ O
improved _ _ O
BMD _ _ O
in _ _ O
more _ _ O
than _ _ O
69% _ _ O
of _ _ O
male _ _ O
veterans _ _ O
with _ _ O
epilepsy _ _ O
who _ _ O
were _ _ O
taking _ _ O
AEDs. _ _ O
In _ _ O
the _ _ O
group _ _ O
receiving _ _ O
risedronate _ _ O
plus _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
there _ _ O
was _ _ O
a _ _ O
significant _ _ O
improvement _ _ O
of _ _ O
BMD _ _ O
at _ _ O
the _ _ O
lumbar _ _ O
spine _ _ O
as _ _ O
compared _ _ O
to _ _ O
the _ _ O
placebo _ _ O
group, _ _ O
which _ _ O
also _ _ O
received _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D. _ _ O
The _ _ O
use _ _ O
of _ _ O
risedronate _ _ O
plus _ _ O
calcium _ _ O
and _ _ O
vitamin _ _ O
D _ _ O
prevented _ _ O
the _ _ O
incidence _ _ O
of _ _ O
new _ _ O
vertebral _ _ O
fractures _ _ O
and _ _ O
one _ _ O
nonvertebral _ _ O
fracture _ _ O
in _ _ O
this _ _ O
cohort. _ _ O


-DOCSTART- -X- -X- O

Epilepsy _ _ O
is _ _ O
defined _ _ O
as _ _ O
drug-resistant _ _ O
when _ _ O
existing _ _ O
anti-epileptic _ _ O
drugs _ _ O
(AED) _ _ O
are _ _ O
found _ _ O
to _ _ O
have _ _ O
minimal _ _ O
to _ _ O
no _ _ O
effect _ _ O
on _ _ O
patient's _ _ O
condition. _ _ O
Therefore _ _ O
the _ _ O
search _ _ O
and _ _ O
testing _ _ O
of _ _ O
new _ _ O
treatment _ _ O
strategies _ _ O
is _ _ O
warranted. _ _ O
This _ _ O
study _ _ O
focuses _ _ O
on _ _ O
the _ _ O
effects _ _ O
of _ _ O
autologous _ _ B-Intervention
mesenchymal _ _ I-Intervention
stem _ _ I-Intervention
cells _ _ I-Intervention
(MSC) _ _ I-Intervention
in _ _ O
drug-resistant _ _ B-Patient
epilepsy _ _ I-Patient
patients _ _ I-Patient
within _ _ O
a _ _ O
Phase _ _ O
I/II _ _ O
open-label _ _ O
registered _ _ O
clinical _ _ O
trial _ _ O
NCT02497443. _ _ O
A _ _ O
total _ _ O
of _ _ O
67 _ _ O
patients _ _ O
was _ _ O
included _ _ O
(29 _ _ B-Patient
males, _ _ I-Patient
38 _ _ I-Patient
females, _ _ I-Patient
mean _ _ I-Patient
age _ _ I-Patient
33 _ _ I-Patient
± _ _ I-Patient
1.3 _ _ I-Patient
yo). _ _ I-Patient
The _ _ O
patients _ _ O
received _ _ O
either _ _ O
standard _ _ B-Control
treatment _ _ I-Control
with _ _ I-Control
AEDs, _ _ I-Control
or _ _ O
AEDs _ _ B-Intervention
supplemented _ _ I-Intervention
with _ _ I-Intervention
one _ _ I-Intervention
or _ _ I-Intervention
two _ _ I-Intervention
courses _ _ I-Intervention
of _ _ I-Intervention
therapy _ _ I-Intervention
with _ _ I-Intervention
autologous _ _ I-Intervention
bone _ _ I-Intervention
marrow-derived _ _ I-Intervention
MSCs _ _ I-Intervention
expanded _ _ I-Intervention
in _ _ I-Intervention
vitro. _ _ I-Intervention
MSC _ _ B-Intervention
therapy _ _ I-Intervention
courses _ _ O
were _ _ O
6 _ _ O
months _ _ O
apart, _ _ O
and _ _ O
each _ _ O
course _ _ O
consisted _ _ O
of _ _ O
two _ _ O
cell _ _ O
injections: _ _ O
an _ _ O
intravenous _ _ O
infusion _ _ O
of _ _ O
MSCs, _ _ O
followed _ _ O
within _ _ O
1 _ _ O
week _ _ O
by _ _ O
an _ _ O
intrathecal _ _ O
injection. _ _ O
Primary _ _ O
outcome _ _ O
of _ _ O
the _ _ O
study _ _ O
was _ _ O
safety, _ _ O
secondary _ _ O
outcome _ _ O
was _ _ O
efficacy _ _ O
in _ _ O
terms _ _ O
of _ _ O
seizure _ _ O
frequency _ _ O
reduction _ _ O
and _ _ O
response _ _ O
to _ _ O
treatment. _ _ O
MSC _ _ B-Intervention
injections _ _ I-Intervention
proved _ _ B-Outcome
safe _ _ I-Outcome
and _ _ I-Outcome
did _ _ I-Outcome
not _ _ I-Outcome
cause _ _ I-Outcome
any _ _ I-Outcome
severe _ _ I-Outcome
side _ _ I-Outcome
effects. _ _ I-Outcome
In _ _ O
MSC _ _ O
group _ _ O
(n _ _ O
= _ _ O
34), _ _ O
61.7% _ _ O
patients _ _ O
responded _ _ O
to _ _ O
therapy _ _ O
at _ _ O
6 _ _ O
months _ _ O
timepoint _ _ O
(p _ _ O
< _ _ O
0.01 _ _ O
vs _ _ O
control, _ _ O
n _ _ O
= _ _ O
33), _ _ O
and _ _ O
the _ _ O
number _ _ O
rose _ _ O
to _ _ O
76.5% _ _ O
by _ _ O
12 _ _ O
months _ _ O
timepoint. _ _ O
Decrease _ _ O
in _ _ O
anxiety _ _ O
and _ _ O
depression _ _ O
scores _ _ O
and _ _ O
paroxysmal _ _ O
epileptiform _ _ O
activity _ _ O
was _ _ O
observed _ _ O
in _ _ O
MSC _ _ O
group _ _ O
based _ _ O
on _ _ O
HADS _ _ O
and _ _ O
EEG, _ _ O
respectively, _ _ O
and _ _ O
MMSE _ _ O
score _ _ O
has _ _ O
also _ _ O
improved. _ _ O
Another _ _ O
observation _ _ O
was _ _ O
that _ _ O
concomitant _ _ O
administration _ _ O
of _ _ O
levetiracetam, _ _ O
but _ _ O
not _ _ O
other _ _ O
AEDs, _ _ O
correlated _ _ O
significantly _ _ O
with _ _ O
the _ _ O
success _ _ O
of _ _ O
MSC _ _ O
therapy. _ _ O
Second _ _ O
course _ _ O
of _ _ O
MSC _ _ O
therapy _ _ O
facilitated _ _ O
further _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
count _ _ O
and _ _ O
epileptiform _ _ O
EEG _ _ O
activity _ _ O
(p _ _ O
< _ _ O
0.05 _ _ O
vs _ _ O
single _ _ O
course). _ _ O
Application _ _ O
of _ _ O
autologous _ _ O
mesenchymal _ _ O
stem _ _ O
cell-based _ _ O
therapy _ _ O
in _ _ O
patients _ _ O
with _ _ O
pharmacoresistant _ _ O
epilepsy _ _ O
demonstrated _ _ O
significant _ _ O
anticonvulsant _ _ O
potential. _ _ O
This _ _ O
effect _ _ O
lasted _ _ O
for _ _ O
at _ _ O
least _ _ O
1 _ _ O
year, _ _ O
with _ _ O
repeated _ _ O
administration _ _ O
of _ _ O
MSCs _ _ O
conveying _ _ O
additional _ _ O
clinical _ _ O
benefit. _ _ O


-DOCSTART- -X- -X- O

Methylxanthine _ _ O
therapy _ _ O
is _ _ O
commonly _ _ O
used _ _ O
for _ _ O
apnea _ _ O
of _ _ O
prematurity _ _ O
but _ _ O
in _ _ O
the _ _ O
absence _ _ O
of _ _ O
adequate _ _ O
data _ _ O
on _ _ O
its _ _ O
efficacy _ _ O
and _ _ O
safety. _ _ O
It _ _ O
is _ _ O
uncertain _ _ O
whether _ _ O
methylxanthines _ _ O
have _ _ O
long-term _ _ O
effects _ _ O
on _ _ O
neurodevelopment _ _ O
and _ _ O
growth. _ _ O
We _ _ O
randomly _ _ O
assigned _ _ O
2006 _ _ O
infants _ _ B-Patient
with _ _ I-Patient
birth _ _ I-Patient
weights _ _ I-Patient
of _ _ I-Patient
500 _ _ I-Patient
to _ _ I-Patient
1250 _ _ I-Patient
g _ _ I-Patient
to _ _ O
receive _ _ O
either _ _ O
caffeine _ _ B-Intervention
or _ _ O
placebo _ _ B-Control
until _ _ O
therapy _ _ O
for _ _ O
apnea _ _ O
of _ _ O
prematurity _ _ O
was _ _ O
no _ _ O
longer _ _ O
needed. _ _ O
The _ _ O
primary _ _ O
outcome _ _ O
was _ _ O
a _ _ O
composite _ _ O
of _ _ O
death, _ _ O
cerebral _ _ O
palsy, _ _ O
cognitive _ _ O
delay _ _ O
(defined _ _ O
as _ _ O
a _ _ O
Mental _ _ O
Development _ _ O
Index _ _ O
score _ _ O
of _ _ O
<85 _ _ O
on _ _ O
the _ _ O
Bayley _ _ O
Scales _ _ O
of _ _ O
Infant _ _ O
Development), _ _ O
deafness, _ _ O
or _ _ O
blindness _ _ O
at _ _ O
a _ _ O
corrected _ _ O
age _ _ O
of _ _ O
18 _ _ O
to _ _ O
21 _ _ O
months. _ _ O
Of _ _ O
the _ _ O
937 _ _ O
infants _ _ O
assigned _ _ O
to _ _ O
caffeine _ _ O
for _ _ O
whom _ _ O
adequate _ _ O
data _ _ O
on _ _ O
the _ _ O
primary _ _ O
outcome _ _ O
were _ _ O
available, _ _ O
377 _ _ O
(40.2%) _ _ O
died _ _ O
or _ _ O
survived _ _ O
with _ _ O
a _ _ O
neurodevelopmental _ _ O
disability, _ _ O
as _ _ O
compared _ _ O
with _ _ O
431 _ _ O
of _ _ O
the _ _ O
932 _ _ O
infants _ _ O
(46.2%) _ _ O
assigned _ _ O
to _ _ O
placebo _ _ O
for _ _ O
whom _ _ O
adequate _ _ O
data _ _ O
on _ _ O
the _ _ O
primary _ _ O
outcome _ _ O
were _ _ O
available _ _ O
(odds _ _ O
ratio _ _ O
adjusted _ _ O
for _ _ O
center, _ _ O
0.77; _ _ O
95% _ _ O
confidence _ _ O
interval _ _ O
[CI], _ _ O
0.64 _ _ O
to _ _ O
0.93; _ _ O
P=0.008). _ _ O
Treatment _ _ O
with _ _ O
caffeine _ _ O
as _ _ O
compared _ _ O
with _ _ O
placebo _ _ O
reduced _ _ O
the _ _ O
incidence _ _ O
of _ _ O
cerebral _ _ O
palsy _ _ O
(4.4% _ _ O
vs. _ _ O
7.3%; _ _ O
adjusted _ _ O
odds _ _ O
ratio, _ _ O
0.58; _ _ O
95% _ _ O
CI, _ _ O
0.39 _ _ O
to _ _ O
0.87; _ _ O
P=0.009) _ _ O
and _ _ O
of _ _ O
cognitive _ _ O
delay _ _ O
(33.8% _ _ O
vs. _ _ O
38.3%; _ _ O
adjusted _ _ O
odds _ _ O
ratio, _ _ O
0.81; _ _ O
95% _ _ O
CI, _ _ O
0.66 _ _ O
to _ _ O
0.99; _ _ O
P=0.04). _ _ O
The _ _ O
rates _ _ O
of _ _ O
death, _ _ O
deafness, _ _ O
and _ _ O
blindness _ _ O
and _ _ O
the _ _ O
mean _ _ O
percentiles _ _ O
for _ _ O
height, _ _ O
weight, _ _ O
and _ _ O
head _ _ O
circumference _ _ O
at _ _ O
follow-up _ _ O
did _ _ O
not _ _ O
differ _ _ O
significantly _ _ O
between _ _ O
the _ _ O
two _ _ O
groups. _ _ O
Caffeine _ _ O
therapy _ _ O
for _ _ O
apnea _ _ O
of _ _ O
prematurity _ _ O
improves _ _ O
the _ _ O
rate _ _ O
of _ _ O
survival _ _ O
without _ _ O
neurodevelopmental _ _ O
disability _ _ O
at _ _ O
18 _ _ O
to _ _ O
21 _ _ O
months _ _ O
in _ _ O
infants _ _ O
with _ _ O
very _ _ O
low _ _ O
birth _ _ O
weight. _ _ O
(ClinicalTrials.gov _ _ O
number, _ _ O
NCT00182312 _ _ O
[ClinicalTrials.gov].). _ _ O


-DOCSTART- -X- -X- O

Extended-release _ _ B-Intervention
vinpocetine _ _ I-Intervention
is _ _ O
effective _ _ O
to _ _ O
control _ _ O
focal _ _ B-Patient
onset _ _ I-Patient
epileptic _ _ I-Patient
seizures _ _ I-Patient
with _ _ O
a _ _ O
low _ _ O
rate _ _ O
of _ _ O
adverse _ _ O
events. _ _ O
A _ _ O
clinical _ _ O
study _ _ O
was _ _ O
performed _ _ O
to _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
vinpocetine _ _ B-Intervention
as _ _ I-Intervention
an _ _ I-Intervention
adjuvant _ _ I-Intervention
treatment _ _ I-Intervention
in _ _ O
patients _ _ O
with _ _ O
this _ _ O
condition. _ _ O
A _ _ O
double-blind _ _ O
clinical _ _ O
study _ _ O
of _ _ O
parallel _ _ O
groups _ _ O
was _ _ O
conducted, _ _ O
in _ _ O
which _ _ O
87 _ _ O
patients _ _ O
with _ _ O
a _ _ O
diagnosis _ _ O
of _ _ O
focal _ _ O
epilepsy _ _ O
treated _ _ O
with _ _ O
one _ _ O
to _ _ O
three _ _ O
antiepileptic _ _ O
drugs _ _ O
were _ _ O
recruited. _ _ O
Patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
vinpocetine _ _ O
(n _ _ O
= _ _ O
41) _ _ O
or _ _ O
placebo _ _ O
(n _ _ O
= _ _ O
46) _ _ O
adjuvant _ _ O
to _ _ O
their _ _ O
treatment. _ _ O
Patients _ _ O
entered _ _ O
the _ _ O
baseline _ _ O
phase _ _ O
(4 _ _ O
weeks), _ _ O
the _ _ O
titration _ _ O
phase _ _ O
(4 _ _ O
weeks) _ _ O
and _ _ O
the _ _ O
evaluation _ _ O
phase _ _ O
(8 _ _ O
weeks), _ _ O
maintaining _ _ O
stable _ _ O
doses _ _ O
of _ _ O
vinpocetine _ _ O
and _ _ O
their _ _ O
respective _ _ O
antiepileptic _ _ O
drug _ _ O
treatment. _ _ O
Vinpocetine _ _ O
was _ _ O
more _ _ O
effective _ _ O
than _ _ O
placebo _ _ O
in _ _ O
reducing _ _ O
seizures _ _ O
at _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
evaluation _ _ O
phase _ _ O
(p _ _ O
< _ _ O
0.0001). _ _ O
Sixty-nine _ _ O
percent _ _ O
of _ _ O
the _ _ O
vinpocetine-treated _ _ O
patients _ _ O
had _ _ O
a _ _ O
50% _ _ O
reduction _ _ O
in _ _ O
seizures _ _ O
compared _ _ O
to _ _ O
13% _ _ O
of _ _ O
placebo-treated _ _ O
patients. _ _ O
No _ _ O
significant _ _ O
differences _ _ O
in _ _ O
the _ _ O
presence _ _ O
of _ _ O
adverse _ _ O
effects _ _ O
in _ _ O
patients _ _ O
treated _ _ O
with _ _ O
vinpocetine _ _ O
compared _ _ O
to _ _ O
those _ _ O
treated _ _ O
with _ _ O
placebo _ _ O
were _ _ O
observed. _ _ O
The _ _ O
most _ _ O
frequent _ _ O
adverse _ _ O
events _ _ O
observed _ _ O
with _ _ O
vinpocetine _ _ O
were _ _ O
headache _ _ O
(7.9%) _ _ O
and _ _ O
diplopia _ _ O
(5.2%). _ _ O
As _ _ O
an _ _ O
adjuvant _ _ O
treatment, _ _ O
vinpocetine _ _ O
(2 _ _ O
mg/kg/day) _ _ O
effectively _ _ O
reduced _ _ O
the _ _ O
frequency _ _ O
of _ _ O
epileptic _ _ O
seizures _ _ O
and _ _ O
proved _ _ O
to _ _ O
be _ _ O
well _ _ O
tolerated. _ _ O
Vinpocetine _ _ O
has _ _ O
a _ _ O
wide _ _ O
safety _ _ O
profile _ _ O
and _ _ O
well-known _ _ O
adverse _ _ O
events, _ _ O
which _ _ O
are _ _ O
transient _ _ O
and _ _ O
with _ _ O
no _ _ O
sequelae. _ _ O
La _ _ O
vinpocetina _ _ O
de _ _ O
liberación _ _ O
prolongada _ _ O
ha _ _ O
demostrado _ _ O
ser _ _ O
efectiva _ _ O
en _ _ O
el _ _ O
control _ _ O
de _ _ O
crisis _ _ O
de _ _ O
inicio _ _ O
focal _ _ O
en _ _ O
pacientes _ _ O
epilépticos _ _ O
con _ _ O
una _ _ O
baja _ _ O
frecuencia _ _ O
de _ _ O
eventos _ _ O
adversos. _ _ O
Se _ _ O
realizó _ _ O
un _ _ O
estudio _ _ O
clínico _ _ O
para _ _ O
evaluar _ _ O
la _ _ O
eficacia _ _ O
y _ _ O
tolerabilidad _ _ O
de _ _ O
la _ _ O
vinpocetina _ _ O
como _ _ O
tratamiento _ _ O
adyuvante _ _ O
en _ _ O
pacientes _ _ O
con _ _ O
este _ _ O
padecimiento. _ _ O
Se _ _ O
realizó _ _ O
un _ _ O
estudio _ _ O
clínico, _ _ O
doble _ _ O
ciego, _ _ O
de _ _ O
grupos _ _ O
paralelos. _ _ O
Se _ _ O
reclutaron _ _ O
87 _ _ O
pacientes _ _ O
con _ _ O
diagnóstico _ _ O
de _ _ O
epilepsia _ _ O
focal _ _ O
tratados _ _ O
con _ _ O
uno _ _ O
a _ _ O
tres _ _ O
fármacos _ _ O
antiepilépticos. _ _ O
Los _ _ O
pacientes _ _ O
se _ _ O
aleatorizaron _ _ O
para _ _ O
ser _ _ O
tratados _ _ O
con _ _ O
vinpocetina _ _ O
(n _ _ O
= _ _ O
41) _ _ O
o _ _ O
placebo _ _ O
(n _ _ O
= _ _ O
46) _ _ O
de _ _ O
manera _ _ O
adyuvante _ _ O
a _ _ O
su _ _ O
tratamiento, _ _ O
e _ _ O
ingresaron _ _ O
a _ _ O
la _ _ O
fase _ _ O
basal _ _ O
(4 _ _ O
semanas), _ _ O
a _ _ O
la _ _ O
fase _ _ O
de _ _ O
titulación _ _ O
(4 _ _ O
semanas) _ _ O
y _ _ O
a _ _ O
la _ _ O
fase _ _ O
de _ _ O
evaluación _ _ O
(8 _ _ O
semanas) _ _ O
conservando _ _ O
estables _ _ O
las _ _ O
dosis _ _ O
de _ _ O
la _ _ O
vinpocetina _ _ O
y _ _ O
de _ _ O
los _ _ O
fármacos _ _ O
antiepilépticos. _ _ O
La _ _ O
vinpocetina _ _ O
fue _ _ O
más _ _ O
efectiva _ _ O
que _ _ O
el _ _ O
placebo _ _ O
en _ _ O
la _ _ O
reducción _ _ O
de _ _ O
las _ _ O
crisis _ _ O
al _ _ O
finalizar _ _ O
la _ _ O
fase _ _ O
de _ _ O
evaluación _ _ O
(p _ _ O
< _ _ O
0.0001). _ _ O
El _ _ O
69% _ _ O
de _ _ O
los _ _ O
pacientes _ _ O
tratados _ _ O
con _ _ O
vinpocetina _ _ O
presentaron _ _ O
una _ _ O
reducción _ _ O
mayor _ _ O
al _ _ O
50% _ _ O
en _ _ O
las _ _ O
crisis _ _ O
en _ _ O
comparación _ _ O
con _ _ O
el _ _ O
13% _ _ O
de _ _ O
los _ _ O
pacientes _ _ O
tratados _ _ O
con _ _ O
placebo. _ _ O
No _ _ O
se _ _ O
presentaron _ _ O
diferencias _ _ O
significativas _ _ O
en _ _ O
cuanto _ _ O
a _ _ O
la _ _ O
presencia _ _ O
de _ _ O
efectos _ _ O
adversos _ _ O
en _ _ O
los _ _ O
pacientes _ _ O
tratados _ _ O
con _ _ O
vinpocetina _ _ O
comparados _ _ O
con _ _ O
los _ _ O
tratados _ _ O
con _ _ O
placebo. _ _ O
Los _ _ O
eventos _ _ O
adversos _ _ O
más _ _ O
frecuentes _ _ O
observados _ _ O
con _ _ O
vinpocetina _ _ O
fueron _ _ O
cefalea _ _ O
(7.9%) _ _ O
y _ _ O
diplopía _ _ O
(5.2%). _ _ O
Como _ _ O
tratamiento _ _ O
adyuvante, _ _ O
la _ _ O
vinpocetina _ _ O
(2 _ _ O
mg/kg/día) _ _ O
redujo _ _ O
eficazmente _ _ O
la _ _ O
frecuencia _ _ O
de _ _ O
crisis _ _ O
epilépticas _ _ O
y _ _ O
demostró _ _ O
ser _ _ O
bien _ _ O
tolerada. _ _ O
Presenta _ _ O
un _ _ O
amplio _ _ O
perfil _ _ O
de _ _ O
seguridad _ _ O
y _ _ O
eventos _ _ O
adversos _ _ O
conocidos, _ _ O
que _ _ O
son _ _ O
transitorios _ _ O
y _ _ O
sin _ _ O
secuelas. _ _ O


-DOCSTART- -X- -X- O

Bright _ _ B-Intervention
light _ _ I-Intervention
therapy _ _ I-Intervention
is _ _ O
an _ _ O
effective _ _ O
treatment _ _ O
for _ _ O
seasonal _ _ O
affective _ _ O
disorder _ _ O
and _ _ O
non-seasonal _ _ O
depression. _ _ O
Depression _ _ O
and _ _ O
anxiety _ _ O
are _ _ O
common _ _ O
psychiatric _ _ O
comorbidities _ _ O
in _ _ O
epilepsy. _ _ O
To _ _ O
examine _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
bright _ _ O
light _ _ O
therapy _ _ O
for _ _ O
symptoms _ _ O
of _ _ O
anxiety _ _ O
and _ _ O
depression _ _ O
in _ _ O
adults _ _ O
with _ _ O
focal _ _ O
epilepsy _ _ O
(trial _ _ O
registration _ _ O
at _ _ O
ClinicalTrials.gov: _ _ O
NCT01028456). _ _ O
We _ _ O
recruited _ _ O
101 _ _ O
adults _ _ O
with _ _ O
medically _ _ O
intractable _ _ O
focal _ _ O
epilepsy. _ _ O
Participants _ _ O
completed _ _ O
the _ _ O
Hospital _ _ O
Anxiety _ _ O
and _ _ O
Depression _ _ O
Scale _ _ O
(HADS) _ _ O
at _ _ O
the _ _ O
beginning _ _ O
(T1) _ _ O
and _ _ O
end _ _ O
of _ _ O
a _ _ O
12-week _ _ O
baseline _ _ O
period _ _ O
(T2) _ _ O
and _ _ O
again _ _ O
after _ _ O
12 _ _ O
weeks _ _ O
of _ _ O
daily _ _ O
light _ _ O
therapy _ _ O
(T3), _ _ O
with _ _ O
51 _ _ O
participants _ _ O
using _ _ O
a _ _ O
high-intensity _ _ O
light _ _ O
box _ _ O
and _ _ O
50 _ _ O
using _ _ O
a _ _ O
low-intensity _ _ O
one. _ _ O
Seizure _ _ O
diaries _ _ O
were _ _ O
kept _ _ O
throughout _ _ O
the _ _ O
baseline _ _ O
and _ _ O
trial _ _ O
period. _ _ O
A _ _ O
total _ _ O
of _ _ O
58 _ _ O
patients _ _ O
completed _ _ O
the _ _ O
trial. _ _ O
Anxiety _ _ O
and _ _ O
depression _ _ O
scores _ _ O
were _ _ O
significantly _ _ O
reduced _ _ O
following _ _ O
the _ _ O
light _ _ O
therapy _ _ O
at _ _ O
T3 _ _ O
in _ _ O
both _ _ O
the _ _ O
high- _ _ O
and _ _ O
low-intensity _ _ O
groups. _ _ O
Light _ _ O
therapy _ _ O
resulted _ _ O
in _ _ O
a _ _ O
significant _ _ O
reduction _ _ O
in _ _ O
symptoms _ _ O
of _ _ O
anxiety _ _ O
and _ _ O
depression _ _ O
but _ _ O
we _ _ O
did _ _ O
not _ _ O
find _ _ O
any _ _ O
differences _ _ O
between _ _ O
high- _ _ O
v. _ _ O
low-intensity _ _ O
treatment. _ _ O
This _ _ O
may, _ _ O
therefore, _ _ O
be _ _ O
an _ _ O
effective _ _ O
treatment _ _ O
for _ _ O
symptoms _ _ O
of _ _ O
low _ _ O
mood _ _ O
in _ _ O
epilepsy _ _ O
at _ _ O
lower _ _ O
intensities _ _ O
than _ _ O
those _ _ O
typically _ _ O
used _ _ O
to _ _ O
treat _ _ O
seasonal _ _ O
affective _ _ O
disorder. _ _ O
Further _ _ O
work _ _ O
is _ _ O
needed _ _ O
to _ _ O
investigate _ _ O
this _ _ O
possibility _ _ O
with _ _ O
an _ _ O
adequate _ _ O
placebo _ _ O
condition. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
investigate _ _ O
the _ _ O
effectiveness _ _ O
of _ _ O
mindfulness-based _ _ B-Intervention
therapy _ _ I-Intervention
(MT) _ _ I-Intervention
and _ _ O
social _ _ B-Control
support _ _ I-Control
(SS) _ _ I-Control
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy. _ _ I-Patient
We _ _ O
performed _ _ O
an _ _ O
assessor-blinded _ _ O
randomized _ _ O
control _ _ O
trial. _ _ O
Sixty _ _ O
patients _ _ B-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy _ _ I-Patient
were _ _ O
randomly _ _ O
allocated _ _ O
to _ _ O
MT _ _ B-Intervention
or _ _ O
SS _ _ B-Control
(30 _ _ O
per _ _ O
group). _ _ O
Each _ _ O
group _ _ O
received _ _ O
4 _ _ O
biweekly _ _ O
intervention _ _ O
sessions. _ _ O
The _ _ O
primary _ _ O
outcome _ _ O
was _ _ O
the _ _ O
change _ _ O
in _ _ O
the _ _ O
total _ _ O
score _ _ O
of _ _ O
the _ _ O
Patient-Weighted _ _ B-Outcome
Quality _ _ I-Outcome
of _ _ I-Outcome
Life _ _ I-Outcome
in _ _ I-Outcome
Epilepsy _ _ I-Outcome
Inventory _ _ I-Outcome
(QOLIE-31-P). _ _ I-Outcome
Secondary _ _ O
outcomes _ _ O
included _ _ O
seizure _ _ O
frequency, _ _ O
mood _ _ O
symptoms, _ _ O
and _ _ O
neurocognitive _ _ O
functions. _ _ O
The _ _ O
assessors _ _ O
were _ _ O
blinded _ _ O
to _ _ O
the _ _ O
patient's _ _ O
intervention _ _ O
grouping. _ _ O
Results _ _ O
were _ _ O
analyzed _ _ O
using _ _ O
general _ _ O
linear _ _ O
model _ _ O
with _ _ O
repeated _ _ O
measure. _ _ O
Following _ _ B-Outcome
intervention, _ _ I-Outcome
both _ _ I-Outcome
the _ _ I-Outcome
MT _ _ I-Outcome
(n=30) _ _ I-Outcome
and _ _ I-Outcome
SS _ _ I-Outcome
(n=30) _ _ I-Outcome
groups _ _ I-Outcome
had _ _ I-Outcome
an _ _ I-Outcome
improved _ _ I-Outcome
total _ _ I-Outcome
QOLIE-31-P, _ _ I-Outcome
with _ _ I-Outcome
an _ _ I-Outcome
improvement _ _ I-Outcome
of _ _ I-Outcome
+6.23 _ _ I-Outcome
for _ _ I-Outcome
MT _ _ I-Outcome
(95% _ _ I-Outcome
confidence _ _ I-Outcome
interval _ _ I-Outcome
[CI] _ _ I-Outcome
+4.22 _ _ I-Outcome
to _ _ I-Outcome
+10.40) _ _ I-Outcome
and _ _ I-Outcome
+3.30 _ _ I-Outcome
for _ _ I-Outcome
SS _ _ I-Outcome
(95% _ _ I-Outcome
CI _ _ I-Outcome
+1.03 _ _ I-Outcome
to _ _ I-Outcome
+5.58). _ _ I-Outcome
Significantly _ _ O
more _ _ O
patients _ _ O
in _ _ O
the _ _ O
MT _ _ O
group _ _ O
had _ _ O
a _ _ O
clinically _ _ O
important _ _ O
improvement _ _ O
in _ _ O
QOLIE-31-P _ _ O
(+11.8 _ _ O
or _ _ O
above) _ _ O
compared _ _ O
to _ _ O
those _ _ O
who _ _ O
received _ _ O
SS _ _ O
(11 _ _ O
patients _ _ O
vs _ _ O
4 _ _ O
patients). _ _ O
Significantly _ _ O
greater _ _ O
reduction _ _ O
in _ _ O
depressive _ _ O
and _ _ O
anxiety _ _ O
symptoms, _ _ O
seizure _ _ O
frequency, _ _ O
and _ _ O
improvement _ _ O
in _ _ O
delayed _ _ O
memory _ _ O
was _ _ O
observed _ _ O
in _ _ O
the _ _ O
MT _ _ O
group _ _ O
compared _ _ O
with _ _ O
the _ _ O
SS _ _ O
group. _ _ O
We _ _ O
found _ _ O
benefits _ _ O
of _ _ O
short-term _ _ O
psychotherapy _ _ O
on _ _ O
patients _ _ O
with _ _ O
drug-resistant _ _ O
epilepsy. _ _ O
Mindfulness _ _ O
therapy _ _ O
was _ _ O
associated _ _ O
with _ _ O
greater _ _ O
benefits _ _ O
than _ _ O
SS _ _ O
alone _ _ O
in _ _ O
quality _ _ O
of _ _ O
life, _ _ O
mood, _ _ O
seizure _ _ O
frequency, _ _ O
and _ _ O
verbal _ _ O
memory. _ _ O
This _ _ O
study _ _ O
provides _ _ O
Class _ _ O
II _ _ O
evidence _ _ O
that _ _ O
mindfulness-based _ _ O
therapy _ _ O
significantly _ _ O
improves _ _ O
quality _ _ O
of _ _ O
life _ _ O
in _ _ O
patients _ _ O
with _ _ O
drug-resistant _ _ O
epilepsy. _ _ O


-DOCSTART- -X- -X- O

Few _ _ O
randomized, _ _ O
controlled _ _ O
trials _ _ O
evaluating _ _ O
antiepileptic _ _ O
drug _ _ O
(AED) _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
have _ _ O
focused _ _ O
solely _ _ O
on _ _ O
patients _ _ B-Patient
with _ _ I-Patient
juvenile _ _ I-Patient
myoclonic _ _ I-Patient
epilepsy _ _ I-Patient
(JME). _ _ I-Patient
We _ _ O
conducted _ _ O
a _ _ O
pilot, _ _ O
randomized _ _ O
controlled _ _ O
trial _ _ O
comparing _ _ O
topiramate _ _ B-Intervention
(N=19) _ _ O
and _ _ O
valproate _ _ B-Control
(N=9) _ _ O
in _ _ O
adolescents/adults _ _ B-Patient
with _ _ I-Patient
JME _ _ I-Patient
to _ _ O
evaluate _ _ O
clinical _ _ O
response _ _ O
when _ _ O
these _ _ O
broad-spectrum _ _ O
agents _ _ O
are _ _ O
titrated _ _ O
to _ _ O
optimal _ _ O
effect. _ _ O
Rating _ _ O
scales _ _ O
were _ _ O
used _ _ O
to _ _ O
systematically _ _ O
assess _ _ O
tolerability. _ _ O
Among _ _ B-Outcome
patients _ _ I-Outcome
completing _ _ I-Outcome
26 _ _ I-Outcome
weeks _ _ I-Outcome
of _ _ I-Outcome
treatment, _ _ I-Outcome
8 _ _ I-Outcome
of _ _ I-Outcome
12 _ _ I-Outcome
(67%) _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
topiramate _ _ I-Outcome
group _ _ I-Outcome
and _ _ I-Outcome
4 _ _ I-Outcome
of _ _ I-Outcome
7 _ _ I-Outcome
(57%) _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
valproate _ _ I-Outcome
group _ _ I-Outcome
were _ _ I-Outcome
seizure-free _ _ I-Outcome
during _ _ I-Outcome
the _ _ I-Outcome
12-week _ _ I-Outcome
maintenance _ _ I-Outcome
period. _ _ I-Outcome
Median _ _ O
daily _ _ O
dose _ _ O
was _ _ O
250mg _ _ O
topiramate _ _ O
or _ _ O
750mg _ _ O
valproate. _ _ O
Two _ _ O
(11%) _ _ O
topiramate-treated _ _ O
patients _ _ O
and _ _ O
one _ _ O
(11%) _ _ O
valproate-treated _ _ O
patient _ _ O
discontinued _ _ O
due _ _ O
to _ _ O
adverse _ _ O
events. _ _ O
Systemic _ _ O
toxicity _ _ O
scores, _ _ O
but _ _ O
not _ _ O
neurotoxicity _ _ O
scores, _ _ O
differed _ _ O
substantially _ _ O
between _ _ O
the _ _ O
two _ _ O
groups; _ _ O
greater _ _ O
systemic _ _ O
toxicity _ _ O
was _ _ O
associated _ _ O
with _ _ O
valproate. _ _ O
Our _ _ O
preliminary _ _ O
findings _ _ O
that _ _ O
topiramate _ _ O
may _ _ O
be _ _ O
an _ _ O
effective, _ _ O
well-tolerated _ _ O
alternative _ _ O
to _ _ O
valproate _ _ O
warrant _ _ O
validation _ _ O
in _ _ O
a _ _ O
double-blind _ _ O
trial. _ _ O


-DOCSTART- -X- -X- O

The _ _ B-Intervention
Program _ _ I-Intervention
of _ _ I-Intervention
Active _ _ I-Intervention
Consumer _ _ I-Intervention
Engagement _ _ I-Intervention
in _ _ I-Intervention
Self-Management _ _ I-Intervention
in _ _ I-Intervention
Epilepsy _ _ I-Intervention
(PACES) _ _ I-Intervention
is _ _ O
an _ _ O
evidenced-based _ _ O
self-management _ _ O
intervention _ _ O
for _ _ O
adults _ _ B-Patient
with _ _ I-Patient
epilepsy. _ _ I-Patient
Prior _ _ O
randomized _ _ O
controlled _ _ O
trial _ _ O
(RCT) _ _ O
data _ _ O
show _ _ O
that _ _ O
PACES _ _ B-Intervention
reduces _ _ O
depression _ _ O
and _ _ O
improves _ _ O
self-management, _ _ O
self-efficacy, _ _ O
and _ _ O
quality _ _ O
of _ _ O
life _ _ O
for _ _ O
6 _ _ O
months _ _ O
postprogram. _ _ O
The _ _ O
objective _ _ O
of _ _ O
this _ _ O
study _ _ O
was _ _ O
to _ _ O
replicate _ _ O
a _ _ O
PACES _ _ B-Intervention
RCT _ _ O
with _ _ O
key _ _ O
extensions: _ _ O
more _ _ O
diverse _ _ O
patient _ _ O
pool _ _ O
from _ _ O
community-based _ _ O
epilepsy _ _ O
centers; _ _ O
option _ _ O
for _ _ O
telephone-based _ _ O
participation; _ _ O
and _ _ O
longer _ _ O
follow-up _ _ O
(12 _ _ O
months _ _ O
with _ _ O
booster _ _ O
support _ _ O
for _ _ O
intervention _ _ O
group), _ _ O
to _ _ O
examine _ _ O
duration _ _ O
of _ _ O
impact _ _ O
and _ _ O
inform _ _ O
dissemination _ _ O
and _ _ O
implementation. _ _ O
Participants _ _ B-Patient
were _ _ I-Patient
adults _ _ I-Patient
with _ _ I-Patient
chronic _ _ I-Patient
epilepsy _ _ I-Patient
(n _ _ I-Patient
= _ _ I-Patient
101) _ _ I-Patient
without _ _ I-Patient
serious _ _ I-Patient
mental _ _ I-Patient
illness _ _ I-Patient
or _ _ I-Patient
substantive _ _ I-Patient
intellectual _ _ I-Patient
impairment, _ _ I-Patient
recruited _ _ O
from _ _ O
three _ _ O
epilepsy _ _ O
centers. _ _ O
Participants _ _ O
were _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
intervention _ _ O
or _ _ O
waitlist _ _ O
control _ _ O
groups. _ _ O
Outcomes _ _ O
included _ _ O
the _ _ O
Epilepsy _ _ O
Self-Management _ _ O
Scale _ _ O
(ESMS), _ _ O
Epilepsy _ _ O
Self-Efficacy _ _ O
Scale _ _ O
(ESES), _ _ O
Quality _ _ O
of _ _ O
Life _ _ O
in _ _ O
Epilepsy-31, _ _ O
Patient _ _ O
Health _ _ O
Questionnaire-9, _ _ O
and _ _ O
Generalized _ _ O
Anxiety _ _ O
Disorder-7, _ _ O
administered _ _ O
at _ _ O
baseline, _ _ O
postintervention _ _ O
(8 _ _ O
weeks), _ _ O
and _ _ O
6 _ _ O
and _ _ O
12 _ _ O
months _ _ O
postintervention. _ _ O
Intervention _ _ O
was _ _ O
an _ _ O
8-week _ _ O
group _ _ O
of _ _ O
five _ _ O
to _ _ O
eight _ _ O
adults _ _ O
co-led _ _ O
by _ _ O
a _ _ O
psychologist _ _ O
and _ _ O
trained _ _ O
peer _ _ O
with _ _ O
epilepsy _ _ O
that _ _ O
met _ _ O
once _ _ O
per _ _ O
week _ _ O
by _ _ O
teleconference _ _ O
or _ _ O
in _ _ O
person _ _ O
at _ _ O
a _ _ O
hospital _ _ O
for _ _ O
60-75 _ _ O
minutes. _ _ O
Topics _ _ O
included _ _ O
medical, _ _ O
psychosocial, _ _ O
cognitive, _ _ O
and _ _ O
self-management _ _ O
aspects _ _ O
of _ _ O
epilepsy, _ _ O
as _ _ O
well _ _ O
as _ _ O
community _ _ O
integration _ _ O
and _ _ O
epilepsy-related _ _ O
communication. _ _ O
Treatment _ _ O
group _ _ O
provided _ _ O
program _ _ O
evaluation. _ _ O
PACES _ _ O
participants _ _ O
(n _ _ O
= _ _ O
49) _ _ O
improved _ _ O
relative _ _ O
to _ _ O
controls _ _ O
(n _ _ O
= _ _ O
52) _ _ O
on _ _ O
the _ _ O
ESES _ _ O
(P _ _ O
< _ _ O
.022) _ _ O
and _ _ O
overall _ _ O
distress _ _ O
composite _ _ O
(P _ _ O
= _ _ O
.008). _ _ O
At _ _ O
6 _ _ O
months, _ _ O
PACES _ _ O
participants _ _ O
remained _ _ O
improved _ _ O
on _ _ O
the _ _ O
ESES _ _ O
(P _ _ O
= _ _ O
.008) _ _ O
and _ _ O
composite _ _ O
(P _ _ O
= _ _ O
.001), _ _ O
and _ _ O
were _ _ O
improved _ _ O
on _ _ O
the _ _ O
ESMS _ _ O
(P _ _ O
= _ _ O
.005). _ _ O
At _ _ O
12 _ _ O
months, _ _ O
PACES _ _ O
participants _ _ O
remained _ _ O
improved _ _ O
on _ _ O
the _ _ O
ESMS _ _ O
(P _ _ O
= _ _ O
.006) _ _ O
and _ _ O
were _ _ O
improved _ _ O
on _ _ O
an _ _ O
overall _ _ O
distress _ _ O
composite _ _ O
of _ _ O
combined _ _ O
measures _ _ O
(P _ _ O
= _ _ O
.018). _ _ O
Attrition _ _ O
was _ _ O
low _ _ O
(<6% _ _ O
in _ _ O
each _ _ O
group), _ _ O
and _ _ O
all _ _ O
program _ _ O
satisfaction _ _ O
ratings _ _ O
exceeded _ _ O
4.0/5.0. _ _ O
A _ _ O
consumer-generated _ _ O
epilepsy _ _ O
self-management _ _ O
program _ _ O
with _ _ O
broad _ _ O
psychosocial _ _ O
and _ _ O
medical _ _ O
emphasis _ _ O
can _ _ O
be _ _ O
effectively _ _ O
delivered _ _ O
by _ _ O
telephone _ _ O
or _ _ O
in _ _ O
person _ _ O
and _ _ O
facilitates _ _ O
long-term _ _ O
epilepsy _ _ O
self-management, _ _ O
adjustment, _ _ O
and _ _ O
coping _ _ O
up _ _ O
to _ _ O
1 _ _ O
year _ _ O
after _ _ O
treatment. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
determine _ _ O
the _ _ O
neurocognitive _ _ O
deficits _ _ O
associated _ _ O
with _ _ O
newly _ _ B-Patient
diagnosed _ _ I-Patient
untreated _ _ I-Patient
childhood _ _ I-Patient
absence _ _ I-Patient
epilepsy _ _ I-Patient
(CAE), _ _ I-Patient
develop _ _ O
a _ _ O
model _ _ O
describing _ _ O
the _ _ O
factorial _ _ O
structure _ _ O
of _ _ O
items _ _ O
measuring _ _ O
academic _ _ O
achievement _ _ O
and _ _ O
3 _ _ O
neuropsychological _ _ O
constructs, _ _ O
and _ _ O
determine _ _ O
short-term _ _ O
differential _ _ O
neuropsychological _ _ O
effects _ _ O
on _ _ O
attention _ _ O
among _ _ O
ethosuximide, _ _ B-Intervention
valproic _ _ I-Intervention
acid, _ _ I-Intervention
and _ _ O
lamotrigine. _ _ B-Control
Subjects _ _ B-Patient
with _ _ I-Patient
newly _ _ I-Patient
diagnosed _ _ I-Patient
CAE _ _ I-Patient
entering _ _ O
a _ _ O
double-blind, _ _ O
randomized _ _ O
controlled _ _ O
clinical _ _ O
trial _ _ O
had _ _ O
neuropsychological _ _ O
testing _ _ O
including _ _ O
assessments _ _ O
of _ _ O
general _ _ O
intellectual _ _ O
functioning, _ _ O
attention, _ _ O
memory, _ _ O
executive _ _ O
function, _ _ O
and _ _ O
achievement. _ _ O
Attention _ _ O
was _ _ O
reassessed _ _ O
at _ _ O
the _ _ O
week _ _ O
16-20 _ _ O
visit. _ _ O
At _ _ O
study _ _ O
entry, _ _ O
36% _ _ O
of _ _ O
the _ _ O
cohort _ _ O
exhibited _ _ O
attention _ _ O
deficits _ _ O
despite _ _ O
otherwise _ _ O
intact _ _ O
neurocognitive _ _ O
functioning. _ _ O
Structural _ _ O
equation _ _ O
modeling _ _ O
of _ _ O
baseline _ _ O
neuropsychological _ _ O
data _ _ O
revealed _ _ O
a _ _ O
direct _ _ O
sequential _ _ O
effect _ _ O
among _ _ O
attention, _ _ O
memory, _ _ O
executive _ _ O
function, _ _ O
and _ _ O
academic _ _ O
achievement. _ _ O
At _ _ B-Outcome
the _ _ I-Outcome
week _ _ I-Outcome
16-20 _ _ I-Outcome
visit, _ _ I-Outcome
attention _ _ I-Outcome
deficits _ _ I-Outcome
persisted _ _ I-Outcome
even _ _ I-Outcome
if _ _ I-Outcome
seizure _ _ I-Outcome
freedom _ _ I-Outcome
was _ _ I-Outcome
attained. _ _ I-Outcome
More _ _ B-Outcome
subjects _ _ I-Outcome
receiving _ _ I-Outcome
valproic _ _ I-Outcome
acid _ _ I-Outcome
(49%) _ _ I-Outcome
had _ _ I-Outcome
attention _ _ I-Outcome
deficits _ _ I-Outcome
than _ _ I-Outcome
subjects _ _ I-Outcome
receiving _ _ I-Outcome
ethosuximide _ _ I-Outcome
(32%) _ _ I-Outcome
or _ _ I-Outcome
lamotrigine _ _ I-Outcome
(24%) _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.0006). _ _ I-Outcome
Parental _ _ O
assessment _ _ O
did _ _ O
not _ _ O
reliably _ _ O
detect _ _ O
attention _ _ O
deficits _ _ O
before _ _ O
or _ _ O
after _ _ O
treatment _ _ O
(p _ _ O
< _ _ O
0.0001). _ _ O
Children _ _ O
with _ _ O
CAE _ _ O
have _ _ O
a _ _ O
high _ _ O
rate _ _ O
of _ _ O
pretreatment _ _ O
attentional _ _ O
deficits _ _ O
that _ _ O
persist _ _ O
despite _ _ O
seizure _ _ O
freedom. _ _ O
Rates _ _ O
are _ _ O
disproportionately _ _ O
higher _ _ O
for _ _ O
valproic _ _ O
acid _ _ O
treatment _ _ O
compared _ _ O
with _ _ O
ethosuximide _ _ O
or _ _ O
lamotrigine. _ _ O
Parents _ _ O
do _ _ O
not _ _ O
recognize _ _ O
these _ _ O
attentional _ _ O
deficits. _ _ O
These _ _ O
deficits _ _ O
present _ _ O
a _ _ O
threat _ _ O
to _ _ O
academic _ _ O
achievement. _ _ O
Vigilant _ _ O
cognitive _ _ O
and _ _ O
behavioral _ _ O
assessment _ _ O
of _ _ O
these _ _ O
children _ _ O
is _ _ O
warranted. _ _ O
This _ _ O
study _ _ O
provides _ _ O
Class _ _ O
I _ _ O
evidence _ _ O
that _ _ O
valproic _ _ O
acid _ _ O
is _ _ O
associated _ _ O
with _ _ O
more _ _ O
significant _ _ O
attentional _ _ O
dysfunction _ _ O
than _ _ O
ethosuximide _ _ O
or _ _ O
lamotrigine _ _ O
in _ _ O
children _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
CAE. _ _ O


-DOCSTART- -X- -X- O

We _ _ O
evaluated _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
deep _ _ B-Intervention
brain _ _ I-Intervention
anterior _ _ I-Intervention
thalamus _ _ I-Intervention
stimulation _ _ I-Intervention
after _ _ O
7 _ _ O
and _ _ O
10 _ _ O
years, _ _ O
and _ _ O
report _ _ O
the _ _ O
incidence _ _ O
of _ _ O
sudden _ _ O
unexpected _ _ O
death _ _ O
in _ _ O
epilepsy _ _ O
(SUDEP) _ _ O
and _ _ O
overall _ _ O
mortality _ _ O
in _ _ O
adults _ _ O
in _ _ O
the _ _ O
Stimulation _ _ O
of _ _ O
the _ _ O
Anterior _ _ O
Nucleus _ _ O
of _ _ O
the _ _ O
Thalamus _ _ O
for _ _ O
Epilepsy _ _ O
(SANTÉ) _ _ O
study. _ _ O
After _ _ O
the _ _ O
3-month _ _ O
blinded _ _ O
and _ _ O
9-month _ _ O
unblinded _ _ O
phases, _ _ O
subjects _ _ O
continued _ _ O
to _ _ O
be _ _ O
assessed _ _ O
during _ _ O
long-term _ _ O
follow-up _ _ O
(LTFU) _ _ O
and _ _ O
later _ _ O
a _ _ O
continued _ _ O
therapy _ _ O
access _ _ O
phase _ _ O
(CAP), _ _ O
to _ _ O
further _ _ O
characterize _ _ O
adverse _ _ O
events _ _ O
and _ _ O
the _ _ O
incidence _ _ O
of _ _ O
SUDEP. _ _ O
Stimulus _ _ O
parameter _ _ O
and _ _ O
medication _ _ O
changes _ _ O
were _ _ O
allowed. _ _ O
One _ _ O
hundred _ _ O
ten _ _ O
implanted _ _ O
subjects _ _ O
accumulated _ _ O
a _ _ O
total _ _ O
of _ _ O
938 _ _ O
device-years _ _ O
of _ _ O
experience _ _ O
(69 _ _ O
subjects _ _ O
during _ _ O
the _ _ O
LTFU _ _ O
phase _ _ O
and _ _ O
61 _ _ O
subjects _ _ O
in _ _ O
the _ _ O
CAP _ _ O
phase). _ _ O
Prior _ _ O
to _ _ O
study _ _ O
closure, _ _ O
57 _ _ O
active _ _ O
subjects _ _ O
continued _ _ O
therapy _ _ O
at _ _ O
14 _ _ O
study _ _ O
centers, _ _ O
with _ _ O
follow-up _ _ O
of _ _ O
at _ _ O
least _ _ O
10 _ _ O
(maximum _ _ O
14) _ _ O
years. _ _ O
At _ _ O
7 _ _ O
years, _ _ O
median _ _ O
seizure _ _ O
frequency _ _ O
percent _ _ O
reduction _ _ O
from _ _ O
baseline _ _ O
was _ _ O
75% _ _ O
(p _ _ O
< _ _ O
.001), _ _ O
with _ _ O
no _ _ O
outcome _ _ O
differences _ _ O
related _ _ O
to _ _ O
prior _ _ O
vagus _ _ O
nerve _ _ O
stimulation _ _ O
or _ _ O
resective _ _ O
surgery. _ _ O
The _ _ O
most _ _ O
severe _ _ O
seizure _ _ O
type, _ _ O
focal _ _ O
to _ _ O
bilateral _ _ O
tonic-clonic, _ _ O
was _ _ O
reduced _ _ O
by _ _ O
71%. _ _ O
Adding _ _ O
new _ _ O
antiseizure _ _ O
medications _ _ O
did _ _ O
not _ _ O
impact _ _ O
the _ _ O
pattern _ _ O
of _ _ O
seizure _ _ O
reduction _ _ O
over _ _ O
time. _ _ O
There _ _ O
were _ _ O
no _ _ O
unanticipated _ _ O
serious _ _ O
adverse _ _ O
events _ _ O
in _ _ O
the _ _ O
study. _ _ O
The _ _ O
definite-plus-probable _ _ O
SUDEP _ _ O
rate, _ _ O
based _ _ O
on _ _ O
SANTÉ _ _ O
study _ _ O
experience _ _ O
(two _ _ O
deaths _ _ O
in _ _ O
938 _ _ O
years) _ _ O
and _ _ O
previous _ _ O
pilot _ _ O
studies _ _ O
(0 _ _ O
deaths _ _ O
in _ _ O
76 _ _ O
years), _ _ O
indicated _ _ O
a _ _ O
rate _ _ O
of _ _ O
2.0 _ _ O
deaths _ _ O
for _ _ O
1000 _ _ O
person-years. _ _ O
Overall _ _ O
mortality _ _ O
was _ _ O
6.9 _ _ O
deaths _ _ O
per _ _ O
1000 _ _ O
person-years. _ _ O
The _ _ O
long-term _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
profiles _ _ O
of _ _ O
the _ _ O
deep _ _ O
brain _ _ O
stimulation _ _ O
(DBS) _ _ O
system _ _ O
for _ _ O
epilepsy _ _ O
are _ _ O
favorable _ _ O
and _ _ O
demonstrate _ _ O
stable _ _ O
outcomes. _ _ O
Improvement _ _ O
in _ _ O
frequency _ _ O
of _ _ O
the _ _ O
most _ _ O
severe _ _ O
seizure _ _ O
type _ _ O
may _ _ O
reduce _ _ O
SUDEP _ _ O
risk. _ _ O
The _ _ O
SUDEP _ _ O
rate _ _ O
with _ _ O
DBS _ _ O
(2.0) _ _ O
is _ _ O
comparable _ _ O
to _ _ O
other _ _ O
neuromodulation _ _ O
treatments _ _ O
(i.e., _ _ O
vagus _ _ O
nerve _ _ O
stimulation, _ _ O
responsive _ _ O
neurostimulation) _ _ O
for _ _ O
drug-resistant _ _ O
focal _ _ O
epilepsy. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
safety _ _ O
and _ _ O
preliminary _ _ O
pharmacokinetics _ _ O
of _ _ O
a _ _ B-Intervention
pharmaceutical _ _ I-Intervention
formulation _ _ I-Intervention
of _ _ I-Intervention
purified _ _ I-Intervention
cannabidiol _ _ I-Intervention
(CBD) _ _ I-Intervention
in _ _ O
children _ _ B-Patient
with _ _ I-Patient
Dravet _ _ I-Patient
syndrome. _ _ I-Patient
Patients _ _ B-Patient
aged _ _ I-Patient
4-10 _ _ I-Patient
years _ _ I-Patient
were _ _ O
randomized _ _ O
4:1 _ _ O
to _ _ O
CBD _ _ B-Intervention
(5, _ _ I-Intervention
10, _ _ I-Intervention
or _ _ I-Intervention
20 _ _ I-Intervention
mg/kg/d) _ _ I-Intervention
or _ _ O
placebo _ _ B-Control
taken _ _ I-Control
twice _ _ I-Control
daily. _ _ I-Control
The _ _ O
double-blind _ _ O
trial _ _ O
comprised _ _ O
4-week _ _ O
baseline, _ _ O
3-week _ _ O
treatment _ _ O
(including _ _ O
titration), _ _ O
10-day _ _ O
taper, _ _ O
and _ _ O
4-week _ _ O
follow-up _ _ O
periods. _ _ O
Completers _ _ O
could _ _ O
continue _ _ O
in _ _ O
an _ _ O
open-label _ _ O
extension. _ _ O
Multiple _ _ O
pharmacokinetic _ _ O
blood _ _ O
samples _ _ O
were _ _ O
taken _ _ O
on _ _ O
the _ _ O
first _ _ O
day _ _ O
of _ _ O
dosing _ _ O
and _ _ O
at _ _ O
end _ _ O
of _ _ O
treatment _ _ O
for _ _ O
measurement _ _ O
of _ _ O
CBD, _ _ O
its _ _ O
metabolites _ _ O
6-OH-CBD, _ _ O
7-OH-CBD, _ _ O
and _ _ O
7-COOH-CBD, _ _ O
and _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs; _ _ O
clobazam _ _ O
and _ _ O
metabolite _ _ O
N-desmethylclobazam _ _ O
[N-CLB], _ _ O
valproate, _ _ O
levetiracetam, _ _ O
topiramate, _ _ O
and _ _ O
stiripentol). _ _ O
Safety _ _ O
assessments _ _ O
were _ _ O
clinical _ _ O
laboratory _ _ O
tests, _ _ O
physical _ _ O
examinations, _ _ O
vital _ _ O
signs, _ _ O
ECGs, _ _ O
adverse _ _ O
events _ _ O
(AEs), _ _ O
seizure _ _ O
frequency, _ _ O
and _ _ O
suicidality. _ _ O
Thirty-four _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
(10, _ _ O
8, _ _ O
and _ _ O
9 _ _ O
to _ _ O
the _ _ O
5, _ _ O
10, _ _ O
and _ _ O
20 _ _ O
mg/kg/d _ _ O
CBD _ _ O
groups, _ _ O
and _ _ O
7 _ _ O
to _ _ O
placebo); _ _ O
32 _ _ O
(94%) _ _ O
completed _ _ O
treatment. _ _ O
Exposure _ _ O
to _ _ O
CBD _ _ O
and _ _ O
its _ _ O
metabolites _ _ O
was _ _ O
dose-proportional _ _ O
(AUC0-t). _ _ O
CBD _ _ O
did _ _ O
not _ _ O
affect _ _ O
concomitant _ _ O
AED _ _ O
levels, _ _ O
apart _ _ O
from _ _ O
an _ _ O
increase _ _ O
in _ _ O
N-CLB _ _ O
(except _ _ O
in _ _ O
patients _ _ O
taking _ _ O
stiripentol). _ _ O
The _ _ O
most _ _ O
common _ _ O
AEs _ _ O
on _ _ O
CBD _ _ O
were _ _ O
pyrexia, _ _ O
somnolence, _ _ O
decreased _ _ O
appetite, _ _ O
sedation, _ _ O
vomiting, _ _ O
ataxia, _ _ O
and _ _ O
abnormal _ _ O
behavior. _ _ O
Six _ _ O
patients _ _ O
taking _ _ O
CBD _ _ O
and _ _ O
valproate _ _ O
developed _ _ O
elevated _ _ O
transaminases; _ _ O
none _ _ O
met _ _ O
criteria _ _ O
for _ _ O
drug-induced _ _ O
liver _ _ O
injury _ _ O
and _ _ O
all _ _ O
recovered. _ _ O
No _ _ O
other _ _ O
clinically _ _ O
relevant _ _ O
safety _ _ O
signals _ _ O
were _ _ O
observed. _ _ O
Exposure _ _ O
to _ _ O
CBD _ _ O
and _ _ O
its _ _ O
metabolites _ _ O
increased _ _ O
proportionally _ _ O
with _ _ O
dose. _ _ O
An _ _ O
interaction _ _ O
with _ _ O
N-CLB _ _ O
was _ _ O
observed, _ _ O
likely _ _ O
related _ _ O
to _ _ O
CBD _ _ O
inhibition _ _ O
of _ _ O
cytochrome _ _ O
P450 _ _ O
subtype _ _ O
2C19. _ _ O
CBD _ _ O
resulted _ _ O
in _ _ O
more _ _ O
AEs _ _ O
than _ _ O
placebo _ _ O
but _ _ O
was _ _ O
generally _ _ O
well-tolerated. _ _ O
This _ _ O
study _ _ O
provides _ _ O
Class _ _ O
I _ _ O
evidence _ _ O
that _ _ O
for _ _ O
children _ _ O
with _ _ O
Dravet _ _ O
syndrome, _ _ O
CBD _ _ O
resulted _ _ O
in _ _ O
more _ _ O
AEs _ _ O
than _ _ O
placebo _ _ O
but _ _ O
was _ _ O
generally _ _ O
well-tolerated. _ _ O


-DOCSTART- -X- -X- O

Although _ _ O
generalized _ _ B-Patient
convulsive _ _ I-Patient
status _ _ I-Patient
epilepticus _ _ I-Patient
(GCSE) _ _ I-Patient
is _ _ O
a _ _ O
life-threatening _ _ O
emergency, _ _ O
evidence-based _ _ O
data _ _ O
to _ _ O
guide _ _ O
initial _ _ O
drug _ _ O
treatment _ _ O
choices _ _ O
are _ _ O
lacking _ _ O
in _ _ O
the _ _ B-Patient
Chinese _ _ I-Patient
population. _ _ I-Patient
We _ _ O
conducted _ _ O
this _ _ O
prospective, _ _ O
randomized, _ _ O
controlled _ _ O
trial _ _ O
to _ _ O
evaluate _ _ O
the _ _ O
relative _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
intravenous _ _ B-Intervention
phenobarbital _ _ I-Intervention
and _ _ O
valproate _ _ B-Control
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
GCSE. _ _ I-Patient
After _ _ O
the _ _ O
failure _ _ O
of _ _ O
first-line _ _ O
diazepam _ _ O
treatment, _ _ O
Chinese _ _ B-Patient
adult _ _ I-Patient
patients _ _ I-Patient
with _ _ I-Patient
GCSE _ _ I-Patient
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
either _ _ O
intravenous _ _ B-Intervention
phenobarbital _ _ I-Intervention
(standard _ _ I-Intervention
doses, _ _ I-Intervention
low _ _ I-Intervention
rate) _ _ I-Intervention
or _ _ O
valproate _ _ B-Control
(standard). _ _ I-Control
Successful _ _ B-Outcome
treatment _ _ I-Outcome
was _ _ I-Outcome
considered _ _ I-Outcome
when _ _ I-Outcome
clinical _ _ I-Outcome
and _ _ I-Outcome
electroencephalographic _ _ I-Outcome
seizure _ _ I-Outcome
activity _ _ I-Outcome
ceased. _ _ I-Outcome
Adverse _ _ O
events _ _ O
following _ _ O
treatment, _ _ O
as _ _ O
well _ _ O
as _ _ O
the _ _ O
neurological _ _ O
outcomes _ _ O
at _ _ O
discharge _ _ O
and _ _ O
3 _ _ O
months _ _ O
later, _ _ O
were _ _ O
also _ _ O
evaluated. _ _ O
Overall, _ _ O
73 _ _ O
cases _ _ O
were _ _ O
enrolled _ _ O
in _ _ O
the _ _ O
study. _ _ O
Intravenous _ _ B-Intervention
phenobarbital _ _ I-Intervention
was _ _ B-Outcome
successful _ _ I-Outcome
in _ _ I-Outcome
81.1% _ _ I-Outcome
of _ _ I-Outcome
patients, _ _ I-Outcome
and _ _ I-Outcome
intravenous _ _ I-Outcome
valproate _ _ I-Outcome
was _ _ I-Outcome
successful _ _ I-Outcome
in _ _ I-Outcome
44.4% _ _ I-Outcome
of _ _ I-Outcome
patients _ _ I-Outcome
(p _ _ I-Outcome
< _ _ I-Outcome
0.05). _ _ I-Outcome
The _ _ O
relapse _ _ O
rate _ _ O
of _ _ O
status _ _ O
epilepticus _ _ O
within _ _ O
24 _ _ O
h _ _ O
of _ _ O
receiving _ _ O
phenobarbital _ _ O
(6.7%) _ _ O
was _ _ O
significantly _ _ O
lower _ _ O
than _ _ O
that _ _ O
in _ _ O
patients _ _ O
receiving _ _ O
valproate _ _ O
(31.3%), _ _ O
and _ _ O
the _ _ O
total _ _ O
number _ _ O
of _ _ O
adverse _ _ O
events _ _ O
did _ _ O
not _ _ O
differ _ _ O
significantly _ _ O
between _ _ O
the _ _ O
two _ _ O
groups _ _ O
(p _ _ O
> _ _ O
0.05). _ _ O
In _ _ O
the _ _ O
phenobarbital _ _ O
group, _ _ O
two _ _ O
patients _ _ O
(5.4%) _ _ O
required _ _ O
ventilation _ _ O
and _ _ O
two _ _ O
patients _ _ O
(5.4%) _ _ O
developed _ _ O
serious _ _ O
hypotension. _ _ O
The _ _ O
neurological _ _ O
outcomes _ _ O
of _ _ O
the _ _ O
phenobarbital _ _ O
group _ _ O
were _ _ O
generally _ _ O
better _ _ O
than _ _ O
those _ _ O
of _ _ O
the _ _ O
valproate _ _ O
group; _ _ O
however, _ _ O
no _ _ O
significant _ _ O
differences _ _ O
were _ _ O
observed _ _ O
between _ _ O
phenobarbital _ _ O
and _ _ O
valproate _ _ O
with _ _ O
respect _ _ O
to _ _ O
mortality _ _ O
(8.1 _ _ O
vs. _ _ O
16.6%) _ _ O
at _ _ O
discharge, _ _ O
or _ _ O
mortality _ _ O
(16.2 _ _ O
vs. _ _ O
30.5%) _ _ O
and _ _ O
post-symptomatic _ _ O
epilepsy _ _ O
(26.3 _ _ O
vs. _ _ O
42.8%) _ _ O
at _ _ O
3-month _ _ O
follow-up. _ _ O
Intravenous _ _ O
phenobarbital _ _ O
appears _ _ O
to _ _ O
be _ _ O
more _ _ O
effective _ _ O
than _ _ O
intravenous _ _ O
valproate _ _ O
for _ _ O
Chinese _ _ O
adult _ _ O
patients _ _ O
with _ _ O
GCSE. _ _ O
The _ _ O
occurrence _ _ O
of _ _ O
serious _ _ O
respiratory _ _ O
depression _ _ O
and _ _ O
hypotension _ _ O
caused _ _ O
by _ _ O
phenobarbital _ _ O
was _ _ O
reduced _ _ O
by _ _ O
decreasing _ _ O
the _ _ O
intravenous _ _ O
infusion _ _ O
rate; _ _ O
however, _ _ O
even _ _ O
at _ _ O
a _ _ O
lower _ _ O
infusion _ _ O
rate _ _ O
than _ _ O
typically _ _ O
used _ _ O
in _ _ O
other _ _ O
institutions, _ _ O
intravenous _ _ O
phenobarbital _ _ O
resulted _ _ O
in _ _ O
more _ _ O
serious _ _ O
adverse _ _ O
events _ _ O
than _ _ O
intravenous _ _ O
valproate. _ _ O
The _ _ O
better _ _ O
outcomes _ _ O
in _ _ O
the _ _ O
phenobarbital _ _ O
group _ _ O
compared _ _ O
with _ _ O
the _ _ O
valproate _ _ O
group _ _ O
suggest _ _ O
that _ _ O
phenobarbital _ _ O
should _ _ O
be _ _ O
considered _ _ O
for _ _ O
the _ _ O
early _ _ O
successful _ _ O
treatment _ _ O
of _ _ O
GCSE. _ _ O


-DOCSTART- -X- -X- O

A _ _ O
double-blind, _ _ O
dose-controlled _ _ O
study _ _ O
evaluated _ _ O
topiramate _ _ B-Intervention
as _ _ I-Intervention
monotherapy _ _ I-Intervention
in _ _ O
470 _ _ O
patients _ _ B-Patient
with _ _ I-Patient
newly _ _ I-Patient
diagnosed _ _ I-Patient
(< _ _ I-Patient
or _ _ I-Patient
= _ _ I-Patient
3 _ _ I-Patient
months) _ _ I-Patient
epilepsy _ _ I-Patient
or _ _ I-Patient
epilepsy _ _ I-Patient
relapse _ _ I-Patient
in _ _ I-Patient
the _ _ I-Patient
absence _ _ I-Patient
of _ _ I-Patient
therapy. _ _ I-Patient
In _ _ B-Patient
addition _ _ I-Patient
to _ _ I-Patient
having _ _ I-Patient
at _ _ I-Patient
least _ _ I-Patient
2 _ _ I-Patient
lifetime-unprovoked _ _ I-Patient
seizures, _ _ I-Patient
patients _ _ I-Patient
had _ _ I-Patient
1 _ _ I-Patient
or _ _ I-Patient
2 _ _ I-Patient
partial-onset _ _ I-Patient
seizures _ _ I-Patient
or _ _ I-Patient
generalized-onset _ _ I-Patient
tonic-clonic _ _ I-Patient
seizures _ _ I-Patient
during _ _ I-Patient
a _ _ I-Patient
3-month _ _ I-Patient
retrospective _ _ I-Patient
baseline. _ _ I-Patient
The _ _ O
trial _ _ O
included _ _ O
a _ _ O
large _ _ O
cohort _ _ O
(N _ _ O
= _ _ O
151, _ _ O
32%) _ _ O
of _ _ O
children _ _ B-Patient
and _ _ I-Patient
adolescents _ _ I-Patient
6 _ _ I-Patient
to _ _ I-Patient
15 _ _ I-Patient
years _ _ I-Patient
of _ _ I-Patient
age. _ _ I-Patient
Eligible _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
treatment _ _ O
groups _ _ O
in _ _ O
which _ _ O
topiramate _ _ B-Control
was _ _ I-Control
titrated _ _ I-Control
to _ _ I-Control
target _ _ I-Control
maintenance _ _ I-Control
dosages _ _ I-Control
of _ _ I-Control
either _ _ B-Intervention
400 _ _ I-Intervention
mg/day _ _ I-Intervention
(n _ _ O
= _ _ O
77) _ _ O
or _ _ O
50 _ _ B-Control
mg/day _ _ I-Control
(n _ _ O
= _ _ O
74). _ _ O
Patients _ _ O
were _ _ O
followed _ _ O
for _ _ O
at _ _ O
least _ _ O
6 _ _ O
months. _ _ O
Based _ _ B-Outcome
on _ _ I-Outcome
Kaplan-Meier _ _ I-Outcome
analyses, _ _ I-Outcome
the _ _ I-Outcome
primary _ _ I-Outcome
efficacy _ _ I-Outcome
endpoint _ _ I-Outcome
of _ _ I-Outcome
time _ _ I-Outcome
to _ _ I-Outcome
first _ _ I-Outcome
seizure _ _ I-Outcome
favored _ _ I-Outcome
the _ _ I-Outcome
higher _ _ I-Outcome
topiramate _ _ I-Outcome
dose _ _ I-Outcome
in _ _ I-Outcome
both _ _ I-Outcome
the _ _ I-Outcome
overall _ _ I-Outcome
population _ _ I-Outcome
and _ _ I-Outcome
the _ _ I-Outcome
cohort _ _ I-Outcome
of _ _ I-Outcome
children/adolescents. _ _ I-Outcome
The _ _ O
probability _ _ O
that _ _ O
children/adolescents _ _ O
remaining _ _ O
in _ _ O
the _ _ O
study _ _ O
were _ _ O
seizure _ _ O
free _ _ O
at _ _ O
6 _ _ O
months _ _ O
was _ _ O
78% _ _ O
in _ _ O
the _ _ O
50-mg _ _ O
target _ _ O
dose _ _ O
group _ _ O
and _ _ O
90% _ _ O
with _ _ O
the _ _ O
higher _ _ O
dose. _ _ O
At _ _ O
12 _ _ O
months, _ _ O
the _ _ O
probability _ _ O
of _ _ O
being _ _ O
seizure _ _ O
free _ _ O
was _ _ O
62% _ _ O
and _ _ O
85%, _ _ O
respectively. _ _ O
The _ _ O
incidence _ _ O
of _ _ O
treatment-limiting _ _ O
adverse _ _ O
events _ _ O
was _ _ O
4% _ _ O
in _ _ O
the _ _ O
50-mg _ _ O
target _ _ O
dose _ _ O
group _ _ O
and _ _ O
14% _ _ O
in _ _ O
the _ _ O
group _ _ O
assigned _ _ O
to _ _ O
400 _ _ O
mg _ _ O
as _ _ O
a _ _ O
target _ _ O
dose. _ _ O
The _ _ O
most _ _ O
common _ _ O
adverse _ _ O
events, _ _ O
excluding _ _ O
typical _ _ O
childhood _ _ O
illnesses, _ _ O
were _ _ O
headache, _ _ O
appetite _ _ O
decrease, _ _ O
weight _ _ O
loss, _ _ O
somnolence, _ _ O
dizziness, _ _ O
concentration/attention _ _ O
difficulty, _ _ O
and _ _ O
paresthesia. _ _ O
As _ _ O
shown _ _ O
in _ _ O
this _ _ O
subset _ _ O
analysis, _ _ O
topiramate _ _ O
is _ _ O
effective _ _ O
and _ _ O
well _ _ O
tolerated _ _ O
as _ _ O
monotherapy _ _ O
in _ _ O
children _ _ O
and _ _ O
adolescents. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
levetiracetam _ _ B-Intervention
or _ _ O
oxcarbazepine _ _ B-Control
as _ _ I-Control
monotherapy _ _ I-Control
in _ _ O
children _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
benign _ _ O
epilepsy _ _ O
with _ _ O
centrotemporal _ _ O
spikes _ _ O
(BECTS). _ _ O
Twenty-one _ _ O
children _ _ O
(11 _ _ O
males, _ _ O
10 _ _ O
females), _ _ O
aged _ _ O
between _ _ O
5 _ _ O
and _ _ O
13 _ _ O
years _ _ O
(mean _ _ O
10.5 _ _ O
years), _ _ O
and _ _ O
18 _ _ O
(10 _ _ O
M, _ _ O
8 _ _ O
F), _ _ O
aged _ _ O
between _ _ O
3.3 _ _ O
and _ _ O
14 _ _ O
years _ _ O
(mean _ _ O
8.4 _ _ O
years), _ _ O
were _ _ O
randomised _ _ O
to _ _ O
receive _ _ O
monotherapy _ _ O
with _ _ O
levetiracetam _ _ O
or _ _ O
oxcarbazepine, _ _ O
respectively. _ _ O
LEV _ _ O
was _ _ O
titrated _ _ O
up _ _ O
to _ _ O
20-30 _ _ O
mg/kg/once _ _ O
or _ _ O
twice _ _ O
a _ _ O
day, _ _ O
and _ _ O
OXC _ _ O
up _ _ O
to _ _ O
20-35 _ _ O
mg/kg _ _ O
once _ _ O
or _ _ O
twice _ _ O
a _ _ O
day. _ _ O
Thirty-nine _ _ O
consecutive _ _ O
children _ _ O
(21 _ _ O
males, _ _ O
18 _ _ O
females), _ _ O
aged _ _ O
between _ _ O
3.3 _ _ O
and _ _ O
14 _ _ O
years _ _ O
(mean _ _ O
10.7 _ _ O
years), _ _ O
were _ _ O
recruited _ _ O
into _ _ O
the _ _ O
study. _ _ O
Twenty-one _ _ O
were _ _ O
randomised _ _ O
on _ _ O
LEV _ _ O
(11 _ _ O
male, _ _ O
10 _ _ O
female; _ _ O
mean _ _ O
age _ _ O
10.5 _ _ O
years), _ _ O
and _ _ O
18 _ _ O
on _ _ O
OXC _ _ O
(10 _ _ O
male, _ _ O
8 _ _ O
female; _ _ O
mean _ _ O
age _ _ O
8.4 _ _ O
years). _ _ O
After _ _ O
a _ _ O
mean _ _ O
follow-up _ _ O
period _ _ O
of _ _ O
18.5 _ _ O
months _ _ O
(range _ _ O
12-24 _ _ O
months), _ _ O
19 _ _ O
out _ _ O
of _ _ O
21 _ _ O
patients _ _ O
(90.5%) _ _ O
on _ _ O
levetiracetam, _ _ O
and _ _ O
13 _ _ O
out _ _ O
of _ _ O
18 _ _ O
(72,22%) _ _ O
on _ _ O
oxcarbazepine _ _ O
did _ _ O
not _ _ O
have _ _ O
further _ _ O
seizures. _ _ O
Mean _ _ O
serum _ _ O
level _ _ O
of _ _ O
LEV _ _ O
was _ _ O
4.1 _ _ O
microg/ml _ _ O
(range _ _ O
1.3-9.0), _ _ O
and _ _ O
of _ _ O
OXC _ _ O
was _ _ O
15.2 _ _ O
microg/ml _ _ O
(range _ _ O
4.2-27.5). _ _ O
Adverse _ _ O
side _ _ O
effects _ _ O
on _ _ O
LEV _ _ O
were _ _ O
reported _ _ O
in _ _ O
3 _ _ O
children _ _ O
(14.3%), _ _ O
represented _ _ O
by _ _ O
mild _ _ O
and _ _ O
transient _ _ O
decreased _ _ O
appetite _ _ O
(2) _ _ O
and _ _ O
cephalalgia _ _ O
(1). _ _ O
They _ _ O
were _ _ O
reported _ _ O
on _ _ O
OXC _ _ O
in _ _ O
2/18 _ _ O
(11.1%), _ _ O
including _ _ O
headache _ _ O
(1), _ _ O
and _ _ O
sedation _ _ O
(1). _ _ O
These _ _ O
preliminary _ _ O
data _ _ O
from _ _ O
an _ _ O
open, _ _ O
parallel _ _ O
group _ _ O
study _ _ O
suggest _ _ O
that _ _ O
levetiracetam _ _ O
and _ _ O
oxcarbazepine _ _ O
may _ _ O
be _ _ O
potentially _ _ O
effective _ _ O
and _ _ O
well _ _ O
tolerated _ _ O
drugs _ _ O
for _ _ O
children _ _ O
with _ _ O
BECTS _ _ O
who _ _ O
require _ _ O
treatment. _ _ O


-DOCSTART- -X- -X- O

Treatment _ _ O
options _ _ O
for _ _ O
seizure _ _ O
clusters _ _ O
are _ _ O
limited; _ _ O
the _ _ O
need _ _ O
for _ _ O
easy-to-administer _ _ O
treatments _ _ O
remains. _ _ O
The _ _ O
Staccato _ _ O
system _ _ O
delivers _ _ O
drug _ _ O
deep _ _ O
into _ _ O
the _ _ O
lung _ _ O
via _ _ O
inhalation. _ _ O
In _ _ O
this _ _ O
phase _ _ O
2a _ _ O
study, _ _ O
we _ _ O
investigated _ _ O
the _ _ O
ability _ _ O
of _ _ O
three _ _ B-Intervention
different _ _ I-Intervention
doses _ _ I-Intervention
of _ _ I-Intervention
Staccato _ _ I-Intervention
alprazolam _ _ I-Intervention
to _ _ O
suppress _ _ O
the _ _ O
electroencephalographic _ _ B-Patient
(EEG) _ _ I-Patient
photoparoxysmal _ _ I-Patient
response _ _ I-Patient
(PPR) _ _ I-Patient
compared _ _ O
with _ _ O
placebo _ _ B-Control
in _ _ O
participants _ _ B-Patient
with _ _ I-Patient
photosensitive _ _ I-Patient
seizures. _ _ I-Patient
Adults _ _ B-Patient
(18-60 _ _ I-Patient
years) _ _ I-Patient
with _ _ I-Patient
a _ _ I-Patient
diagnosis _ _ I-Patient
and _ _ I-Patient
history _ _ I-Patient
of _ _ I-Patient
PPR _ _ I-Patient
on _ _ I-Patient
EEG _ _ I-Patient
with _ _ I-Patient
or _ _ I-Patient
without _ _ I-Patient
an _ _ I-Patient
epilepsy _ _ I-Patient
diagnosis _ _ I-Patient
were _ _ O
eligible _ _ O
to _ _ O
participate. _ _ O
Participants _ _ O
received _ _ O
Staccato _ _ B-Intervention
alprazolam _ _ I-Intervention
0.5, _ _ I-Intervention
1.0, _ _ I-Intervention
and _ _ I-Intervention
2.0 _ _ I-Intervention
mg, _ _ I-Intervention
and _ _ O
Staccato _ _ B-Control
placebo _ _ I-Control
(twice) _ _ I-Control
in _ _ O
random _ _ O
order. _ _ O
Intermittent _ _ O
photic _ _ O
stimulation _ _ O
and _ _ O
clinical _ _ O
assessments _ _ O
were _ _ O
performed _ _ O
at _ _ O
one _ _ O
predose _ _ O
and _ _ O
seven _ _ O
postdose _ _ O
time _ _ O
points. _ _ O
The _ _ O
primary _ _ O
endpoint _ _ O
of _ _ O
the _ _ O
study _ _ O
was _ _ O
the _ _ O
change _ _ O
in _ _ O
standardized _ _ B-Outcome
photosensitivity _ _ I-Outcome
range _ _ I-Outcome
(SPR) _ _ I-Outcome
in _ _ O
participants _ _ O
receiving _ _ O
each _ _ O
dose _ _ O
of _ _ O
Staccato _ _ B-Intervention
alprazolam. _ _ I-Intervention
Fifteen _ _ O
participants _ _ B-Patient
with _ _ I-Patient
a _ _ I-Patient
prior _ _ I-Patient
epilepsy _ _ I-Patient
diagnosis _ _ I-Patient
were _ _ O
screened; _ _ O
five _ _ O
were _ _ O
enrolled, _ _ O
randomized, _ _ O
and _ _ O
completed _ _ O
the _ _ O
study. _ _ O
All _ _ O
participants _ _ O
were _ _ O
white _ _ B-Patient
females _ _ I-Patient
with _ _ I-Patient
a _ _ I-Patient
mean _ _ I-Patient
(SD) _ _ I-Patient
age _ _ I-Patient
of _ _ I-Patient
27.2 _ _ I-Patient
(6.8) _ _ I-Patient
years. _ _ I-Patient
All _ _ B-Outcome
doses _ _ I-Outcome
of _ _ I-Outcome
Staccato _ _ I-Outcome
alprazolam _ _ I-Outcome
reduced _ _ I-Outcome
the _ _ I-Outcome
SPR _ _ I-Outcome
at _ _ I-Outcome
2 _ _ I-Outcome
minutes; _ _ I-Outcome
the _ _ I-Outcome
effect _ _ I-Outcome
was _ _ I-Outcome
sustained _ _ I-Outcome
through _ _ I-Outcome
4 _ _ I-Outcome
hours _ _ I-Outcome
for _ _ I-Outcome
the _ _ I-Outcome
0.5-mg _ _ I-Outcome
dose _ _ I-Outcome
and _ _ I-Outcome
6 _ _ I-Outcome
hours _ _ I-Outcome
for _ _ I-Outcome
the _ _ I-Outcome
1.0- _ _ I-Outcome
and _ _ I-Outcome
2.0-mg _ _ I-Outcome
doses. _ _ I-Outcome
The _ _ O
magnitude _ _ O
and _ _ O
duration _ _ O
of _ _ O
sedation _ _ O
and _ _ O
sleepiness _ _ O
were _ _ O
dose-related. _ _ O
Four _ _ O
participants _ _ O
(80%) _ _ O
experienced _ _ O
≥1 _ _ O
adverse _ _ O
event _ _ O
(AE); _ _ O
none _ _ O
was _ _ O
severe _ _ O
or _ _ O
serious. _ _ O
Cough, _ _ O
diarrhea, _ _ O
dysgeusia, _ _ O
oral _ _ O
dysesthesia, _ _ O
sedation, _ _ O
and _ _ O
somnolence _ _ O
were _ _ O
experienced _ _ O
by _ _ O
two _ _ O
participants _ _ O
(40%) _ _ O
each. _ _ O
This _ _ O
proof-of-concept _ _ O
study _ _ O
demonstrated _ _ O
that _ _ O
Staccato _ _ O
alprazolam _ _ O
0.5, _ _ O
1.0, _ _ O
and _ _ O
2.0 _ _ O
mg _ _ O
rapidly _ _ O
suppressed _ _ O
epileptiform _ _ O
activity _ _ O
in _ _ O
photosensitive _ _ O
participants _ _ O
with _ _ O
epilepsy. _ _ O
The _ _ O
AE _ _ O
profile _ _ O
of _ _ O
Staccato _ _ O
alprazolam _ _ O
was _ _ O
similar _ _ O
to _ _ O
what _ _ O
has _ _ O
been _ _ O
reported _ _ O
for _ _ O
alprazolam _ _ O
for _ _ O
other _ _ O
indications. _ _ O
The _ _ O
results _ _ O
support _ _ O
further _ _ O
development _ _ O
of _ _ O
Staccato _ _ O
alprazolam _ _ O
as _ _ O
a _ _ O
rescue _ _ O
medication _ _ O
for _ _ O
the _ _ O
acute _ _ O
treatment _ _ O
of _ _ O
seizures. _ _ O


-DOCSTART- -X- -X- O

Epilepsy _ _ O
and _ _ O
autism _ _ O
spectrum _ _ O
disorder _ _ O
(ASD) _ _ O
are _ _ O
the _ _ O
common _ _ O
neurological _ _ O
manifestations _ _ O
of _ _ O
tuberous _ _ B-Patient
sclerosis _ _ I-Patient
complex _ _ I-Patient
(TSC). _ _ I-Patient
EXIST-3 _ _ O
study _ _ O
has _ _ O
recently _ _ O
demonstrated _ _ O
that _ _ O
everolimus _ _ B-Intervention
reduces _ _ O
seizures _ _ B-Patient
in _ _ I-Patient
patients _ _ I-Patient
with _ _ I-Patient
TSC _ _ I-Patient
and _ _ I-Patient
refractory _ _ I-Patient
epilepsy. _ _ I-Patient
Here _ _ O
we _ _ O
report _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
everolimus _ _ B-Intervention
for _ _ O
treatment-refractory _ _ B-Patient
seizures _ _ I-Patient
in _ _ I-Patient
Japanese _ _ I-Patient
patients _ _ I-Patient
of _ _ O
EXIST-3, _ _ O
along _ _ O
with _ _ O
the _ _ O
exploratory _ _ O
analysis _ _ O
evaluating _ _ O
the _ _ O
everolimus _ _ B-Intervention
effect _ _ O
on _ _ O
comorbid _ _ O
ASD _ _ O
symptoms _ _ O
in _ _ O
these _ _ O
patients. _ _ O
Primary _ _ O
endpoint _ _ O
was _ _ O
change _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
from _ _ O
baseline _ _ O
defined _ _ O
as _ _ O
response _ _ O
rate _ _ O
(≥50% _ _ O
reduction) _ _ O
and _ _ O
median _ _ O
percentage _ _ O
reduction _ _ O
in _ _ O
the _ _ O
seizure _ _ O
frequency. _ _ O
Pervasive _ _ O
Developmental _ _ O
Disorders _ _ O
Autism _ _ O
Society _ _ O
Japan _ _ O
Rating _ _ O
Scale _ _ O
(PARS) _ _ O
scores _ _ O
were _ _ O
assessed _ _ O
at _ _ O
baseline _ _ O
and _ _ O
at _ _ O
week-18 _ _ O
for _ _ O
ASD _ _ O
symptoms. _ _ O
Overall, _ _ O
35 _ _ O
Japanese _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
everolimus _ _ O
low-exposure _ _ O
(LE; _ _ O
n _ _ O
= _ _ O
10), _ _ O
everolimus _ _ O
high-exposure _ _ O
(HE; _ _ O
n _ _ O
= _ _ O
14), _ _ O
or _ _ O
placebo _ _ O
(n _ _ O
= _ _ O
11). _ _ O
The _ _ O
response _ _ O
rate _ _ O
was _ _ O
30.0% _ _ O
and _ _ O
28.6% _ _ O
versus _ _ O
0% _ _ O
with _ _ O
the _ _ O
everolimus _ _ O
LE _ _ O
and _ _ O
HE _ _ O
versus _ _ O
placebo _ _ O
arm, _ _ O
respectively. _ _ O
Similarly, _ _ O
the _ _ O
median _ _ O
percentage _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
was _ _ O
6.88% _ _ O
and _ _ O
38.06% _ _ O
versus _ _ O
-6.67%. _ _ O
Stomatitis _ _ O
was _ _ O
the _ _ O
most _ _ O
frequently _ _ O
reported _ _ O
adverse _ _ O
event _ _ O
(everolimus _ _ O
LE, _ _ O
100%; _ _ O
HE, _ _ O
78.6%; _ _ O
placebo, _ _ O
9.1%). _ _ O
Four _ _ O
of _ _ O
11 _ _ O
patients _ _ O
with _ _ O
ASD _ _ O
in _ _ O
the _ _ O
everolimus _ _ O
arms _ _ O
and _ _ O
1 _ _ O
of _ _ O
8 _ _ O
patients _ _ O
with _ _ O
ASD _ _ O
in _ _ O
the _ _ O
placebo _ _ O
arm _ _ O
showed _ _ O
≥5 _ _ O
point _ _ O
decrease _ _ O
in _ _ O
PARS _ _ O
scores. _ _ O
Adjunctive _ _ O
everolimus _ _ O
treatment _ _ O
improved _ _ O
seizure _ _ O
frequency _ _ O
with _ _ O
a _ _ O
tolerable _ _ O
safety _ _ O
relative _ _ O
to _ _ O
placebo _ _ O
among _ _ O
35 _ _ O
Japanese _ _ O
patients _ _ O
with _ _ O
TSC-associated _ _ O
refractory _ _ O
seizures, _ _ O
consistent _ _ O
with _ _ O
the _ _ O
results _ _ O
of _ _ O
overall _ _ O
EXIST-3 _ _ O
study _ _ O
involving _ _ O
366 _ _ O
patients. _ _ O
A _ _ O
favorable _ _ O
trend _ _ O
towards _ _ O
the _ _ O
improvement _ _ O
of _ _ O
ASD _ _ O
symptoms _ _ O
was _ _ O
observed. _ _ O


-DOCSTART- -X- -X- O

Valproate _ _ B-Control
is _ _ O
a _ _ O
first-line _ _ O
treatment _ _ O
for _ _ O
patients _ _ B-Patient
with _ _ I-Patient
newly _ _ I-Patient
diagnosed _ _ I-Patient
idiopathic _ _ I-Patient
generalised _ _ I-Patient
or _ _ I-Patient
difficult _ _ I-Patient
to _ _ I-Patient
classify _ _ I-Patient
epilepsy, _ _ I-Patient
but _ _ O
not _ _ O
for _ _ O
women _ _ O
of _ _ O
child-bearing _ _ O
potential _ _ O
because _ _ O
of _ _ O
teratogenicity. _ _ O
Levetiracetam _ _ B-Intervention
is _ _ O
increasingly _ _ O
prescribed _ _ O
for _ _ O
these _ _ O
patient _ _ O
populations _ _ O
despite _ _ O
scarcity _ _ O
of _ _ O
evidence _ _ O
of _ _ O
clinical _ _ O
effectiveness _ _ O
or _ _ O
cost-effectiveness. _ _ O
We _ _ O
aimed _ _ O
to _ _ O
compare _ _ O
the _ _ O
long-term _ _ O
clinical _ _ O
effectiveness _ _ O
and _ _ O
cost-effectiveness _ _ O
of _ _ O
levetiracetam _ _ B-Intervention
compared _ _ O
with _ _ O
valproate _ _ B-Control
in _ _ O
participants _ _ B-Patient
with _ _ I-Patient
newly _ _ I-Patient
diagnosed _ _ I-Patient
generalised _ _ I-Patient
or _ _ I-Patient
unclassifiable _ _ I-Patient
epilepsy. _ _ I-Patient
We _ _ O
did _ _ O
an _ _ O
open-label, _ _ O
randomised _ _ O
controlled _ _ O
trial _ _ O
to _ _ O
compare _ _ O
levetiracetam _ _ O
with _ _ O
valproate _ _ O
as _ _ O
first-line _ _ O
treatment _ _ O
for _ _ O
patients _ _ O
with _ _ O
generalised _ _ O
or _ _ O
unclassified _ _ O
epilepsy. _ _ O
Adult _ _ O
and _ _ O
paediatric _ _ O
neurology _ _ O
services _ _ O
(69 _ _ O
centres _ _ O
overall) _ _ O
across _ _ O
the _ _ O
UK _ _ O
recruited _ _ O
participants _ _ O
aged _ _ O
5 _ _ O
years _ _ O
or _ _ O
older _ _ O
(with _ _ O
no _ _ O
upper _ _ O
age _ _ O
limit) _ _ O
with _ _ O
two _ _ O
or _ _ O
more _ _ O
unprovoked _ _ O
generalised _ _ O
or _ _ O
unclassifiable _ _ O
seizures. _ _ O
Participants _ _ O
were _ _ O
randomly _ _ O
allocated _ _ O
(1:1) _ _ O
to _ _ O
receive _ _ O
either _ _ O
levetiracetam _ _ O
or _ _ O
valproate, _ _ O
using _ _ O
a _ _ O
minimisation _ _ O
programme _ _ O
with _ _ O
a _ _ O
random _ _ O
element _ _ O
utilising _ _ O
factors. _ _ O
Participants _ _ O
and _ _ O
investigators _ _ O
were _ _ O
aware _ _ O
of _ _ O
treatment _ _ O
allocation. _ _ O
For _ _ O
participants _ _ O
aged _ _ O
12 _ _ O
years _ _ O
or _ _ O
older, _ _ O
the _ _ O
initial _ _ O
advised _ _ O
maintenance _ _ O
doses _ _ O
were _ _ O
500 _ _ O
mg _ _ O
twice _ _ O
per _ _ O
day _ _ O
for _ _ O
levetiracetam _ _ O
and _ _ O
valproate, _ _ O
and _ _ O
for _ _ O
children _ _ O
aged _ _ O
5-12 _ _ O
years, _ _ O
the _ _ O
initial _ _ O
daily _ _ O
maintenance _ _ O
doses _ _ O
advised _ _ O
were _ _ O
25 _ _ O
mg/kg _ _ O
for _ _ O
valproate _ _ O
and _ _ O
40 _ _ O
mg/kg _ _ O
for _ _ O
levetiracetam. _ _ O
All _ _ O
drugs _ _ O
were _ _ O
administered _ _ O
orally. _ _ O
SANAD _ _ O
II _ _ O
was _ _ O
designed _ _ O
to _ _ O
assess _ _ O
the _ _ O
non-inferiority _ _ O
of _ _ O
levetiracetam _ _ O
compared _ _ O
with _ _ O
valproate _ _ O
for _ _ O
the _ _ O
primary _ _ O
outcome _ _ O
time _ _ O
to _ _ O
12-month _ _ O
remission. _ _ O
The _ _ O
non-inferiority _ _ O
limit _ _ O
was _ _ O
a _ _ O
hazard _ _ O
ratio _ _ O
(HR) _ _ O
of _ _ O
1·314, _ _ O
which _ _ O
equates _ _ O
to _ _ O
an _ _ O
absolute _ _ O
difference _ _ O
of _ _ O
10%. _ _ O
A _ _ O
HR _ _ O
greater _ _ O
than _ _ O
1 _ _ O
indicated _ _ O
that _ _ O
an _ _ O
event _ _ O
was _ _ O
more _ _ O
likely _ _ O
on _ _ O
valproate. _ _ O
All _ _ O
participants _ _ O
were _ _ O
included _ _ O
in _ _ O
the _ _ O
intention-to-treat _ _ O
(ITT) _ _ O
analysis. _ _ O
Per-protocol _ _ O
(PP) _ _ O
analyses _ _ O
excluded _ _ O
participants _ _ O
with _ _ O
major _ _ O
protocol _ _ O
deviations _ _ O
and _ _ O
those _ _ O
who _ _ O
were _ _ O
subsequently _ _ O
diagnosed _ _ O
as _ _ O
not _ _ O
having _ _ O
epilepsy. _ _ O
Safety _ _ O
analyses _ _ O
included _ _ O
all _ _ O
participants _ _ O
who _ _ O
received _ _ O
one _ _ O
dose _ _ O
of _ _ O
any _ _ O
study _ _ O
drug. _ _ O
This _ _ O
trial _ _ O
is _ _ O
registered _ _ O
with _ _ O
the _ _ O
ISRCTN _ _ O
registry, _ _ O
30294119 _ _ O
(EudraCt _ _ O
number: _ _ O
2012-001884-64). _ _ O
520 _ _ O
participants _ _ O
were _ _ O
recruited _ _ O
between _ _ O
April _ _ O
30, _ _ O
2013, _ _ O
and _ _ O
Aug _ _ O
2, _ _ O
2016, _ _ O
and _ _ O
followed _ _ O
up _ _ O
for _ _ O
a _ _ O
further _ _ O
2 _ _ O
years. _ _ O
260 _ _ O
participants _ _ O
were _ _ O
randomly _ _ O
allocated _ _ O
to _ _ O
receive _ _ O
levetiracetam _ _ O
and _ _ O
260 _ _ O
participants _ _ O
to _ _ O
receive _ _ O
valproate. _ _ O
The _ _ O
ITT _ _ O
analysis _ _ O
included _ _ O
all _ _ O
participants _ _ O
and _ _ O
the _ _ O
PP _ _ O
analysis _ _ O
included _ _ O
255 _ _ O
participants _ _ O
randomly _ _ O
allocated _ _ O
to _ _ O
valproate _ _ O
and _ _ O
254 _ _ O
randomly _ _ O
allocated _ _ O
to _ _ O
levetiracetam. _ _ O
Median _ _ O
age _ _ O
of _ _ O
participants _ _ O
was _ _ O
13·9 _ _ O
years _ _ O
(range _ _ O
5·0-94·4), _ _ O
65% _ _ O
were _ _ O
male _ _ O
and _ _ O
35% _ _ O
were _ _ O
female, _ _ O
397 _ _ O
participants _ _ O
had _ _ O
generalised _ _ O
epilepsy, _ _ O
and _ _ O
123 _ _ O
unclassified _ _ O
epilepsy. _ _ O
Levetiracetam _ _ O
did _ _ O
not _ _ O
meet _ _ O
the _ _ O
criteria _ _ O
for _ _ O
non-inferiority _ _ O
in _ _ O
the _ _ O
ITT _ _ O
analysis _ _ O
of _ _ O
time _ _ O
to _ _ O
12-month _ _ O
remission _ _ O
(HR _ _ O
1·19 _ _ O
[95% _ _ O
CI _ _ O
0·96-1·47]); _ _ O
non-inferiority _ _ O
margin _ _ O
1·314. _ _ O
The _ _ O
PP _ _ O
analysis _ _ O
showed _ _ O
that _ _ O
the _ _ O
12-month _ _ O
remission _ _ O
was _ _ O
superior _ _ O
with _ _ O
valproate _ _ O
than _ _ O
with _ _ O
levetiracetam. _ _ O
There _ _ O
were _ _ O
two _ _ O
deaths, _ _ O
one _ _ O
in _ _ O
each _ _ O
group, _ _ O
that _ _ O
were _ _ O
unrelated _ _ O
to _ _ O
trial _ _ O
treatments. _ _ O
Adverse _ _ O
reactions _ _ O
were _ _ O
reported _ _ O
by _ _ O
96 _ _ O
(37%) _ _ O
participants _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
valproate _ _ O
and _ _ O
107 _ _ O
(42%) _ _ O
participants _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
levetiracetam. _ _ O
Levetiracetam _ _ O
was _ _ O
dominated _ _ O
by _ _ O
valproate _ _ O
in _ _ O
the _ _ O
cost-utility _ _ O
analysis, _ _ O
with _ _ O
a _ _ O
negative _ _ O
incremental _ _ O
net _ _ O
health _ _ O
benefit _ _ O
of _ _ O
-0·040 _ _ O
(95% _ _ O
central _ _ O
range _ _ O
-0·175 _ _ O
to _ _ O
0·037) _ _ O
and _ _ O
a _ _ O
probability _ _ O
of _ _ O
0·17 _ _ O
of _ _ O
being _ _ O
cost-effectiveness _ _ O
at _ _ O
a _ _ O
threshold _ _ O
of _ _ O
£20 _ _ O
000 _ _ O
per _ _ O
quality-adjusted _ _ O
life-year. _ _ O
Cost-effectiveness _ _ O
was _ _ O
based _ _ O
on _ _ O
differences _ _ O
between _ _ O
treatment _ _ O
groups _ _ O
in _ _ O
costs _ _ O
and _ _ O
quality-adjusted _ _ O
life-years. _ _ O
Compared _ _ O
with _ _ O
valproate, _ _ O
levetiracetam _ _ O
was _ _ O
found _ _ O
to _ _ O
be _ _ O
neither _ _ O
clinically _ _ O
effective _ _ O
nor _ _ O
cost-effective. _ _ O
For _ _ O
girls _ _ O
and _ _ O
women _ _ O
of _ _ O
child-bearing _ _ O
potential, _ _ O
these _ _ O
results _ _ O
inform _ _ O
discussions _ _ O
about _ _ O
benefit _ _ O
and _ _ O
harm _ _ O
of _ _ O
avoiding _ _ O
valproate. _ _ O
National _ _ O
Institute _ _ O
for _ _ O
Health _ _ O
Research _ _ O
Health _ _ O
Technology _ _ O
Assessment _ _ O
Programme. _ _ O


-DOCSTART- -X- -X- O

Teaching _ _ O
people _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
to _ _ O
identify _ _ O
and _ _ O
manage _ _ O
seizure _ _ O
triggers, _ _ O
implement _ _ O
strategies _ _ O
to _ _ O
remember _ _ O
to _ _ O
take _ _ O
antiepileptic _ _ O
drugs, _ _ O
implement _ _ O
precautions _ _ O
to _ _ O
minimize _ _ O
risks _ _ O
during _ _ O
seizures, _ _ O
tell _ _ O
others _ _ O
what _ _ O
to _ _ O
do _ _ O
during _ _ O
a _ _ O
seizure _ _ O
and _ _ O
learn _ _ O
what _ _ O
to _ _ O
do _ _ O
during _ _ O
recovery _ _ O
may _ _ O
lead _ _ O
to _ _ O
better _ _ O
self-management. _ _ O
No _ _ O
teaching _ _ O
programme _ _ O
exists _ _ O
for _ _ O
adults _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
in _ _ I-Patient
the _ _ I-Patient
United _ _ I-Patient
Kingdom _ _ I-Patient
although _ _ O
a _ _ O
number _ _ O
of _ _ O
surveys _ _ O
have _ _ O
shown _ _ O
patients _ _ O
want _ _ O
more _ _ O
information. _ _ O
This _ _ O
is _ _ O
a _ _ O
multicentre, _ _ O
pragmatic, _ _ O
parallel _ _ O
group _ _ O
randomised _ _ O
controlled _ _ O
trial _ _ O
to _ _ O
evaluate _ _ O
the _ _ O
effectiveness _ _ O
and _ _ O
cost-effectiveness _ _ O
of _ _ O
a _ _ B-Intervention
two-day _ _ I-Intervention
Self-Management _ _ I-Intervention
education _ _ I-Intervention
for _ _ I-Intervention
epILEpsy _ _ I-Intervention
(SMILE _ _ I-Intervention
(UK)), _ _ I-Intervention
which _ _ O
was _ _ O
originally _ _ O
developed _ _ O
in _ _ O
Germany _ _ O
(MOSES).Four _ _ O
hundred _ _ O
and _ _ O
twenty _ _ O
eight _ _ O
adult _ _ B-Patient
patients _ _ I-Patient
who _ _ I-Patient
attended _ _ I-Patient
specialist _ _ I-Patient
epilepsy _ _ I-Patient
outpatient _ _ I-Patient
clinics _ _ I-Patient
at _ _ I-Patient
15 _ _ I-Patient
NHS _ _ I-Patient
participating _ _ I-Patient
sites _ _ I-Patient
in _ _ I-Patient
the _ _ I-Patient
previous _ _ I-Patient
12 _ _ I-Patient
months, _ _ I-Patient
and _ _ O
who _ _ O
fulfil _ _ O
other _ _ O
eligibility _ _ O
criteria _ _ O
will _ _ O
be _ _ O
randomised _ _ O
to _ _ O
receive _ _ O
the _ _ B-Intervention
intervention _ _ I-Intervention
(SMILE _ _ I-Intervention
(UK) _ _ I-Intervention
course _ _ I-Intervention
with _ _ I-Intervention
treatment _ _ I-Intervention
as _ _ I-Intervention
usual- _ _ I-Intervention
TAU) _ _ I-Intervention
or _ _ O
to _ _ O
have _ _ O
TAU _ _ B-Control
only _ _ I-Control
(control). _ _ I-Control
The _ _ O
primary _ _ O
outcome _ _ O
is _ _ O
the _ _ O
effect _ _ O
on _ _ O
patient _ _ O
reported _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QoL). _ _ O
Secondary _ _ O
outcomes _ _ O
are _ _ O
seizure _ _ O
frequency _ _ O
and _ _ O
psychological _ _ O
distress _ _ O
(anxiety _ _ O
and _ _ O
depression), _ _ O
perceived _ _ O
impact _ _ O
of _ _ O
epilepsy, _ _ O
adherence _ _ O
to _ _ O
medication, _ _ O
management _ _ O
of _ _ O
adverse _ _ O
effects _ _ O
from _ _ O
medication, _ _ O
and _ _ O
improved _ _ O
self-efficacy _ _ O
in _ _ O
management _ _ O
(mastery/control) _ _ O
of _ _ O
epilepsy.Within _ _ O
the _ _ O
trial _ _ O
there _ _ O
will _ _ O
be _ _ O
a _ _ O
nested _ _ O
qualitative _ _ O
study _ _ O
to _ _ O
explore _ _ O
users' _ _ O
views _ _ O
of _ _ O
the _ _ O
intervention, _ _ O
including _ _ O
barriers _ _ O
to _ _ O
participation _ _ O
and _ _ O
the _ _ O
perceived _ _ O
benefits _ _ O
of _ _ O
the _ _ O
intervention. _ _ O
The _ _ O
cost-effectiveness _ _ O
of _ _ O
the _ _ O
intervention _ _ O
will _ _ O
also _ _ O
be _ _ O
assessed. _ _ O
This _ _ O
study _ _ O
will _ _ O
provide _ _ O
quantitative _ _ O
and _ _ O
qualitative _ _ O
evidence _ _ O
of _ _ O
the _ _ O
impact _ _ O
of _ _ O
a _ _ O
structured _ _ O
self _ _ O
management _ _ O
programme _ _ O
on _ _ O
quality _ _ O
of _ _ O
life _ _ O
and _ _ O
other _ _ O
aspects _ _ O
of _ _ O
clinical _ _ O
and _ _ O
cost _ _ O
effectiveness _ _ O
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
poorly _ _ I-Patient
controlled _ _ I-Patient
epilepsy. _ _ I-Patient
Current _ _ O
Controlled _ _ O
Trials: _ _ O
ISRCTN57937389. _ _ O


-DOCSTART- -X- -X- O

Brivaracetam _ _ B-Intervention
(BRV) _ _ I-Intervention
is _ _ O
a _ _ O
novel _ _ O
high-affinity _ _ O
synaptic _ _ O
vesicle _ _ O
protein _ _ O
2A _ _ O
ligand _ _ O
currently _ _ O
being _ _ O
investigated _ _ O
for _ _ O
the _ _ O
treatment _ _ O
of _ _ O
epilepsy. _ _ O
The _ _ O
purpose _ _ O
of _ _ O
this _ _ O
phase _ _ O
III _ _ O
study _ _ O
was _ _ O
to _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety/tolerability _ _ O
of _ _ O
adjunctive _ _ B-Intervention
BRV _ _ I-Intervention
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
uncontrolled _ _ I-Patient
partial-onset _ _ I-Patient
(focal) _ _ I-Patient
seizures. _ _ I-Patient
This _ _ O
was _ _ O
a _ _ O
prospective, _ _ O
multicenter, _ _ O
randomized, _ _ O
double-blind, _ _ O
placebo-controlled, _ _ B-Control
parallel-group, _ _ O
fixed-dose _ _ O
trial _ _ O
(N01253; _ _ O
NCT00464269). _ _ O
Adults _ _ B-Patient
aged _ _ I-Patient
16-70 _ _ I-Patient
years _ _ I-Patient
with _ _ I-Patient
well-characterized _ _ I-Patient
partial _ _ I-Patient
epilepsy _ _ I-Patient
not _ _ I-Patient
fully _ _ I-Patient
controlled _ _ I-Patient
despite _ _ I-Patient
treatment _ _ I-Patient
with _ _ I-Patient
one _ _ I-Patient
or _ _ I-Patient
two _ _ I-Patient
antiepileptic _ _ I-Patient
drugs _ _ I-Patient
(AEDs) _ _ I-Patient
were _ _ O
enrolled. _ _ O
Patients _ _ B-Patient
who _ _ I-Patient
experienced _ _ I-Patient
eight _ _ I-Patient
or _ _ I-Patient
more _ _ I-Patient
partial-onset _ _ I-Patient
seizures, _ _ I-Patient
whether _ _ I-Patient
or _ _ I-Patient
not _ _ I-Patient
secondarily _ _ I-Patient
generalized, _ _ I-Patient
during _ _ I-Patient
the _ _ I-Patient
8-week _ _ I-Patient
prospective _ _ I-Patient
baseline _ _ I-Patient
period _ _ I-Patient
were _ _ O
randomized _ _ O
(1:1:1:1) _ _ O
to _ _ O
receive _ _ O
twice-daily _ _ B-Intervention
placebo _ _ B-Control
(PBO) _ _ I-Control
or _ _ O
BRV _ _ B-Intervention
(5, _ _ I-Intervention
20, _ _ I-Intervention
or _ _ I-Intervention
50 _ _ I-Intervention
mg/day) _ _ I-Intervention
without _ _ I-Intervention
titration. _ _ I-Intervention
The _ _ O
primary _ _ O
efficacy _ _ O
endpoint _ _ O
was _ _ O
percent _ _ O
reduction _ _ O
over _ _ O
PBO _ _ O
in _ _ O
baseline-adjusted _ _ O
partial-onset _ _ O
seizure _ _ O
frequency/week _ _ O
during _ _ O
the _ _ O
12-week _ _ O
treatment _ _ O
period. _ _ O
Comparison _ _ O
of _ _ O
BRV _ _ O
with _ _ O
PBO _ _ O
was _ _ O
sequential _ _ O
(50, _ _ O
20 _ _ O
mg/day, _ _ O
then _ _ O
5 _ _ O
mg/day). _ _ O
Secondary _ _ O
endpoints _ _ O
included _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
and _ _ O
median _ _ O
percent _ _ O
reduction _ _ O
from _ _ O
baseline _ _ O
in _ _ O
partial-onset _ _ O
seizure _ _ O
frequency/week. _ _ O
Post _ _ O
hoc _ _ O
analyses _ _ O
included _ _ O
the _ _ O
primary _ _ O
efficacy _ _ O
endpoint _ _ O
evaluated _ _ O
over _ _ O
28 _ _ O
days _ _ O
and _ _ O
exploratory _ _ O
subanalyses _ _ O
of _ _ O
efficacy _ _ O
by _ _ O
seizure _ _ O
subtype. _ _ O
Safety _ _ O
and _ _ O
tolerability _ _ O
assessments _ _ O
included _ _ O
treatment-emergent _ _ O
adverse _ _ O
events _ _ O
(TEAEs), _ _ O
laboratory _ _ O
tests, _ _ O
electrocardiography, _ _ O
vital _ _ O
signs, _ _ O
and _ _ O
physical _ _ O
and _ _ O
neurologic _ _ O
examinations. _ _ O
Of _ _ O
400 _ _ O
patients _ _ O
randomized, _ _ O
396 _ _ O
were _ _ O
included _ _ O
in _ _ O
the _ _ O
intent-to-treat _ _ O
(ITT) _ _ O
population _ _ O
(PBO _ _ O
n _ _ O
= _ _ O
98, _ _ O
BRV _ _ O
5 _ _ O
mg/day _ _ O
n _ _ O
= _ _ O
97, _ _ O
BRV _ _ O
20 _ _ O
mg/day _ _ O
n _ _ O
= _ _ O
100, _ _ O
BRV _ _ O
50 _ _ O
mg/day _ _ O
n _ _ O
= _ _ O
101) _ _ O
and _ _ O
392 _ _ O
comprised _ _ O
the _ _ O
modified _ _ O
ITT _ _ O
(mITT) _ _ O
population. _ _ O
A _ _ O
total _ _ O
of _ _ O
361 _ _ O
(91.2%) _ _ O
of _ _ O
396 _ _ O
patients _ _ O
completed _ _ O
the _ _ O
study. _ _ O
Most _ _ O
patients _ _ O
(78.3%) _ _ O
were _ _ O
receiving _ _ O
two _ _ O
concomitant _ _ O
AEDs. _ _ O
Percent _ _ O
reduction _ _ O
in _ _ O
partial-onset _ _ O
seizure _ _ O
frequency/week _ _ O
over _ _ O
PBO _ _ O
was _ _ O
-0.9% _ _ O
(p _ _ O
= _ _ O
0.885) _ _ O
for _ _ O
BRV _ _ O
5 _ _ O
mg/day, _ _ O
4.1% _ _ O
(p _ _ O
= _ _ O
0.492) _ _ O
for _ _ O
BRV _ _ O
20 _ _ O
mg/day, _ _ O
and _ _ O
12.8% _ _ O
(p _ _ O
= _ _ O
0.025) _ _ O
for _ _ O
BRV _ _ O
50 _ _ O
mg/day _ _ O
(mITT _ _ O
population). _ _ O
Statistical _ _ O
significance _ _ O
was _ _ O
also _ _ O
achieved _ _ O
for _ _ O
the _ _ O
percent _ _ O
reduction _ _ O
over _ _ O
PBO _ _ O
in _ _ O
baseline-adjusted _ _ O
partial-onset _ _ O
seizure _ _ O
frequency/28 _ _ O
days _ _ O
for _ _ O
BRV _ _ O
50 _ _ O
mg/day _ _ O
(22.0%; _ _ O
p _ _ O
= _ _ O
0.004) _ _ O
but _ _ O
not _ _ O
for _ _ O
the _ _ O
other _ _ O
BRV _ _ O
dose _ _ O
groups. _ _ O
In _ _ O
the _ _ O
BRV _ _ O
50 _ _ O
mg/day _ _ O
group, _ _ O
statistical _ _ O
significance _ _ O
was _ _ O
also _ _ O
seen _ _ O
for _ _ O
the _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
(BRV _ _ O
32.7% _ _ O
vs. _ _ O
PBO _ _ O
16.7%; _ _ O
p _ _ O
= _ _ O
0.008) _ _ O
and _ _ O
median _ _ O
percent _ _ O
reduction _ _ O
from _ _ O
baseline _ _ O
in _ _ O
partial-onset _ _ O
seizure _ _ O
frequency/week _ _ O
(BRV _ _ O
30.5% _ _ O
vs. _ _ O
PBO _ _ O
17.8%; _ _ O
p _ _ O
= _ _ O
0.003). _ _ O
In _ _ O
the _ _ O
exploratory _ _ O
subanalysis _ _ O
by _ _ O
seizure _ _ O
subtype, _ _ O
median _ _ O
percent _ _ O
reduction _ _ O
from _ _ O
baseline _ _ O
in _ _ O
seizure _ _ O
frequency/week _ _ O
and _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
were _ _ O
numerically _ _ O
greater _ _ O
than _ _ O
PBO _ _ O
in _ _ O
the _ _ O
BRV _ _ O
20 _ _ O
and _ _ O
50 _ _ O
mg/day _ _ O
groups _ _ O
for _ _ O
simple _ _ O
partial, _ _ O
complex _ _ O
partial, _ _ O
and _ _ O
secondarily _ _ O
generalized _ _ O
seizures. _ _ O
BRV _ _ O
was _ _ O
generally _ _ O
well _ _ O
tolerated, _ _ O
with _ _ O
the _ _ O
majority _ _ O
of _ _ O
TEAEs _ _ O
being _ _ O
mild-to-moderate _ _ O
in _ _ O
intensity. _ _ O
Of _ _ O
the _ _ O
TEAEs _ _ O
reported _ _ O
by _ _ O
≥5% _ _ O
patients, _ _ O
those _ _ O
with _ _ O
a _ _ O
frequency _ _ O
>3% _ _ O
higher _ _ O
than _ _ O
PBO _ _ O
for _ _ O
any _ _ O
dose _ _ O
of _ _ O
BRV _ _ O
compared _ _ O
with _ _ O
PBO _ _ O
were _ _ O
somnolence, _ _ O
dizziness, _ _ O
fatigue, _ _ O
influenza, _ _ O
insomnia, _ _ O
nasopharyngitis, _ _ O
vomiting, _ _ O
diarrhea, _ _ O
urinary _ _ O
tract _ _ O
infection, _ _ O
and _ _ O
nausea. _ _ O
Adjunctive _ _ O
BRV _ _ O
at _ _ O
a _ _ O
daily _ _ O
dose _ _ O
of _ _ O
50 _ _ O
mg _ _ O
was _ _ O
associated _ _ O
with _ _ O
statistically _ _ O
significant _ _ O
reductions _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
compared _ _ O
with _ _ O
PBO. _ _ O
All _ _ O
doses _ _ O
of _ _ O
BRV _ _ O
showed _ _ O
good _ _ O
tolerability _ _ O
throughout _ _ O
the _ _ O
study. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
assess _ _ O
anger/hostility _ _ O
during _ _ O
treatment _ _ B-Intervention
with _ _ I-Intervention
lamotrigine _ _ I-Intervention
adjunctive _ _ I-Intervention
therapy _ _ I-Intervention
versus _ _ O
levetiracetam _ _ B-Control
adjunctive _ _ I-Control
therapy _ _ I-Control
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
partial _ _ I-Patient
seizures. _ _ I-Patient
This _ _ O
randomized, _ _ O
double-blind, _ _ O
parallel-group _ _ O
study _ _ O
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
partial _ _ I-Patient
seizures _ _ I-Patient
included _ _ O
an _ _ O
8-week _ _ O
escalation _ _ O
phase, _ _ O
during _ _ O
which _ _ O
adjunctive _ _ B-Intervention
lamotrigine _ _ I-Intervention
(n _ _ O
= _ _ O
132) _ _ O
or _ _ O
adjunctive _ _ B-Control
levetiracetam _ _ I-Control
(n _ _ O
= _ _ O
136) _ _ O
was _ _ O
titrated _ _ O
to _ _ O
a _ _ O
target _ _ O
dose, _ _ O
and _ _ O
a _ _ O
12-week, _ _ O
double-blind _ _ O
maintenance _ _ O
phase, _ _ O
during _ _ O
which _ _ O
dosages _ _ O
of _ _ O
study _ _ O
medication _ _ O
and _ _ O
concomitant _ _ O
antiepileptic _ _ O
drugs _ _ O
were _ _ O
maintained. _ _ O
The _ _ O
primary _ _ O
endpoint _ _ O
was _ _ O
change _ _ O
from _ _ O
baseline _ _ O
to _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
maintenance _ _ O
phase _ _ O
(week _ _ O
20) _ _ O
in _ _ O
the _ _ O
Anger-Hostility _ _ O
subscale _ _ O
score _ _ O
of _ _ O
the _ _ O
Profile _ _ O
of _ _ O
Mood _ _ O
States _ _ O
(POMS). _ _ O
Improvement _ _ B-Outcome
with _ _ I-Outcome
lamotrigine _ _ I-Outcome
relative _ _ I-Outcome
to _ _ I-Outcome
levetiracetam _ _ I-Outcome
was _ _ I-Outcome
observed _ _ I-Outcome
for _ _ I-Outcome
mean _ _ I-Outcome
+/- _ _ I-Outcome
SD _ _ I-Outcome
(standard _ _ I-Outcome
deviation) _ _ I-Outcome
change _ _ I-Outcome
from _ _ I-Outcome
baseline _ _ I-Outcome
to _ _ I-Outcome
the _ _ I-Outcome
end _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
maintenance _ _ I-Outcome
phase _ _ I-Outcome
(week _ _ I-Outcome
20) _ _ I-Outcome
on _ _ I-Outcome
the _ _ I-Outcome
Anger-Hostility _ _ I-Outcome
subscale _ _ I-Outcome
(lamotrigine _ _ I-Outcome
-2.0 _ _ I-Outcome
+/- _ _ I-Outcome
8.2, _ _ I-Outcome
levetiracetam _ _ I-Outcome
-0.3 _ _ I-Outcome
+/- _ _ I-Outcome
8.4; _ _ I-Outcome
p _ _ I-Outcome
= _ _ I-Outcome
0.024) _ _ I-Outcome
(the _ _ I-Outcome
primary _ _ I-Outcome
endpoint); _ _ I-Outcome
the _ _ I-Outcome
Anger-Hostility _ _ I-Outcome
subscale _ _ I-Outcome
on _ _ I-Outcome
weeks _ _ I-Outcome
5, _ _ I-Outcome
6, _ _ I-Outcome
7, _ _ I-Outcome
8, _ _ I-Outcome
9, _ _ I-Outcome
11, _ _ I-Outcome
12, _ _ I-Outcome
14, _ _ I-Outcome
16, _ _ I-Outcome
18, _ _ I-Outcome
and _ _ I-Outcome
19; _ _ I-Outcome
and _ _ I-Outcome
the _ _ I-Outcome
Total _ _ I-Outcome
Mood _ _ I-Outcome
Disturbance _ _ I-Outcome
score _ _ I-Outcome
on _ _ I-Outcome
weeks _ _ I-Outcome
6, _ _ I-Outcome
7, _ _ I-Outcome
8, _ _ I-Outcome
9, _ _ I-Outcome
11, _ _ I-Outcome
12, _ _ I-Outcome
17, _ _ I-Outcome
19, _ _ I-Outcome
and _ _ I-Outcome
20. _ _ I-Outcome
Improvement _ _ O
(p _ _ O
< _ _ O
0.05) _ _ O
with _ _ O
lamotrigine _ _ O
relative _ _ O
to _ _ O
levetiracetam _ _ O
was _ _ O
also _ _ O
observed _ _ O
on _ _ O
the _ _ O
POMS _ _ O
subscales _ _ O
Depression-Dejection, _ _ O
Vigor-Activity, _ _ O
Fatigue-Inertia, _ _ O
and _ _ O
Confusion-Bewilderment. _ _ O
No _ _ O
difference _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
was _ _ O
observed _ _ O
between _ _ O
groups. _ _ O
The _ _ O
most _ _ O
common _ _ O
adverse _ _ O
events _ _ O
with _ _ O
both _ _ O
medications _ _ O
were _ _ O
headache _ _ O
and _ _ O
dizziness. _ _ O
Adjunctive _ _ O
lamotrigine _ _ O
significantly _ _ O
improved _ _ O
Anger-Hostility _ _ O
subscale _ _ O
scores _ _ O
relative _ _ O
to _ _ O
adjunctive _ _ O
levetiracetam _ _ O
in _ _ O
patients _ _ O
with _ _ O
partial _ _ O
seizures _ _ O
at _ _ O
the _ _ O
end _ _ O
of _ _ O
20 _ _ O
weeks. _ _ O
This _ _ O
difference _ _ O
was _ _ O
consistently _ _ O
observed _ _ O
throughout _ _ O
the _ _ O
treatment _ _ O
period. _ _ O
Similar _ _ O
improvement _ _ O
with _ _ O
lamotrigine _ _ O
versus _ _ O
levetiracetam _ _ O
was _ _ O
observed _ _ O
for _ _ O
other _ _ O
mood _ _ O
symptoms. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
compare _ _ O
controlled-release _ _ B-Control
carbamazepine _ _ I-Control
monotherapy _ _ I-Control
(CBZ-CR) _ _ I-Control
with _ _ O
lamotrigine _ _ B-Intervention
and _ _ I-Intervention
valproate _ _ I-Intervention
combination _ _ I-Intervention
therapy _ _ I-Intervention
(LTG _ _ I-Intervention
+ _ _ I-Intervention
VPA) _ _ I-Intervention
in _ _ O
equivalent _ _ O
total _ _ O
drug _ _ O
load, _ _ O
as _ _ O
initial _ _ O
drug _ _ O
regimen _ _ O
in _ _ O
untreated _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
partial _ _ I-Patient
and/or _ _ I-Patient
generalized _ _ I-Patient
tonic-clonic _ _ I-Patient
seizures _ _ I-Patient
(GTCS). _ _ I-Patient
This _ _ O
unblinded, _ _ O
randomized, _ _ O
60-week _ _ O
superiority _ _ O
trial _ _ O
recruited _ _ O
patients _ _ B-Patient
having _ _ I-Patient
two _ _ I-Patient
or _ _ I-Patient
more _ _ I-Patient
unprovoked _ _ I-Patient
seizures _ _ I-Patient
with _ _ I-Patient
at _ _ I-Patient
least _ _ I-Patient
one _ _ I-Patient
seizure _ _ I-Patient
during _ _ I-Patient
previous _ _ I-Patient
three _ _ I-Patient
months. _ _ I-Patient
After _ _ O
randomization _ _ O
into _ _ O
CBZ-CR _ _ B-Control
or _ _ O
LTG _ _ B-Intervention
+ _ _ I-Intervention
VPA, _ _ I-Intervention
patients _ _ O
entered _ _ O
into _ _ O
eight-week _ _ O
titration _ _ O
phase _ _ O
(TP), _ _ O
followed _ _ O
by _ _ O
52-week _ _ O
maintenance _ _ O
phase _ _ O
(MP). _ _ O
Median _ _ O
doses _ _ O
of _ _ O
CBZ-CR _ _ B-Control
and _ _ O
LTG _ _ B-Intervention
+ _ _ I-Intervention
VPA _ _ I-Intervention
were _ _ O
600 _ _ B-Control
mg/day _ _ I-Control
and _ _ O
75 _ _ B-Intervention
mg/day _ _ I-Intervention
+ _ _ I-Intervention
500 _ _ I-Intervention
mg/day, _ _ I-Intervention
respectively. _ _ O
Primary _ _ O
outcome _ _ O
measure _ _ O
was _ _ O
completion _ _ B-Outcome
rate _ _ I-Outcome
(CR), _ _ I-Outcome
a _ _ O
proportion _ _ O
of _ _ O
patients _ _ O
who _ _ O
have _ _ O
completed _ _ O
the _ _ O
60-week _ _ O
study _ _ O
as _ _ O
planned. _ _ O
Secondary _ _ O
efficacy _ _ O
measures _ _ O
included _ _ O
seizure-free _ _ O
rate _ _ O
(SFR) _ _ O
for _ _ O
52-week _ _ O
of _ _ O
MP _ _ O
and _ _ O
time _ _ O
to _ _ O
first _ _ O
seizure _ _ O
(TTFS) _ _ O
during _ _ O
MP. _ _ O
Among _ _ O
207 _ _ O
randomized _ _ O
patients, _ _ O
202 _ _ O
underwent _ _ O
outcome _ _ O
analysis _ _ O
(104 _ _ O
in _ _ O
CBZ-CR, _ _ B-Control
98 _ _ O
in _ _ O
LTG _ _ B-Intervention
+ _ _ I-Intervention
VPA). _ _ I-Intervention
CR _ _ B-Outcome
was _ _ I-Outcome
62.5% _ _ I-Outcome
in _ _ I-Outcome
CBZ-CR _ _ I-Outcome
and _ _ I-Outcome
65.3% _ _ I-Outcome
in _ _ I-Outcome
LTG _ _ I-Outcome
+ _ _ I-Outcome
VPA _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.678). _ _ I-Outcome
SFR _ _ O
during _ _ O
MP _ _ O
was _ _ O
higher _ _ O
in _ _ O
LTG _ _ O
+ _ _ O
VPA _ _ O
(64.1%) _ _ O
than _ _ O
CBZ-CR _ _ O
(47.8%) _ _ O
(P _ _ O
= _ _ O
0.034). _ _ O
TTFS _ _ O
was _ _ O
shorter _ _ O
with _ _ O
CBZ-CR _ _ O
(p _ _ O
= _ _ O
0.041). _ _ O
Incidence _ _ O
of _ _ O
adverse _ _ O
effects _ _ O
(AEs) _ _ O
were _ _ O
57.7% _ _ O
in _ _ O
CBZ-CR _ _ O
and _ _ O
60.2% _ _ O
in _ _ O
LTG _ _ O
+ _ _ O
VPA _ _ O
and _ _ O
premature _ _ O
drug _ _ O
withdrawal _ _ O
rates _ _ O
due _ _ O
to _ _ O
AEs _ _ O
were _ _ O
12.5% _ _ O
and _ _ O
7.1%, _ _ O
respectively, _ _ O
which _ _ O
were _ _ O
not _ _ O
significantly _ _ O
different. _ _ O
CR _ _ O
was _ _ O
comparable _ _ O
between _ _ O
LTG _ _ O
+ _ _ O
VPA _ _ O
and _ _ O
CBZ-CR, _ _ O
however, _ _ O
both _ _ O
SFR _ _ O
for _ _ O
52-week _ _ O
MP _ _ O
and _ _ O
TTFS _ _ O
during _ _ O
MP _ _ O
were _ _ O
in _ _ O
favor _ _ O
of _ _ O
LTG _ _ O
+ _ _ O
VPA _ _ O
than _ _ O
CBZ-CR. _ _ O
The _ _ O
study _ _ O
suggested _ _ O
that _ _ O
LTG _ _ O
+ _ _ O
VPA _ _ O
can _ _ O
be _ _ O
an _ _ O
option _ _ O
as _ _ O
initial _ _ O
drug _ _ O
regimen _ _ O
for _ _ O
untreated _ _ O
patients _ _ O
with _ _ O
partial _ _ O
seizures _ _ O
and/or _ _ O
GTCS _ _ O
except _ _ O
for _ _ O
women _ _ O
of _ _ O
reproductive _ _ O
age. _ _ O


-DOCSTART- -X- -X- O

Cognitive _ _ O
problems _ _ O
are _ _ O
common _ _ O
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ O
significantly _ _ O
affect _ _ O
their _ _ O
quality _ _ O
of _ _ O
life. _ _ O
HOBSCOTCH _ _ B-Intervention
(HOme _ _ I-Intervention
Based _ _ I-Intervention
Self-management _ _ I-Intervention
and _ _ I-Intervention
COgnitive _ _ I-Intervention
Training _ _ I-Intervention
CHanges _ _ I-Intervention
lives) _ _ I-Intervention
was _ _ O
developed _ _ O
to _ _ O
teach _ _ O
problem-solving _ _ O
and _ _ O
compensatory _ _ O
memory _ _ O
strategies _ _ O
to _ _ O
these _ _ O
individuals. _ _ O
This _ _ O
study _ _ O
examined _ _ O
whether _ _ O
HOBSCOTCH _ _ B-Intervention
is _ _ O
associated _ _ O
with _ _ O
improvement _ _ O
in _ _ O
specific _ _ O
aspects _ _ O
of _ _ O
subjective _ _ O
executive _ _ O
functions. _ _ O
Fifty-one _ _ O
adults, _ _ B-Patient
age _ _ I-Patient
18-65, _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
subjective _ _ I-Patient
cognitive _ _ I-Patient
concerns _ _ I-Patient
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
HOBSCOTCH _ _ B-Intervention
(n _ _ O
= _ _ O
31) _ _ O
or _ _ O
a _ _ B-Control
care-as-usual _ _ I-Control
control _ _ I-Control
sample _ _ I-Control
(n _ _ O
= _ _ O
20). _ _ O
Participants _ _ O
completed _ _ O
the _ _ O
Behavior _ _ O
Rating _ _ O
Inventory _ _ O
of _ _ O
Executive _ _ O
Function-Adult _ _ O
version _ _ O
(BRIEF-A), _ _ O
as _ _ O
well _ _ O
as _ _ O
the _ _ O
Patient _ _ O
Health _ _ O
Questionnaire-9 _ _ O
(PHQ-9) _ _ O
to _ _ O
assess _ _ O
depression. _ _ O
Rates _ _ O
of _ _ O
elevated _ _ O
(i.e., _ _ O
T _ _ O
≥ _ _ O
65, _ _ O
impaired) _ _ O
BRIEF-A _ _ O
scores _ _ O
at _ _ O
baseline, _ _ O
as _ _ O
well _ _ O
as _ _ O
pre-post _ _ O
score _ _ O
changes _ _ O
for _ _ O
the _ _ O
BRIEF-A _ _ O
clinical _ _ O
scales _ _ O
were _ _ O
evaluated. _ _ O
Significance _ _ O
was _ _ O
set _ _ O
at _ _ O
α _ _ O
= _ _ O
0.05, _ _ O
one-tailed, _ _ O
given _ _ O
our _ _ O
directional _ _ O
hypothesis. _ _ O
At _ _ O
baseline, _ _ O
a _ _ O
considerable _ _ O
percentage _ _ O
of _ _ O
patients _ _ O
in _ _ O
the _ _ O
overall _ _ O
sample _ _ O
endorsed _ _ O
executive _ _ O
dysfunction _ _ O
on _ _ O
BRIEF-A _ _ O
scales: _ _ O
Inhibit _ _ O
= _ _ O
28%, _ _ O
Shift _ _ O
= _ _ O
51%, _ _ O
Emotional _ _ O
Control _ _ O
= _ _ O
45%, _ _ O
Self-Monitor _ _ O
= _ _ O
33%, _ _ O
Initiate _ _ O
= _ _ O
35%, _ _ O
Working _ _ O
Memory _ _ O
= _ _ O
88%, _ _ O
Plan/Organize _ _ O
= _ _ O
45%, _ _ O
Task _ _ O
Monitor _ _ O
= _ _ O
47%, _ _ O
Organization _ _ O
of _ _ O
Materials _ _ O
= _ _ O
28%. _ _ O
Significant _ _ B-Outcome
improvement _ _ I-Outcome
was _ _ I-Outcome
seen _ _ I-Outcome
in _ _ I-Outcome
mean _ _ I-Outcome
T-scores _ _ I-Outcome
for _ _ I-Outcome
Inhibit, _ _ I-Outcome
Shift, _ _ I-Outcome
Initiate, _ _ I-Outcome
and _ _ I-Outcome
Working _ _ I-Outcome
Memory _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
treatment _ _ I-Outcome
group, _ _ I-Outcome
but _ _ I-Outcome
only _ _ I-Outcome
Working _ _ I-Outcome
Memory _ _ I-Outcome
improved _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
group. _ _ I-Outcome
The _ _ O
control _ _ O
group _ _ O
endorsed _ _ O
worse _ _ O
task _ _ O
monitoring _ _ O
and _ _ O
organization _ _ O
of _ _ O
materials _ _ O
at _ _ O
baseline _ _ O
and _ _ O
follow-up. _ _ O
Change _ _ O
in _ _ O
depression _ _ O
was _ _ O
not _ _ O
observed _ _ O
for _ _ O
either _ _ O
group, _ _ O
and _ _ O
there _ _ O
was _ _ O
no _ _ O
association _ _ O
between _ _ O
changes _ _ O
in _ _ O
depression _ _ O
and _ _ O
BRIEF-A _ _ O
scores. _ _ O
A _ _ O
sizeable _ _ O
subset _ _ O
of _ _ O
adults _ _ O
with _ _ O
epilepsy _ _ O
reported _ _ O
experiencing _ _ O
executive _ _ O
dysfunction _ _ O
in _ _ O
their _ _ O
everyday _ _ O
lives, _ _ O
especially _ _ O
for _ _ O
working _ _ O
memory. _ _ O
HOBSCOTCH _ _ O
resulted _ _ O
in _ _ O
amelioration _ _ O
of _ _ O
subjective _ _ O
executive _ _ O
functioning _ _ O
independent _ _ O
of _ _ O
changes _ _ O
in _ _ O
mood. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
a _ _ B-Intervention
pharmacist _ _ I-Intervention
implemented _ _ I-Intervention
educational _ _ I-Intervention
treatment _ _ I-Intervention
programme _ _ I-Intervention
in _ _ O
improving _ _ O
knowledge _ _ O
and _ _ O
perception _ _ O
of _ _ O
epilepsy _ _ O
among _ _ O
people _ _ O
with _ _ O
the _ _ O
condition. _ _ O
A _ _ O
randomized _ _ O
controlled _ _ O
study _ _ O
was _ _ O
conducted _ _ O
on _ _ O
patients _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
recruited _ _ O
from _ _ O
the _ _ O
medical _ _ O
and _ _ O
neurology _ _ O
out-patient _ _ O
clinics _ _ O
of _ _ O
two _ _ O
tertiary _ _ O
hospitals. _ _ O
Patients _ _ B-Intervention
in _ _ I-Intervention
the _ _ I-Intervention
intervention _ _ I-Intervention
group _ _ I-Intervention
were _ _ I-Intervention
offered _ _ I-Intervention
an _ _ I-Intervention
educational _ _ I-Intervention
treatment _ _ I-Intervention
programme _ _ I-Intervention
implemented _ _ I-Intervention
by _ _ I-Intervention
a _ _ I-Intervention
clinical _ _ I-Intervention
pharmacist. _ _ I-Intervention
The _ _ O
impact _ _ O
of _ _ O
the _ _ B-Intervention
educational _ _ I-Intervention
intervention _ _ I-Intervention
was _ _ O
evaluated _ _ O
by _ _ O
using _ _ O
an _ _ O
epilepsy _ _ O
knowledge _ _ O
scale _ _ O
and _ _ O
the _ _ O
brief _ _ O
illness _ _ O
perception _ _ O
questionnaire. _ _ O
There _ _ B-Outcome
was _ _ I-Outcome
a _ _ I-Outcome
statistical _ _ I-Outcome
significant _ _ I-Outcome
difference _ _ I-Outcome
between _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
and _ _ I-Outcome
intervention _ _ I-Outcome
group _ _ I-Outcome
over _ _ I-Outcome
time _ _ I-Outcome
on _ _ I-Outcome
the _ _ I-Outcome
knowledge _ _ I-Outcome
of _ _ I-Outcome
epilepsy, _ _ I-Outcome
as _ _ I-Outcome
the _ _ I-Outcome
knowledge _ _ I-Outcome
of _ _ I-Outcome
epilepsy _ _ I-Outcome
among _ _ I-Outcome
patients _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
intervention _ _ I-Outcome
group _ _ I-Outcome
significantly _ _ I-Outcome
increased; _ _ I-Outcome
F _ _ I-Outcome
(2154) _ _ I-Outcome
= _ _ I-Outcome
150.15, _ _ I-Outcome
p _ _ I-Outcome
= _ _ I-Outcome
0.000, _ _ I-Outcome
Partial _ _ I-Outcome
η _ _ I-Outcome
2 _ _ I-Outcome
= _ _ I-Outcome
0.661. _ _ I-Outcome
Also, _ _ O
there _ _ O
was _ _ O
a _ _ O
statistical _ _ O
significant _ _ O
difference _ _ O
between _ _ O
the _ _ O
control _ _ O
and _ _ O
intervention _ _ O
group _ _ O
over _ _ O
time _ _ O
on _ _ O
the _ _ O
perception _ _ O
of _ _ O
epilepsy, _ _ O
as _ _ O
the _ _ O
perception _ _ O
of _ _ O
epilepsy _ _ O
among _ _ O
patients _ _ O
in _ _ O
the _ _ O
intervention _ _ O
group _ _ O
significantly _ _ O
improved; _ _ O
F _ _ O
(2, _ _ O
154) _ _ O
= _ _ O
12.386, _ _ O
p _ _ O
= _ _ O
0.000, _ _ O
Partial _ _ O
η _ _ O
2 _ _ O
= _ _ O
0.138. _ _ O
The _ _ O
Pharmacist _ _ O
implemented _ _ O
educational _ _ O
intervention _ _ O
improved _ _ O
patients' _ _ O
knowledge _ _ O
and _ _ O
perception _ _ O
of _ _ O
epilepsy. _ _ O
This _ _ O
finding _ _ O
has _ _ O
revealed _ _ O
the _ _ O
potential _ _ O
positive _ _ O
impact _ _ O
of _ _ O
pharmacists' _ _ O
involvement _ _ O
in _ _ O
the _ _ O
management _ _ O
of _ _ O
epilepsy. _ _ O


-DOCSTART- -X- -X- O

Parents _ _ B-Patient
of _ _ I-Patient
children _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
other _ _ I-Patient
neurological _ _ I-Patient
conditions _ _ I-Patient
live _ _ O
with _ _ O
a _ _ O
feeling _ _ O
of _ _ O
constant _ _ O
uncertainty. _ _ O
The _ _ O
uncertainty _ _ O
associated _ _ O
with _ _ O
caring _ _ O
for _ _ O
a _ _ O
child _ _ O
with _ _ O
a _ _ O
neurological _ _ O
condition _ _ O
produces _ _ O
stress, _ _ O
which _ _ O
leads _ _ O
to _ _ O
decreased _ _ O
parental _ _ O
belief _ _ O
in _ _ O
caregiving _ _ O
skills, _ _ O
anxiety, _ _ O
and _ _ O
depression, _ _ O
ultimately _ _ O
altering _ _ O
parental _ _ O
functioning _ _ O
resulting _ _ O
in _ _ O
an _ _ O
increase _ _ O
in _ _ O
child _ _ O
behavioral _ _ O
problems. _ _ O
The _ _ O
stress _ _ O
associated _ _ O
with _ _ O
caring _ _ O
for _ _ O
children _ _ O
with _ _ O
neurological _ _ O
conditions _ _ O
is _ _ O
unlike _ _ O
caring _ _ O
for _ _ O
children _ _ O
with _ _ O
other _ _ O
chronic _ _ O
conditions. _ _ O
Neurological _ _ O
conditions _ _ O
are _ _ O
unpredictable, _ _ O
and _ _ O
there _ _ O
are _ _ O
often _ _ O
no _ _ O
warning _ _ O
signs _ _ O
before _ _ O
an _ _ O
acute _ _ O
event. _ _ O
This _ _ O
unpredictability _ _ O
accompanied _ _ O
with _ _ O
stigma _ _ O
results _ _ O
in _ _ O
social _ _ O
isolation _ _ O
and _ _ O
impacts _ _ O
family _ _ O
functioning. _ _ O
In _ _ O
addition, _ _ O
children _ _ O
with _ _ O
neurological _ _ O
conditions _ _ O
have _ _ O
a _ _ O
higher _ _ O
rate _ _ O
of _ _ O
psychological _ _ O
comorbidities _ _ O
and _ _ O
behavior _ _ O
problems _ _ O
when _ _ O
compared _ _ O
with _ _ O
children _ _ O
with _ _ O
other _ _ O
chronic _ _ O
conditions. _ _ O
This _ _ O
produces _ _ O
an _ _ O
additional _ _ O
burden _ _ O
on _ _ O
the _ _ O
parents _ _ O
and _ _ O
family. _ _ O
This _ _ O
randomized _ _ O
controlled _ _ O
trial _ _ O
tested _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
the _ _ B-Intervention
Creating _ _ I-Intervention
Opportunities _ _ I-Intervention
for _ _ I-Intervention
Parent _ _ I-Intervention
Empowerment _ _ I-Intervention
intervention _ _ I-Intervention
for _ _ O
parents _ _ B-Patient
of _ _ I-Patient
children _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
other _ _ I-Patient
neurological _ _ I-Patient
conditions. _ _ I-Patient
This _ _ B-Intervention
intervention _ _ I-Intervention
was _ _ I-Intervention
administered _ _ I-Intervention
at _ _ I-Intervention
three _ _ I-Intervention
intervals: _ _ I-Intervention
(a) _ _ I-Intervention
during _ _ I-Intervention
hospital _ _ I-Intervention
admission, _ _ I-Intervention
(b) _ _ I-Intervention
3 _ _ I-Intervention
days _ _ I-Intervention
after _ _ I-Intervention
hospital _ _ I-Intervention
discharge _ _ I-Intervention
by _ _ I-Intervention
telephone, _ _ I-Intervention
and _ _ I-Intervention
(c) _ _ I-Intervention
4-6 _ _ I-Intervention
weeks _ _ I-Intervention
after _ _ I-Intervention
hospital _ _ I-Intervention
discharge. _ _ I-Intervention
Forty-six _ _ O
parents _ _ B-Patient
of _ _ I-Patient
children _ _ I-Patient
admitted _ _ I-Patient
to _ _ I-Patient
the _ _ I-Patient
inpatient _ _ I-Patient
neuroscience _ _ I-Patient
unit _ _ I-Patient
at _ _ I-Patient
Boston _ _ I-Patient
Children's _ _ I-Patient
Hospital _ _ I-Patient
participated _ _ O
in _ _ O
the _ _ O
study. _ _ O
Several _ _ O
study _ _ O
limitations _ _ O
resulted _ _ O
in _ _ O
an _ _ O
inadequate _ _ O
sample _ _ O
size _ _ O
to _ _ O
obtain _ _ O
the _ _ O
power _ _ O
necessary _ _ O
to _ _ O
reach _ _ O
statistically _ _ O
significant _ _ O
results _ _ O
for _ _ O
most _ _ O
of _ _ O
the _ _ O
research _ _ O
questions. _ _ O
A _ _ B-Outcome
one-between, _ _ I-Outcome
one-within _ _ I-Outcome
multivariate _ _ I-Outcome
analysis _ _ I-Outcome
of _ _ I-Outcome
variance _ _ I-Outcome
revealed _ _ I-Outcome
that _ _ I-Outcome
the _ _ I-Outcome
main _ _ I-Outcome
effect _ _ I-Outcome
of _ _ I-Outcome
time _ _ I-Outcome
was _ _ I-Outcome
significant _ _ I-Outcome
for _ _ I-Outcome
differences _ _ I-Outcome
in _ _ I-Outcome
state _ _ I-Outcome
anxiety _ _ I-Outcome
for _ _ I-Outcome
both _ _ I-Outcome
the _ _ I-Outcome
usual _ _ I-Outcome
care _ _ I-Outcome
group _ _ I-Outcome
and _ _ I-Outcome
the _ _ I-Outcome
intervention _ _ I-Outcome
group, _ _ I-Outcome
F(1, _ _ I-Outcome
20) _ _ I-Outcome
= _ _ I-Outcome
9.86, _ _ I-Outcome
p _ _ I-Outcome
= _ _ I-Outcome
.005, _ _ I-Outcome
indicating _ _ I-Outcome
that _ _ I-Outcome
state _ _ I-Outcome
anxiety _ _ I-Outcome
for _ _ I-Outcome
both _ _ I-Outcome
groups _ _ I-Outcome
combined _ _ I-Outcome
was _ _ I-Outcome
more _ _ I-Outcome
pronounced _ _ I-Outcome
during _ _ I-Outcome
the _ _ I-Outcome
hospitalization. _ _ I-Outcome
A _ _ O
one-between, _ _ O
one-within _ _ O
multivariate _ _ O
analysis _ _ O
of _ _ O
variance _ _ O
showed _ _ O
that _ _ O
the _ _ O
effect _ _ O
of _ _ O
the _ _ O
interaction _ _ O
between _ _ O
time _ _ O
and _ _ O
group _ _ O
was _ _ O
significant _ _ O
for _ _ O
internalized _ _ O
behavior _ _ O
assessment _ _ O
system _ _ O
score _ _ O
only _ _ O
(p _ _ O
= _ _ O
.037) _ _ O
because _ _ O
the _ _ O
usual _ _ O
care _ _ O
group _ _ O
reported _ _ O
a _ _ O
significant _ _ O
decrease _ _ O
in _ _ O
internalizing _ _ O
behavior _ _ O
scores _ _ O
in _ _ O
their _ _ O
children _ _ O
over _ _ O
time. _ _ O
Findings _ _ O
from _ _ O
this _ _ O
study _ _ O
have _ _ O
significant _ _ O
implications _ _ O
for _ _ O
clinical _ _ O
practice _ _ O
and _ _ O
future _ _ O
research. _ _ O
Parents _ _ O
of _ _ O
children _ _ O
with _ _ O
neurological _ _ O
conditions _ _ O
often _ _ O
struggle _ _ O
to _ _ O
manage _ _ O
a _ _ O
constant _ _ O
feeling _ _ O
of _ _ O
uncertainty _ _ O
in _ _ O
their _ _ O
daily _ _ O
lives. _ _ O
Nurses _ _ O
possess _ _ O
the _ _ O
knowledge _ _ O
and _ _ O
expertise _ _ O
necessary _ _ O
to _ _ O
identify _ _ O
the _ _ O
psychosocial _ _ O
needs _ _ O
of _ _ O
these _ _ O
parents _ _ O
and _ _ O
provide _ _ O
education _ _ O
and _ _ O
support _ _ O
as _ _ O
needed. _ _ O
Future _ _ O
research _ _ O
should _ _ O
focus _ _ O
on _ _ O
designing _ _ O
interventions _ _ O
to _ _ O
meet _ _ O
the _ _ O
needs _ _ O
of _ _ O
these _ _ O
families _ _ O
and _ _ O
develop _ _ O
strategies _ _ O
to _ _ O
help _ _ O
improve _ _ O
the _ _ O
quality _ _ O
of _ _ O
life _ _ O
for _ _ O
both _ _ O
the _ _ O
parent _ _ O
and _ _ O
child _ _ O
living _ _ O
with _ _ O
a _ _ O
neurological _ _ O
condition. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
estimate _ _ O
time _ _ O
to _ _ O
onset _ _ O
of _ _ O
cannabidiol _ _ B-Intervention
(CBD) _ _ I-Intervention
treatment _ _ I-Intervention
effect _ _ O
(seizure _ _ O
reduction _ _ O
and _ _ O
adverse _ _ O
events _ _ O
[AEs]), _ _ O
we _ _ O
conducted _ _ O
post _ _ O
hoc _ _ O
analyses _ _ O
of _ _ O
data _ _ O
from _ _ O
two _ _ O
randomized, _ _ O
placebo-controlled, _ _ B-Control
Phase _ _ O
3 _ _ O
trials, _ _ O
GWPCARE3 _ _ O
(NCT02224560) _ _ O
and _ _ O
GWPCARE4 _ _ O
(NCT02224690), _ _ O
of _ _ O
patients _ _ B-Patient
with _ _ I-Patient
Lennox-Gastaut _ _ I-Patient
syndrome. _ _ I-Patient
Patients _ _ B-Intervention
received _ _ I-Intervention
plant-derived _ _ I-Intervention
pharmaceutical _ _ I-Intervention
formulation _ _ I-Intervention
of _ _ I-Intervention
highly _ _ I-Intervention
purified _ _ I-Intervention
CBD _ _ I-Intervention
(Epidiolex, _ _ I-Intervention
100 _ _ I-Intervention
mg/ml _ _ I-Intervention
oral _ _ I-Intervention
solution) _ _ I-Intervention
at _ _ I-Intervention
10 _ _ I-Intervention
mg/kg/day _ _ I-Intervention
(CBD10; _ _ I-Intervention
GWPCARE3) _ _ I-Intervention
or _ _ I-Intervention
20 _ _ I-Intervention
mg/kg/day _ _ I-Intervention
(CBD20; _ _ I-Intervention
both _ _ I-Intervention
trials) _ _ I-Intervention
or _ _ O
placebo _ _ B-Control
for _ _ I-Control
14 _ _ I-Control
weeks. _ _ I-Control
Treatment _ _ O
started _ _ O
at _ _ O
2.5 _ _ O
mg/kg/day _ _ O
for _ _ O
all _ _ O
groups _ _ O
and _ _ O
reached _ _ O
10 _ _ O
mg/kg/day _ _ O
on _ _ O
Day _ _ O
7 _ _ O
and _ _ O
20 _ _ O
mg/kg/day _ _ O
(CBD20 _ _ O
and _ _ O
matching _ _ O
placebo _ _ O
only) _ _ O
on _ _ O
Day _ _ O
11. _ _ O
Percentage _ _ O
change _ _ O
from _ _ O
baseline _ _ O
in _ _ O
drop _ _ O
seizure _ _ O
frequency _ _ O
was _ _ O
calculated _ _ O
by _ _ O
cumulative _ _ O
day _ _ O
(i.e., _ _ O
including _ _ O
all _ _ O
previous _ _ O
days). _ _ O
Time _ _ O
to _ _ O
onset _ _ O
and _ _ O
resolution _ _ O
of _ _ O
AEs _ _ O
were _ _ O
evaluated. _ _ O
Overall, _ _ O
235 _ _ O
patients _ _ O
received _ _ O
CBD _ _ O
(CBD10 _ _ O
[GWPCARE3 _ _ O
only], _ _ O
n _ _ O
= _ _ O
67; _ _ O
CBD20 _ _ O
[pooled _ _ O
GWPCARE3&4], _ _ O
n _ _ O
= _ _ O
168) _ _ O
and _ _ O
161 _ _ O
received _ _ O
placebo. _ _ O
Mean _ _ O
(range) _ _ O
age _ _ O
was _ _ O
15.3 _ _ O
years _ _ O
(2.6-48.0). _ _ O
Patients _ _ O
had _ _ O
previously _ _ O
discontinued _ _ O
a _ _ O
median _ _ O
(range) _ _ O
of _ _ O
six _ _ O
(0-28) _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs) _ _ O
and _ _ O
were _ _ O
currently _ _ O
taking _ _ O
a _ _ O
median _ _ O
of _ _ O
three _ _ O
(0-5) _ _ O
AEDs. _ _ O
Differences _ _ O
in _ _ O
drop _ _ O
seizure _ _ O
reduction _ _ O
between _ _ O
placebo _ _ O
and _ _ O
CBD _ _ O
emerged _ _ O
during _ _ O
the _ _ O
titration _ _ O
period _ _ O
and _ _ O
became _ _ O
nominally _ _ O
significant _ _ O
by _ _ O
Day _ _ O
6 _ _ O
(p _ _ O
= _ _ O
.008) _ _ O
for _ _ O
pooled _ _ O
CBD _ _ O
treatment _ _ O
groups. _ _ O
Separation _ _ O
between _ _ O
placebo _ _ O
and _ _ O
CBD _ _ O
in _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
emerged _ _ O
by _ _ O
Day _ _ O
6. _ _ O
Onset _ _ O
of _ _ O
the _ _ O
first _ _ O
reported _ _ O
AE _ _ O
occurred _ _ O
during _ _ O
the _ _ O
titration _ _ O
period _ _ O
in _ _ O
45% _ _ O
of _ _ O
patients _ _ O
(CBD10, _ _ O
46%; _ _ O
CBD20, _ _ O
52%; _ _ O
placebo, _ _ O
38%). _ _ O
In _ _ O
patients _ _ O
with _ _ O
AEs, _ _ O
resolution _ _ O
occurred _ _ O
within _ _ O
4 _ _ O
weeks _ _ O
of _ _ O
onset _ _ O
in _ _ O
53% _ _ O
of _ _ O
placebo _ _ O
and _ _ O
39% _ _ O
of _ _ O
CBD _ _ O
patients _ _ O
and _ _ O
by _ _ O
end _ _ O
of _ _ O
study _ _ O
in _ _ O
63% _ _ O
of _ _ O
placebo _ _ O
and _ _ O
61% _ _ O
of _ _ O
CBD _ _ O
patients. _ _ O
Treatment _ _ O
effect _ _ O
(efficacy _ _ O
and _ _ O
AEs) _ _ O
of _ _ O
CBD _ _ O
may _ _ O
occur _ _ O
within _ _ O
1 _ _ O
week _ _ O
of _ _ O
starting _ _ O
treatment. _ _ O
Although _ _ O
AEs _ _ O
lasted _ _ O
longer _ _ O
for _ _ O
CBD _ _ O
than _ _ O
placebo, _ _ O
most _ _ O
resolved _ _ O
within _ _ O
the _ _ O
14-week _ _ O
period. _ _ O


-DOCSTART- -X- -X- O

Ketogenic _ _ O
diets _ _ O
reduce _ _ O
seizures _ _ O
in _ _ O
children _ _ O
with _ _ O
drug-resistant _ _ O
epilepsy. _ _ O
Whether _ _ O
adults _ _ O
benefit _ _ O
from _ _ O
similar _ _ O
treatment _ _ O
has _ _ O
not _ _ O
been _ _ O
clarified. _ _ O
We _ _ O
therefore _ _ O
examined _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
the _ _ B-Intervention
modified _ _ I-Intervention
Atkins _ _ I-Intervention
diet _ _ I-Intervention
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
focal _ _ I-Patient
epilepsy. _ _ I-Patient
We _ _ O
performed _ _ O
a _ _ O
randomized _ _ O
clinical _ _ O
trial _ _ O
(RCT) _ _ O
with _ _ O
patients _ _ B-Patient
>16 _ _ I-Patient
years _ _ I-Patient
who _ _ I-Patient
had _ _ I-Patient
at _ _ I-Patient
least _ _ I-Patient
3 _ _ I-Patient
seizures _ _ I-Patient
per _ _ I-Patient
month _ _ I-Patient
despite _ _ I-Patient
having _ _ I-Patient
tried _ _ I-Patient
at _ _ I-Patient
least _ _ I-Patient
3 _ _ I-Patient
antiepileptic _ _ I-Patient
drugs. _ _ I-Patient
They _ _ O
were _ _ O
randomized _ _ O
to _ _ O
either _ _ O
12 _ _ B-Intervention
weeks _ _ I-Intervention
on _ _ I-Intervention
the _ _ I-Intervention
modified _ _ I-Intervention
Atkins _ _ I-Intervention
diet _ _ I-Intervention
(diet _ _ I-Intervention
group) _ _ I-Intervention
or _ _ O
habitual _ _ B-Control
diet _ _ I-Control
(control _ _ I-Control
group). _ _ I-Control
Primary _ _ O
endpoint _ _ O
was _ _ O
a _ _ O
change _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
from _ _ O
baseline _ _ O
to _ _ O
the _ _ O
intervention _ _ O
period, _ _ O
comparing _ _ O
those _ _ O
on _ _ O
diet _ _ O
with _ _ O
controls. _ _ B-Control
We _ _ O
assigned _ _ O
37 _ _ O
patients _ _ O
to _ _ O
the _ _ B-Intervention
diet _ _ I-Intervention
group _ _ I-Intervention
and _ _ O
38 _ _ O
to _ _ O
the _ _ B-Control
control _ _ I-Control
group. _ _ I-Control
Nine _ _ O
of _ _ O
the _ _ O
patients _ _ O
in _ _ O
the _ _ B-Intervention
diet _ _ I-Intervention
group _ _ I-Intervention
and _ _ O
4 _ _ O
controls _ _ B-Control
were _ _ O
excluded. _ _ O
Of _ _ B-Outcome
those _ _ I-Outcome
who _ _ I-Outcome
completed _ _ I-Outcome
the _ _ I-Outcome
dietary _ _ I-Outcome
intervention _ _ I-Outcome
(n _ _ I-Outcome
= _ _ I-Outcome
24), _ _ I-Outcome
median _ _ I-Outcome
seizure _ _ I-Outcome
change _ _ I-Outcome
was _ _ I-Outcome
-1.0 _ _ I-Outcome
(interquartile _ _ I-Outcome
range _ _ I-Outcome
[IQR] _ _ I-Outcome
-13.7-8.8), _ _ I-Outcome
while _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
group _ _ I-Outcome
(n _ _ I-Outcome
= _ _ I-Outcome
32) _ _ I-Outcome
the _ _ I-Outcome
median _ _ I-Outcome
change _ _ I-Outcome
was _ _ I-Outcome
4.5 _ _ I-Outcome
(IQR _ _ I-Outcome
-4.8-33.5). _ _ I-Outcome
The _ _ O
median _ _ O
difference _ _ O
between _ _ O
the _ _ O
groups _ _ O
was _ _ O
-7.0 _ _ O
(95% _ _ O
confidence _ _ O
interval _ _ O
[CI] _ _ O
-37.0-3.0; _ _ O
P _ _ O
= _ _ O
.21). _ _ O
In _ _ O
the _ _ O
intention-to-treat _ _ O
analysis, _ _ O
the _ _ O
relative _ _ O
risk _ _ O
(RR) _ _ O
for _ _ O
achieving _ _ O
>50% _ _ O
seizure _ _ O
reduction _ _ O
was _ _ O
1.8 _ _ O
(95% _ _ O
CI _ _ O
0.3-10.2; _ _ O
P _ _ O
= _ _ O
.65), _ _ O
while _ _ O
for _ _ O
achieving _ _ O
>25% _ _ O
seizure _ _ O
reduction _ _ O
RR _ _ O
was _ _ O
2.43 _ _ O
(95% _ _ O
CI _ _ O
0.94-6.28; _ _ O
P _ _ O
= _ _ O
.06). _ _ O
We _ _ O
observed _ _ O
no _ _ O
serious _ _ O
adverse _ _ O
events. _ _ O
In _ _ O
this _ _ O
RCT _ _ O
investigating _ _ O
the _ _ O
effect _ _ O
of _ _ O
an _ _ O
adjunctive _ _ O
modified _ _ O
Atkins _ _ O
diet _ _ O
on _ _ O
seizure _ _ O
frequency _ _ O
in _ _ O
adults _ _ O
with _ _ O
difficult-to-treat _ _ O
focal _ _ O
epilepsy, _ _ O
we _ _ O
found _ _ O
a _ _ O
significant _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
in _ _ O
the _ _ O
diet _ _ O
group _ _ O
compared _ _ O
to _ _ O
the _ _ O
controls, _ _ O
but _ _ O
only _ _ O
for _ _ O
moderate _ _ O
benefit _ _ O
(>25% _ _ O
seizure _ _ O
reduction) _ _ O
among _ _ O
those _ _ O
who _ _ O
completed _ _ O
the _ _ O
intervention. _ _ O
However, _ _ O
seizure _ _ O
response _ _ O
varied _ _ O
considerably _ _ O
between _ _ O
individuals, _ _ O
perhaps _ _ O
negatively _ _ O
influenced _ _ O
by _ _ O
a _ _ O
drop _ _ O
in _ _ O
serum _ _ O
concentrations _ _ O
of _ _ O
antiepileptic _ _ O
drugs. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
lacosamide _ _ B-Intervention
when _ _ O
added _ _ O
to _ _ O
1 _ _ O
or _ _ O
2 _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs) _ _ O
in _ _ O
adults _ _ B-Patient
with _ _ I-Patient
uncontrolled _ _ I-Patient
partial-onset _ _ I-Patient
seizures, _ _ I-Patient
and _ _ O
assess _ _ O
plasma _ _ O
concentrations _ _ O
of _ _ O
concomitant _ _ O
AEDs _ _ O
to _ _ O
determine _ _ O
any _ _ O
potential _ _ O
for _ _ O
drug _ _ O
interactions. _ _ O
During _ _ O
this _ _ O
multicenter, _ _ O
double-blind, _ _ O
placebo-controlled _ _ B-Control
trial, _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
placebo _ _ B-Control
or _ _ O
lacosamide _ _ B-Intervention
200, _ _ I-Intervention
400, _ _ I-Intervention
or _ _ I-Intervention
600 _ _ I-Intervention
mg/day _ _ I-Intervention
after _ _ O
an _ _ O
8-week _ _ O
baseline _ _ O
period. _ _ O
Lacosamide _ _ B-Intervention
was _ _ I-Intervention
titrated _ _ I-Intervention
in _ _ I-Intervention
weekly _ _ I-Intervention
increments _ _ I-Intervention
of _ _ I-Intervention
100 _ _ I-Intervention
mg/day _ _ I-Intervention
over _ _ I-Intervention
6 _ _ I-Intervention
weeks _ _ I-Intervention
and _ _ I-Intervention
maintained _ _ I-Intervention
for _ _ I-Intervention
12 _ _ I-Intervention
weeks. _ _ I-Intervention
Results _ _ O
were _ _ O
analyzed _ _ O
on _ _ O
an _ _ O
intention-to-treat _ _ O
basis. _ _ O
Four _ _ O
hundred _ _ O
eighteen _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
and _ _ O
received _ _ O
trial _ _ O
medication; _ _ O
312 _ _ O
completed _ _ O
the _ _ O
trial. _ _ O
The _ _ B-Outcome
median _ _ I-Outcome
percent _ _ I-Outcome
reduction _ _ I-Outcome
in _ _ I-Outcome
seizure _ _ I-Outcome
frequency _ _ I-Outcome
per _ _ I-Outcome
28 _ _ I-Outcome
days _ _ I-Outcome
was _ _ I-Outcome
10%, _ _ I-Outcome
26%, _ _ I-Outcome
39%, _ _ I-Outcome
and _ _ I-Outcome
40% _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
placebo, _ _ I-Outcome
lacosamide _ _ I-Outcome
200, _ _ I-Outcome
400, _ _ I-Outcome
and _ _ I-Outcome
600 _ _ I-Outcome
mg/day _ _ I-Outcome
treatment _ _ I-Outcome
groups, _ _ I-Outcome
respectively. _ _ I-Outcome
The _ _ O
median _ _ O
percent _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
over _ _ O
placebo _ _ O
was _ _ O
significant _ _ O
for _ _ O
lacosamide _ _ O
400 _ _ O
mg/day _ _ O
(p=0.0023) _ _ O
and _ _ O
600 _ _ O
mg/day _ _ O
(p=0.0084). _ _ O
The _ _ O
50% _ _ O
responder _ _ O
rates _ _ O
were _ _ O
22%, _ _ O
33%, _ _ O
41%, _ _ O
and _ _ O
38% _ _ O
for _ _ O
placebo, _ _ O
lacosamide _ _ O
200, _ _ O
400, _ _ O
and _ _ O
600 _ _ O
mg/day, _ _ O
respectively. _ _ O
The _ _ O
50% _ _ O
responder _ _ O
rate _ _ O
over _ _ O
placebo _ _ O
was _ _ O
significant _ _ O
for _ _ O
lacosamide _ _ O
400 _ _ O
mg/day _ _ O
(p=0.0038) _ _ O
and _ _ O
600 _ _ O
mg/day _ _ O
(p=0.0141). _ _ O
Adverse _ _ O
events _ _ O
that _ _ O
appeared _ _ O
dose-related _ _ O
included _ _ O
dizziness, _ _ O
nausea, _ _ O
fatigue, _ _ O
ataxia, _ _ O
vision _ _ O
abnormal, _ _ O
diplopia, _ _ O
and _ _ O
nystagmus. _ _ O
Lacosamide _ _ O
did _ _ O
not _ _ O
affect _ _ O
mean _ _ O
plasma _ _ O
concentrations _ _ O
of _ _ O
concomitantly _ _ O
administered _ _ O
AEDs. _ _ O
In _ _ O
this _ _ O
trial, _ _ O
adjunctive _ _ O
lacosamide _ _ O
significantly _ _ O
reduced _ _ O
seizure _ _ O
frequency _ _ O
in _ _ O
patients _ _ O
with _ _ O
uncontrolled _ _ O
partial-onset _ _ O
seizures. _ _ O
Along _ _ O
with _ _ O
favorable _ _ O
pharmacokinetic _ _ O
and _ _ O
tolerability _ _ O
profiles, _ _ O
these _ _ O
results _ _ O
support _ _ O
further _ _ O
development _ _ O
of _ _ O
lacosamide _ _ O
as _ _ O
an _ _ O
AED. _ _ O


-DOCSTART- -X- -X- O

Controlled _ _ O
randomized _ _ O
studies _ _ O
recommending _ _ O
the _ _ O
clinical _ _ O
use _ _ O
of _ _ O
lamotrigine _ _ B-Intervention
in _ _ O
adult _ _ B-Patient
populations _ _ I-Patient
with _ _ I-Patient
the _ _ I-Patient
diagnosis _ _ I-Patient
of _ _ I-Patient
Juvenile _ _ I-Patient
Myoclonic _ _ I-Patient
Epilepsy _ _ I-Patient
are _ _ O
still _ _ O
lacking. _ _ O
To _ _ O
compare _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
lamotrigine _ _ B-Intervention
versus _ _ O
valproate _ _ B-Control
in _ _ O
adult _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
JME. _ _ I-Patient
This _ _ O
was _ _ O
a _ _ O
prospective, _ _ O
randomized, _ _ O
controlled, _ _ O
pragmatic, _ _ O
long-term _ _ O
and _ _ O
open-label _ _ O
treatment _ _ O
trial. _ _ O
Patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
use _ _ O
valproate _ _ B-Control
or _ _ O
lamotrigine. _ _ B-Intervention
The _ _ O
primary _ _ O
end _ _ O
points _ _ O
of _ _ O
the _ _ O
study _ _ O
were: _ _ O
(1) _ _ O
time _ _ O
from _ _ O
randomization _ _ O
to _ _ O
treatment _ _ O
failure _ _ O
(withdrawal); _ _ O
(2) _ _ O
time _ _ O
from _ _ O
randomization _ _ O
to _ _ O
seizures _ _ O
remission. _ _ O
Secondary _ _ O
ending _ _ O
points _ _ O
were: _ _ O
(1) _ _ O
frequency _ _ O
of _ _ O
clinically _ _ O
important _ _ O
adverse _ _ O
events _ _ O
and _ _ O
(2) _ _ O
change _ _ O
in _ _ O
the _ _ O
QOLIE-31 _ _ O
after _ _ O
randomization. _ _ O
The _ _ O
definition _ _ O
of _ _ O
seizure _ _ O
remission _ _ O
was _ _ O
based _ _ O
on _ _ O
disappearance _ _ O
of _ _ O
all _ _ O
seizure _ _ O
types _ _ O
and _ _ O
EEG _ _ O
discharges. _ _ O
We _ _ O
found _ _ O
that _ _ O
the _ _ B-Outcome
time _ _ I-Outcome
to _ _ I-Outcome
withdraw _ _ I-Outcome
treatment _ _ I-Outcome
after _ _ I-Outcome
randomization _ _ I-Outcome
was _ _ I-Outcome
not _ _ I-Outcome
significantly _ _ I-Outcome
different _ _ I-Outcome
in _ _ I-Outcome
lamotrigine _ _ I-Outcome
and _ _ I-Outcome
valproate _ _ I-Outcome
groups. _ _ I-Outcome
Long-term _ _ O
seizures _ _ O
freedom _ _ O
was _ _ O
equal _ _ O
in _ _ O
the _ _ O
both _ _ O
groups _ _ O
of _ _ O
the _ _ O
trial; _ _ O
only _ _ O
8 _ _ O
(19.1%) _ _ O
patients _ _ O
randomized _ _ O
to _ _ O
lamotrigine _ _ O
and _ _ O
6 _ _ O
(19.4%) _ _ O
randomized _ _ O
to _ _ O
valproate _ _ O
were _ _ O
not _ _ O
seizure _ _ O
free _ _ O
after _ _ O
4 _ _ O
months _ _ O
of _ _ O
treatment. _ _ O
Between _ _ O
17.03% _ _ O
(lamotrigine) _ _ O
and _ _ O
35.3% _ _ O
(valproate) _ _ O
of _ _ O
patients _ _ O
reported _ _ O
adverse _ _ O
reactions _ _ O
at _ _ O
some _ _ O
point _ _ O
in _ _ O
the _ _ O
intention-to _ _ O
treat _ _ O
study _ _ O
(p _ _ O
= _ _ O
0.07). _ _ O
All _ _ O
subscales _ _ O
of _ _ O
the _ _ O
QOLIE-31 _ _ O
questionnaire, _ _ O
except _ _ O
that _ _ O
related _ _ O
to _ _ O
side _ _ O
effects _ _ O
of _ _ O
medication, _ _ O
improved _ _ O
more _ _ O
than _ _ O
5 _ _ O
points _ _ O
with _ _ O
respect _ _ O
to _ _ O
baseline _ _ O
period _ _ O
in _ _ O
both _ _ O
groups _ _ O
Lamotrigine _ _ O
is _ _ O
effective _ _ O
in _ _ O
adult _ _ O
patients _ _ O
with _ _ O
Juvenile _ _ O
Myoclonic _ _ O
Epilepsy _ _ O
and _ _ O
better _ _ O
tolerated _ _ O
than _ _ O
valproate, _ _ O
although _ _ O
the _ _ O
incidence _ _ O
of _ _ O
idiosyncratic _ _ O
reactions _ _ O
could _ _ O
be _ _ O
a _ _ O
cause _ _ O
of _ _ O
concern. _ _ O


-DOCSTART- -X- -X- O

Health _ _ O
literacy, _ _ O
the _ _ O
ability _ _ O
to _ _ O
understand _ _ O
necessary _ _ O
health _ _ O
information _ _ O
to _ _ O
make _ _ O
proper _ _ O
health _ _ O
decisions, _ _ O
has _ _ O
been _ _ O
linked _ _ O
to _ _ O
greater _ _ O
frequency _ _ O
of _ _ O
hospitalizations. _ _ O
However, _ _ O
there _ _ O
is _ _ O
limited _ _ O
literature _ _ O
on _ _ O
the _ _ O
associations _ _ O
between _ _ O
health _ _ O
literacy _ _ O
and _ _ O
outcomes _ _ O
in _ _ O
patients _ _ O
with _ _ O
epilepsy, _ _ O
and _ _ O
thus, _ _ O
this _ _ O
secondary _ _ O
analysis _ _ O
investigates _ _ O
the _ _ O
associations _ _ O
between _ _ O
health _ _ O
literacy _ _ O
and _ _ O
outcomes _ _ O
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
enrolled _ _ O
in _ _ O
the _ _ O
self-management _ _ O
intervention _ _ O
Self-management _ _ O
for _ _ O
people _ _ O
with _ _ O
epilepsy _ _ O
and _ _ O
a _ _ O
history _ _ O
of _ _ O
negative _ _ O
events _ _ O
(SMART). _ _ O
We _ _ O
examined _ _ O
the _ _ O
associations _ _ O
between _ _ O
higher _ _ O
health _ _ O
literacy _ _ O
and _ _ O
higher _ _ O
education _ _ O
level _ _ O
and _ _ O
outcomes _ _ O
of _ _ O
the _ _ O
SMART _ _ O
trial. _ _ O
This _ _ O
is _ _ O
a _ _ O
secondary _ _ O
analysis _ _ O
of _ _ O
data _ _ O
from _ _ O
the _ _ O
SMART _ _ O
self-management _ _ O
intervention, _ _ O
where _ _ O
individuals _ _ O
were _ _ O
randomized _ _ O
to _ _ O
the _ _ O
SMART _ _ O
intervention _ _ O
or _ _ O
a _ _ O
6-month _ _ O
waitlist _ _ O
(WL) _ _ O
control. _ _ O
Health _ _ O
literacy _ _ O
was _ _ O
assessed _ _ O
at _ _ O
baseline _ _ O
before _ _ O
randomization _ _ O
using _ _ O
the _ _ O
Rapid _ _ O
Estimate _ _ O
of _ _ O
Adult _ _ O
Literacy _ _ O
in _ _ O
Medicine _ _ O
(REALM-R). _ _ O
Education _ _ O
level _ _ O
was _ _ O
self-reported _ _ O
by _ _ O
participants _ _ O
at _ _ O
baseline. _ _ O
Pearson _ _ O
correlations _ _ O
between _ _ O
REALM-R _ _ O
scores _ _ O
and _ _ O
continuous _ _ O
demographic _ _ O
and _ _ O
clinical _ _ O
variables _ _ O
were _ _ O
conducted. _ _ O
Point-biserial _ _ O
Pearson _ _ O
correlations _ _ O
were _ _ O
computed _ _ O
for _ _ O
REALM-R _ _ O
and _ _ O
dichotomous _ _ O
variables. _ _ O
The _ _ O
effect _ _ O
of _ _ O
education _ _ O
on _ _ O
change _ _ O
in _ _ O
negative _ _ O
health _ _ O
events _ _ O
(NHEs) _ _ O
counts _ _ O
from _ _ O
baseline _ _ O
to _ _ O
six _ _ O
months _ _ O
was _ _ O
conducted _ _ O
using _ _ O
a _ _ O
linear _ _ O
regression. _ _ O
A _ _ O
logistic _ _ O
regression _ _ O
with _ _ O
health _ _ O
literacy _ _ O
and _ _ O
randomization _ _ O
arm _ _ O
as _ _ O
predictors _ _ O
and _ _ O
improvement _ _ O
in _ _ O
NHE _ _ O
(1 _ _ O
= _ _ O
improvement, _ _ O
0 _ _ O
= _ _ O
no _ _ O
change _ _ O
or _ _ O
increased _ _ O
NHEs _ _ O
at _ _ O
6 _ _ O
months) _ _ O
as _ _ O
the _ _ O
outcome _ _ O
was _ _ O
conducted. _ _ O
Lower _ _ O
education _ _ O
and _ _ O
lower _ _ O
income _ _ O
were _ _ O
significantly _ _ O
correlated _ _ O
with _ _ O
lower _ _ O
health _ _ O
literacy _ _ O
(p _ _ O
< _ _ O
0.001 _ _ O
and _ _ O
p _ _ O
= _ _ O
0.03). _ _ O
Higher _ _ O
education _ _ O
level _ _ O
was _ _ O
associated _ _ O
with _ _ O
a _ _ O
greater _ _ O
improvement _ _ O
in _ _ O
6-month _ _ O
seizure _ _ O
counts _ _ O
(rs(105) _ _ O
= _ _ O
0.29, _ _ O
p _ _ O
= _ _ O
0.002), _ _ O
and _ _ O
a _ _ O
greater _ _ O
improvement _ _ O
in _ _ O
total _ _ O
6-month _ _ O
NHEs _ _ O
(rs(95) _ _ O
= _ _ O
0.20, _ _ O
p _ _ O
= _ _ O
0.045). _ _ O
Health _ _ O
literacy _ _ O
was _ _ O
not _ _ O
associated _ _ O
with _ _ O
change _ _ O
in _ _ O
NHEs _ _ O
or _ _ O
with _ _ O
study _ _ O
retention. _ _ O
The _ _ O
SMART _ _ O
intervention _ _ O
appears _ _ O
effective _ _ O
for _ _ O
individuals _ _ O
regardless _ _ O
of _ _ O
health _ _ O
literacy _ _ O
competency. _ _ O
Nevertheless, _ _ O
individuals _ _ O
with _ _ O
higher _ _ O
levels _ _ O
of _ _ O
education _ _ O
have _ _ O
fewer _ _ O
epilepsy _ _ O
complications, _ _ O
and _ _ O
thus, _ _ O
those _ _ O
with _ _ O
limited _ _ O
education _ _ O
may _ _ O
still _ _ O
require _ _ O
additional _ _ O
support _ _ O
while _ _ O
participating _ _ O
in _ _ O
epilepsy _ _ O
self-management _ _ O
programs. _ _ O


-DOCSTART- -X- -X- O

Transcranial _ _ B-Intervention
direct _ _ I-Intervention
current _ _ I-Intervention
stimulation _ _ I-Intervention
(tDCS) _ _ I-Intervention
has _ _ O
been _ _ O
evaluated _ _ O
in _ _ O
medication _ _ O
refractory _ _ O
epilepsy _ _ O
patients. _ _ O
The _ _ O
results _ _ O
have _ _ O
been _ _ O
inconclusive _ _ O
and _ _ O
protocols _ _ O
have _ _ O
varied _ _ O
between _ _ O
studies. _ _ O
To _ _ O
evaluate _ _ O
the _ _ O
safety _ _ O
and _ _ O
efficacy _ _ O
of _ _ O
two _ _ O
protocols _ _ O
of _ _ O
tDCS _ _ B-Intervention
in _ _ O
adult _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
mesial _ _ I-Patient
temporal _ _ I-Patient
lobe _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
hippocampal _ _ I-Patient
sclerosis _ _ I-Patient
(MTLE-HS). _ _ I-Patient
This _ _ O
is _ _ O
a _ _ O
randomized _ _ O
placebo-controlled, _ _ B-Control
double-blinded _ _ O
clinical _ _ O
trial, _ _ O
with _ _ O
3 _ _ O
arms, _ _ O
3 _ _ B-Intervention
sessions, _ _ I-Intervention
5 _ _ B-Intervention
sessions _ _ I-Intervention
and _ _ O
placebo _ _ B-Control
stimulation. _ _ I-Control
Frequency _ _ O
of _ _ O
seizures _ _ O
(SZs), _ _ O
interictal _ _ O
epileptiform _ _ O
discharges _ _ O
(IEDs) _ _ O
and _ _ O
adverse _ _ O
effects _ _ O
(AEs) _ _ O
were _ _ O
registered _ _ O
before _ _ O
and _ _ O
after _ _ O
treatment, _ _ O
and _ _ O
at _ _ O
30 _ _ O
and _ _ O
60 _ _ O
days _ _ O
follow-up. _ _ O
Descriptive _ _ O
statistics, _ _ O
k-related _ _ O
samples, _ _ O
Friedman's _ _ O
test, _ _ O
and _ _ O
relative _ _ O
risk _ _ O
(RR) _ _ O
estimation _ _ O
were _ _ O
used _ _ O
for _ _ O
analysis. _ _ O
We _ _ O
included _ _ O
twenty-eight _ _ O
subjects _ _ O
(3d _ _ O
n _ _ O
= _ _ O
12, _ _ O
5d _ _ O
n _ _ O
= _ _ O
8, _ _ O
placebo _ _ O
n _ _ O
= _ _ O
8), _ _ O
16/28 _ _ O
(57%) _ _ O
men, _ _ O
age _ _ O
37.8(±10.9) _ _ O
years _ _ O
old. _ _ O
There _ _ O
was _ _ O
a _ _ O
significant _ _ O
reduction _ _ O
of _ _ O
the _ _ O
frequency _ _ O
of _ _ O
SZs _ _ O
at _ _ O
one _ _ O
(p _ _ O
= _ _ O
0.001) _ _ O
and _ _ O
two _ _ O
(p _ _ O
= _ _ O
0.0001) _ _ O
months _ _ O
following _ _ O
cathodal _ _ O
tDCS _ _ O
compared _ _ O
to _ _ O
baseline _ _ O
in _ _ O
the _ _ O
3 _ _ O
arms _ _ O
(p _ _ O
= _ _ O
0.0001). _ _ O
The _ _ O
mean _ _ O
reduction _ _ O
of _ _ O
SZ _ _ O
frequency _ _ O
at _ _ O
two _ _ O
months _ _ O
in _ _ O
both _ _ O
active _ _ O
groups _ _ O
was _ _ O
significantly _ _ O
higher _ _ O
than _ _ O
placebo _ _ O
(-48% _ _ O
vs. _ _ O
-6.25%, _ _ O
p _ _ O
< _ _ O
0.008). _ _ O
At _ _ O
3 _ _ O
days _ _ O
(-43.4% _ _ O
vs. _ _ O
-6.25%, _ _ O
p _ _ O
< _ _ O
0.007) _ _ O
and _ _ O
5 _ _ O
days _ _ O
(-54.6% _ _ O
vs. _ _ O
-6.25%, _ _ O
p _ _ O
< _ _ O
0.010) _ _ O
individual _ _ O
groups _ _ O
showed _ _ O
a _ _ O
greater _ _ O
reduction _ _ O
of _ _ O
SZs. _ _ O
A _ _ O
significant _ _ O
IED _ _ O
reduction _ _ O
effect _ _ O
was _ _ O
found _ _ O
between _ _ O
baseline _ _ O
and _ _ O
immediately _ _ O
after _ _ O
interventions _ _ O
(p _ _ O
= _ _ O
0.041) _ _ O
in _ _ O
all _ _ O
groups. _ _ O
Side _ _ O
effects _ _ O
were _ _ O
minor. _ _ O
Cathodal _ _ O
tDCS _ _ O
technique _ _ O
of _ _ O
3 _ _ O
and _ _ O
5 _ _ O
sessions _ _ O
decreased _ _ O
the _ _ O
frequency _ _ O
of _ _ O
SZs _ _ O
and _ _ O
IEDs _ _ O
(between _ _ O
baseline _ _ O
and _ _ O
immediately _ _ O
post-tDCS) _ _ O
in _ _ O
adult _ _ O
patients _ _ O
with _ _ O
MTLE-HS _ _ O
compared _ _ O
to _ _ O
placebo _ _ O
tDCS. _ _ O


-DOCSTART- -X- -X- O

Subjects _ _ B-Patient
who _ _ O
received _ _ O
eslicarbazepine _ _ B-Intervention
acetate _ _ I-Intervention
(ESL) _ _ I-Intervention
as _ _ I-Intervention
adjunctive _ _ I-Intervention
therapy _ _ I-Intervention
experienced _ _ O
significantly _ _ O
greater _ _ O
seizure _ _ O
frequency _ _ O
reduction _ _ O
(SFR) _ _ O
than _ _ O
placebo _ _ O
in _ _ O
three _ _ O
phase _ _ O
III, _ _ O
randomized, _ _ O
double-blind _ _ O
trials. _ _ O
This _ _ O
analysis _ _ O
compared _ _ O
changes _ _ O
in _ _ O
health-related _ _ O
quality _ _ O
of _ _ O
life _ _ O
(HRQOL) _ _ O
between _ _ O
treatment _ _ B-Intervention
responders _ _ I-Intervention
and _ _ O
non-responders _ _ O
across _ _ O
the _ _ O
pooled, _ _ O
per-protocol _ _ O
population _ _ O
(N=842) _ _ O
using _ _ O
the _ _ O
validated _ _ O
Quality _ _ O
of _ _ O
Life _ _ O
in _ _ O
Epilepsy _ _ O
Inventory-31 _ _ O
(QOLIE-31). _ _ O
QOLIE-31 _ _ O
scores _ _ O
were _ _ O
calculated _ _ O
for _ _ O
Total _ _ O
Score _ _ O
(TS) _ _ O
and _ _ O
seven _ _ O
subscales; _ _ O
higher _ _ O
scores _ _ O
indicate _ _ O
better _ _ O
HRQOL. _ _ O
Mean _ _ O
changes _ _ O
from _ _ O
baseline _ _ O
were _ _ O
calculated. _ _ O
Analysis _ _ O
of _ _ O
covariance _ _ O
examined _ _ O
least _ _ O
square _ _ O
mean _ _ O
(LSM) _ _ O
differences _ _ O
in _ _ O
final _ _ O
scores _ _ O
between _ _ O
responders _ _ O
(≥50% _ _ O
and _ _ O
≥75% _ _ O
SFR) _ _ O
and _ _ O
non-responders. _ _ O
Clinical _ _ O
significance _ _ O
was _ _ O
based _ _ O
on _ _ O
established _ _ O
minimal _ _ O
clinically _ _ O
important _ _ O
differences _ _ O
(MCIDs). _ _ O
Mean _ _ O
changes _ _ O
were _ _ O
greater _ _ O
among _ _ O
responders _ _ O
for _ _ O
TS _ _ O
(5.2 _ _ O
versus _ _ O
1.4 _ _ O
for _ _ O
≥50% _ _ O
SFR; _ _ O
7.5 _ _ O
versus _ _ O
1.9 _ _ O
for _ _ O
≥75% _ _ O
SFR) _ _ O
and _ _ O
all _ _ O
subscales. _ _ O
Additionally, _ _ O
the _ _ O
percentage _ _ O
of _ _ O
subjects _ _ O
with _ _ O
changes _ _ O
meeting _ _ O
or _ _ O
exceeding _ _ O
MCIDs _ _ O
was _ _ O
higher _ _ O
among _ _ O
responders _ _ O
for _ _ O
TS _ _ O
(48.4% _ _ O
versus _ _ O
33.9% _ _ O
for _ _ O
≥50% _ _ O
SFR; _ _ O
56.9% _ _ O
versus _ _ O
35.8% _ _ O
for _ _ O
≥75% _ _ O
SFR) _ _ O
and _ _ O
all _ _ O
subscales. _ _ O
Responders _ _ O
had _ _ O
significantly _ _ O
higher _ _ O
final _ _ O
scores _ _ O
for _ _ O
TS _ _ O
(LSM _ _ O
difference=4.0 _ _ O
for _ _ O
≥50% _ _ O
SFR; _ _ O
LSM _ _ O
difference=5.7 _ _ O
for _ _ O
≥75% _ _ O
SFR) _ _ O
and _ _ O
all _ _ O
subscales _ _ O
except _ _ O
emotional _ _ O
well-being _ _ O
at _ _ O
≥50% _ _ O
SFR. _ _ O
LSM _ _ O
differences _ _ O
exceeded _ _ O
MCIDs _ _ O
at _ _ O
≥75% _ _ O
SFR _ _ O
for _ _ O
TS _ _ O
and _ _ O
five _ _ O
of _ _ O
seven _ _ O
subscales, _ _ O
and _ _ O
two _ _ O
subscales _ _ O
at _ _ O
≥50% _ _ O
SFR. _ _ O
In _ _ O
a _ _ O
subgroup _ _ O
analysis _ _ O
with _ _ O
placebo _ _ O
removed, _ _ O
LSM _ _ O
differences _ _ O
were _ _ O
larger _ _ O
overall. _ _ O
In _ _ O
clinical _ _ O
trials _ _ O
of _ _ O
adjunctive _ _ O
ESL, _ _ O
higher _ _ O
levels _ _ O
of _ _ O
SFR _ _ O
were _ _ O
associated _ _ O
with _ _ O
greater _ _ O
improvements _ _ O
in _ _ O
HRQOL. _ _ O


-DOCSTART- -X- -X- O

Our _ _ O
objective _ _ O
was _ _ O
to _ _ O
assess _ _ O
how _ _ O
telephonic _ _ B-Intervention
review _ _ I-Intervention
of _ _ O
outpatients _ _ B-Patient
with _ _ I-Patient
stable _ _ I-Patient
epilepsy _ _ I-Patient
compared _ _ O
with _ _ O
conventional _ _ O
face-to-face _ _ O
clinic _ _ O
management. _ _ O
We _ _ O
constructed _ _ O
a _ _ O
randomized _ _ O
parallel _ _ O
group _ _ O
study _ _ O
of _ _ O
suitable _ _ O
patients _ _ O
attending _ _ O
our _ _ O
Epilepsy _ _ O
Clinic _ _ O
and _ _ O
compared _ _ O
telephonic _ _ O
review _ _ O
with _ _ O
conventional _ _ O
clinic _ _ O
visit _ _ O
based _ _ O
management. _ _ O
Primary _ _ O
outcomes _ _ O
were _ _ O
the _ _ O
percentage _ _ O
of _ _ O
patients _ _ O
with _ _ O
breakthrough _ _ O
seizures _ _ O
and _ _ O
total _ _ O
number _ _ O
of _ _ O
breakthrough _ _ O
seizures. _ _ O
We _ _ O
also _ _ O
compared _ _ O
cost, _ _ O
patient _ _ O
satisfaction _ _ O
and _ _ O
numbers _ _ O
defaulting. _ _ O
A _ _ O
total _ _ O
of _ _ O
465 _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
and _ _ O
429 _ _ O
were _ _ O
included _ _ O
in _ _ O
the _ _ O
final _ _ O
analysis. _ _ O
There _ _ O
was _ _ O
no _ _ O
significant _ _ O
difference _ _ O
in _ _ O
breakthrough _ _ O
seizures _ _ O
between _ _ O
the _ _ O
two _ _ O
groups. _ _ O
Mean _ _ O
time _ _ O
spent _ _ O
in _ _ O
the _ _ O
consultation _ _ O
was _ _ O
10min _ _ O
in _ _ O
the _ _ O
telephone _ _ O
group _ _ O
(FT) _ _ O
and _ _ O
22h _ _ O
in _ _ O
the _ _ O
face-to-face _ _ O
group _ _ O
(FC) _ _ O
and _ _ O
cost _ _ O
was _ _ O
INR _ _ O
865 _ _ O
more _ _ O
expensive _ _ O
on _ _ O
an _ _ O
average _ _ O
in _ _ O
the _ _ O
FC _ _ O
group. _ _ O
Satisfaction _ _ O
was _ _ O
over _ _ O
90% _ _ O
in _ _ O
the _ _ O
FT _ _ O
group. _ _ O
Significantly _ _ O
more _ _ O
people _ _ O
in _ _ O
the _ _ O
FC _ _ O
group _ _ O
were _ _ O
lost _ _ O
to _ _ O
follow-up. _ _ O
This _ _ O
study _ _ O
provides _ _ O
Class _ _ O
I _ _ O
evidence _ _ O
that _ _ O
the _ _ O
number _ _ O
of _ _ O
stable _ _ O
epilepsy _ _ O
patients _ _ O
who _ _ O
have _ _ O
breakthrough _ _ O
seizures _ _ O
and _ _ O
the _ _ O
total _ _ O
number _ _ O
of _ _ O
breakthrough _ _ O
seizures _ _ O
remain _ _ O
the _ _ O
same _ _ O
irrespective _ _ O
of _ _ O
whether _ _ O
patients _ _ O
are _ _ O
reviewed _ _ O
telephonically _ _ O
or _ _ O
face-to-face _ _ O
in _ _ O
the _ _ O
clinic. _ _ O
Clinicians _ _ O
managing _ _ O
epilepsy _ _ O
patients _ _ O
should _ _ O
consider _ _ O
using _ _ O
telephonic _ _ O
review _ _ O
for _ _ O
selected _ _ O
patients. _ _ O
Telephonic _ _ O
reviews _ _ O
have _ _ O
the _ _ O
potential _ _ O
of _ _ O
effectively _ _ O
reducing _ _ O
the _ _ O
secondary _ _ O
treatment _ _ O
gap _ _ O
in _ _ O
millions _ _ O
of _ _ O
patients _ _ O
who _ _ O
do _ _ O
not _ _ O
have _ _ O
easy _ _ O
access _ _ O
to _ _ O
doctors. _ _ O


-DOCSTART- -X- -X- O

MINDSET, _ _ B-Intervention
a _ _ I-Intervention
bilingual _ _ I-Intervention
(Eng./Span.) _ _ I-Intervention
decision _ _ I-Intervention
support _ _ I-Intervention
tool _ _ I-Intervention
was _ _ O
found _ _ O
feasible _ _ O
for _ _ O
facilitating _ _ O
goal-based _ _ O
epilepsy _ _ O
self-management _ _ O
(ESM) _ _ O
in _ _ O
the _ _ O
clinic. _ _ O
To _ _ O
evaluate _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
MINDSET _ _ O
to _ _ O
increase _ _ O
ESM _ _ O
adherence _ _ O
among _ _ O
Hispanic _ _ O
patients. _ _ O
A _ _ O
RCT _ _ O
was _ _ O
conducted _ _ O
from _ _ O
August _ _ O
2017 _ _ O
through _ _ O
January _ _ O
2019. _ _ O
Spanish _ _ O
and _ _ O
English _ _ O
speaking _ _ O
Hispanic _ _ O
adult _ _ O
patients _ _ O
(n=94) _ _ O
with _ _ O
epilepsy _ _ O
in _ _ O
Arizona _ _ O
(n=53) _ _ O
and _ _ O
Texas _ _ O
(n=41) _ _ O
were _ _ O
randomly _ _ O
assigned _ _ O
within _ _ O
6 _ _ O
neurology _ _ O
clinics _ _ O
to _ _ O
treatment _ _ O
(MINDSET _ _ O
plus _ _ O
Usual _ _ O
Care, _ _ O
hereafter _ _ O
referred _ _ O
to _ _ O
as _ _ O
MINDSET; _ _ O
n=46) _ _ O
and _ _ O
comparison _ _ O
(Usual _ _ O
Care _ _ O
Only; _ _ O
n=48) _ _ O
conditions. _ _ O
Self-reported _ _ O
self-management _ _ O
behavior _ _ O
(assessed _ _ O
through _ _ O
the _ _ O
Epilepsy _ _ O
Self-management _ _ O
scale) _ _ O
were _ _ O
categorized _ _ O
as _ _ O
adherent _ _ O
if _ _ O
performed _ _ O
'usually' _ _ O
or _ _ O
'always.' _ _ O
The _ _ O
proportion _ _ O
of _ _ O
adherence _ _ O
was _ _ O
compared _ _ O
between _ _ O
study _ _ O
conditions _ _ O
for _ _ O
36 _ _ O
individual _ _ O
ESM _ _ O
behaviors _ _ O
and _ _ O
5 _ _ O
ESM _ _ O
domains _ _ O
using _ _ O
Fischer's _ _ O
exact _ _ O
test. _ _ O
The _ _ O
average _ _ O
time _ _ O
between _ _ O
visit _ _ O
1 _ _ O
through _ _ O
3 _ _ O
was _ _ O
350+/-79 _ _ O
days _ _ O
with _ _ O
retention _ _ O
at _ _ O
96.8%. _ _ O
Participants _ _ O
in _ _ O
the _ _ O
treatment _ _ O
condition _ _ O
had _ _ O
more _ _ O
college _ _ O
education _ _ O
and _ _ O
less _ _ O
unemployment. _ _ O
Self-management _ _ O
adherence _ _ O
improved _ _ O
across _ _ O
visits _ _ O
for _ _ O
all _ _ O
self-management _ _ O
behaviors _ _ O
irrespective _ _ O
of _ _ O
study _ _ O
condition. _ _ O
Compared _ _ O
to _ _ O
usual _ _ O
care _ _ O
MINDSET _ _ O
use _ _ O
led _ _ O
to _ _ O
greater _ _ O
ESM _ _ O
adherence _ _ O
for _ _ O
86.1% _ _ O
behaviors _ _ O
(5 _ _ O
with _ _ O
statistical _ _ O
significance; _ _ O
p<0.05) _ _ O
and _ _ O
to _ _ O
significant _ _ O
improvement _ _ O
in _ _ O
the _ _ O
ESM _ _ O
domain _ _ O
of _ _ O
'information _ _ O
management' _ _ O
(p<0.05). _ _ O
Implementation _ _ O
of _ _ O
MINDSET _ _ O
within _ _ O
regular _ _ O
neurology _ _ O
visits _ _ O
may _ _ O
assist _ _ O
Hispanic _ _ O
adults _ _ O
with _ _ O
epilepsy _ _ O
to _ _ O
increase _ _ O
their _ _ O
adherence _ _ O
to _ _ O
ESM _ _ O
behaviors _ _ O
and _ _ O
maintain _ _ O
this _ _ O
adherence _ _ O
longitudinally. _ _ O
Replication _ _ O
with _ _ O
a _ _ O
broader _ _ O
demographic _ _ O
population _ _ O
of _ _ O
people _ _ O
with _ _ O
epilepsy _ _ O
is _ _ O
indicated. _ _ O


-DOCSTART- -X- -X- O

We _ _ O
studied _ _ O
the _ _ O
association _ _ O
between _ _ O
maternal _ _ O
epilepsy, _ _ O
antiepileptic _ _ O
drug _ _ O
(AED) _ _ O
treatment, _ _ O
and _ _ O
behavioral _ _ O
problems _ _ O
in _ _ O
preschool _ _ O
children. _ _ O
In _ _ O
the _ _ O
Danish _ _ O
National _ _ O
Birth _ _ O
Cohort, _ _ O
we _ _ O
identified _ _ O
4- _ _ B-Patient
to _ _ I-Patient
5-year-old _ _ I-Patient
children _ _ I-Patient
whose _ _ I-Patient
mothers _ _ I-Patient
had _ _ I-Patient
epilepsy _ _ I-Patient
and _ _ I-Patient
received _ _ I-Patient
AED _ _ I-Patient
treatment _ _ I-Patient
(n=133) _ _ I-Patient
or _ _ I-Patient
not _ _ I-Patient
(n=304) _ _ I-Patient
during _ _ I-Patient
pregnancy _ _ I-Patient
and _ _ O
compared _ _ O
them _ _ O
with _ _ O
randomly _ _ O
selected _ _ O
children _ _ O
whose _ _ O
mothers _ _ O
did _ _ O
not _ _ O
have _ _ O
epilepsy _ _ O
(n=1193). _ _ O
The _ _ O
children's _ _ O
behavioral _ _ O
problems _ _ O
were _ _ O
assessed _ _ O
by _ _ O
the _ _ O
use _ _ O
of _ _ O
the _ _ O
Strengths _ _ O
and _ _ O
Difficulties _ _ O
Questionnaire _ _ O
(SDQ). _ _ O
Children _ _ O
prenatally _ _ O
exposed _ _ O
to _ _ O
AEDs _ _ O
more _ _ O
often _ _ O
had _ _ O
an _ _ O
abnormal _ _ O
total _ _ O
SDQ _ _ O
score _ _ O
as _ _ O
compared _ _ O
with _ _ O
children _ _ O
of _ _ O
women _ _ O
without _ _ O
epilepsy _ _ O
(odds _ _ O
ratio _ _ O
(OR)=4.8 _ _ O
(95% _ _ O
CI: _ _ O
1.9-12.1)) _ _ O
and _ _ O
as _ _ O
compared _ _ O
with _ _ O
children _ _ O
of _ _ O
women _ _ O
with _ _ O
epilepsy _ _ O
who _ _ O
were _ _ O
not _ _ O
treated _ _ O
with _ _ O
AEDs _ _ O
during _ _ O
their _ _ O
pregnancy _ _ O
(OR=4.0 _ _ O
(95% _ _ O
CI: _ _ O
1.3-12.8)). _ _ O
In _ _ O
conclusion, _ _ O
prenatal _ _ O
AED _ _ O
exposure _ _ O
may _ _ O
increase _ _ O
the _ _ O
risk _ _ O
of _ _ O
behavioral _ _ O
problems _ _ O
in _ _ O
preschool _ _ O
children _ _ O
even _ _ O
after _ _ O
adjustments _ _ O
for _ _ O
potential _ _ O
confounders _ _ O
and _ _ O
maternal _ _ O
epilepsy. _ _ O


-DOCSTART- -X- -X- O

Pregnant _ _ B-Patient
women _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
on _ _ I-Patient
antiepileptic _ _ I-Patient
drugs _ _ I-Patient
(AEDs) _ _ I-Patient
may _ _ O
experience _ _ O
a _ _ O
reduction _ _ O
in _ _ O
serum _ _ O
AED _ _ O
levels. _ _ O
This _ _ O
has _ _ O
the _ _ O
potential _ _ O
to _ _ O
worsen _ _ O
seizure _ _ O
control. _ _ O
To _ _ O
determine _ _ O
if, _ _ O
in _ _ O
pregnant _ _ B-Patient
women _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
on _ _ I-Patient
AEDs, _ _ I-Patient
additional _ _ B-Intervention
therapeutic _ _ I-Intervention
drug _ _ I-Intervention
monitoring _ _ I-Intervention
reduces _ _ O
seizure _ _ O
deterioration _ _ O
compared _ _ O
with _ _ O
clinical _ _ O
features _ _ O
monitoring _ _ O
after _ _ O
a _ _ O
reduction _ _ O
in _ _ O
serum _ _ O
AED _ _ O
levels. _ _ O
A _ _ O
double-blind, _ _ O
randomised _ _ O
trial _ _ O
nested _ _ O
within _ _ O
a _ _ O
cohort _ _ O
study _ _ O
was _ _ O
conducted _ _ O
and _ _ O
a _ _ O
qualitative _ _ O
study _ _ O
of _ _ O
acceptability _ _ O
of _ _ O
the _ _ O
two _ _ O
strategies _ _ O
was _ _ O
undertaken. _ _ O
Stratified _ _ O
block _ _ O
randomisation _ _ O
with _ _ O
a _ _ O
1 _ _ O
: _ _ O
1 _ _ O
allocation _ _ O
method _ _ O
was _ _ O
carried _ _ O
out. _ _ O
Fifty _ _ O
obstetric _ _ O
and _ _ O
epilepsy _ _ O
clinics _ _ O
in _ _ O
secondary _ _ O
and _ _ O
tertiary _ _ O
care _ _ O
units _ _ O
in _ _ O
the _ _ B-Patient
UK. _ _ I-Patient
Pregnant _ _ B-Patient
women _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
on _ _ I-Patient
one _ _ I-Patient
or _ _ I-Patient
more _ _ I-Patient
of _ _ I-Patient
the _ _ I-Patient
following _ _ I-Patient
AEDs: _ _ I-Patient
lamotrigine, _ _ I-Patient
carbamazepine, _ _ I-Patient
phenytoin _ _ I-Patient
or _ _ I-Patient
levetiracetam. _ _ I-Patient
Women _ _ O
with _ _ O
a _ _ O
≥ _ _ O
25% _ _ O
decrease _ _ O
in _ _ O
serum _ _ O
AED _ _ O
level _ _ O
from _ _ O
baseline _ _ O
were _ _ O
randomised _ _ O
to _ _ O
therapeutic _ _ B-Intervention
drug _ _ I-Intervention
monitoring _ _ I-Intervention
or _ _ O
clinical _ _ B-Control
features _ _ I-Control
monitoring _ _ I-Control
strategies. _ _ I-Control
In _ _ B-Intervention
the _ _ I-Intervention
therapeutic _ _ I-Intervention
drug _ _ I-Intervention
monitoring _ _ I-Intervention
group, _ _ I-Intervention
clinicians _ _ I-Intervention
had _ _ I-Intervention
access _ _ I-Intervention
to _ _ I-Intervention
clinical _ _ I-Intervention
findings _ _ I-Intervention
and _ _ I-Intervention
monthly _ _ I-Intervention
serum _ _ I-Intervention
AED _ _ I-Intervention
levels _ _ I-Intervention
to _ _ I-Intervention
guide _ _ I-Intervention
AED _ _ I-Intervention
dosage _ _ I-Intervention
adjustment _ _ I-Intervention
for _ _ I-Intervention
seizure _ _ I-Intervention
control. _ _ I-Intervention
In _ _ B-Control
the _ _ I-Control
clinical _ _ I-Control
features _ _ I-Control
monitoring _ _ I-Control
group, _ _ I-Control
AED _ _ I-Control
dosage _ _ I-Control
adjustment _ _ I-Control
was _ _ I-Control
based _ _ I-Control
only _ _ I-Control
on _ _ I-Control
clinical _ _ I-Control
features. _ _ I-Control
Primary _ _ O
outcome _ _ O
- _ _ O
seizure _ _ O
deterioration, _ _ O
defined _ _ O
as _ _ O
time _ _ O
to _ _ O
first _ _ O
seizure _ _ O
and _ _ O
to _ _ O
all _ _ O
seizures _ _ O
after _ _ O
randomisation _ _ O
per _ _ O
woman _ _ O
until _ _ O
6 _ _ O
weeks _ _ O
post _ _ O
partum. _ _ O
Secondary _ _ O
outcomes _ _ O
- _ _ O
pregnancy _ _ O
complications _ _ O
in _ _ O
mother _ _ O
and _ _ O
offspring, _ _ O
maternal _ _ O
quality _ _ O
of _ _ O
life, _ _ O
seizure _ _ O
rates _ _ O
in _ _ O
cohorts _ _ O
with _ _ O
stable _ _ O
serum _ _ O
AED _ _ O
level, _ _ O
AED _ _ O
dose _ _ O
exposure _ _ O
and _ _ O
adverse _ _ O
events _ _ O
related _ _ O
to _ _ O
AEDs. _ _ O
Analysis _ _ O
of _ _ O
time _ _ O
to _ _ O
first _ _ O
and _ _ O
to _ _ O
all _ _ O
seizures _ _ O
after _ _ O
randomisation _ _ O
was _ _ O
performed _ _ O
using _ _ O
a _ _ O
Cox _ _ O
proportional _ _ O
hazards _ _ O
model, _ _ O
and _ _ O
multivariate _ _ O
failure _ _ O
time _ _ O
analysis _ _ O
by _ _ O
the _ _ O
Andersen-Gill _ _ O
model. _ _ O
The _ _ O
effects _ _ O
were _ _ O
reported _ _ O
as _ _ O
hazard _ _ O
ratios _ _ O
(HRs) _ _ O
with _ _ O
95% _ _ O
confidence _ _ O
intervals _ _ O
(CIs). _ _ O
Secondary _ _ O
outcomes _ _ O
were _ _ O
reported _ _ O
as _ _ O
mean _ _ O
differences _ _ O
(MDs) _ _ O
or _ _ O
odds _ _ O
ratios. _ _ O
A _ _ O
total _ _ O
of _ _ O
130 _ _ O
women _ _ O
were _ _ O
randomised _ _ O
to _ _ O
the _ _ B-Intervention
therapeutic _ _ I-Intervention
drug _ _ I-Intervention
monitoring _ _ I-Intervention
group _ _ I-Intervention
and _ _ O
133 _ _ O
to _ _ O
the _ _ O
clinical _ _ O
features _ _ O
monitoring _ _ O
group; _ _ O
294 _ _ O
women _ _ O
did _ _ O
not _ _ O
have _ _ O
a _ _ O
reduction _ _ O
in _ _ O
serum _ _ O
AED _ _ O
level. _ _ O
A _ _ O
total _ _ O
of _ _ O
127 _ _ O
women _ _ O
in _ _ O
the _ _ O
therapeutic _ _ O
drug _ _ O
monitoring _ _ O
group _ _ O
and _ _ O
130 _ _ O
women _ _ O
in _ _ O
the _ _ O
clinical _ _ O
features _ _ O
monitoring _ _ O
group _ _ O
(98% _ _ O
of _ _ O
complete _ _ O
data) _ _ O
were _ _ O
included _ _ O
in _ _ O
the _ _ O
primary _ _ O
analysis. _ _ O
There _ _ O
were _ _ O
no _ _ O
significant _ _ O
differences _ _ O
in _ _ O
the _ _ O
time _ _ O
to _ _ O
first _ _ O
seizure _ _ O
(HR _ _ O
0.82, _ _ O
95% _ _ O
CI _ _ O
0.55 _ _ O
to _ _ O
1.2) _ _ O
or _ _ O
timing _ _ O
of _ _ O
all _ _ O
seizures _ _ O
after _ _ O
randomisation _ _ O
(HR _ _ O
1.3, _ _ O
95% _ _ O
CI _ _ O
0.7 _ _ O
to _ _ O
2.5) _ _ O
between _ _ O
both _ _ O
trial _ _ O
groups. _ _ O
In _ _ O
comparison _ _ O
with _ _ O
the _ _ O
group _ _ O
with _ _ O
stable _ _ O
serum _ _ O
AED _ _ O
levels, _ _ O
there _ _ O
were _ _ O
no _ _ O
significant _ _ O
increases _ _ O
in _ _ O
seizures _ _ O
in _ _ O
the _ _ O
clinical _ _ O
features _ _ O
monitoring _ _ O
(odds _ _ O
ratio _ _ O
0.93, _ _ O
95% _ _ O
CI _ _ O
0.56 _ _ O
to _ _ O
1.5) _ _ O
or _ _ O
therapeutic _ _ O
drug _ _ O
monitoring _ _ O
group _ _ O
(odds _ _ O
ratio _ _ O
0.93, _ _ O
95% _ _ O
CI _ _ O
0.56 _ _ O
to _ _ O
1.5) _ _ O
associated _ _ O
with _ _ O
a _ _ O
reduction _ _ O
in _ _ O
serum _ _ O
AED _ _ O
levels. _ _ O
Maternal _ _ O
and _ _ O
neonatal _ _ O
outcomes _ _ O
were _ _ O
similar _ _ O
in _ _ O
both _ _ O
groups, _ _ O
except _ _ O
for _ _ O
higher _ _ O
cord _ _ O
blood _ _ O
levels _ _ O
of _ _ O
lamotrigine _ _ O
(MD _ _ O
0.55 _ _ O
mg/l, _ _ O
95% _ _ O
CI _ _ O
0.11 _ _ O
to _ _ O
1 _ _ O
mg/l) _ _ O
or _ _ O
levetiracetam _ _ O
(MD _ _ O
7.8 _ _ O
mg/l, _ _ O
95% _ _ O
CI _ _ O
0.86 _ _ O
to _ _ O
14.8 _ _ O
mg/l) _ _ O
in _ _ O
the _ _ O
therapeutic _ _ O
drug _ _ O
monitoring _ _ O
group _ _ O
than _ _ O
in _ _ O
the _ _ O
clinical _ _ O
features _ _ O
monitoring _ _ O
group. _ _ O
There _ _ O
were _ _ O
no _ _ O
differences _ _ O
between _ _ O
the _ _ O
groups _ _ O
on _ _ O
daily _ _ O
AED _ _ O
exposure _ _ O
or _ _ O
quality _ _ O
of _ _ O
life. _ _ O
An _ _ O
increase _ _ O
in _ _ O
exposure _ _ O
to _ _ O
lamotrigine, _ _ O
levetiracetam _ _ O
and _ _ O
carbamazepine _ _ O
significantly _ _ O
increased _ _ O
the _ _ O
cord _ _ O
blood _ _ O
levels _ _ O
of _ _ O
the _ _ O
AEDs, _ _ O
but _ _ O
not _ _ O
maternal _ _ O
or _ _ O
fetal _ _ O
complications. _ _ O
Women _ _ O
with _ _ O
epilepsy _ _ O
perceived _ _ O
the _ _ O
need _ _ O
for _ _ O
weighing _ _ O
up _ _ O
their _ _ O
increased _ _ O
vulnerability _ _ O
to _ _ O
seizures _ _ O
during _ _ O
pregnancy _ _ O
against _ _ O
the _ _ O
side _ _ O
effects _ _ O
of _ _ O
AEDs. _ _ O
Fewer _ _ O
women _ _ O
than _ _ O
the _ _ O
original _ _ O
target _ _ O
were _ _ O
recruited. _ _ O
There _ _ O
is _ _ O
no _ _ O
evidence _ _ O
to _ _ O
suggest _ _ O
that _ _ O
regular _ _ O
monitoring _ _ O
of _ _ O
serum _ _ O
AED _ _ O
levels _ _ O
in _ _ O
pregnancy _ _ O
improves _ _ O
seizure _ _ O
control _ _ O
or _ _ O
affects _ _ O
maternal _ _ O
or _ _ O
fetal _ _ O
outcomes. _ _ O
Further _ _ O
evaluation _ _ O
of _ _ O
the _ _ O
risks _ _ O
of _ _ O
seizure _ _ O
deterioration _ _ O
for _ _ O
various _ _ O
threshold _ _ O
levels _ _ O
of _ _ O
reduction _ _ O
in _ _ O
AEDs _ _ O
and _ _ O
the _ _ O
long-term _ _ O
neurodevelopment _ _ O
of _ _ O
infants _ _ O
born _ _ O
to _ _ O
mothers _ _ O
in _ _ O
both _ _ O
randomised _ _ O
groups _ _ O
is _ _ O
needed. _ _ O
An _ _ O
individualised _ _ O
prediction _ _ O
model _ _ O
will _ _ O
help _ _ O
to _ _ O
identify _ _ O
those _ _ O
women _ _ O
who _ _ O
need _ _ O
close _ _ O
monitoring _ _ O
in _ _ O
pregnancy. _ _ O
Current _ _ O
Controlled _ _ O
Trials _ _ O
ISRCTN01253916. _ _ O
This _ _ O
project _ _ O
was _ _ O
funded _ _ O
by _ _ O
the _ _ O
National _ _ O
Institute _ _ O
for _ _ O
Health _ _ O
Research _ _ O
(NIHR) _ _ O
Health _ _ O
Technology _ _ O
Assessment _ _ O
programme _ _ O
and _ _ O
will _ _ O
be _ _ O
published _ _ O
in _ _ O
full _ _ O
in _ _ O
Health _ _ O
Technology _ _ O
Assessment; _ _ O
Vol. _ _ O
22, _ _ O
No. _ _ O
23. _ _ O
See _ _ O
the _ _ O
NIHR _ _ O
Journals _ _ O
Library _ _ O
website _ _ O
for _ _ O
further _ _ O
project _ _ O
information. _ _ O


-DOCSTART- -X- -X- O

Perampanel _ _ O
is _ _ O
a _ _ O
selective, _ _ O
noncompetitive _ _ O
AMPA _ _ O
receptor _ _ O
antagonist _ _ O
with _ _ O
demonstrated _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
in _ _ O
partial _ _ B-Patient
seizures _ _ I-Patient
in _ _ I-Patient
patients _ _ I-Patient
aged _ _ I-Patient
≥ _ _ I-Patient
12 _ _ I-Patient
years _ _ I-Patient
in _ _ O
Phase _ _ O
III _ _ O
studies. _ _ O
Post-hoc _ _ O
analysis _ _ O
of _ _ O
these _ _ O
studies _ _ O
was _ _ O
conducted _ _ O
to _ _ O
determine _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
perampanel _ _ O
based _ _ O
on _ _ O
the _ _ O
number _ _ O
of _ _ O
concomitant _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs) _ _ O
at _ _ O
baseline, _ _ O
as _ _ O
well _ _ O
as _ _ O
to _ _ O
examine _ _ O
which _ _ O
baseline _ _ O
characteristics, _ _ O
if _ _ O
any, _ _ O
were _ _ O
predictors _ _ O
of _ _ O
efficacy. _ _ O
Efficacy _ _ O
parameters _ _ O
were _ _ O
based _ _ O
on _ _ O
the _ _ O
number _ _ O
of _ _ O
baseline _ _ O
AEDs, _ _ O
and _ _ O
logistic _ _ O
regression _ _ O
analyses _ _ O
were _ _ O
used _ _ O
to _ _ O
evaluate _ _ O
the _ _ O
association _ _ O
of _ _ O
demographic _ _ O
and _ _ O
baseline _ _ O
clinical _ _ O
factors _ _ O
with _ _ O
probability _ _ O
of _ _ O
≥ _ _ O
50% _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency. _ _ O
Patients _ _ O
on _ _ O
1 _ _ O
AED _ _ O
at _ _ O
baseline _ _ O
were _ _ O
significantly _ _ O
more _ _ O
likely _ _ O
to _ _ O
have _ _ O
reduced _ _ O
seizure _ _ O
frequency _ _ O
(P<0.02) _ _ O
and _ _ O
improved _ _ O
50% _ _ O
responder _ _ O
rate _ _ O
(P<0.02) _ _ O
than _ _ O
patients _ _ O
on _ _ O
3 _ _ O
AEDs _ _ O
at _ _ O
baseline. _ _ O
Secondarily _ _ O
generalized _ _ O
seizures _ _ O
at _ _ O
baseline, _ _ O
unknown _ _ O
etiology, _ _ O
and _ _ O
use _ _ O
of _ _ O
concomitant _ _ O
non-inducer _ _ O
AEDs _ _ O
were _ _ O
also _ _ O
established _ _ O
as _ _ O
positive _ _ O
predictors _ _ O
of _ _ O
efficacy _ _ O
(50% _ _ O
responder _ _ O
rate; _ _ O
P<0.01). _ _ O
Patients _ _ O
with _ _ O
more _ _ O
AEDs _ _ O
at _ _ O
baseline _ _ O
were _ _ O
associated _ _ O
with _ _ O
greater _ _ O
use _ _ O
of _ _ O
inducers _ _ O
(P<0.01), _ _ O
which _ _ O
may _ _ O
result _ _ O
in _ _ O
decreased _ _ O
exposure _ _ O
of _ _ O
perampanel _ _ O
in _ _ O
these _ _ O
patients _ _ O
and _ _ O
lower _ _ O
efficacy. _ _ O
Patients _ _ O
with _ _ O
1 _ _ O
AED _ _ O
at _ _ O
baseline _ _ O
had _ _ O
a _ _ O
significantly _ _ O
shorter _ _ O
time _ _ O
since _ _ O
diagnosis _ _ O
compared _ _ O
with _ _ O
patients _ _ O
in _ _ O
the _ _ O
3 _ _ O
(P<0.01) _ _ O
AEDs _ _ O
group, _ _ O
as _ _ O
well _ _ O
as _ _ O
a _ _ O
lower _ _ O
median _ _ O
seizure _ _ O
frequency _ _ O
at _ _ O
baseline _ _ O
compared _ _ O
to _ _ O
patients _ _ O
on _ _ O
3 _ _ O
AEDs _ _ O
(P<0.05), _ _ O
suggesting _ _ O
that _ _ O
the _ _ O
reduced _ _ O
efficacy _ _ O
of _ _ O
perampanel _ _ O
with _ _ O
3 _ _ O
AEDs _ _ O
may _ _ O
also _ _ O
be _ _ O
associated _ _ O
with _ _ O
the _ _ O
greater _ _ O
severity _ _ O
of _ _ O
seizures _ _ O
in _ _ O
the _ _ O
patient _ _ O
groups. _ _ O
The _ _ O
incidence _ _ O
of _ _ O
adverse _ _ O
events _ _ O
in _ _ O
perampanel-treated _ _ O
patients _ _ O
was _ _ O
similar _ _ O
regardless _ _ O
of _ _ O
the _ _ O
number _ _ O
of _ _ O
AEDs _ _ O
at _ _ O
baseline. _ _ O
Greater _ _ O
efficacy _ _ O
is _ _ O
predicted _ _ O
for _ _ O
patients _ _ O
receiving _ _ O
fewer _ _ O
concomitant _ _ O
AEDs _ _ O
when _ _ O
starting _ _ O
perampanel, _ _ O
as _ _ O
well _ _ O
as _ _ O
for _ _ O
those _ _ O
receiving _ _ O
concomitant _ _ O
treatment _ _ O
with _ _ O
AEDs _ _ O
that _ _ O
are _ _ O
not _ _ O
CYP3A4 _ _ O
enzyme-inducers, _ _ O
compared _ _ O
to _ _ O
patients _ _ O
treated _ _ O
with _ _ O
multiple _ _ O
concomitant _ _ O
AEDs. _ _ O
The _ _ O
results _ _ O
of _ _ O
this _ _ O
study _ _ O
provide _ _ O
additional _ _ O
information _ _ O
for _ _ O
clinicians _ _ O
considering _ _ O
adding _ _ O
perampanel _ _ O
to _ _ O
their _ _ O
patients' _ _ O
treatment _ _ O
regimen _ _ O
earlier _ _ O
rather _ _ O
than _ _ O
later, _ _ O
and _ _ O
offer _ _ O
evidence _ _ O
regarding _ _ O
the _ _ O
potential _ _ O
for _ _ O
increased _ _ O
efficacy _ _ O
with _ _ O
a _ _ O
decreased _ _ O
medication _ _ O
burden. _ _ O


-DOCSTART- -X- -X- O

A _ _ O
study _ _ O
of _ _ O
epilepsy _ _ O
patients _ _ O
with _ _ O
a _ _ O
reproducible _ _ O
range _ _ O
of _ _ O
photoparoxysmal _ _ B-Outcome
responses _ _ I-Outcome
(PPR) _ _ I-Outcome
(epileptiform _ _ O
discharges _ _ O
evoked _ _ O
by _ _ O
flashing _ _ O
lights) _ _ O
has _ _ O
been _ _ O
used _ _ O
as _ _ O
a _ _ O
proof-of-concept _ _ O
trial _ _ O
to _ _ O
determine _ _ O
if _ _ O
novel _ _ O
potential _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs) _ _ O
should _ _ O
proceed _ _ O
in _ _ O
development. _ _ O
The _ _ O
standard _ _ O
design _ _ O
for _ _ O
this _ _ O
trial _ _ O
requires _ _ O
a _ _ O
3-day _ _ O
inpatient _ _ O
stay _ _ O
and _ _ O
is _ _ O
single-blind. _ _ O
We _ _ O
evaluated _ _ O
two _ _ O
marketed _ _ O
and _ _ O
effective _ _ O
AEDs-one _ _ O
narrow-spectrum _ _ O
[carbamazepine _ _ B-Intervention
(CBZ)], _ _ I-Intervention
and _ _ O
one _ _ O
broad-spectrum _ _ O
[levetiracetam _ _ B-Intervention
(LEV)]-using _ _ I-Intervention
a _ _ O
novel _ _ O
double-blinded, _ _ O
cross-over _ _ O
outpatient _ _ O
version _ _ O
of _ _ O
the _ _ O
trial _ _ O
to _ _ O
detect _ _ O
acute _ _ O
drug _ _ O
effects _ _ O
of _ _ O
the _ _ O
two _ _ O
marketed _ _ O
AEDs _ _ O
on _ _ O
photosensitivity. _ _ O
We _ _ O
tested _ _ O
6 _ _ O
patients _ _ B-Patient
with _ _ I-Patient
a _ _ I-Patient
known _ _ I-Patient
stable _ _ I-Patient
photosensitivity _ _ I-Patient
response, _ _ I-Patient
using _ _ O
single _ _ B-Intervention
oral _ _ I-Intervention
doses _ _ I-Intervention
of _ _ I-Intervention
CBZ _ _ I-Intervention
400 _ _ I-Intervention
mg _ _ I-Intervention
and _ _ I-Intervention
LEV _ _ I-Intervention
1000 _ _ I-Intervention
mg, _ _ I-Intervention
compared _ _ O
to _ _ O
2 _ _ B-Control
test _ _ I-Control
days _ _ I-Control
with _ _ I-Control
single _ _ I-Control
placebo _ _ I-Control
doses. _ _ I-Control
Patients _ _ B-Outcome
who _ _ I-Outcome
received _ _ I-Outcome
LEV _ _ I-Outcome
had _ _ I-Outcome
the _ _ I-Outcome
lowest _ _ I-Outcome
mean _ _ I-Outcome
PPR _ _ I-Outcome
(compared _ _ I-Outcome
with _ _ I-Outcome
placebo _ _ I-Outcome
and _ _ I-Outcome
CBZ). _ _ I-Outcome
The _ _ O
mixed _ _ O
effect _ _ O
model _ _ O
showed _ _ O
a _ _ O
significant _ _ O
effect _ _ O
of _ _ O
LEV _ _ O
in _ _ O
all _ _ O
eye _ _ O
closure _ _ O
conditions _ _ O
(p _ _ O
< _ _ O
0.001). _ _ O
There _ _ O
was _ _ O
no _ _ O
evidence _ _ O
of _ _ O
a _ _ O
significant _ _ O
change _ _ O
in _ _ O
PPR _ _ O
after _ _ O
CBZ _ _ O
or _ _ O
placebo _ _ O
treatment. _ _ O
In _ _ O
conclusion, _ _ O
LEV _ _ O
1000 _ _ O
mg, _ _ O
but _ _ O
not _ _ O
CBZ _ _ O
400 _ _ O
mg, _ _ O
was _ _ O
effective _ _ O
in _ _ O
suppressing _ _ O
photosensitivity _ _ O
within _ _ O
a _ _ O
6-h _ _ O
period _ _ O
compared _ _ O
with _ _ O
placebo _ _ O
showing _ _ O
the _ _ O
ability _ _ O
of _ _ O
our _ _ O
novel _ _ O
photosensitivity _ _ O
trial _ _ O
design _ _ O
to _ _ O
demonstrate _ _ O
effects _ _ O
of _ _ O
broad-spectrum _ _ O
AEDs. _ _ O
We _ _ O
cannot _ _ O
confirm _ _ O
the _ _ O
ability _ _ O
of _ _ O
the _ _ O
photosensitivity _ _ O
trial _ _ O
to _ _ O
detect _ _ O
the _ _ O
narrow-spectrum _ _ O
AED _ _ O
CBZ _ _ O
in _ _ O
our _ _ O
design. _ _ O
The _ _ O
novel _ _ O
outpatient _ _ O
study _ _ O
design _ _ O
is _ _ O
feasible _ _ O
and _ _ O
is _ _ O
expected _ _ O
to _ _ O
reduce _ _ O
costs _ _ O
compared _ _ O
with _ _ O
previous _ _ O
methodology. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
pharmacokinetics _ _ O
of _ _ O
a _ _ B-Control
purified _ _ I-Control
oral _ _ I-Control
cannabidiol _ _ I-Control
(CBD) _ _ I-Control
capsule _ _ I-Control
administered _ _ I-Control
with _ _ B-Intervention
and _ _ O
without _ _ B-Control
food _ _ I-Control
in _ _ O
adults _ _ O
with _ _ O
refractory _ _ O
epilepsy. _ _ O
Adult _ _ O
patients _ _ O
who _ _ O
were _ _ O
prescribed _ _ O
CBD _ _ O
for _ _ O
seizures, _ _ O
had _ _ O
localization-related _ _ O
intractable _ _ O
epilepsy _ _ O
with _ _ O
≥4 _ _ O
seizures _ _ O
per _ _ O
month, _ _ O
and _ _ O
qualified _ _ O
for _ _ O
Minnesota _ _ O
cannabis _ _ O
were _ _ O
enrolled. _ _ O
A _ _ O
single _ _ O
dose _ _ O
of _ _ O
99% _ _ O
pure _ _ O
CBD _ _ O
capsules _ _ O
was _ _ O
taken _ _ O
under _ _ O
both _ _ O
fasting _ _ O
(no _ _ O
breakfast) _ _ O
and _ _ O
fed _ _ O
(high _ _ O
fat _ _ O
840-860 _ _ O
calorie) _ _ O
conditions. _ _ O
Blood _ _ O
sampling _ _ O
for _ _ O
CBD _ _ O
plasma _ _ O
concentrations _ _ O
was _ _ O
performed _ _ O
under _ _ O
each _ _ O
condition _ _ O
between _ _ O
0 _ _ O
and _ _ O
72 _ _ O
hours _ _ O
post-dose _ _ O
and _ _ O
measured _ _ O
by _ _ O
a _ _ O
validated _ _ O
liquid _ _ O
chormatography-mass _ _ O
spectometry _ _ O
assay. _ _ O
CBD _ _ O
pharmacokinetic _ _ O
profiles _ _ O
including _ _ O
maximum _ _ O
concentration _ _ O
(Cmax _ _ O
), _ _ O
area-under-the-curve _ _ O
from _ _ O
zero _ _ O
to _ _ O
infinity _ _ O
(AUC0-∞ _ _ O
), _ _ O
and _ _ O
time-to-maximum _ _ O
concentration _ _ O
(Tmax _ _ O
) _ _ O
were _ _ O
calculated. _ _ O
The _ _ O
confidence _ _ O
intervals _ _ O
(CIs) _ _ O
for _ _ O
log-transformed _ _ O
Cmax _ _ O
and _ _ O
AUC0-∞ _ _ O
ratios _ _ O
between _ _ O
fed _ _ O
and _ _ O
fasting _ _ O
states _ _ O
were _ _ O
calculated. _ _ O
Seizure _ _ O
and _ _ O
adverse _ _ O
events _ _ O
information _ _ O
was _ _ O
collected. _ _ O
Eight _ _ O
patients _ _ O
completed _ _ O
the _ _ O
study. _ _ O
On _ _ O
average _ _ O
Cmax _ _ O
was _ _ O
14 _ _ O
times _ _ O
and _ _ O
AUC0-∞ _ _ O
4 _ _ O
times _ _ O
higher _ _ O
in _ _ O
the _ _ O
fed _ _ O
state. _ _ O
The _ _ O
90% _ _ O
CI _ _ O
for _ _ O
the _ _ O
ratio _ _ O
of _ _ O
fed _ _ O
versus _ _ O
fast _ _ O
conditions _ _ O
for _ _ O
Cmax _ _ O
and _ _ O
AUC0-∞ _ _ O
were _ _ O
7.47-31.86 _ _ O
and _ _ O
3.42-7.82, _ _ O
respectively. _ _ O
No _ _ O
sequence _ _ O
or _ _ O
period _ _ O
effect _ _ O
for _ _ O
Cmax _ _ O
and _ _ O
AUC0-∞ _ _ O
was _ _ O
observed. _ _ O
No _ _ O
adverse _ _ O
events _ _ O
were _ _ O
reported. _ _ O
Administering _ _ O
CBD _ _ O
as _ _ O
a _ _ O
capsule _ _ O
rather _ _ O
than _ _ O
a _ _ O
liquid _ _ O
allows _ _ O
for _ _ O
more _ _ O
precise _ _ O
determination _ _ O
of _ _ O
pharmacokinetics _ _ O
parameters _ _ O
and _ _ O
is _ _ O
more _ _ O
representative _ _ O
of _ _ O
CBD _ _ O
swallowed _ _ O
products. _ _ O
The _ _ O
fat _ _ O
content _ _ O
of _ _ O
a _ _ O
meal _ _ O
can _ _ O
lead _ _ O
to _ _ O
significant _ _ O
increases _ _ O
in _ _ O
Cmax _ _ O
and _ _ O
AUC0-∞ _ _ O
and _ _ O
can _ _ O
account _ _ O
for _ _ O
variability _ _ O
in _ _ O
bioavailability _ _ O
and _ _ O
overall _ _ O
drug _ _ O
exposure _ _ O
within _ _ O
patients _ _ O
with _ _ O
oral _ _ O
products. _ _ O


-DOCSTART- -X- -X- O

Valproate _ _ B-Control
is _ _ O
widely _ _ O
accepted _ _ O
as _ _ O
a _ _ O
drug _ _ O
of _ _ O
first _ _ O
choice _ _ O
for _ _ O
patients _ _ B-Patient
with _ _ I-Patient
generalised _ _ I-Patient
onset _ _ I-Patient
seizures, _ _ I-Patient
and _ _ O
its _ _ O
broad _ _ O
spectrum _ _ O
of _ _ O
efficacy _ _ O
means _ _ O
it _ _ O
is _ _ O
recommended _ _ O
for _ _ O
patients _ _ B-Patient
with _ _ I-Patient
seizures _ _ I-Patient
that _ _ I-Patient
are _ _ I-Patient
difficult _ _ I-Patient
to _ _ I-Patient
classify. _ _ I-Patient
Lamotrigine _ _ B-Intervention
and _ _ I-Intervention
topiramate _ _ I-Intervention
are _ _ O
also _ _ O
thought _ _ O
to _ _ O
possess _ _ O
broad _ _ O
spectrum _ _ O
activity. _ _ O
The _ _ O
SANAD _ _ O
study _ _ O
aimed _ _ O
to _ _ O
compare _ _ O
the _ _ O
longer-term _ _ O
effects _ _ O
of _ _ O
these _ _ O
drugs _ _ O
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
generalised _ _ I-Patient
onset _ _ I-Patient
seizures _ _ I-Patient
or _ _ I-Patient
seizures _ _ I-Patient
that _ _ I-Patient
are _ _ I-Patient
difficult _ _ I-Patient
to _ _ I-Patient
classify. _ _ I-Patient
SANAD _ _ O
was _ _ O
an _ _ O
unblinded _ _ O
randomised _ _ O
controlled _ _ O
trial _ _ O
in _ _ O
hospital-based _ _ O
outpatient _ _ O
clinics _ _ O
in _ _ O
the _ _ B-Patient
UK. _ _ I-Patient
Arm _ _ O
B _ _ O
of _ _ O
the _ _ O
study _ _ O
recruited _ _ O
716 _ _ O
patients _ _ B-Patient
for _ _ I-Patient
whom _ _ I-Patient
valproate _ _ I-Patient
was _ _ I-Patient
considered _ _ I-Patient
to _ _ I-Patient
be _ _ I-Patient
standard _ _ I-Patient
treatment. _ _ I-Patient
Patients _ _ O
were _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
valproate, _ _ B-Control
lamotrigine, _ _ B-Intervention
or _ _ I-Intervention
topiramate _ _ I-Intervention
between _ _ O
Jan _ _ O
12, _ _ O
1999, _ _ O
and _ _ O
Aug _ _ O
31, _ _ O
2004, _ _ O
and _ _ O
follow-up _ _ O
data _ _ O
were _ _ O
obtained _ _ O
up _ _ O
to _ _ O
Jan _ _ O
13, _ _ O
2006. _ _ O
Primary _ _ O
outcomes _ _ O
were _ _ O
time _ _ O
to _ _ O
treatment _ _ O
failure, _ _ O
and _ _ O
time _ _ O
to _ _ O
1-year _ _ O
remission, _ _ O
and _ _ O
analysis _ _ O
was _ _ O
by _ _ O
both _ _ O
intention _ _ O
to _ _ O
treat _ _ O
and _ _ O
per _ _ O
protocol. _ _ O
This _ _ O
study _ _ O
is _ _ O
registered _ _ O
as _ _ O
an _ _ O
International _ _ O
Standard _ _ O
Randomised _ _ O
Controlled _ _ O
Trial, _ _ O
number _ _ O
ISRCTN38354748. _ _ O
For _ _ B-Outcome
time _ _ I-Outcome
to _ _ I-Outcome
treatment _ _ I-Outcome
failure, _ _ I-Outcome
valproate _ _ I-Outcome
was _ _ I-Outcome
significantly _ _ I-Outcome
better _ _ I-Outcome
than _ _ I-Outcome
topiramate _ _ I-Outcome
(hazard _ _ I-Outcome
ratio _ _ I-Outcome
1.57 _ _ I-Outcome
[95% _ _ I-Outcome
CI _ _ I-Outcome
1.19-2.08]), _ _ I-Outcome
but _ _ I-Outcome
there _ _ I-Outcome
was _ _ I-Outcome
no _ _ I-Outcome
significant _ _ I-Outcome
difference _ _ I-Outcome
between _ _ I-Outcome
valproate _ _ I-Outcome
and _ _ I-Outcome
lamotrigine _ _ I-Outcome
(1.25 _ _ I-Outcome
[0.94-1.68]). _ _ I-Outcome
For _ _ O
patients _ _ O
with _ _ O
an _ _ O
idiopathic _ _ O
generalised _ _ O
epilepsy, _ _ O
valproate _ _ O
was _ _ O
significantly _ _ O
better _ _ O
than _ _ O
both _ _ O
lamotrigine _ _ O
(1.55 _ _ O
[1.07-2.24] _ _ O
and _ _ O
topiramate _ _ O
(1.89 _ _ O
[1.32-2.70]). _ _ O
For _ _ O
time _ _ O
to _ _ O
12-month _ _ O
remission _ _ O
valproate _ _ O
was _ _ O
significantly _ _ O
better _ _ O
than _ _ O
lamotrigine _ _ O
overall _ _ O
(0.76 _ _ O
[0.62-0.94]), _ _ O
and _ _ O
for _ _ O
the _ _ O
subgroup _ _ O
with _ _ O
an _ _ O
idiopathic _ _ O
generalised _ _ O
epilepsy _ _ O
0.68 _ _ O
(0.53-0.89). _ _ O
But _ _ O
there _ _ O
was _ _ O
no _ _ O
significant _ _ O
difference _ _ O
between _ _ O
valproate _ _ O
and _ _ O
topiramate _ _ O
in _ _ O
either _ _ O
the _ _ O
analysis _ _ O
overall _ _ O
or _ _ O
for _ _ O
the _ _ O
subgroup _ _ O
with _ _ O
an _ _ O
idiopathic _ _ O
generalised _ _ O
epilepsy. _ _ O
Valproate _ _ O
is _ _ O
better _ _ O
tolerated _ _ O
than _ _ O
topiramate _ _ O
and _ _ O
more _ _ O
efficacious _ _ O
than _ _ O
lamotrigine, _ _ O
and _ _ O
should _ _ O
remain _ _ O
the _ _ O
drug _ _ O
of _ _ O
first _ _ O
choice _ _ O
for _ _ O
many _ _ O
patients _ _ O
with _ _ O
generalised _ _ O
and _ _ O
unclassified _ _ O
epilepsies. _ _ O
However, _ _ O
because _ _ O
of _ _ O
known _ _ O
potential _ _ O
adverse _ _ O
effects _ _ O
of _ _ O
valproate _ _ O
during _ _ O
pregnancy, _ _ O
the _ _ O
benefits _ _ O
for _ _ O
seizure _ _ O
control _ _ O
in _ _ O
women _ _ O
of _ _ O
childbearing _ _ O
years _ _ O
should _ _ O
be _ _ O
considered. _ _ O


-DOCSTART- -X- -X- O

In _ _ O
this _ _ O
prospective, _ _ O
randomized, _ _ O
open _ _ O
label _ _ O
study, _ _ O
we _ _ O
compared _ _ O
the _ _ O
effect _ _ O
on _ _ O
seizure _ _ O
recurrence _ _ O
and _ _ O
quality-of-life _ _ O
parameters, _ _ O
of _ _ O
two _ _ O
different _ _ O
protocols _ _ O
of _ _ O
music _ _ O
therapy _ _ O
in _ _ O
children _ _ B-Patient
and _ _ I-Patient
adolescents _ _ I-Patient
with _ _ I-Patient
refractory _ _ I-Patient
epileptic _ _ I-Patient
encephalopathies. _ _ I-Patient
Nine _ _ O
out _ _ O
of _ _ O
19 _ _ O
patients _ _ B-Patient
(13 _ _ I-Patient
males _ _ I-Patient
and _ _ I-Patient
6 _ _ I-Patient
females, _ _ I-Patient
aged _ _ I-Patient
between _ _ I-Patient
1 _ _ I-Patient
and _ _ I-Patient
24years) _ _ I-Patient
were _ _ O
randomized _ _ O
to _ _ O
listen _ _ O
to _ _ O
Mozart's _ _ B-Intervention
sonata _ _ I-Intervention
in _ _ I-Intervention
D _ _ I-Intervention
major _ _ I-Intervention
for _ _ I-Intervention
two _ _ I-Intervention
pianos _ _ I-Intervention
K448 _ _ I-Intervention
for _ _ I-Intervention
2h/day _ _ I-Intervention
for _ _ I-Intervention
2weeks; _ _ I-Intervention
other _ _ O
10 _ _ O
children _ _ O
were _ _ O
randomized _ _ O
on _ _ O
a _ _ B-Control
set _ _ I-Control
of _ _ I-Control
Mozart's _ _ I-Control
compositions. _ _ I-Control
In _ _ B-Outcome
group _ _ I-Outcome
1 _ _ I-Outcome
(K448), _ _ I-Outcome
2/9 _ _ I-Outcome
children _ _ I-Outcome
(22.2%) _ _ I-Outcome
had _ _ I-Outcome
a _ _ I-Outcome
≥75% _ _ I-Outcome
seizure _ _ I-Outcome
decrease; _ _ I-Outcome
two _ _ I-Outcome
patients _ _ I-Outcome
had _ _ I-Outcome
less _ _ I-Outcome
than _ _ I-Outcome
50% _ _ I-Outcome
seizure _ _ I-Outcome
reduction, _ _ I-Outcome
and _ _ I-Outcome
the _ _ I-Outcome
other _ _ I-Outcome
five _ _ I-Outcome
were _ _ I-Outcome
unchanged. _ _ I-Outcome
In _ _ O
group _ _ O
2 _ _ O
(set _ _ O
Mozart), _ _ O
7/10 _ _ O
patients _ _ O
(70%) _ _ O
had _ _ O
a _ _ O
significant _ _ O
seizure _ _ O
reduction _ _ O
(specifically, _ _ O
≥50% _ _ O
in _ _ O
1/10; _ _ O
≥75% _ _ O
in _ _ O
4/10; _ _ O
100% _ _ O
in _ _ O
2/10). _ _ O
An _ _ O
overall _ _ O
more _ _ O
significant _ _ O
behavioral _ _ O
improvement _ _ O
including _ _ O
less _ _ O
irritability _ _ O
and _ _ O
tearfulness, _ _ O
reduced _ _ O
self-/heteroaggression, _ _ O
a _ _ O
better _ _ O
daytime _ _ O
vigilance, _ _ O
and _ _ O
nighttime _ _ O
sleep _ _ O
quality, _ _ O
was _ _ O
also _ _ O
reported _ _ O
in _ _ O
children _ _ O
from _ _ O
group _ _ O
2. _ _ O
In _ _ O
conclusion, _ _ O
the _ _ O
present _ _ O
study _ _ O
seems _ _ O
to _ _ O
confirm _ _ O
that _ _ O
music _ _ O
therapy _ _ O
may _ _ O
be _ _ O
an _ _ O
additional, _ _ O
nonpharmacological, _ _ O
effective _ _ O
treatment _ _ O
for _ _ O
patients _ _ O
with _ _ O
refractory _ _ O
epileptic _ _ O
seizures _ _ O
in _ _ O
childhood. _ _ O
The _ _ O
Mozart's _ _ O
set _ _ O
of _ _ O
different _ _ O
compositions _ _ O
can _ _ O
be _ _ O
better _ _ O
accepted _ _ O
and _ _ O
effective _ _ O
than _ _ O
the _ _ O
K448. _ _ O


-DOCSTART- -X- -X- O

This _ _ O
randomized, _ _ O
double-blind, _ _ O
dose-ranging _ _ O
study _ _ O
evaluated _ _ O
safety _ _ O
and _ _ O
efficacy _ _ O
of _ _ O
clobazam _ _ B-Intervention
(CLB) _ _ I-Intervention
as _ _ I-Intervention
adjunctive _ _ I-Intervention
therapy _ _ I-Intervention
for _ _ O
drop _ _ B-Patient
seizures _ _ I-Patient
in _ _ I-Patient
patients _ _ I-Patient
with _ _ I-Patient
Lennox-Gastaut _ _ I-Patient
syndrome _ _ I-Patient
(LGS). _ _ I-Patient
Sixty-eight _ _ O
patients _ _ B-Patient
with _ _ I-Patient
LGS _ _ I-Patient
aged _ _ I-Patient
2-26 _ _ I-Patient
years _ _ I-Patient
were _ _ O
administered _ _ O
CLB _ _ B-Intervention
(low _ _ I-Intervention
dose _ _ I-Intervention
= _ _ I-Intervention
target _ _ I-Intervention
0.25 _ _ I-Intervention
mg/kg/day; _ _ I-Intervention
high _ _ B-Control
dose _ _ I-Control
= _ _ I-Control
target _ _ I-Control
1.0 _ _ I-Control
mg/kg/day). _ _ I-Control
The _ _ O
study _ _ O
consisted _ _ O
of _ _ O
4-week _ _ O
baseline, _ _ O
3-week _ _ O
titration, _ _ O
and _ _ O
4-week _ _ O
maintenance _ _ O
periods, _ _ O
followed _ _ O
by _ _ O
a _ _ O
3-week _ _ O
taper _ _ O
or _ _ O
continuation _ _ O
in _ _ O
an _ _ O
open-label _ _ O
study. _ _ O
Seizure _ _ O
frequency _ _ O
was _ _ O
recorded _ _ O
in _ _ O
a _ _ O
diary _ _ O
by _ _ O
the _ _ O
parent/caregiver _ _ O
throughout _ _ O
the _ _ O
study. _ _ O
Weekly _ _ B-Outcome
drop _ _ I-Outcome
seizure _ _ I-Outcome
rates _ _ I-Outcome
were _ _ I-Outcome
significantly _ _ I-Outcome
reduced _ _ I-Outcome
from _ _ I-Outcome
baseline _ _ I-Outcome
in _ _ I-Outcome
both _ _ I-Outcome
the _ _ I-Outcome
high-dose _ _ I-Outcome
and _ _ I-Outcome
low-dose _ _ I-Outcome
groups; _ _ I-Outcome
the _ _ I-Outcome
reduction _ _ I-Outcome
was _ _ I-Outcome
significantly _ _ I-Outcome
greater _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
high-dose _ _ I-Outcome
group. _ _ I-Outcome
A _ _ O
significantly _ _ O
greater _ _ O
proportion _ _ O
of _ _ O
patients _ _ O
in _ _ O
the _ _ O
high-dose _ _ O
group _ _ O
experienced _ _ O
reductions _ _ O
in _ _ O
drop _ _ O
seizures _ _ O
of _ _ O
>or=25%, _ _ O
>or=50%, _ _ O
and _ _ O
>or=75% _ _ O
compared _ _ O
to _ _ O
the _ _ O
low-dose _ _ O
group; _ _ O
more _ _ O
patients _ _ O
in _ _ O
the _ _ O
high-dose _ _ O
group _ _ O
experienced _ _ O
a _ _ O
100% _ _ O
reduction, _ _ O
but _ _ O
the _ _ O
difference _ _ O
was _ _ O
not _ _ O
significant. _ _ O
Nondrop _ _ O
seizures _ _ O
were _ _ O
also _ _ O
reduced _ _ O
in _ _ O
a _ _ O
dose-dependent _ _ O
manner. _ _ O
In _ _ O
both _ _ O
investigator _ _ O
and _ _ O
parent/caregiver _ _ O
global _ _ O
evaluations, _ _ O
patients _ _ O
in _ _ O
the _ _ O
high-dose _ _ O
group _ _ O
showed _ _ O
significantly _ _ O
greater _ _ O
improvements _ _ O
in _ _ O
overall _ _ O
symptoms _ _ O
compared _ _ O
to _ _ O
low-dose _ _ O
CLB. _ _ O
Adverse _ _ O
events _ _ O
were _ _ O
generally _ _ O
mild _ _ O
or _ _ O
moderate, _ _ O
and _ _ O
were _ _ O
similar _ _ O
between _ _ O
dose _ _ O
groups. _ _ O
Five _ _ O
serious _ _ O
adverse _ _ O
events _ _ O
were _ _ O
reported _ _ O
in _ _ O
four _ _ O
patients, _ _ O
but _ _ O
in _ _ O
no _ _ O
case _ _ O
was _ _ O
CLB _ _ O
discontinued. _ _ O
Clobazam _ _ O
was _ _ O
well _ _ O
tolerated _ _ O
and _ _ O
reduced _ _ O
drop _ _ O
seizure _ _ O
rates; _ _ O
high-dose _ _ O
CLB _ _ O
was _ _ O
more _ _ O
effective _ _ O
than _ _ O
low-dose _ _ O
CLB. _ _ O
Other _ _ O
seizure _ _ O
types _ _ O
were _ _ O
also _ _ O
reduced. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
determine _ _ O
whether _ _ O
an _ _ B-Intervention
acetylcholinesterase _ _ I-Intervention
inhibitor, _ _ I-Intervention
such _ _ I-Intervention
as _ _ I-Intervention
donepezil, _ _ I-Intervention
would _ _ O
improve _ _ O
memory _ _ O
or _ _ O
other _ _ O
cognitive/psychological _ _ O
functions _ _ O
in _ _ O
epilepsy _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
subjective _ _ I-Patient
memory _ _ I-Patient
complaints. _ _ I-Patient
Twenty-three _ _ O
epilepsy _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
subjective _ _ I-Patient
memory _ _ I-Patient
difficulty _ _ I-Patient
were _ _ O
randomized _ _ O
to _ _ O
either _ _ O
3 _ _ B-Intervention
months _ _ I-Intervention
of _ _ I-Intervention
donepezil _ _ I-Intervention
(10 _ _ I-Intervention
mg/day) _ _ I-Intervention
or _ _ O
3 _ _ B-Control
months _ _ I-Control
of _ _ I-Control
placebo _ _ I-Control
treatment, _ _ I-Control
and _ _ O
then _ _ O
crossed _ _ O
over _ _ O
to _ _ O
the _ _ O
other _ _ O
treatment _ _ O
arm. _ _ O
Patients _ _ O
and _ _ O
physicians _ _ O
were _ _ O
blinded _ _ O
to _ _ O
treatment _ _ O
phase _ _ O
throughout _ _ O
data _ _ O
acquisition. _ _ O
Assessment _ _ O
of _ _ O
memory _ _ O
and _ _ O
other _ _ O
cognitive _ _ O
functions, _ _ O
subjective _ _ O
memory, _ _ O
mood, _ _ O
and _ _ O
self-rated _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QOL) _ _ O
and _ _ O
social _ _ O
functioning _ _ O
was _ _ O
performed _ _ O
at _ _ O
baseline _ _ O
and _ _ O
following _ _ O
completion _ _ O
of _ _ O
both _ _ O
treatment _ _ O
phases. _ _ O
Seizure _ _ O
frequency _ _ O
and _ _ O
severity _ _ O
as _ _ O
well _ _ O
as _ _ O
treatment _ _ O
emergent _ _ O
adverse _ _ O
effects _ _ O
were _ _ O
also _ _ O
monitored. _ _ O
Donepezil _ _ B-Intervention
treatment _ _ I-Intervention
was _ _ B-Outcome
not _ _ I-Outcome
associated _ _ I-Outcome
with _ _ I-Outcome
improvement _ _ I-Outcome
in _ _ I-Outcome
memory _ _ I-Outcome
or _ _ I-Outcome
other _ _ I-Outcome
cognitive _ _ I-Outcome
functions, _ _ I-Outcome
mood, _ _ I-Outcome
social _ _ I-Outcome
functioning _ _ I-Outcome
or _ _ I-Outcome
QOL. _ _ I-Outcome
Comparable _ _ B-Outcome
increases _ _ I-Outcome
in _ _ I-Outcome
self-rated _ _ I-Outcome
memory _ _ I-Outcome
functioning _ _ I-Outcome
relative _ _ I-Outcome
to _ _ I-Outcome
baseline _ _ I-Outcome
were _ _ I-Outcome
evident _ _ I-Outcome
during _ _ I-Outcome
donepezil _ _ I-Outcome
and _ _ I-Outcome
placebo _ _ I-Outcome
phases. _ _ I-Outcome
Donepezil _ _ O
treatment _ _ O
was _ _ O
not _ _ O
associated _ _ O
with _ _ O
increased _ _ O
seizure _ _ O
frequency _ _ O
or _ _ O
severity. _ _ O
Similar _ _ O
to _ _ O
group _ _ O
results, _ _ O
analysis _ _ O
of _ _ O
change _ _ O
within _ _ O
individual _ _ O
patients _ _ O
as _ _ O
a _ _ O
function _ _ O
of _ _ O
treatment _ _ O
phase _ _ O
also _ _ O
showed _ _ O
neither _ _ O
significant _ _ O
benefit _ _ O
nor _ _ O
detriment _ _ O
associated _ _ O
with _ _ O
donepezil. _ _ O
This _ _ O
study _ _ O
found _ _ O
no _ _ O
benefit _ _ O
on _ _ O
memory _ _ O
or _ _ O
other _ _ O
cognitive/psychological _ _ O
functions _ _ O
in _ _ O
a _ _ O
heterogeneous _ _ O
group _ _ O
of _ _ O
epilepsy _ _ O
patients _ _ O
with _ _ O
subjective _ _ O
memory _ _ O
difficulty. _ _ O
Further _ _ O
investigation _ _ O
would _ _ O
be _ _ O
required _ _ O
to _ _ O
determine _ _ O
whether _ _ O
individual _ _ O
patients, _ _ O
or _ _ O
those _ _ O
with _ _ O
particular _ _ O
epilepsy _ _ O
syndromes, _ _ O
might _ _ O
benefit _ _ O
from _ _ O
donepezil _ _ O
or _ _ O
other _ _ O
acetylcholinesterase _ _ O
inhibitors, _ _ O
or _ _ O
if _ _ O
a _ _ O
higher _ _ O
dosage _ _ O
might _ _ O
be _ _ O
effective. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
assess _ _ O
the _ _ O
developmental _ _ O
progression _ _ O
and _ _ O
compare _ _ O
the _ _ O
developmental _ _ O
attainments _ _ O
of _ _ O
children _ _ B-Patient
treated _ _ I-Patient
with _ _ I-Patient
two _ _ I-Patient
hormonal _ _ I-Patient
therapies _ _ I-Patient
for _ _ I-Patient
infantile _ _ I-Patient
spasms _ _ I-Patient
(IS) _ _ I-Patient
over _ _ I-Patient
two _ _ I-Patient
years _ _ I-Patient
(seizure _ _ O
and _ _ O
EEG _ _ O
outcomes _ _ O
of _ _ O
this _ _ O
RCT _ _ O
published _ _ O
previously). _ _ O
Newly _ _ B-Patient
diagnosed _ _ I-Patient
infants _ _ I-Patient
with _ _ I-Patient
IS _ _ I-Patient
were _ _ O
randomised _ _ O
to _ _ O
receive _ _ O
adrenocorticotrophin _ _ B-Intervention
(ACTH) _ _ I-Intervention
or _ _ O
prednisolone _ _ B-Control
for _ _ I-Control
14 _ _ I-Control
days. _ _ I-Control
All _ _ O
underwent _ _ O
Bayley _ _ O
III _ _ O
Infant _ _ O
and _ _ O
Toddler _ _ O
Assessments _ _ O
in _ _ O
cognitive _ _ O
(Cog), _ _ O
receptive _ _ O
(RC) _ _ O
and _ _ O
expressive _ _ O
(EC) _ _ O
communication, _ _ O
fine _ _ O
(FM) _ _ O
and _ _ O
gross _ _ O
(GM) _ _ O
motor _ _ O
developmental _ _ O
subsets _ _ O
at _ _ O
baseline _ _ O
(T0), _ _ O
one-year _ _ O
(T1) _ _ O
and _ _ O
two-years _ _ O
(T2). _ _ O
95 _ _ O
infants _ _ O
randomised _ _ O
to _ _ O
prednisolone _ _ O
(n _ _ O
= _ _ O
48) _ _ O
and _ _ O
ACTH _ _ O
(n _ _ O
= _ _ O
47) _ _ O
groups _ _ O
were _ _ O
eligible _ _ O
for _ _ O
developmental _ _ O
assessments. _ _ O
Mean _ _ O
age _ _ O
at _ _ O
initial _ _ O
assessment _ _ O
was _ _ O
8.75 _ _ O
months _ _ O
(SD _ _ O
= _ _ O
6.37, _ _ O
range _ _ O
1.46-34.4 _ _ O
months). _ _ O
48 _ _ O
children _ _ O
presented _ _ O
for _ _ O
all _ _ O
three _ _ O
assessments. _ _ O
Mean _ _ O
composite _ _ O
scores _ _ O
of _ _ O
each _ _ O
developmental _ _ O
domain _ _ O
improved _ _ O
across _ _ O
the _ _ O
three _ _ O
time _ _ O
points; _ _ O
but _ _ O
the _ _ O
progression _ _ O
was _ _ O
significant _ _ O
only _ _ O
in _ _ O
relation _ _ O
to _ _ O
motor _ _ O
development _ _ O
(p _ _ O
= _ _ O
0.04). _ _ O
When _ _ O
comparing _ _ O
the _ _ O
treatment _ _ O
outcomes _ _ O
at _ _ O
2-years, _ _ O
mean _ _ O
composite _ _ O
scores _ _ O
of _ _ O
children _ _ O
treated _ _ O
with _ _ O
ACTH _ _ O
were _ _ O
significantly _ _ O
lower _ _ O
in _ _ O
motor _ _ O
domain _ _ O
(p _ _ O
= _ _ O
0.023). _ _ O
As _ _ O
for _ _ O
developmental _ _ O
delay, _ _ O
the _ _ O
ACTH _ _ O
group _ _ O
(n _ _ O
= _ _ O
32) _ _ O
showed _ _ O
significant _ _ O
delay _ _ O
in _ _ O
expressive _ _ O
communication _ _ O
(adjusted _ _ O
OR _ _ O
5.46, _ _ O
95% _ _ O
CI: _ _ O
1.1, _ _ O
28.57; _ _ O
p _ _ O
= _ _ O
0.04) _ _ O
and _ _ O
fine _ _ O
motor _ _ O
(adjusted _ _ O
OR _ _ O
9.4, _ _ O
95% _ _ O
CI: _ _ O
1.1, _ _ O
83.3; _ _ O
p _ _ O
= _ _ O
0.04) _ _ O
at _ _ O
T2 _ _ O
compared _ _ O
to _ _ O
the _ _ O
prednisolone _ _ O
(n _ _ O
= _ _ O
30) _ _ O
in _ _ O
a _ _ O
regression _ _ O
analysis. _ _ O
The _ _ O
number _ _ O
of _ _ O
children _ _ O
with _ _ O
delay _ _ O
at _ _ O
the _ _ O
2 _ _ O
year _ _ O
follow _ _ O
up _ _ O
were _ _ O
significantly _ _ O
higher _ _ O
in _ _ O
two _ _ O
domains _ _ O
in _ _ O
the _ _ O
ACTH _ _ O
group _ _ O
compared _ _ O
to _ _ O
the _ _ O
prednisolone _ _ O
group. _ _ O
Overall _ _ O
results _ _ O
do _ _ O
not _ _ O
show _ _ O
a _ _ O
significant _ _ O
advantage _ _ O
of _ _ O
ACTH _ _ O
over _ _ O
prednisolone _ _ O
for _ _ O
developmental _ _ O
outcomes _ _ O
at _ _ O
two _ _ O
years, _ _ O
but _ _ O
further _ _ O
comparative _ _ O
studies _ _ O
over _ _ O
longer _ _ O
periods _ _ O
are _ _ O
required _ _ O
for _ _ O
more _ _ O
definitive _ _ O
conclusions. _ _ O


-DOCSTART- -X- -X- O

this _ _ O
study _ _ O
examined _ _ O
a _ _ B-Intervention
brief _ _ I-Intervention
lifestyle _ _ I-Intervention
self-management _ _ I-Intervention
intervention, _ _ I-Intervention
based _ _ I-Intervention
on _ _ I-Intervention
self-determination _ _ I-Intervention
theory, _ _ I-Intervention
to _ _ O
manage _ _ O
seizure _ _ O
frequency, _ _ O
and _ _ O
its _ _ O
effects _ _ O
on _ _ O
health-related _ _ O
quality _ _ O
of _ _ O
life _ _ O
and _ _ O
resilience _ _ O
in _ _ O
people _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
aged _ _ I-Patient
over _ _ I-Patient
18 _ _ I-Patient
years. _ _ I-Patient
most _ _ O
people _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
can _ _ O
identify _ _ O
factors _ _ O
that _ _ O
may _ _ O
trigger _ _ O
seizures _ _ O
and _ _ O
may _ _ O
try _ _ O
to _ _ O
avoid _ _ O
these; _ _ O
however, _ _ O
education _ _ O
from _ _ O
clinicians _ _ O
on _ _ O
this _ _ O
varies. _ _ O
a _ _ O
cohort _ _ O
study _ _ O
with _ _ O
control _ _ O
design. _ _ O
sixty _ _ O
participants _ _ O
were _ _ O
purposively _ _ O
sampled _ _ O
and _ _ O
allocated _ _ O
to _ _ O
an _ _ O
intervention _ _ O
or _ _ O
a _ _ B-Control
control _ _ I-Control
group. _ _ I-Control
moderate _ _ O
correlations _ _ O
were _ _ O
found, _ _ O
particularly _ _ O
between: _ _ O
resilience _ _ O
and _ _ O
satisfaction _ _ O
with _ _ O
life; _ _ O
medication _ _ O
adherence _ _ O
and _ _ O
psychological _ _ O
quality _ _ O
of _ _ O
life; _ _ O
and _ _ O
psychological _ _ O
quality _ _ O
of _ _ O
life _ _ O
and _ _ O
satisfaction _ _ O
with _ _ O
life. _ _ O
The _ _ B-Outcome
mean _ _ I-Outcome
seizure _ _ I-Outcome
occurrences _ _ I-Outcome
between _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
and _ _ I-Outcome
intervention _ _ I-Outcome
groups _ _ I-Outcome
were _ _ I-Outcome
12.71 _ _ I-Outcome
(SD _ _ I-Outcome
24.55) _ _ I-Outcome
and _ _ I-Outcome
6.76 _ _ I-Outcome
(SD _ _ I-Outcome
13.40) _ _ I-Outcome
respectively _ _ I-Outcome
after _ _ I-Outcome
the _ _ I-Outcome
intervention. _ _ I-Outcome
While _ _ O
the _ _ O
study _ _ O
was _ _ O
not _ _ O
powered _ _ O
to _ _ O
assess _ _ O
this, _ _ O
the _ _ O
intervention _ _ O
may _ _ O
be _ _ O
most _ _ O
effective _ _ O
regarding _ _ O
medication _ _ O
adherence _ _ O
and _ _ O
physical _ _ O
health _ _ O
quality _ _ O
of _ _ O
life. _ _ O
the _ _ O
relationship _ _ O
between _ _ O
self-efficacy _ _ O
and _ _ O
seizure _ _ O
management _ _ O
appeared _ _ O
to _ _ O
be _ _ O
strengthened _ _ O
by _ _ O
the _ _ O
programme. _ _ O
This _ _ O
study _ _ O
is _ _ O
the _ _ O
first _ _ O
known _ _ O
to _ _ O
measure _ _ O
resilience _ _ O
in _ _ O
relation _ _ O
to _ _ O
lifestyle _ _ O
self-management _ _ O
for _ _ O
seizure _ _ O
control _ _ O
in _ _ O
people _ _ O
with _ _ O
epilepsy. _ _ O
Relevance _ _ O
to _ _ O
practice: _ _ O
nurses _ _ O
are _ _ O
well _ _ O
placed _ _ O
to _ _ O
work _ _ O
with _ _ O
patients' _ _ O
strengths _ _ O
towards _ _ O
self-efficacy _ _ O
and _ _ O
potentially _ _ O
resilient _ _ O
coping. _ _ O


-DOCSTART- -X- -X- O

We _ _ O
assessed _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
once-daily _ _ B-Intervention
eslicarbazepine _ _ I-Intervention
acetate _ _ I-Intervention
in _ _ O
comparison _ _ O
with _ _ O
twice-daily _ _ B-Control
(BID) _ _ I-Control
controlled-release _ _ I-Control
carbamazepine _ _ I-Control
(carbamazepine-CR) _ _ I-Control
monotherapy _ _ I-Control
in _ _ O
newly _ _ B-Patient
diagnosed _ _ I-Patient
focal _ _ I-Patient
epilepsy _ _ I-Patient
patients. _ _ I-Patient
This _ _ O
randomized, _ _ O
double-blind, _ _ O
noninferiority _ _ O
trial _ _ O
(NCT01162460) _ _ O
utilized _ _ O
a _ _ O
stepwise _ _ O
design _ _ O
with _ _ O
3 _ _ O
dose _ _ O
levels. _ _ O
Patients _ _ O
who _ _ O
remained _ _ O
seizure-free _ _ O
for _ _ O
the _ _ O
26-week _ _ O
evaluation _ _ O
period _ _ O
(level _ _ O
A: _ _ O
eslicarbazepine _ _ B-Intervention
acetate _ _ I-Intervention
800 _ _ I-Intervention
mg/carbamazepine-CR _ _ I-Intervention
200 _ _ B-Control
mg _ _ I-Control
BID) _ _ I-Control
entered _ _ O
a _ _ O
6-month _ _ O
maintenance _ _ O
period. _ _ O
If _ _ O
a _ _ O
seizure _ _ O
occurred _ _ O
during _ _ O
the _ _ O
evaluation _ _ O
period, _ _ O
patients _ _ O
were _ _ O
titrated _ _ O
to _ _ O
the _ _ O
next _ _ O
target _ _ O
level _ _ O
(level _ _ O
B: _ _ O
eslicarbazepine _ _ B-Intervention
acetate _ _ I-Intervention
1200 _ _ I-Intervention
mg/carbamazepine-CR _ _ I-Intervention
400 _ _ B-Control
mg _ _ I-Control
BID, _ _ I-Control
level _ _ O
C: _ _ O
eslicarbazepine _ _ B-Intervention
acetate _ _ I-Intervention
1600 _ _ I-Intervention
mg/carbamazepine-CR _ _ I-Intervention
600 _ _ B-Control
mg _ _ I-Control
BID) _ _ I-Control
and _ _ O
the _ _ O
evaluation _ _ O
period _ _ O
began _ _ O
again. _ _ O
The _ _ O
primary _ _ O
endpoint _ _ O
was _ _ O
the _ _ O
proportion _ _ O
of _ _ O
seizure-free _ _ O
patients _ _ O
for _ _ O
6 _ _ O
months _ _ O
after _ _ O
stabilization _ _ O
in _ _ O
the _ _ O
per _ _ O
protocol _ _ O
set. _ _ O
The _ _ O
predefined _ _ O
noninferiority _ _ O
criteria _ _ O
were _ _ O
-12% _ _ O
absolute _ _ O
and _ _ O
-20% _ _ O
relative _ _ O
difference _ _ O
between _ _ O
treatment _ _ O
groups. _ _ O
Eight _ _ O
hundred _ _ O
fifteen _ _ O
patients _ _ O
were _ _ O
randomly _ _ O
assigned; _ _ O
785 _ _ O
(388 _ _ O
in _ _ O
the _ _ B-Intervention
eslicarbazepine _ _ I-Intervention
acetate _ _ I-Intervention
group _ _ I-Intervention
and _ _ O
397 _ _ O
in _ _ O
the _ _ B-Control
carbamazepine-CR _ _ I-Control
group) _ _ I-Control
were _ _ O
included _ _ O
in _ _ O
the _ _ O
per _ _ O
protocol _ _ O
set, _ _ O
and _ _ O
813 _ _ O
(401 _ _ O
in _ _ O
the _ _ B-Intervention
eslicarbazepine _ _ I-Intervention
acetate _ _ I-Intervention
group _ _ I-Intervention
and _ _ O
412 _ _ O
in _ _ O
the _ _ B-Control
carbamazepine-CR _ _ I-Control
group) _ _ I-Control
were _ _ O
included _ _ O
in _ _ O
the _ _ O
full _ _ O
analysis _ _ O
set _ _ O
for _ _ O
the _ _ O
primary _ _ O
analysis. _ _ O
Overall, _ _ O
71.1% _ _ B-Outcome
of _ _ I-Outcome
eslicarbazepine _ _ I-Outcome
acetate-treated _ _ I-Outcome
patients _ _ I-Outcome
and _ _ I-Outcome
75.6% _ _ I-Outcome
of _ _ I-Outcome
carbamazepine-CR-treated _ _ I-Outcome
patients _ _ I-Outcome
were _ _ I-Outcome
seizure-free _ _ I-Outcome
for _ _ I-Outcome
≥6 _ _ I-Outcome
months _ _ I-Outcome
at _ _ I-Outcome
the _ _ I-Outcome
last _ _ I-Outcome
evaluated _ _ I-Outcome
dose _ _ I-Outcome
(average _ _ I-Outcome
risk _ _ I-Outcome
difference _ _ I-Outcome
= _ _ I-Outcome
-4.28%, _ _ I-Outcome
95% _ _ I-Outcome
confidence _ _ I-Outcome
interval _ _ I-Outcome
[CI] _ _ I-Outcome
= _ _ I-Outcome
-10.30 _ _ I-Outcome
to _ _ I-Outcome
1.74; _ _ I-Outcome
relative _ _ I-Outcome
risk _ _ I-Outcome
difference _ _ I-Outcome
= _ _ I-Outcome
-5.87%, _ _ I-Outcome
95% _ _ I-Outcome
CI _ _ I-Outcome
= _ _ I-Outcome
-13.50 _ _ I-Outcome
to _ _ I-Outcome
2.44) _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
per _ _ I-Outcome
protocol _ _ I-Outcome
set. _ _ I-Outcome
Rates _ _ O
of _ _ O
treatment-emergent _ _ O
adverse _ _ O
events _ _ O
were _ _ O
similar _ _ O
between _ _ O
groups _ _ O
for _ _ O
patients _ _ O
in _ _ O
the _ _ O
safety _ _ O
set. _ _ O
Noninferiority _ _ O
was _ _ O
also _ _ O
demonstrated _ _ O
in _ _ O
the _ _ O
full _ _ O
analysis _ _ O
set, _ _ O
as _ _ O
70.8% _ _ O
of _ _ O
patients _ _ O
with _ _ O
eslicarbazepine _ _ O
acetate _ _ O
and _ _ O
74.0% _ _ O
with _ _ O
carbamazepine-CR _ _ O
were _ _ O
seizure-free _ _ O
at _ _ O
the _ _ O
last _ _ O
evaluated _ _ O
dose _ _ O
(average _ _ O
risk _ _ O
difference _ _ O
= _ _ O
-3.07, _ _ O
95% _ _ O
CI _ _ O
= _ _ O
-9.04 _ _ O
to _ _ O
2.89). _ _ O
Treatment _ _ O
with _ _ O
eslicarbazepine _ _ O
acetate _ _ O
was _ _ O
noninferior _ _ O
to _ _ O
BID _ _ O
carbamazepine-CR. _ _ O
With _ _ O
its _ _ O
once-daily _ _ O
formulation, _ _ O
eslicarbazepine _ _ O
acetate _ _ O
provides _ _ O
a _ _ O
useful _ _ O
option _ _ O
for _ _ O
first-line _ _ O
monotherapy _ _ O
for _ _ O
adults _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
epilepsy _ _ O
and _ _ O
focal _ _ O
onset _ _ O
seizures. _ _ O


-DOCSTART- -X- -X- O

This _ _ O
study _ _ O
aimed _ _ O
to _ _ O
test _ _ O
the _ _ O
hypothesis _ _ O
that _ _ O
high-dose _ _ B-Intervention
prednisolone _ _ I-Intervention
(4 _ _ I-Intervention
mg/kg/day) _ _ I-Intervention
may _ _ O
be _ _ O
more _ _ O
efficacious _ _ O
than _ _ O
usual-dose _ _ B-Control
(2 _ _ I-Control
mg/kg/day) _ _ I-Control
prednisolone _ _ I-Control
for _ _ O
spasm _ _ O
resolution _ _ O
at _ _ O
14-days _ _ O
in _ _ O
children _ _ B-Patient
with _ _ I-Patient
infantile _ _ I-Patient
spasms. _ _ I-Patient
This _ _ O
was _ _ O
a _ _ O
randomized, _ _ O
open-label-trial _ _ O
conducted _ _ O
at _ _ O
a _ _ O
tertiary-level-hospital _ _ O
from _ _ O
February-2012 _ _ O
to _ _ O
March-2013. _ _ O
Children _ _ B-Patient
aged _ _ I-Patient
3-months _ _ I-Patient
to _ _ I-Patient
2-years _ _ I-Patient
presenting _ _ I-Patient
with _ _ I-Patient
infantile _ _ I-Patient
spasms _ _ I-Patient
in _ _ I-Patient
clusters _ _ I-Patient
(at _ _ I-Patient
least _ _ I-Patient
1 _ _ I-Patient
cluster/day) _ _ I-Patient
with _ _ I-Patient
hypsarrhythmia _ _ I-Patient
or _ _ I-Patient
its _ _ I-Patient
variants _ _ I-Patient
on _ _ I-Patient
EEG _ _ I-Patient
were _ _ O
enrolled. _ _ O
The _ _ O
study _ _ O
participants _ _ O
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
either _ _ O
high-dose _ _ B-Intervention
prednisolone _ _ I-Intervention
(4 _ _ I-Intervention
mg/kg/day) _ _ I-Intervention
or _ _ O
the _ _ B-Control
usual-dose _ _ I-Control
(2 _ _ I-Control
mg/kg/day) _ _ I-Control
prednisolone. _ _ I-Control
The _ _ O
primary _ _ O
outcome _ _ O
measure _ _ O
was _ _ O
the _ _ O
proportion _ _ O
of _ _ O
children _ _ O
who _ _ O
achieved _ _ O
spasm _ _ O
freedom _ _ O
for _ _ O
48-h _ _ O
at _ _ O
day-14 _ _ O
after _ _ O
treatment _ _ O
initiation _ _ O
as _ _ O
per _ _ O
parental _ _ O
reports _ _ O
in _ _ O
both _ _ O
the _ _ O
groups. _ _ O
The _ _ O
adverse _ _ O
effects _ _ O
were _ _ O
also _ _ O
monitored. _ _ O
The _ _ O
study _ _ O
was _ _ O
registered _ _ O
with _ _ O
the _ _ O
clinicaltrials.gov _ _ O
(ClinicalTrials.gov _ _ O
Identifier: _ _ O
NCT01575639). _ _ O
Sixty-three _ _ O
children _ _ O
were _ _ O
randomized _ _ O
into _ _ O
the _ _ O
two _ _ O
groups _ _ O
with _ _ O
comparable _ _ O
baseline _ _ O
characteristics. _ _ O
The _ _ B-Outcome
proportion _ _ I-Outcome
of _ _ I-Outcome
children _ _ I-Outcome
with _ _ I-Outcome
spasm _ _ I-Outcome
cessation _ _ I-Outcome
on _ _ I-Outcome
day-14 _ _ I-Outcome
was _ _ I-Outcome
significantly _ _ I-Outcome
higher _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
high-dose _ _ I-Outcome
group _ _ I-Outcome
as _ _ I-Outcome
compared _ _ I-Outcome
to _ _ I-Outcome
the _ _ I-Outcome
usual-dose _ _ I-Outcome
group _ _ I-Outcome
(51.6% _ _ I-Outcome
vs. _ _ I-Outcome
25%, _ _ I-Outcome
p=0.03). _ _ I-Outcome
The _ _ O
absolute _ _ O
risk _ _ O
reduction _ _ O
was _ _ O
26.6% _ _ O
(95% _ _ O
confidence _ _ O
interval _ _ O
11.5-41.7%) _ _ O
with _ _ O
number _ _ O
needed _ _ O
to _ _ O
treat _ _ O
being _ _ O
4. _ _ O
The _ _ O
adverse _ _ O
effects _ _ O
were _ _ O
comparable _ _ O
in _ _ O
both _ _ O
the _ _ O
groups. _ _ O
High-dose _ _ O
prednisolone _ _ O
(4 _ _ O
mg/kg/d) _ _ O
was _ _ O
more _ _ O
effective _ _ O
than _ _ O
low-dose _ _ O
prednisolone _ _ O
(2mg/kg/d) _ _ O
in _ _ O
achieving _ _ O
spasm _ _ O
cessation _ _ O
at _ _ O
14-days _ _ O
(as _ _ O
per _ _ O
parental _ _ O
reports) _ _ O
in _ _ O
children _ _ O
with _ _ O
infantile _ _ O
spasms. _ _ O


-DOCSTART- -X- -X- O

There _ _ O
are _ _ O
no _ _ O
reliable _ _ O
prospective _ _ O
studies _ _ O
on _ _ O
the _ _ O
effectiveness _ _ O
of _ _ O
topiramate _ _ B-Intervention
in _ _ O
Bulgarian _ _ B-Patient
adult _ _ I-Patient
patients _ _ I-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy. _ _ I-Patient
The _ _ O
aim _ _ O
of _ _ O
the _ _ O
study _ _ O
was _ _ O
to _ _ O
conduct _ _ O
an _ _ O
open, _ _ O
prospective _ _ O
study _ _ O
on _ _ O
various _ _ O
aspects _ _ O
of _ _ O
topiramate _ _ B-Intervention
(TPM) _ _ I-Intervention
effectiveness _ _ O
in _ _ O
Bulgarian _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy. _ _ I-Patient
The _ _ O
study _ _ O
included _ _ O
patients _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
who _ _ I-Patient
attended _ _ I-Patient
the _ _ I-Patient
Clinic _ _ I-Patient
of _ _ I-Patient
Neurology _ _ I-Patient
at _ _ I-Patient
the _ _ I-Patient
University _ _ I-Patient
Hospital _ _ I-Patient
in _ _ I-Patient
Plovdiv, _ _ I-Patient
Bulgaria. _ _ I-Patient
Patients _ _ O
completed _ _ O
diaries _ _ O
for _ _ O
seizure _ _ O
frequency, _ _ O
seizure _ _ O
severity, _ _ O
and _ _ O
adverse _ _ O
events. _ _ O
There _ _ O
were _ _ O
regular _ _ O
documented _ _ O
visits _ _ O
at _ _ O
3 _ _ O
or _ _ O
6 _ _ O
months _ _ O
during _ _ O
the _ _ O
first _ _ O
year _ _ O
of _ _ O
TPM _ _ B-Intervention
treatment _ _ I-Intervention
and _ _ O
at _ _ O
6 _ _ O
months _ _ O
afterwards, _ _ O
with _ _ O
a _ _ O
dynamic _ _ O
assessment _ _ O
of _ _ O
seizure _ _ O
fre-quency, _ _ O
severity, _ _ O
adverse _ _ O
events, _ _ O
and _ _ O
EEG _ _ O
recordings. _ _ O
TPM _ _ B-Intervention
was _ _ I-Intervention
used _ _ I-Intervention
as _ _ I-Intervention
an _ _ I-Intervention
add-on _ _ I-Intervention
treatment _ _ I-Intervention
in _ _ O
120 _ _ O
patients _ _ B-Patient
(69 _ _ I-Patient
males, _ _ I-Patient
mean _ _ I-Patient
age _ _ I-Patient
37 _ _ I-Patient
years). _ _ I-Patient
There _ _ B-Outcome
was _ _ I-Outcome
a _ _ I-Outcome
relatively _ _ I-Outcome
mild _ _ I-Outcome
and _ _ I-Outcome
stable _ _ I-Outcome
dynamic _ _ I-Outcome
improvement _ _ I-Outcome
of _ _ I-Outcome
seizure _ _ I-Outcome
severity, _ _ I-Outcome
a _ _ I-Outcome
satisfactory _ _ I-Outcome
seizure _ _ I-Outcome
frequency _ _ I-Outcome
reduction _ _ I-Outcome
in _ _ I-Outcome
37% _ _ I-Outcome
of _ _ I-Outcome
participants, _ _ I-Outcome
a _ _ I-Outcome
stable _ _ I-Outcome
mean _ _ I-Outcome
seizure _ _ I-Outcome
fre-quency _ _ I-Outcome
reduction _ _ I-Outcome
(47%) _ _ I-Outcome
from _ _ I-Outcome
month _ _ I-Outcome
6 _ _ I-Outcome
to _ _ I-Outcome
month _ _ I-Outcome
24 _ _ I-Outcome
of _ _ I-Outcome
treatment _ _ I-Outcome
and _ _ I-Outcome
a _ _ I-Outcome
stable _ _ I-Outcome
responder _ _ I-Outcome
rate _ _ I-Outcome
(48-51%) _ _ I-Outcome
during _ _ I-Outcome
the _ _ I-Outcome
same _ _ I-Outcome
period. _ _ I-Outcome
New _ _ B-Outcome
seizure _ _ I-Outcome
types _ _ I-Outcome
(focal _ _ I-Outcome
with _ _ I-Outcome
impaired _ _ I-Outcome
awareness _ _ I-Outcome
with/without _ _ I-Outcome
evolution _ _ I-Outcome
to _ _ I-Outcome
bilateral _ _ I-Outcome
tonic-clonic _ _ I-Outcome
seizures) _ _ I-Outcome
occurred _ _ I-Outcome
in _ _ I-Outcome
5 _ _ I-Outcome
patients. _ _ I-Outcome
There _ _ O
were _ _ O
adverse _ _ O
events _ _ O
(dizziness/vertigo, _ _ O
irritability, _ _ O
speech _ _ O
disturbances, _ _ O
memory _ _ O
impairment, _ _ O
concentration _ _ O
problems, _ _ O
tremor, _ _ O
loss _ _ O
of _ _ O
appe-tite _ _ O
and _ _ O
weight, _ _ O
weakness, _ _ O
numbness, _ _ O
bradypsychia, _ _ O
confusion, _ _ O
visual _ _ O
hallucinations, _ _ O
sleepiness, _ _ O
insomnia, _ _ O
headache, _ _ O
itching, _ _ O
unstable _ _ O
gait, _ _ O
nausea, _ _ O
and _ _ O
vomiting) _ _ O
in _ _ O
20% _ _ O
of _ _ O
patients. _ _ O
TPM _ _ B-Intervention
treatment _ _ I-Intervention
is _ _ O
associated _ _ O
with _ _ O
low _ _ O
and _ _ O
stable _ _ O
improvement _ _ O
of _ _ O
seizure _ _ O
severity, _ _ O
good _ _ O
and _ _ O
stable _ _ O
improvement _ _ O
of _ _ O
sei-zure _ _ O
frequency, _ _ O
possible _ _ O
worsening _ _ O
of _ _ O
seizure _ _ O
control _ _ O
and _ _ O
appearance _ _ O
of _ _ O
new _ _ O
seizure _ _ O
types, _ _ O
good _ _ O
safety _ _ O
and _ _ O
tolerability. _ _ O


-DOCSTART- -X- -X- O

The _ _ O
purpose _ _ O
of _ _ O
this _ _ O
post _ _ O
hoc _ _ O
exploratory _ _ O
analysis _ _ O
was _ _ O
to _ _ O
determine _ _ O
the _ _ O
effects _ _ O
of _ _ O
the _ _ B-Intervention
antiepileptic _ _ I-Intervention
drug, _ _ I-Intervention
lacosamide, _ _ I-Intervention
on _ _ O
focal _ _ O
(partial-onset) _ _ O
seizure _ _ O
subtypes. _ _ O
Patient _ _ O
data _ _ O
from _ _ O
the _ _ O
three _ _ O
lacosamide _ _ B-Intervention
pivotal _ _ O
trials _ _ O
were _ _ O
grouped _ _ O
and _ _ O
pooled _ _ O
by _ _ O
focal _ _ O
seizure _ _ O
subtype _ _ O
at _ _ O
Baseline: _ _ O
simple _ _ B-Patient
partial _ _ I-Patient
seizures _ _ I-Patient
(SPS), _ _ I-Patient
complex _ _ I-Patient
partial _ _ I-Patient
seizures _ _ I-Patient
(CPS), _ _ I-Patient
and _ _ I-Patient
secondarily _ _ I-Patient
generalized _ _ I-Patient
partial _ _ I-Patient
seizures _ _ I-Patient
(SGPS). _ _ I-Patient
Both _ _ O
efficacy _ _ O
outcomes _ _ O
(median _ _ O
percent _ _ O
change _ _ O
from _ _ O
Baseline _ _ O
to _ _ O
Maintenance _ _ O
Phase _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
per _ _ O
28 _ _ O
days _ _ O
and _ _ O
the _ _ O
proportion _ _ O
of _ _ O
patients _ _ O
experiencing _ _ O
at _ _ O
least _ _ O
a _ _ O
50% _ _ O
reduction _ _ O
in _ _ O
seizures) _ _ O
were _ _ O
evaluated _ _ O
by _ _ O
lacosamide _ _ B-Intervention
dose _ _ I-Intervention
(200, _ _ I-Intervention
400, _ _ I-Intervention
or _ _ I-Intervention
600 _ _ I-Intervention
mg/day) _ _ I-Intervention
compared _ _ O
to _ _ O
placebo _ _ B-Control
for _ _ O
each _ _ O
seizure _ _ O
subtype. _ _ O
An _ _ O
additional _ _ O
analysis _ _ O
was _ _ O
performed _ _ O
to _ _ O
determine _ _ O
whether _ _ O
a _ _ O
shift _ _ O
from _ _ O
more _ _ O
severe _ _ O
focal _ _ O
seizure _ _ O
subtypes _ _ O
to _ _ O
less _ _ O
severe _ _ O
occurred _ _ O
upon _ _ O
treatment _ _ B-Intervention
with _ _ I-Intervention
lacosamide. _ _ I-Intervention
In _ _ B-Outcome
patients _ _ I-Outcome
with _ _ I-Outcome
CPS _ _ I-Outcome
or _ _ I-Outcome
SGPS _ _ I-Outcome
at _ _ I-Outcome
Baseline, _ _ I-Outcome
lacosamide _ _ I-Outcome
400 _ _ I-Outcome
mg/day _ _ I-Outcome
(maximum _ _ I-Outcome
recommended _ _ I-Outcome
daily _ _ I-Outcome
dose) _ _ I-Outcome
and _ _ I-Outcome
600 _ _ I-Outcome
mg/day _ _ I-Outcome
reduced _ _ I-Outcome
the _ _ I-Outcome
frequency _ _ I-Outcome
of _ _ I-Outcome
CPS _ _ I-Outcome
and _ _ I-Outcome
SGPS _ _ I-Outcome
compared _ _ I-Outcome
to _ _ I-Outcome
placebo. _ _ I-Outcome
Likewise, _ _ O
a _ _ O
proportion _ _ O
of _ _ O
patients _ _ O
with _ _ O
CPS _ _ O
and _ _ O
SGPS _ _ O
at _ _ O
Baseline _ _ O
experienced _ _ O
at _ _ O
least _ _ O
a _ _ O
50% _ _ O
reduction _ _ O
in _ _ O
the _ _ O
frequency _ _ O
of _ _ O
CPS _ _ O
and _ _ O
SGPS _ _ O
(≥50% _ _ O
responder _ _ O
rate) _ _ O
in _ _ O
the _ _ O
lacosamide _ _ O
400 _ _ O
and _ _ O
600 _ _ O
mg/day _ _ O
groups _ _ O
compared _ _ O
with _ _ O
placebo. _ _ O
For _ _ O
both _ _ O
outcomes, _ _ O
numerically _ _ O
greatest _ _ O
responses _ _ O
were _ _ O
observed _ _ O
in _ _ O
the _ _ O
lacosamide _ _ O
600 _ _ O
mg/day _ _ O
group _ _ O
among _ _ O
patients _ _ O
with _ _ O
SGPS _ _ O
at _ _ O
Baseline. _ _ O
In _ _ O
patients _ _ O
with _ _ O
SPS _ _ O
at _ _ O
Baseline, _ _ O
no _ _ O
difference _ _ O
between _ _ O
placebo _ _ O
and _ _ O
lacosamide _ _ O
was _ _ O
observed _ _ O
for _ _ O
either _ _ O
efficacy _ _ O
outcome. _ _ O
An _ _ O
additional _ _ O
exploratory _ _ O
analysis _ _ O
suggests _ _ O
that _ _ O
in _ _ O
patients _ _ O
with _ _ O
SPS _ _ O
at _ _ O
Baseline, _ _ O
CPS _ _ O
and _ _ O
SGPS _ _ O
may _ _ O
have _ _ O
been _ _ O
shifted _ _ O
to _ _ O
less _ _ O
severe _ _ O
SPS _ _ O
upon _ _ O
treatment _ _ O
with _ _ O
lacosamide. _ _ O
The _ _ O
results _ _ O
of _ _ O
these _ _ O
exploratory _ _ O
analyses _ _ O
revealed _ _ O
reductions _ _ O
in _ _ O
CPS _ _ O
and _ _ O
SGPS _ _ O
frequency _ _ O
with _ _ O
adjunctive _ _ O
lacosamide. _ _ O
Reduction _ _ O
in _ _ O
CPS _ _ O
and _ _ O
SGPS _ _ O
may _ _ O
confound _ _ O
assessment _ _ O
of _ _ O
SPS _ _ O
since _ _ O
the _ _ O
CPS _ _ O
or _ _ O
SGPS _ _ O
may _ _ O
possibly _ _ O
change _ _ O
to _ _ O
SPS _ _ O
by _ _ O
effective _ _ O
treatment. _ _ O


-DOCSTART- -X- -X- O

Few _ _ O
clinical _ _ O
trials _ _ O
have _ _ O
evaluated _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
antiepileptic _ _ O
drugs _ _ O
(AEDs) _ _ O
as _ _ O
initial _ _ O
monotherapy _ _ O
for _ _ O
elderly _ _ B-Patient
patients. _ _ I-Patient
This _ _ O
post-hoc _ _ O
subgroup _ _ O
analysis _ _ O
of _ _ O
data _ _ O
from _ _ O
an _ _ O
unblinded, _ _ O
randomized, _ _ O
52-week _ _ O
superiority _ _ O
study _ _ O
(KOMET) _ _ O
compared _ _ O
the _ _ O
effectiveness _ _ O
of _ _ O
levetiracetam _ _ B-Intervention
(LEV) _ _ I-Intervention
with _ _ O
extended-release _ _ B-Control
sodium _ _ I-Control
valproate _ _ I-Control
(VPA-ER) _ _ I-Control
and _ _ I-Control
controlled-release _ _ I-Control
carbamazepine _ _ I-Control
(CBZ-CR) _ _ I-Control
as _ _ I-Control
monotherapy _ _ I-Control
in _ _ O
patients _ _ O
aged _ _ O
≥ _ _ O
60 _ _ O
years _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
epilepsy. _ _ O
The _ _ O
physician _ _ O
chose _ _ O
VPA _ _ O
or _ _ O
CBZ _ _ O
as _ _ O
preferred _ _ O
standard _ _ O
treatment; _ _ O
patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
standard _ _ O
AEDs _ _ O
or _ _ O
LEV. _ _ O
The _ _ O
primary _ _ O
endpoint _ _ O
was _ _ O
time _ _ O
to _ _ O
treatment _ _ O
withdrawal. _ _ O
Results _ _ O
are _ _ O
exploratory, _ _ O
since _ _ O
KOMET _ _ O
was _ _ O
not _ _ O
powered _ _ O
for _ _ O
a _ _ O
subgroup _ _ O
analysis _ _ O
by _ _ O
age. _ _ O
Patients _ _ O
(n _ _ O
= _ _ O
308) _ _ O
were _ _ O
randomized _ _ O
to _ _ O
LEV _ _ O
(n _ _ O
= _ _ O
48) _ _ O
or _ _ O
VPA-ER _ _ O
(n _ _ O
= _ _ O
53) _ _ O
in _ _ O
the _ _ O
VPE-ER _ _ O
stratum _ _ O
or _ _ O
to _ _ O
LEV _ _ O
(n _ _ O
= _ _ O
104) _ _ O
or _ _ O
CBZ-CR _ _ O
(n _ _ O
= _ _ O
103) _ _ O
in _ _ O
the _ _ O
CBZ-CR _ _ O
stratum. _ _ O
Mean _ _ O
age _ _ O
was _ _ O
69.6 _ _ O
years, _ _ O
range _ _ O
60.2-89.9 _ _ O
years _ _ O
(intention-to-treat _ _ O
population _ _ O
n _ _ O
= _ _ O
307). _ _ O
Time _ _ O
to _ _ O
treatment _ _ O
withdrawal _ _ O
hazard _ _ O
ratio _ _ O
[HR] _ _ O
(95 _ _ O
% _ _ O
confidence _ _ O
interval _ _ O
[CI]) _ _ O
for _ _ O
LEV _ _ O
vs. _ _ O
standard _ _ O
AEDs _ _ O
was _ _ O
0.44 _ _ O
(0.28-0.67); _ _ O
LEV _ _ O
vs. _ _ O
0.46 _ _ O
(0.16-1.33); _ _ O
LEV _ _ O
vs. _ _ O
0.45 _ _ O
(0.28-0.72). _ _ O
Twelve-month _ _ O
withdrawal _ _ O
rates _ _ O
were: _ _ O
LEV _ _ O
vs. _ _ O
standard _ _ O
AEDs, _ _ O
20.4 _ _ O
vs. _ _ O
38.7 _ _ O
%; _ _ O
LEV _ _ O
vs. _ _ O
VPA-ER, _ _ O
10.4 _ _ O
vs. _ _ O
23.1 _ _ O
%; _ _ O
LEV _ _ O
vs. _ _ O
CBZ-CR, _ _ O
25.0 _ _ O
vs. _ _ O
46.6 _ _ O
%. _ _ O
Time _ _ O
to _ _ O
first _ _ O
seizure _ _ O
was _ _ O
similar _ _ O
between _ _ O
LEV _ _ O
and _ _ O
standard _ _ O
AEDs _ _ O
(HR: _ _ O
0.92, _ _ O
95 _ _ O
% _ _ O
CI: _ _ O
0.63-1.35), _ _ O
LEV _ _ O
and _ _ O
VPA-ER _ _ O
(0.77, _ _ O
0.38-1.56), _ _ O
and _ _ O
LEV _ _ O
and _ _ O
CBZ-CR _ _ O
(1.02, _ _ O
0.64-1.63). _ _ O
Adverse _ _ O
events _ _ O
were _ _ O
reported _ _ O
by _ _ O
76.2, _ _ O
67.3, _ _ O
and _ _ O
82.5 _ _ O
% _ _ O
of _ _ O
patients _ _ O
for _ _ O
LEV, _ _ O
VPA-ER, _ _ O
and _ _ O
CBZ-CR, _ _ O
respectively. _ _ O
Discontinuation _ _ O
rates _ _ O
due _ _ O
to _ _ O
AEs _ _ O
were _ _ O
11.3, _ _ O
10.2, _ _ O
and _ _ O
35.0 _ _ O
% _ _ O
for _ _ O
LEV, _ _ O
VPA-ER, _ _ O
and _ _ O
CBZ-CR, _ _ O
respectively. _ _ O
Time _ _ O
to _ _ O
treatment _ _ O
withdrawal _ _ O
was _ _ O
longer _ _ O
with _ _ O
LEV _ _ O
compared _ _ O
with _ _ O
standard _ _ O
AEDs. _ _ O
This _ _ O
finding _ _ O
was _ _ O
driven _ _ O
primarly _ _ O
by _ _ O
the _ _ O
result _ _ O
in _ _ O
the _ _ O
CBZ-CR _ _ O
stratum, _ _ O
which _ _ O
in _ _ O
turn _ _ O
was _ _ O
likely _ _ O
due _ _ O
to _ _ O
the _ _ O
more _ _ O
favorable _ _ O
tolerability _ _ O
profile _ _ O
of _ _ O
LEV. _ _ O
Results _ _ O
of _ _ O
this _ _ O
post-hoc _ _ O
analysis _ _ O
suggest _ _ O
that _ _ O
LEV _ _ O
may _ _ O
be _ _ O
a _ _ O
suitable _ _ O
option _ _ O
for _ _ O
initial _ _ O
monotherapy _ _ O
for _ _ O
patients _ _ O
aged _ _ O
≥ _ _ O
60 _ _ O
years _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
epilepsy. _ _ O
ClinicalTrials.gov: _ _ O
NCT00175903 _ _ O
; _ _ O
September _ _ O
9, _ _ O
2005. _ _ O


-DOCSTART- -X- -X- O

This _ _ O
study _ _ O
comprised _ _ O
two _ _ O
phases _ _ O
and _ _ O
evaluated _ _ O
the _ _ O
effects _ _ O
of _ _ O
levetiracetam _ _ B-Intervention
(LEV), _ _ I-Intervention
as _ _ I-Intervention
an _ _ I-Intervention
add-on _ _ I-Intervention
treatment, _ _ I-Intervention
on _ _ O
cognitive _ _ O
function _ _ O
and _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QOL) _ _ O
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
refractory _ _ I-Patient
partial _ _ I-Patient
seizures. _ _ I-Patient
The _ _ O
short-term _ _ O
phase _ _ O
employed _ _ O
a _ _ O
randomized, _ _ O
double-blind, _ _ O
placebo-controlled _ _ B-Control
design _ _ O
including _ _ O
an _ _ O
8-week _ _ O
baseline _ _ O
period, _ _ O
4-week _ _ O
titration _ _ O
interval, _ _ O
and _ _ O
12-week _ _ O
period _ _ O
at _ _ O
the _ _ B-Intervention
maximum _ _ I-Intervention
LEV _ _ I-Intervention
dose _ _ I-Intervention
(1500 _ _ I-Intervention
mg _ _ I-Intervention
twice _ _ I-Intervention
daily). _ _ I-Intervention
The _ _ O
long-term _ _ O
phase _ _ O
was _ _ O
an _ _ O
open-label _ _ O
study _ _ O
in _ _ O
which _ _ O
the _ _ O
maximum _ _ O
LEV _ _ O
dose _ _ O
was _ _ O
administered _ _ O
for _ _ O
another _ _ O
24 _ _ O
weeks. _ _ O
Neuropsychological _ _ O
tests _ _ O
and _ _ O
the _ _ O
31-item _ _ O
Quality _ _ B-Outcome
of _ _ I-Outcome
Life _ _ I-Outcome
in _ _ I-Outcome
Epilepsy _ _ I-Outcome
(QOLIE-31) _ _ I-Outcome
inventory _ _ O
were _ _ O
administered _ _ O
at _ _ O
baseline, _ _ O
at _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
short-term _ _ O
phase, _ _ O
and _ _ O
at _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
long-term _ _ O
phase. _ _ O
Twenty-four _ _ O
eligible _ _ O
patients _ _ O
entered _ _ O
into _ _ O
the _ _ O
final _ _ O
phase. _ _ O
After _ _ B-Outcome
short-term _ _ I-Outcome
LEV _ _ I-Outcome
treatment, _ _ I-Outcome
performance _ _ I-Outcome
time _ _ I-Outcome
on _ _ I-Outcome
the _ _ I-Outcome
Wisconsin _ _ I-Outcome
Card _ _ I-Outcome
Sorting _ _ I-Outcome
Test _ _ I-Outcome
(WCST) _ _ I-Outcome
and _ _ I-Outcome
Delayed _ _ I-Outcome
Logic _ _ I-Outcome
Memory _ _ I-Outcome
significantly _ _ I-Outcome
improved _ _ I-Outcome
for _ _ I-Outcome
the _ _ I-Outcome
patient _ _ I-Outcome
group, _ _ I-Outcome
but _ _ I-Outcome
not _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
group. _ _ I-Outcome
Subscale _ _ O
scores _ _ O
on _ _ O
the _ _ O
QOLIE-31, _ _ O
including _ _ O
scores _ _ O
on _ _ O
Cognitive _ _ O
Functioning _ _ O
and _ _ O
Social _ _ O
Function, _ _ O
also _ _ O
improved _ _ O
only _ _ O
for _ _ O
the _ _ O
LEV _ _ O
group. _ _ O
At _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
long-term _ _ O
phase, _ _ O
these _ _ O
improvements _ _ O
were _ _ O
maintained, _ _ O
and _ _ O
both _ _ O
groups _ _ O
performed _ _ O
better _ _ O
in _ _ O
more _ _ O
areas, _ _ O
as _ _ O
measured _ _ O
by _ _ O
the _ _ O
Trail _ _ O
Making _ _ O
Test, _ _ O
WCST, _ _ O
and _ _ O
Delayed _ _ O
Visual _ _ O
Memory _ _ O
in _ _ O
the _ _ O
neuropsychological _ _ O
battery _ _ O
and _ _ O
the _ _ O
QOLIE-31 _ _ O
subscales _ _ O
Overall _ _ O
QOL _ _ O
and _ _ O
Health _ _ O
Status. _ _ O
Thus, _ _ O
as _ _ O
an _ _ O
adjunctive _ _ O
therapy, _ _ O
LEV _ _ O
did _ _ O
not _ _ O
negatively _ _ O
affect _ _ O
and, _ _ O
in _ _ O
a _ _ O
way, _ _ O
improved _ _ O
cognitive _ _ O
function _ _ O
and _ _ O
QOL _ _ O
in _ _ O
patients _ _ O
with _ _ O
medically _ _ O
refractory _ _ O
partial _ _ O
seizures. _ _ O
Some _ _ O
of _ _ O
these _ _ O
improvements _ _ O
may _ _ O
be _ _ O
maintained _ _ O
during _ _ O
long-term _ _ O
treatment. _ _ O


-DOCSTART- -X- -X- O

The _ _ O
role _ _ O
of _ _ O
P-glycoprotein _ _ O
(Pgp), _ _ O
one _ _ O
of _ _ O
the _ _ O
known _ _ O
multidrug _ _ O
transporters, _ _ O
has _ _ O
been _ _ O
suggested _ _ O
in _ _ O
drug-resistant _ _ B-Patient
epilepsy _ _ I-Patient
(DRE). _ _ I-Patient
The _ _ O
following _ _ O
study _ _ O
aimed _ _ O
to _ _ O
measure _ _ O
the _ _ O
serum _ _ O
level _ _ O
of _ _ O
Pgp _ _ O
as _ _ O
a _ _ O
possible _ _ O
indicator _ _ O
of _ _ O
tissue _ _ O
Pgp _ _ O
overexpression _ _ O
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
DRE _ _ I-Patient
and _ _ O
to _ _ O
assess _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
verapamil _ _ B-Intervention
(as _ _ I-Intervention
a _ _ I-Intervention
Pgp _ _ I-Intervention
inhibitor _ _ I-Intervention
agent) _ _ I-Intervention
in _ _ O
these _ _ O
patients. _ _ O
A _ _ O
group _ _ O
of _ _ O
24 _ _ O
patients _ _ B-Patient
with _ _ I-Patient
DRE _ _ I-Patient
were _ _ O
recruited _ _ O
and _ _ O
subdivided _ _ O
into _ _ O
two _ _ O
groups, _ _ O
one _ _ O
receiving _ _ O
verapamil _ _ B-Intervention
and _ _ O
the _ _ O
other _ _ O
receiving _ _ O
a _ _ B-Control
placebo _ _ I-Control
in _ _ O
a _ _ O
double-blind _ _ O
randomized _ _ O
study. _ _ O
Pgp _ _ O
serum _ _ O
levels _ _ O
were _ _ O
measured _ _ O
at _ _ O
enrollment _ _ O
and _ _ O
12 _ _ O
months _ _ O
later. _ _ O
Twenty _ _ B-Control
medically _ _ I-Control
controlled _ _ I-Control
epileptic _ _ I-Control
patients _ _ I-Control
served _ _ I-Control
as _ _ I-Control
a _ _ I-Control
control _ _ I-Control
group. _ _ I-Control
A _ _ B-Outcome
significant _ _ I-Outcome
statistical _ _ I-Outcome
increase _ _ I-Outcome
was _ _ I-Outcome
found _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
Pgp _ _ I-Outcome
level _ _ I-Outcome
of _ _ I-Outcome
patients _ _ I-Outcome
when _ _ I-Outcome
compared _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
group. _ _ I-Outcome
Patients _ _ O
on _ _ O
both _ _ O
verapamil _ _ O
and _ _ O
the _ _ O
placebo _ _ O
showed _ _ O
improvement _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
and _ _ O
severity _ _ O
where _ _ O
statistical _ _ O
analysis _ _ O
showed _ _ O
no _ _ O
significant _ _ O
differences. _ _ O
Pgp _ _ O
serum _ _ O
levels _ _ O
in _ _ O
patients _ _ O
with _ _ O
DRE _ _ O
were _ _ O
significantly _ _ O
elevated _ _ O
compared _ _ O
to _ _ O
patients _ _ O
with _ _ O
medically _ _ O
controlled _ _ O
epilepsy. _ _ O
The _ _ O
effect _ _ O
of _ _ O
verapamil _ _ O
as _ _ O
Pgp _ _ O
inhibitor _ _ O
on _ _ O
DRE _ _ O
requires _ _ O
further _ _ O
evaluation _ _ O
and _ _ O
research. _ _ O


-DOCSTART- -X- -X- O

Currently _ _ O
recommended _ _ O
dosing _ _ O
of _ _ O
lacosamide _ _ B-Intervention
often _ _ O
necessitates _ _ O
long _ _ O
titration _ _ O
periods. _ _ O
However, _ _ O
the _ _ B-Intervention
use _ _ I-Intervention
of _ _ I-Intervention
a _ _ I-Intervention
regimen _ _ I-Intervention
consisting _ _ I-Intervention
of _ _ I-Intervention
initial _ _ I-Intervention
loading _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
200 _ _ I-Intervention
mg _ _ I-Intervention
followed _ _ I-Intervention
by _ _ I-Intervention
a _ _ I-Intervention
maintenance _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
200 _ _ I-Intervention
mg/day _ _ I-Intervention
in _ _ I-Intervention
practice _ _ I-Intervention
suggests _ _ O
tolerability _ _ O
of _ _ O
more _ _ B-Intervention
rapid _ _ I-Intervention
titration _ _ I-Intervention
schedules. _ _ I-Intervention
We _ _ O
aimed _ _ O
to _ _ O
clarify _ _ O
whether _ _ O
the _ _ B-Intervention
shortened _ _ I-Intervention
titration _ _ I-Intervention
schedule _ _ I-Intervention
affects _ _ O
tolerability _ _ O
of _ _ O
lacosamide. _ _ B-Intervention
We _ _ O
evaluated _ _ O
the _ _ O
safety _ _ O
of _ _ O
two _ _ B-Intervention
rapid _ _ I-Intervention
titration _ _ I-Intervention
protocols _ _ I-Intervention
designed _ _ I-Intervention
to _ _ I-Intervention
reach _ _ I-Intervention
the _ _ I-Intervention
target _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
400 _ _ I-Intervention
mg/day _ _ I-Intervention
within _ _ I-Intervention
1 _ _ I-Intervention
week, _ _ I-Intervention
and _ _ O
the _ _ B-Control
conventional _ _ I-Control
weekly _ _ I-Control
titration _ _ I-Control
protocol _ _ I-Control
(reaching _ _ I-Control
the _ _ I-Control
target _ _ I-Control
dose _ _ I-Control
of _ _ I-Control
400 _ _ I-Control
mg/day _ _ I-Control
in _ _ I-Control
three _ _ I-Control
weeks). _ _ I-Control
The _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
and _ _ O
steady-state _ _ O
plasma _ _ O
concentration _ _ O
of _ _ O
lacosamide _ _ B-Intervention
were _ _ O
also _ _ O
analyzed. _ _ O
Adverse _ _ O
events _ _ O
were _ _ O
assessed _ _ O
at _ _ O
1 _ _ O
week _ _ O
and _ _ O
5 _ _ O
weeks _ _ O
after _ _ O
reaching _ _ O
the _ _ O
target _ _ O
dose. _ _ O
Seventy-five _ _ O
patients _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
were _ _ O
enrolled _ _ O
and _ _ O
evenly _ _ O
distributed _ _ O
to _ _ O
three _ _ O
titration _ _ O
protocols, _ _ O
from _ _ O
which _ _ O
5 _ _ O
patients _ _ O
were _ _ O
lost _ _ O
to _ _ O
follow-up _ _ O
and _ _ O
excluded _ _ O
from _ _ O
the _ _ O
safety _ _ O
analysis. _ _ O
Discontinuation _ _ B-Outcome
of _ _ I-Outcome
lacosamide _ _ I-Outcome
or _ _ I-Outcome
dose _ _ I-Outcome
reductions _ _ I-Outcome
due _ _ I-Outcome
to _ _ I-Outcome
adverse _ _ I-Outcome
events _ _ I-Outcome
occurred _ _ I-Outcome
in _ _ I-Outcome
32 _ _ I-Outcome
patients _ _ I-Outcome
(46%), _ _ I-Outcome
of _ _ I-Outcome
whom _ _ I-Outcome
a _ _ I-Outcome
large _ _ I-Outcome
majority _ _ I-Outcome
(74%) _ _ I-Outcome
had _ _ I-Outcome
experienced _ _ I-Outcome
adverse _ _ I-Outcome
events _ _ I-Outcome
after _ _ I-Outcome
reaching _ _ I-Outcome
400 _ _ I-Outcome
mg/day, _ _ I-Outcome
demonstrating _ _ I-Outcome
apparent _ _ I-Outcome
dose-dependency. _ _ I-Outcome
There _ _ O
was _ _ O
no _ _ O
difference _ _ O
in _ _ O
safety _ _ O
outcomes _ _ O
among _ _ O
the _ _ O
three _ _ O
titration _ _ O
groups. _ _ O
Concomitant _ _ O
use _ _ O
of _ _ O
sodium _ _ O
channel _ _ O
blockers _ _ O
significantly _ _ O
increased _ _ O
the _ _ O
risk _ _ O
of _ _ O
adverse _ _ O
events. _ _ O
Rapid _ _ O
titration _ _ O
protocols _ _ O
for _ _ O
lacosamide _ _ O
were _ _ O
not _ _ O
associated _ _ O
with _ _ O
an _ _ O
increased _ _ O
risk _ _ O
of _ _ O
adverse _ _ O
events _ _ O
compared _ _ O
to _ _ O
the _ _ O
conventional _ _ O
weekly _ _ O
titration _ _ O
protocol. _ _ O
Uptitration _ _ O
of _ _ O
lacosamide _ _ O
at _ _ O
shorter _ _ O
intervals _ _ O
to _ _ O
an _ _ O
effective _ _ O
target _ _ O
dosage _ _ O
may _ _ O
be _ _ O
feasible _ _ O
in _ _ O
appropriate _ _ O
clinical _ _ O
situations. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
evaluate _ _ O
the _ _ O
safety, _ _ O
tolerability, _ _ O
and _ _ O
pharmacokinetics _ _ O
(PK) _ _ O
of _ _ O
pregabalin _ _ B-Intervention
as _ _ I-Intervention
adjunctive _ _ I-Intervention
therapy _ _ I-Intervention
in _ _ O
children _ _ B-Patient
with _ _ I-Patient
refractory _ _ I-Patient
partial _ _ I-Patient
seizures. _ _ I-Patient
This _ _ O
was _ _ O
a _ _ O
phase _ _ O
1, _ _ O
randomized, _ _ O
placebo-controlled, _ _ B-Control
parallel-group, _ _ O
escalating-dose, _ _ O
multiple-dose _ _ O
study _ _ O
comprising _ _ O
a _ _ O
7-day, _ _ O
double-blind _ _ O
treatment _ _ O
period _ _ O
and _ _ O
a _ _ O
single-blind, _ _ O
single _ _ B-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
pregabalin _ _ I-Intervention
administered _ _ O
to _ _ O
all _ _ O
children _ _ O
on _ _ O
day _ _ O
8. _ _ O
Children _ _ B-Patient
in _ _ I-Patient
four _ _ I-Patient
age _ _ I-Patient
cohorts _ _ I-Patient
(1-23 _ _ I-Patient
months, _ _ I-Patient
2-6, _ _ I-Patient
7-11, _ _ I-Patient
and _ _ I-Patient
12-16 _ _ I-Patient
years) _ _ I-Patient
received _ _ O
one _ _ B-Intervention
of _ _ I-Intervention
four _ _ I-Intervention
doses _ _ I-Intervention
of _ _ I-Intervention
pregabalin _ _ I-Intervention
(2.5, _ _ I-Intervention
5, _ _ I-Intervention
10, _ _ I-Intervention
or _ _ I-Intervention
15 _ _ I-Intervention
mg/kg/day) _ _ I-Intervention
or _ _ O
placebo. _ _ B-Control
Safety _ _ O
and _ _ O
tolerability _ _ O
were _ _ O
assessed _ _ O
throughout _ _ O
the _ _ O
study. _ _ O
Steady-state _ _ O
and _ _ O
single-dose _ _ O
PK _ _ O
parameters _ _ O
on _ _ O
day _ _ O
8 _ _ O
were _ _ O
analyzed _ _ O
using _ _ O
standard _ _ O
noncompartmental _ _ O
procedures. _ _ O
Sixty-five _ _ O
children _ _ O
received _ _ O
at _ _ O
least _ _ O
one _ _ O
dose _ _ O
of _ _ O
treatment. _ _ O
Four _ _ O
pregabalin-treated _ _ O
children _ _ O
discontinued _ _ O
treatment, _ _ O
three _ _ O
of _ _ O
whom _ _ O
received _ _ O
15 _ _ B-Intervention
mg/kg/day. _ _ I-Intervention
Two _ _ B-Outcome
children _ _ I-Outcome
experienced _ _ I-Outcome
serious _ _ I-Outcome
adverse _ _ I-Outcome
events, _ _ I-Outcome
one _ _ I-Outcome
of _ _ I-Outcome
whom _ _ I-Outcome
received _ _ I-Outcome
pregabalin _ _ I-Outcome
15 _ _ I-Outcome
mg/kg/day. _ _ I-Outcome
During _ _ O
double-blind _ _ O
treatment, _ _ O
the _ _ O
most _ _ O
common _ _ O
adverse _ _ O
events _ _ O
reported _ _ O
in _ _ O
the _ _ O
pregabalin-treated _ _ O
population _ _ O
were _ _ O
somnolence _ _ O
(27.1%) _ _ O
and _ _ O
dizziness _ _ O
(12.5%). _ _ O
Steady-state _ _ O
pregabalin _ _ O
peak _ _ O
and _ _ O
total _ _ O
exposure _ _ O
in _ _ O
each _ _ O
age _ _ O
cohort _ _ O
appeared _ _ O
to _ _ O
increase _ _ O
linearly _ _ O
with _ _ O
dose. _ _ O
Apparent _ _ O
oral _ _ O
clearance _ _ O
(CL/F) _ _ O
was _ _ O
directly _ _ O
related _ _ O
to _ _ O
creatinine _ _ O
clearance, _ _ O
consistent _ _ O
with _ _ O
adults. _ _ O
CL/F _ _ O
normalized _ _ O
for _ _ O
body _ _ O
weight _ _ O
was _ _ O
43% _ _ O
higher _ _ O
in _ _ O
patients _ _ O
weighing _ _ O
<30 _ _ O
kg. _ _ O
Steady-state _ _ O
and _ _ O
single-dose _ _ O
PK _ _ O
were _ _ O
consistent. _ _ O
Pregabalin _ _ O
at _ _ O
doses _ _ O
up _ _ O
to _ _ O
10 _ _ O
mg/kg/day _ _ O
in _ _ O
children _ _ O
aged _ _ O
1 _ _ O
month _ _ O
to _ _ O
16 _ _ O
years, _ _ O
and _ _ O
at _ _ O
doses _ _ O
up _ _ O
to _ _ O
15 _ _ O
mg/kg/day _ _ O
in _ _ O
those _ _ O
aged _ _ O
<6 _ _ O
years, _ _ O
demonstrated _ _ O
acceptable _ _ O
safety _ _ O
and _ _ O
tolerability. _ _ O
For _ _ O
children _ _ O
weighing _ _ O
<30 _ _ O
kg, _ _ O
a _ _ O
dose _ _ O
increase _ _ O
of _ _ O
40% _ _ O
(mg/kg _ _ O
dosing) _ _ O
is _ _ O
required _ _ O
to _ _ O
achieve _ _ O
comparable _ _ O
exposure _ _ O
with _ _ O
adults _ _ O
or _ _ O
children _ _ O
weighing _ _ O
≥30 _ _ O
kg. _ _ O
These _ _ O
data _ _ O
will _ _ O
inform _ _ O
dose _ _ O
selection _ _ O
in _ _ O
phase _ _ O
3 _ _ O
trials _ _ O
of _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
adjunctive _ _ O
pregabalin _ _ O
in _ _ O
children _ _ O
with _ _ O
refractory _ _ O
partial _ _ O
seizures. _ _ O


-DOCSTART- -X- -X- O

Vagus _ _ B-Intervention
nerve _ _ I-Intervention
stimulation _ _ I-Intervention
(VNS) _ _ I-Intervention
is _ _ O
an _ _ O
effective _ _ O
treatment _ _ O
for _ _ O
intractable _ _ O
epilepsy. _ _ O
It _ _ O
is _ _ O
unknown _ _ O
whether _ _ O
acute _ _ O
response _ _ O
is _ _ O
correlated _ _ O
with _ _ O
the _ _ O
amplitude _ _ O
of _ _ O
output _ _ O
current. _ _ O
The _ _ O
purpose _ _ O
of _ _ O
this _ _ O
study _ _ O
was _ _ O
to _ _ O
determine _ _ O
if _ _ O
the _ _ O
output _ _ O
current _ _ O
of _ _ O
VNS _ _ O
is _ _ O
correlated _ _ O
with _ _ O
percent _ _ O
reductions _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
and _ _ O
response. _ _ O
Retrospective _ _ O
analysis _ _ O
of _ _ O
a _ _ O
multicenter _ _ O
randomized _ _ O
trial _ _ O
of _ _ O
three _ _ O
unique _ _ O
paradigms _ _ O
of _ _ O
VNS _ _ O
was _ _ O
carried _ _ O
out _ _ O
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
intractable _ _ I-Patient
partial _ _ I-Patient
onset _ _ I-Patient
epilepsy. _ _ I-Patient
Output _ _ O
current _ _ O
at _ _ O
1 _ _ O
and _ _ O
3 _ _ O
months _ _ O
was _ _ O
correlated _ _ O
with _ _ O
percent _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
and _ _ O
response _ _ O
rates. _ _ O
Sixty-one _ _ O
subjects _ _ O
were _ _ O
enrolled _ _ O
and _ _ O
completed _ _ O
the _ _ O
study. _ _ O
Output _ _ O
current, _ _ O
ranging _ _ O
from _ _ O
0.25 _ _ O
to _ _ O
1.5 _ _ O
mA, _ _ O
was _ _ O
not _ _ O
correlated _ _ O
with _ _ O
reductions _ _ O
in _ _ O
seizure _ _ O
frequency, _ _ O
or _ _ O
with _ _ O
> _ _ O
or _ _ O
= _ _ O
50% _ _ O
reduction _ _ O
in _ _ O
seizures. _ _ O
Six _ _ O
of _ _ O
seven _ _ O
initial _ _ O
non-responders _ _ O
did _ _ O
experience _ _ O
> _ _ O
or _ _ O
= _ _ O
50% _ _ O
reductions _ _ O
in _ _ O
seizures _ _ O
after _ _ O
current _ _ O
was _ _ O
increased. _ _ O
The _ _ O
output _ _ O
current _ _ O
is _ _ O
not _ _ O
a _ _ O
major _ _ O
determinant _ _ O
of _ _ O
acute _ _ O
response _ _ O
to _ _ O
VNS _ _ O
for _ _ O
epilepsy. _ _ O
Many _ _ O
patients _ _ O
respond _ _ O
to _ _ O
low _ _ O
current _ _ O
(<1 _ _ O
mA). _ _ O
Some _ _ O
(20%) _ _ O
initial _ _ O
non-responders _ _ O
may _ _ O
respond _ _ O
to _ _ O
an _ _ O
increase _ _ O
in _ _ O
output _ _ O
current. _ _ O


-DOCSTART- -X- -X- O

Previous _ _ O
studies _ _ O
demonstrated _ _ O
that _ _ O
vagus _ _ O
nerve _ _ O
stimulation _ _ O
(VNS) _ _ O
is _ _ O
an _ _ O
effective _ _ O
therapy _ _ O
for _ _ O
drug-resistant _ _ O
epilepsy. _ _ O
Acupuncture _ _ O
is _ _ O
also _ _ O
used _ _ O
to _ _ O
treat _ _ O
epilepsy. _ _ O
This _ _ O
study _ _ O
was _ _ O
designed _ _ O
to _ _ O
examine _ _ O
the _ _ O
safety _ _ O
and _ _ O
effectiveness _ _ O
of _ _ O
transcutaneous _ _ B-Intervention
auricular _ _ I-Intervention
vagus _ _ I-Intervention
nerve _ _ I-Intervention
stimulation _ _ I-Intervention
(ta-VNS) _ _ I-Intervention
for _ _ O
patients _ _ B-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy. _ _ I-Patient
A _ _ O
total _ _ O
of _ _ O
50 _ _ O
volunteer _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
drug-resistant _ _ I-Patient
epilepsy _ _ I-Patient
were _ _ O
selected _ _ O
for _ _ O
a _ _ O
random _ _ O
clinical _ _ O
trial _ _ O
to _ _ O
observe _ _ O
the _ _ O
therapeutic _ _ O
effect _ _ O
of _ _ O
ta-VNS. _ _ B-Intervention
The _ _ O
seizure _ _ O
frequency, _ _ O
quality _ _ O
of _ _ O
life, _ _ O
and _ _ O
severity _ _ O
were _ _ O
assessed _ _ O
in _ _ O
weeks _ _ O
8, _ _ O
16, _ _ O
and _ _ O
24 _ _ O
of _ _ O
the _ _ O
treatment _ _ O
according _ _ O
to _ _ O
the _ _ O
percentage _ _ O
of _ _ O
seizure _ _ O
frequency _ _ O
reduction. _ _ O
In _ _ O
the _ _ O
pilot _ _ O
study, _ _ O
47 _ _ O
of _ _ O
the _ _ O
50 _ _ O
epilepsy _ _ B-Patient
patients _ _ I-Patient
completed _ _ O
the _ _ O
24-week _ _ O
treatment; _ _ O
three _ _ O
dropped _ _ O
off. _ _ O
After _ _ B-Outcome
8-week _ _ I-Outcome
treatment, _ _ I-Outcome
six _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
47 _ _ I-Outcome
patients _ _ I-Outcome
(12%) _ _ I-Outcome
were _ _ I-Outcome
seizure _ _ I-Outcome
free _ _ I-Outcome
and _ _ I-Outcome
12 _ _ I-Outcome
(24%) _ _ I-Outcome
had _ _ I-Outcome
a _ _ I-Outcome
reduction _ _ I-Outcome
in _ _ I-Outcome
seizure _ _ I-Outcome
frequency. _ _ I-Outcome
In _ _ B-Outcome
week _ _ I-Outcome
16 _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
continuous _ _ I-Outcome
treatment, _ _ I-Outcome
six _ _ I-Outcome
of _ _ I-Outcome
the _ _ I-Outcome
47 _ _ I-Outcome
patients _ _ I-Outcome
(12%) _ _ I-Outcome
were _ _ I-Outcome
seizure _ _ I-Outcome
free; _ _ I-Outcome
17 _ _ I-Outcome
(34%) _ _ I-Outcome
had _ _ I-Outcome
a _ _ I-Outcome
reduction _ _ I-Outcome
in _ _ I-Outcome
seizure _ _ I-Outcome
frequency. _ _ I-Outcome
After _ _ B-Outcome
24 _ _ I-Outcome
weeks' _ _ I-Outcome
treatment, _ _ I-Outcome
eight _ _ I-Outcome
patients _ _ I-Outcome
(16%) _ _ I-Outcome
were _ _ I-Outcome
seizure _ _ I-Outcome
free; _ _ I-Outcome
19 _ _ I-Outcome
(38%) _ _ I-Outcome
had _ _ I-Outcome
reduced _ _ I-Outcome
seizure _ _ I-Outcome
frequency. _ _ I-Outcome
Similar _ _ O
to _ _ O
the _ _ O
therapeutic _ _ O
effect _ _ O
of _ _ O
VNS, _ _ O
ta-VNS _ _ B-Intervention
can _ _ O
suppress _ _ O
epileptic _ _ O
seizures _ _ O
and _ _ O
is _ _ O
a _ _ O
safe, _ _ O
effective, _ _ O
economical, _ _ O
and _ _ O
widely _ _ O
applicable _ _ O
treatment _ _ O
option _ _ O
for _ _ O
drug-resistant _ _ O
epilepsy. _ _ O
(ChiCTR-TRC-10001023). _ _ O


-DOCSTART- -X- -X- O

In _ _ O
recent _ _ O
randomized, _ _ O
placebo-controlled, _ _ O
phase _ _ O
III _ _ O
trials, _ _ O
highly _ _ O
purified _ _ O
cannabidiol _ _ O
demonstrated _ _ O
efficacy _ _ O
with _ _ O
an _ _ O
acceptable _ _ O
safety _ _ O
profile _ _ O
in _ _ O
patients _ _ O
with _ _ O
Lennox-Gastaut _ _ O
syndrome _ _ O
or _ _ O
Dravet _ _ O
syndrome. _ _ O
It _ _ O
is _ _ O
anticipated _ _ O
that _ _ O
antiepileptic _ _ O
drugs _ _ O
such _ _ O
as _ _ O
stiripentol _ _ O
and _ _ O
valproate _ _ O
will _ _ O
be _ _ O
administered _ _ O
concomitantly _ _ O
with _ _ O
cannabidiol. _ _ B-Intervention
This _ _ O
trial _ _ O
evaluated _ _ O
the _ _ O
effect _ _ O
of _ _ O
cannabidiol _ _ B-Intervention
on _ _ O
steady-state _ _ O
pharmacokinetics _ _ O
of _ _ O
stiripentol _ _ B-Intervention
or _ _ I-Intervention
valproate _ _ I-Intervention
in _ _ O
patients _ _ B-Patient
with _ _ I-Patient
epilepsy, _ _ I-Patient
and _ _ O
the _ _ O
safety _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
cannabidiol. _ _ B-Intervention
This _ _ O
phase _ _ O
II, _ _ O
two-arm, _ _ O
parallel-group, _ _ O
double-blind, _ _ O
randomized, _ _ O
placebo-controlled _ _ B-Control
trial _ _ O
recruited _ _ O
male _ _ B-Patient
and _ _ I-Patient
female _ _ I-Patient
patients _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
aged _ _ I-Patient
16-55 _ _ I-Patient
years. _ _ I-Patient
Patients _ _ O
receiving _ _ O
a _ _ B-Intervention
stable _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
stiripentol _ _ I-Intervention
or _ _ I-Intervention
valproate _ _ I-Intervention
were _ _ O
randomized _ _ O
4:1 _ _ O
to _ _ O
receive _ _ O
concomitant _ _ B-Intervention
double-blind _ _ I-Intervention
cannabidiol _ _ I-Intervention
or _ _ O
placebo. _ _ B-Control
Patients _ _ B-Intervention
received _ _ I-Intervention
plant-derived, _ _ I-Intervention
highly _ _ I-Intervention
purified _ _ I-Intervention
cannabidiol _ _ I-Intervention
medicine _ _ I-Intervention
(Epidiolex _ _ I-Intervention
® _ _ I-Intervention
in _ _ I-Intervention
the _ _ I-Intervention
USA; _ _ I-Intervention
Epidyolex _ _ I-Intervention
® _ _ I-Intervention
in _ _ I-Intervention
the _ _ I-Intervention
EU; _ _ I-Intervention
100 _ _ I-Intervention
mg/mL _ _ I-Intervention
oral _ _ I-Intervention
solution) _ _ I-Intervention
at _ _ I-Intervention
a _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
20 _ _ I-Intervention
mg/kg/day _ _ I-Intervention
from _ _ I-Intervention
day _ _ I-Intervention
12 _ _ I-Intervention
to _ _ I-Intervention
26, _ _ I-Intervention
following _ _ I-Intervention
a _ _ I-Intervention
10-day _ _ I-Intervention
dose-escalation _ _ I-Intervention
period. _ _ I-Intervention
Blood _ _ O
samples _ _ O
for _ _ O
pharmacokinetic _ _ O
evaluations _ _ O
were _ _ O
collected _ _ O
on _ _ O
days _ _ O
1 _ _ O
and _ _ O
26 _ _ O
before _ _ O
stiripentol/valproate _ _ B-Intervention
dosing _ _ O
and _ _ O
up _ _ O
to _ _ O
12 _ _ O
h _ _ O
postdose. _ _ O
Treatment-emergent _ _ O
adverse _ _ O
events _ _ O
(AEs) _ _ O
were _ _ O
recorded. _ _ O
In _ _ O
total, _ _ O
35 _ _ O
patients _ _ O
were _ _ O
recruited _ _ O
to _ _ O
the _ _ B-Intervention
stiripentol _ _ I-Intervention
arm _ _ I-Intervention
(n _ _ O
= _ _ O
14) _ _ O
or _ _ O
the _ _ B-Intervention
valproate _ _ I-Intervention
arm _ _ I-Intervention
(n _ _ O
= _ _ O
21). _ _ O
Both _ _ O
the _ _ O
safety _ _ O
and _ _ O
the _ _ O
pharmacokinetic _ _ O
populations _ _ O
of _ _ O
the _ _ B-Intervention
stiripentol _ _ I-Intervention
arm _ _ I-Intervention
comprised _ _ O
14 _ _ O
patients _ _ O
(2 _ _ O
placebo; _ _ B-Control
12 _ _ O
cannabidiol). _ _ B-Intervention
The _ _ O
safety _ _ O
population _ _ O
of _ _ O
the _ _ B-Intervention
valproate _ _ I-Intervention
arm _ _ I-Intervention
comprised _ _ O
20 _ _ O
patients _ _ O
(4 _ _ O
placebo; _ _ B-Control
16 _ _ O
cannabidiol; _ _ B-Intervention
one _ _ O
withdrew _ _ O
before _ _ O
receiving _ _ O
treatment); _ _ O
the _ _ O
pharmacokinetic _ _ O
population _ _ O
comprised _ _ O
15 _ _ O
patients _ _ O
(3 _ _ O
placebo; _ _ B-Control
12 _ _ O
cannabidiol). _ _ B-Intervention
Concomitant _ _ B-Intervention
cannabidiol _ _ I-Intervention
led _ _ B-Outcome
to _ _ I-Outcome
a _ _ I-Outcome
small _ _ I-Outcome
increase _ _ I-Outcome
in _ _ I-Outcome
stiripentol _ _ I-Outcome
exposure _ _ I-Outcome
(17% _ _ I-Outcome
increase _ _ I-Outcome
in _ _ I-Outcome
maximum _ _ I-Outcome
observed _ _ I-Outcome
plasma _ _ I-Outcome
concentration _ _ I-Outcome
[Cmax]; _ _ I-Outcome
30% _ _ I-Outcome
increase _ _ I-Outcome
in _ _ I-Outcome
area _ _ I-Outcome
under _ _ I-Outcome
the _ _ I-Outcome
concentration-time _ _ I-Outcome
curve _ _ I-Outcome
over _ _ I-Outcome
the _ _ I-Outcome
dosing _ _ I-Outcome
interval _ _ I-Outcome
[AUCtau]). _ _ I-Outcome
Concomitant _ _ O
cannabidiol _ _ O
also _ _ O
had _ _ O
little _ _ O
effect _ _ O
on _ _ O
valproate _ _ O
exposure _ _ O
(13% _ _ O
decrease _ _ O
in _ _ O
Cmax; _ _ O
17% _ _ O
decrease _ _ O
in _ _ O
AUCtau) _ _ O
or _ _ O
its _ _ O
metabolite, _ _ O
2-propyl-4-pentenoic _ _ O
acid _ _ O
(4-ene-VPA) _ _ O
(23% _ _ O
decrease _ _ O
in _ _ O
Cmax; _ _ O
30% _ _ O
decrease _ _ O
in _ _ O
AUCtau). _ _ O
All _ _ O
changes _ _ O
in _ _ O
exposure _ _ O
are _ _ O
expressed _ _ O
as _ _ O
the _ _ O
dose-normalized _ _ O
geometric _ _ O
mean _ _ O
(CV%) _ _ O
day _ _ O
26 _ _ O
to _ _ O
day _ _ O
1 _ _ O
ratio. _ _ O
The _ _ O
most _ _ O
common _ _ O
AE _ _ O
was _ _ O
diarrhea; _ _ O
most _ _ O
AEs _ _ O
were _ _ O
mild. _ _ O
Two _ _ O
patients _ _ O
discontinued _ _ O
cannabidiol _ _ O
because _ _ O
of _ _ O
serious _ _ O
AEs _ _ O
(rash _ _ O
[n _ _ O
= _ _ O
1] _ _ O
in _ _ O
the _ _ O
stiripentol _ _ O
arm; _ _ O
hypertransaminasemia _ _ O
[n _ _ O
= _ _ O
1] _ _ O
in _ _ O
the _ _ O
valproate _ _ O
arm). _ _ O
A _ _ O
separate _ _ O
in _ _ O
vitro _ _ O
study _ _ O
investigated _ _ O
the _ _ O
bidirectional _ _ O
effect _ _ O
of _ _ O
cannabidiol, _ _ O
or _ _ O
its _ _ O
metabolite _ _ O
7-carboxy-cannabidiol, _ _ O
on _ _ O
valproate _ _ O
plasma _ _ O
protein _ _ O
binding; _ _ O
no _ _ O
change _ _ O
in _ _ O
plasma _ _ O
protein _ _ O
binding _ _ O
was _ _ O
observed _ _ O
for _ _ O
either _ _ O
compound. _ _ O
The _ _ O
clinical _ _ O
relevance _ _ O
of _ _ O
the _ _ O
increase _ _ O
in _ _ O
stiripentol _ _ O
exposure _ _ O
is _ _ O
unknown; _ _ O
patients _ _ O
receiving _ _ O
cannabidiol _ _ O
and _ _ O
stiripentol _ _ O
concomitantly _ _ O
should _ _ O
be _ _ O
monitored _ _ O
for _ _ O
adverse _ _ O
reactions _ _ O
as _ _ O
individual _ _ O
patient _ _ O
responses _ _ O
may _ _ O
vary. _ _ O
Coadministration _ _ O
of _ _ O
cannabidiol _ _ O
did _ _ O
not _ _ O
affect _ _ O
the _ _ O
pharmacokinetics _ _ O
of _ _ O
valproate _ _ O
or _ _ O
its _ _ O
metabolite, _ _ O
4-ene-VPA, _ _ O
in _ _ O
adult _ _ O
patients _ _ O
with _ _ O
epilepsy. _ _ O
Safety _ _ O
results _ _ O
were _ _ O
consistent _ _ O
with _ _ O
the _ _ O
known _ _ O
safety _ _ O
profile _ _ O
of _ _ O
cannabidiol _ _ O
at _ _ O
a _ _ O
dose _ _ O
of _ _ O
20 _ _ O
mg/kg/day. _ _ O
Clinicaltrials.gov: _ _ O
NCT02607891. _ _ O


-DOCSTART- -X- -X- O

This _ _ O
post _ _ O
hoc _ _ O
analysis _ _ O
evaluated _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
safety _ _ O
of _ _ O
adjunctive _ _ B-Intervention
perampanel _ _ I-Intervention
4 _ _ I-Intervention
mg/d _ _ I-Intervention
received _ _ I-Intervention
as _ _ I-Intervention
modal _ _ I-Intervention
dose, _ _ I-Intervention
which _ _ O
may _ _ O
have _ _ O
differed _ _ O
from _ _ O
randomized _ _ O
dose, _ _ O
for _ _ O
treatment _ _ O
of _ _ O
focal _ _ O
seizures. _ _ O
Data _ _ O
were _ _ O
pooled _ _ O
from _ _ O
four _ _ O
randomized, _ _ O
double-blind, _ _ O
placebo-controlled, _ _ B-Control
phase _ _ O
III _ _ O
studies _ _ O
of _ _ O
adjunctive _ _ B-Intervention
perampanel _ _ I-Intervention
in _ _ O
patients _ _ B-Patient
(aged _ _ I-Patient
≥12 _ _ I-Patient
years) _ _ I-Patient
with _ _ I-Patient
focal _ _ I-Patient
seizures, _ _ I-Patient
with/without _ _ I-Patient
focal _ _ I-Patient
to _ _ I-Patient
bilateral _ _ I-Patient
tonic-clonic _ _ I-Patient
(FBTC) _ _ I-Patient
seizures: _ _ I-Patient
studies _ _ O
304 _ _ O
(NCT00699972), _ _ O
305 _ _ O
(NCT00699582), _ _ O
306 _ _ O
(NCT00700310), _ _ O
and _ _ O
335 _ _ O
(NCT01618695). _ _ O
Efficacy _ _ O
assessments _ _ O
included _ _ O
median _ _ O
percentage _ _ O
reductions _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
per _ _ O
28 _ _ O
days _ _ O
and _ _ O
seizure-freedom _ _ O
rates _ _ O
for _ _ O
patients _ _ O
receiving _ _ O
placebo _ _ B-Control
and _ _ O
perampanel _ _ B-Intervention
4 _ _ I-Intervention
mg/d _ _ I-Intervention
(modal _ _ I-Intervention
dose). _ _ I-Intervention
Treatment-emergent _ _ O
adverse _ _ O
events _ _ O
(TEAEs) _ _ O
were _ _ O
assessed _ _ O
in _ _ O
patients _ _ O
receiving _ _ O
perampanel _ _ B-Intervention
4 _ _ I-Intervention
mg/d _ _ I-Intervention
at _ _ O
their _ _ O
TEAE _ _ O
onset. _ _ O
Outcomes _ _ O
were _ _ O
also _ _ O
assessed _ _ O
with/without _ _ O
enzyme-inducing _ _ O
antiseizure _ _ O
medications _ _ O
(EIASMs). _ _ O
The _ _ O
full _ _ O
analysis _ _ O
set _ _ O
included _ _ O
979 _ _ O
patients _ _ B-Patient
with _ _ I-Patient
focal _ _ I-Patient
seizures _ _ I-Patient
(placebo: _ _ B-Control
n _ _ O
= _ _ O
616 _ _ O
[235 _ _ O
with _ _ O
FBTC _ _ O
seizures]; _ _ O
perampanel _ _ B-Intervention
4 _ _ I-Intervention
mg/d: _ _ I-Intervention
n _ _ O
= _ _ O
363 _ _ O
[134 _ _ O
with _ _ O
FBTC _ _ O
seizures]). _ _ O
Compared _ _ B-Outcome
with _ _ I-Outcome
placebo, _ _ I-Outcome
perampanel _ _ I-Outcome
4 _ _ I-Outcome
mg/d _ _ I-Outcome
conferred _ _ I-Outcome
significantly _ _ I-Outcome
greater _ _ I-Outcome
median _ _ I-Outcome
percentage _ _ I-Outcome
reductions _ _ I-Outcome
in _ _ I-Outcome
seizure _ _ I-Outcome
frequency _ _ I-Outcome
per _ _ I-Outcome
28 _ _ I-Outcome
days _ _ I-Outcome
for _ _ I-Outcome
focal _ _ I-Outcome
(12.6% _ _ I-Outcome
vs _ _ I-Outcome
21.1%; _ _ I-Outcome
P _ _ I-Outcome
= _ _ I-Outcome
.0004) _ _ I-Outcome
and _ _ I-Outcome
FBTC _ _ I-Outcome
seizures _ _ I-Outcome
(17.4% _ _ I-Outcome
vs _ _ I-Outcome
49.8%; _ _ I-Outcome
P _ _ I-Outcome
< _ _ I-Outcome
.0001), _ _ I-Outcome
and _ _ I-Outcome
seizure-freedom _ _ I-Outcome
rates _ _ I-Outcome
for _ _ I-Outcome
focal _ _ I-Outcome
(0.8% _ _ I-Outcome
vs _ _ I-Outcome
3.6%; _ _ I-Outcome
P _ _ I-Outcome
= _ _ I-Outcome
.0018) _ _ I-Outcome
and _ _ I-Outcome
FBTC _ _ I-Outcome
seizures _ _ I-Outcome
(11.1% _ _ I-Outcome
vs _ _ I-Outcome
18.7%; _ _ I-Outcome
P _ _ I-Outcome
= _ _ I-Outcome
.0424). _ _ I-Outcome
Seizure _ _ O
improvements _ _ O
with _ _ O
perampanel _ _ O
4 _ _ O
mg/d _ _ O
were _ _ O
greater _ _ O
without _ _ O
EIASMs _ _ O
than _ _ O
with _ _ O
EIASMs. _ _ O
For _ _ O
assessment _ _ O
of _ _ O
TEAEs, _ _ O
overall _ _ O
1376 _ _ O
patients _ _ O
with _ _ O
focal _ _ O
seizures _ _ O
received _ _ O
perampanel _ _ O
4 _ _ O
mg/d _ _ O
at _ _ O
any _ _ O
time _ _ O
(FBTC _ _ O
seizures, _ _ O
n _ _ O
= _ _ O
499). _ _ O
TEAEs _ _ O
with _ _ O
perampanel _ _ O
4 _ _ O
mg/d _ _ O
occurred _ _ O
in _ _ O
419 _ _ O
of _ _ O
1376 _ _ O
(30.5%) _ _ O
and _ _ O
148 _ _ O
of _ _ O
499 _ _ O
(29.7%) _ _ O
patients _ _ O
with _ _ O
focal _ _ O
and _ _ O
FBTC _ _ O
seizures, _ _ O
respectively; _ _ O
most _ _ O
common _ _ O
was _ _ O
dizziness. _ _ O
The _ _ O
proportion _ _ O
of _ _ O
TEAEs _ _ O
was _ _ O
similar _ _ O
with _ _ O
or _ _ O
without _ _ O
EIASMs. _ _ O
This _ _ O
post _ _ O
hoc _ _ O
analysis _ _ O
showed _ _ O
adjunctive _ _ O
perampanel _ _ O
4 _ _ O
mg/d _ _ O
was _ _ O
efficacious _ _ O
and _ _ O
well _ _ O
tolerated _ _ O
in _ _ O
patients _ _ O
with _ _ O
focal _ _ O
seizures, _ _ O
with _ _ O
or _ _ O
without _ _ O
FBTC _ _ O
seizures. _ _ O
This _ _ O
dose _ _ O
may _ _ O
be _ _ O
a _ _ O
valuable _ _ O
treatment _ _ O
option _ _ O
in _ _ O
patients _ _ O
unable _ _ O
to _ _ O
tolerate _ _ O
higher _ _ O
perampanel _ _ O
doses _ _ O
up _ _ O
to _ _ O
12 _ _ O
mg/d. _ _ O


-DOCSTART- -X- -X- O

We _ _ O
have _ _ O
performed _ _ O
a _ _ O
randomised, _ _ O
prospective _ _ O
study _ _ O
to _ _ O
compare _ _ O
the _ _ O
efficacy _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
sodium _ _ B-Intervention
valproate _ _ I-Intervention
(VPA) _ _ I-Intervention
and _ _ O
lamotrigine _ _ B-Control
(LTG) _ _ I-Control
monotherapy, _ _ I-Control
and _ _ O
their _ _ O
effects _ _ O
on _ _ O
circulating _ _ O
androgenic _ _ O
hormones, _ _ O
in _ _ O
newly _ _ O
diagnosed _ _ O
epilepsy. _ _ O
A _ _ O
total _ _ O
of _ _ O
225 _ _ O
patients _ _ O
(116 _ _ O
male; _ _ O
median _ _ O
age _ _ O
35 _ _ O
years, _ _ O
range _ _ O
13-80 _ _ O
years) _ _ O
were _ _ O
followed-up _ _ O
at _ _ O
6-weekly _ _ O
intervals _ _ O
until _ _ O
they _ _ O
reached _ _ O
an _ _ O
end-point _ _ O
(12 _ _ O
months' _ _ O
seizure _ _ O
freedom; _ _ O
withdrawal _ _ O
due _ _ O
to _ _ O
intolerable _ _ O
side-effects; _ _ O
lack _ _ O
of _ _ O
efficacy _ _ O
despite _ _ O
adequate _ _ O
dosing). _ _ O
Twelve _ _ O
month _ _ O
seizure-free _ _ O
rates _ _ O
were _ _ O
identical _ _ O
(47%) _ _ O
in _ _ O
the _ _ O
VPA _ _ O
(n=111) _ _ O
and _ _ O
LTG _ _ O
(n=114) _ _ O
treatment _ _ O
arms. _ _ O
More _ _ O
patients _ _ O
taking _ _ O
VPA _ _ O
withdrew _ _ O
from _ _ O
the _ _ O
study _ _ O
due _ _ O
to _ _ O
adverse _ _ O
events _ _ O
(26 _ _ O
VPA _ _ O
versus _ _ O
15 _ _ O
LTG; _ _ O
p=0.046). _ _ O
Eight _ _ O
patients, _ _ O
all _ _ O
taking _ _ O
VPA, _ _ O
dropped _ _ O
out _ _ O
during _ _ O
the _ _ O
first _ _ O
6 _ _ O
months _ _ O
due _ _ O
to _ _ O
weight _ _ O
gain. _ _ O
There _ _ O
were _ _ O
no _ _ O
changes _ _ O
in _ _ O
mean _ _ O
serum _ _ O
concentrations _ _ O
of _ _ O
testosterone, _ _ O
sex-hormone _ _ O
binding _ _ O
globulin _ _ O
and _ _ O
androstenedione _ _ O
or _ _ O
in _ _ O
the _ _ O
free _ _ O
androgen _ _ O
index _ _ O
after _ _ O
6 _ _ O
or _ _ O
12 _ _ O
months' _ _ O
treatment _ _ O
with _ _ O
either _ _ O
drug _ _ O
in _ _ O
112 _ _ O
patients _ _ O
who _ _ O
fulfilled _ _ O
the _ _ O
criteria _ _ O
for _ _ O
hormone _ _ O
analysis. _ _ O
No _ _ O
difference _ _ O
in _ _ O
efficacy _ _ O
was _ _ O
found _ _ O
between _ _ O
VPA _ _ O
and _ _ O
LTG _ _ O
in _ _ O
our _ _ O
patients _ _ O
with _ _ O
newly _ _ O
diagnosed _ _ O
epilepsy. _ _ O
LTG _ _ O
appeared _ _ O
to _ _ O
be _ _ O
better _ _ O
tolerated. _ _ O
Neither _ _ O
drug _ _ O
appeared _ _ O
to _ _ O
alter _ _ O
the _ _ O
circulating _ _ O
levels _ _ O
of _ _ O
androgenic _ _ O
hormones. _ _ O


-DOCSTART- -X- -X- O

To _ _ O
compare _ _ O
the _ _ O
impact _ _ O
of _ _ O
policies _ _ O
of _ _ O
immediate _ _ B-Intervention
vs _ _ O
deferred _ _ B-Control
treatment _ _ I-Control
in _ _ O
patients _ _ O
with _ _ O
few _ _ O
or _ _ O
infrequent _ _ O
seizures _ _ O
on _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QoL) _ _ O
outcomes. _ _ O
We _ _ O
conducted _ _ O
a _ _ O
multicenter, _ _ O
randomized, _ _ O
unblinded _ _ O
study _ _ O
of _ _ O
immediate _ _ O
and _ _ O
deferred _ _ O
treatment. _ _ O
QoL _ _ O
data _ _ O
were _ _ O
collected _ _ O
by _ _ O
mail, _ _ O
using _ _ O
validated _ _ O
measures, _ _ O
for _ _ O
participants _ _ O
living _ _ O
in _ _ O
the _ _ O
UK _ _ O
and _ _ O
without _ _ O
major _ _ O
learning _ _ O
disability. _ _ O
Baseline _ _ O
questionnaires _ _ O
were _ _ O
returned _ _ O
by _ _ O
441 _ _ O
adult _ _ O
patients; _ _ O
333 _ _ O
returned _ _ O
2-year _ _ O
follow-up _ _ O
questionnaires. _ _ O
This _ _ O
analysis _ _ O
is _ _ O
based _ _ O
on _ _ O
331 _ _ O
patients _ _ O
(162 _ _ O
randomized _ _ O
to _ _ O
immediate, _ _ O
169 _ _ O
to _ _ O
deferred _ _ O
treatment) _ _ O
returning _ _ O
both _ _ O
baseline _ _ O
and _ _ O
2-year _ _ O
questionnaires. _ _ O
There _ _ O
were _ _ O
no _ _ O
significant _ _ O
differences _ _ O
at _ _ O
2 _ _ O
years _ _ O
in _ _ O
QoL _ _ O
outcomes _ _ O
by _ _ O
treatment _ _ O
group. _ _ O
Patients _ _ O
randomized _ _ O
to _ _ O
deferred _ _ O
treatment _ _ O
were _ _ O
no _ _ O
more _ _ O
likely _ _ O
to _ _ O
report _ _ O
impairments _ _ O
in _ _ O
general _ _ O
health, _ _ O
cognitive _ _ O
function, _ _ O
psychological _ _ O
well-being, _ _ O
or _ _ O
social _ _ O
function. _ _ O
The _ _ O
one _ _ O
area _ _ O
of _ _ O
functioning _ _ O
affected _ _ O
was _ _ O
driving, _ _ O
where _ _ O
those _ _ O
randomized _ _ O
to _ _ O
deferred _ _ O
treatment _ _ O
were _ _ O
disadvantaged. _ _ O
There _ _ O
were _ _ O
clear _ _ O
QoL _ _ O
impacts _ _ O
both _ _ O
of _ _ O
taking _ _ O
antiepileptic _ _ O
drugs _ _ O
and, _ _ O
to _ _ O
an _ _ O
even _ _ O
greater _ _ O
extent, _ _ O
of _ _ O
continuing _ _ O
seizures. _ _ O
In _ _ O
treatment _ _ O
uncertain _ _ O
patients, _ _ O
there _ _ O
is _ _ O
a _ _ O
clear _ _ O
trade-off _ _ O
between _ _ O
adverse _ _ O
effects _ _ O
of _ _ O
seizures _ _ O
and _ _ O
adverse _ _ O
effects _ _ O
of _ _ O
taking _ _ O
antiepileptic _ _ O
drugs, _ _ O
i.e., _ _ O
neither _ _ O
policy _ _ O
examined _ _ O
in _ _ O
our _ _ O
study _ _ O
was _ _ O
associated _ _ O
with _ _ O
overall _ _ O
quality _ _ O
of _ _ O
life _ _ O
gains _ _ O
or _ _ O
losses _ _ O
longer _ _ O
term. _ _ O


-DOCSTART- -X- -X- O

We _ _ O
investigated _ _ O
the _ _ O
efficacy _ _ O
of _ _ O
mindfulness-based _ _ B-Intervention
intervention _ _ I-Intervention
(MBI) _ _ I-Intervention
in _ _ O
promoting _ _ O
psychological _ _ O
wellbeing _ _ O
in _ _ O
people _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
(PWE) _ _ I-Patient
using _ _ O
an _ _ O
assessor-blinded _ _ O
randomized _ _ O
controlled _ _ O
design. _ _ O
A _ _ O
total _ _ O
of _ _ O
28 _ _ O
PWE _ _ B-Patient
were _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
either _ _ O
intervention _ _ O
(n _ _ O
= _ _ O
14 _ _ O
cases) _ _ O
or _ _ O
control _ _ B-Control
group _ _ I-Control
(n _ _ O
= _ _ O
14 _ _ O
controls). _ _ O
The _ _ B-Intervention
intervention _ _ I-Intervention
group _ _ I-Intervention
received _ _ I-Intervention
a _ _ I-Intervention
six _ _ I-Intervention
2.5-hour _ _ I-Intervention
weekly _ _ I-Intervention
MBI, _ _ I-Intervention
while _ _ O
the _ _ B-Control
control _ _ I-Control
group _ _ I-Control
did _ _ I-Control
not _ _ I-Control
receive _ _ I-Control
any _ _ I-Control
intervention. _ _ I-Control
They _ _ O
were _ _ O
assessed _ _ O
at _ _ O
three _ _ O
timepoints _ _ O
(T0: _ _ O
before _ _ O
intervention, _ _ O
T1: _ _ O
immediately _ _ O
after _ _ O
intervention, _ _ O
and _ _ O
T2: _ _ O
6 _ _ O
weeks _ _ O
after _ _ O
intervention). _ _ O
Repeated _ _ O
measures _ _ O
of _ _ O
analyses _ _ O
of _ _ O
variance _ _ O
(RM-ANOVAs) _ _ O
were _ _ O
used _ _ O
for _ _ O
inter-group _ _ O
comparisons _ _ O
to _ _ O
determine _ _ O
intervention _ _ O
effect _ _ O
from _ _ O
baseline _ _ O
-to _ _ O
T1 _ _ O
and _ _ O
-to _ _ O
T2 _ _ O
for _ _ O
all _ _ O
outcome _ _ O
measures. _ _ O
The _ _ O
individual _ _ O
changes _ _ O
were _ _ O
calculated _ _ O
using _ _ O
the _ _ O
reliable _ _ B-Outcome
change _ _ I-Outcome
index _ _ I-Outcome
(RCI). _ _ I-Outcome
Key _ _ O
outcomes _ _ O
included _ _ O
depression _ _ B-Outcome
(BDI-II), _ _ I-Outcome
anxiety _ _ I-Outcome
(BAI), _ _ I-Outcome
epilepsy-related _ _ I-Outcome
quality _ _ I-Outcome
of _ _ I-Outcome
life _ _ I-Outcome
(QOLIE-31), _ _ I-Outcome
satisfaction _ _ I-Outcome
with _ _ I-Outcome
life _ _ I-Outcome
(SWLS), _ _ I-Outcome
and _ _ I-Outcome
level _ _ I-Outcome
of _ _ I-Outcome
mindfulness _ _ I-Outcome
(MAAS). _ _ I-Outcome
Participants _ _ B-Outcome
who _ _ I-Outcome
participated _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
MBI _ _ I-Outcome
showed _ _ I-Outcome
significant _ _ I-Outcome
reduction _ _ I-Outcome
in _ _ I-Outcome
BDI-II _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.001), _ _ I-Outcome
significant _ _ I-Outcome
increases _ _ I-Outcome
in _ _ I-Outcome
MAAS _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.027) _ _ I-Outcome
and _ _ I-Outcome
QOLIE-31 _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.001) _ _ I-Outcome
at _ _ I-Outcome
T1 _ _ I-Outcome
when _ _ I-Outcome
compared _ _ I-Outcome
with _ _ I-Outcome
the _ _ I-Outcome
control _ _ I-Outcome
group. _ _ I-Outcome
However, _ _ O
BAI _ _ O
and _ _ O
SWLS _ _ O
were _ _ O
not _ _ O
significant. _ _ O
The _ _ O
trend _ _ O
was _ _ O
similar _ _ O
at _ _ O
6-week _ _ O
follow-up, _ _ O
all _ _ O
outcome _ _ O
measures _ _ O
of _ _ O
MBI _ _ O
remained _ _ O
significant _ _ O
(p _ _ O
< _ _ O
0.05) _ _ O
except _ _ O
for _ _ O
BAI _ _ O
and _ _ O
SWLS. _ _ O
Beyond _ _ O
the _ _ O
6-week _ _ O
intervention, _ _ O
RCI _ _ O
analysis _ _ O
showed _ _ O
a _ _ O
significant _ _ O
improvement _ _ O
in _ _ O
levels _ _ O
of _ _ O
mindfulness _ _ O
(45.45% _ _ O
vs. _ _ O
21.43%, _ _ O
p _ _ O
= _ _ O
0.009), _ _ O
depression _ _ O
(45.45% _ _ O
vs. _ _ O
0.00%, _ _ O
p _ _ O
= _ _ O
0.016), _ _ O
quality _ _ O
of _ _ O
life _ _ O
(45.45% _ _ O
vs. _ _ O
14.29%, _ _ O
p _ _ O
= _ _ O
0.017) _ _ O
with _ _ O
MBI, _ _ O
as _ _ O
compared _ _ O
to _ _ O
the _ _ O
no-intervention _ _ O
phase. _ _ O
Mindfulness-based _ _ O
intervention _ _ O
is _ _ O
effective _ _ O
in _ _ O
reducing _ _ O
psychological _ _ O
distress _ _ O
and _ _ O
improving _ _ O
the _ _ O
quality _ _ O
of _ _ O
life _ _ O
in _ _ O
PWE. _ _ O


-DOCSTART- -X- -X- O

Cathodal _ _ B-Intervention
transcranial _ _ I-Intervention
direct _ _ I-Intervention
current _ _ I-Intervention
stimulation _ _ I-Intervention
(tDCS) _ _ I-Intervention
is _ _ O
a _ _ O
noninvasive _ _ O
brain _ _ O
stimulation _ _ O
method _ _ O
for _ _ O
suppressing _ _ O
regional _ _ O
cortical _ _ O
excitability. _ _ O
We _ _ O
examine _ _ O
the _ _ O
safety _ _ O
and _ _ O
antiepileptic _ _ O
efficacy _ _ O
of _ _ O
cathodal _ _ B-Intervention
tDCS _ _ I-Intervention
in _ _ O
children _ _ B-Patient
with _ _ I-Patient
refractory _ _ I-Patient
focal _ _ I-Patient
epilepsy. _ _ I-Patient
Although _ _ O
a _ _ O
prior _ _ O
cathodal _ _ O
tDCS _ _ O
trial _ _ O
in _ _ O
adults _ _ O
with _ _ O
epilepsy _ _ O
revealed _ _ O
EEG _ _ O
improvement, _ _ O
neither _ _ O
the _ _ O
antiepileptic _ _ O
potential _ _ O
nor _ _ O
the _ _ O
safety _ _ O
and _ _ O
tolerability _ _ O
of _ _ O
tDCS _ _ O
has _ _ O
been _ _ O
tested _ _ O
in _ _ O
children. _ _ O
The _ _ O
study _ _ O
consisted _ _ O
of _ _ O
three _ _ O
phases: _ _ O
1) _ _ O
a _ _ O
4-week _ _ O
pre-treatment _ _ O
monitoring _ _ O
period _ _ O
with _ _ O
vital _ _ O
sign _ _ O
measures, _ _ O
EEG, _ _ O
seizure _ _ O
diary, _ _ O
and _ _ O
baseline _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QOL) _ _ O
questionnaire; _ _ O
2) _ _ O
a _ _ B-Intervention
single _ _ I-Intervention
treatment _ _ I-Intervention
with _ _ I-Intervention
1 _ _ I-Intervention
mA _ _ I-Intervention
cathodal _ _ I-Intervention
tDCS _ _ I-Intervention
for _ _ I-Intervention
20 _ _ I-Intervention
min _ _ I-Intervention
with _ _ I-Intervention
cathode _ _ I-Intervention
positioned _ _ I-Intervention
over _ _ I-Intervention
the _ _ I-Intervention
seizure _ _ I-Intervention
focus _ _ I-Intervention
and _ _ I-Intervention
anode _ _ I-Intervention
on _ _ I-Intervention
the _ _ I-Intervention
contralateral _ _ I-Intervention
shoulder; _ _ I-Intervention
3) _ _ O
follow-ups _ _ O
immediately _ _ O
after _ _ O
stimulation, _ _ O
and _ _ O
at _ _ O
24, _ _ O
48 _ _ O
h, _ _ O
and _ _ O
4 _ _ O
weeks _ _ O
after _ _ O
tDCS _ _ B-Intervention
with _ _ O
continued _ _ O
seizure _ _ O
diary _ _ O
and _ _ O
epileptic _ _ O
discharge _ _ O
counts _ _ O
on _ _ O
EEG; _ _ O
the _ _ O
QOL _ _ O
questionnaire _ _ O
was _ _ O
also _ _ O
repeated _ _ O
4 _ _ O
weeks _ _ O
after _ _ O
stimulation. _ _ O
Patients _ _ O
were _ _ O
randomized _ _ O
to _ _ O
receive _ _ O
either _ _ O
single _ _ B-Control
session _ _ I-Control
active _ _ B-Intervention
or _ _ O
sham _ _ B-Control
tDCS _ _ I-Control
1 _ _ I-Control
mA, _ _ I-Control
20 _ _ I-Control
min. _ _ I-Control
Thirty _ _ O
six _ _ O
children _ _ O
(6-15 _ _ O
years) _ _ O
with _ _ O
focal _ _ O
epilepsy _ _ O
were _ _ O
enrolled, _ _ O
27 _ _ O
in _ _ O
active _ _ O
and _ _ O
9 _ _ O
in _ _ O
sham _ _ O
group. _ _ O
All _ _ O
patients _ _ O
tolerated _ _ O
tDCS _ _ O
well. _ _ O
No _ _ O
serious _ _ O
adverse _ _ O
events _ _ O
occurred. _ _ O
Active _ _ O
tDCS _ _ O
treatment _ _ O
was _ _ O
associated _ _ O
with _ _ O
significant _ _ O
reductions _ _ O
in _ _ O
epileptic _ _ O
discharge _ _ O
frequency _ _ O
immediately _ _ O
and _ _ O
24 _ _ O
and _ _ O
48 _ _ O
h _ _ O
after _ _ O
tDCS. _ _ O
Four _ _ O
weeks _ _ O
after _ _ O
treatment, _ _ O
a _ _ O
small _ _ O
(clinically _ _ O
negligible _ _ O
but _ _ O
statistically _ _ O
significant) _ _ O
decrease _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
was _ _ O
also _ _ O
detected. _ _ O
A _ _ O
single _ _ O
session _ _ O
of _ _ O
cathodal _ _ O
tDCS _ _ O
improves _ _ O
epileptic _ _ O
EEG _ _ O
abnormalities _ _ O
for _ _ O
48 _ _ O
h _ _ O
and _ _ O
is _ _ O
well-tolerated _ _ O
in _ _ O
children. _ _ O


-DOCSTART- -X- -X- O

The _ _ O
objective _ _ O
of _ _ O
this _ _ O
trial _ _ O
was _ _ O
to _ _ O
compare _ _ O
the _ _ O
effectiveness _ _ O
of _ _ O
levetiracetam _ _ B-Intervention
(LEV) _ _ I-Intervention
and _ _ O
topiramate _ _ B-Control
(TPM) _ _ I-Control
as _ _ I-Control
adjunctive _ _ I-Control
treatment _ _ I-Control
for _ _ O
patients _ _ B-Patient
with _ _ I-Patient
focal _ _ I-Patient
seizures _ _ I-Patient
in _ _ I-Patient
Korea. _ _ I-Patient
In _ _ O
this _ _ O
Phase _ _ O
IV, _ _ O
open-label, _ _ O
multicenter _ _ O
trial _ _ O
(NCT01229735), _ _ O
adults _ _ B-Patient
were _ _ O
randomized _ _ O
to _ _ O
treatment _ _ B-Intervention
with _ _ I-Intervention
LEV _ _ I-Intervention
(1000-3000 _ _ I-Intervention
mg/day) _ _ I-Intervention
or _ _ O
TPM _ _ B-Control
(200-400 _ _ I-Control
mg/day). _ _ I-Control
Only _ _ O
patients _ _ O
achieving _ _ O
LEV _ _ B-Intervention
≥1000 _ _ I-Intervention
mg/day _ _ I-Intervention
or _ _ O
TPM _ _ B-Control
≥100 _ _ I-Control
mg/day _ _ I-Control
after _ _ O
a _ _ O
4-week _ _ O
up-titration _ _ O
entered _ _ O
the _ _ O
20-week _ _ O
dose-finding _ _ O
and _ _ O
subsequent _ _ O
28-week _ _ O
maintenance _ _ O
periods. _ _ O
The _ _ O
primary _ _ O
outcome _ _ O
was _ _ O
the _ _ O
52-week _ _ O
retention _ _ O
rate; _ _ O
others _ _ O
included _ _ O
safety _ _ O
and _ _ O
exploratory _ _ O
efficacy _ _ O
outcomes. _ _ O
Of _ _ O
343 _ _ O
randomized _ _ O
patients _ _ O
(LEV _ _ B-Intervention
177; _ _ O
TPM _ _ B-Control
166), _ _ O
211 _ _ O
(61.5%) _ _ O
completed _ _ O
the _ _ O
trial. _ _ O
In _ _ B-Outcome
the _ _ I-Outcome
full _ _ I-Outcome
analysis _ _ I-Outcome
set _ _ I-Outcome
(FAS), _ _ I-Outcome
retention _ _ I-Outcome
rate _ _ I-Outcome
was _ _ I-Outcome
59.1% _ _ I-Outcome
with _ _ I-Outcome
LEV _ _ I-Outcome
vs _ _ I-Outcome
56.6% _ _ I-Outcome
with _ _ I-Outcome
TPM _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.7007), _ _ I-Outcome
while _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
prespecified _ _ I-Outcome
sensitivity _ _ I-Outcome
analysis, _ _ I-Outcome
based _ _ I-Outcome
on _ _ I-Outcome
data _ _ I-Outcome
from _ _ I-Outcome
patients _ _ I-Outcome
who _ _ I-Outcome
received _ _ I-Outcome
drug _ _ I-Outcome
doses _ _ I-Outcome
in _ _ I-Outcome
the _ _ I-Outcome
recommended _ _ I-Outcome
range _ _ I-Outcome
(LEV _ _ I-Outcome
176; _ _ I-Outcome
TPM _ _ I-Outcome
113), _ _ I-Outcome
it _ _ I-Outcome
was _ _ I-Outcome
59.1% _ _ I-Outcome
with _ _ I-Outcome
LEV _ _ I-Outcome
vs _ _ I-Outcome
42.5% _ _ I-Outcome
with _ _ I-Outcome
TPM _ _ I-Outcome
(p _ _ I-Outcome
= _ _ I-Outcome
0.0086). _ _ I-Outcome
In _ _ O
the _ _ O
FAS, _ _ O
median _ _ O
percent _ _ O
reduction _ _ O
in _ _ O
seizure _ _ O
frequency _ _ O
from _ _ O
baseline _ _ O
was _ _ O
74.47% _ _ O
with _ _ O
LEV _ _ O
and _ _ O
67.86% _ _ O
with _ _ O
TPM _ _ O
(p _ _ O
= _ _ O
0.0665); _ _ O
≥50% _ _ O
responder _ _ O
rate _ _ O
was _ _ O
69.0% _ _ O
vs _ _ O
64.8% _ _ O
(p _ _ O
= _ _ O
0.4205), _ _ O
and _ _ O
the _ _ O
6-month _ _ O
seizure-freedom _ _ O
rate _ _ O
was _ _ O
35.8% _ _ O
vs _ _ O
22.3% _ _ O
(p _ _ O
= _ _ O
0.0061). _ _ O
In _ _ O
the _ _ O
sensitivity _ _ O
analysis, _ _ O
differences _ _ O
between _ _ O
groups _ _ O
were _ _ O
greater, _ _ O
favoring _ _ O
LEV. _ _ O
Incidences _ _ O
of _ _ O
treatment-emergent _ _ O
adverse _ _ O
events _ _ O
(TEAEs) _ _ O
were _ _ O
70.6% _ _ O
with _ _ O
LEV _ _ O
vs _ _ O
77.1% _ _ O
with _ _ O
TPM; _ _ O
most _ _ O
frequently _ _ O
somnolence _ _ O
(20.3%), _ _ O
dizziness _ _ O
(18.1%), _ _ O
and _ _ O
nasopharyngitis _ _ O
(13.6%) _ _ O
with _ _ O
LEV; _ _ O
and _ _ O
decreased _ _ O
appetite _ _ O
(15.7%), _ _ O
dizziness _ _ O
(14.5%), _ _ O
and _ _ O
headache _ _ O
(14.5%) _ _ O
with _ _ O
TPM. _ _ O
Discontinuations _ _ O
due _ _ O
to _ _ O
TEAEs _ _ O
were _ _ O
7.9% _ _ O
with _ _ O
LEV _ _ O
and _ _ O
12.7% _ _ O
with _ _ O
TPM. _ _ O
In _ _ O
this _ _ O
open-label _ _ O
trial, _ _ O
the _ _ O
52-week _ _ O
retention _ _ O
rate _ _ O
was _ _ O
not _ _ O
significantly _ _ O
different _ _ O
between _ _ O
LEV _ _ O
and _ _ O
TPM. _ _ O
However, _ _ O
LEV _ _ O
was _ _ O
associated _ _ O
with _ _ O
a _ _ O
substantially _ _ O
higher _ _ O
seizure _ _ O
freedom _ _ O
rate _ _ O
and _ _ O
a _ _ O
more _ _ O
favorable _ _ O
safety _ _ O
profile _ _ O
than _ _ O
TPM _ _ O
in _ _ O
this _ _ O
population _ _ O
of _ _ O
Korean _ _ O
patients _ _ O
with _ _ O
focal _ _ O
seizures. _ _ O


-DOCSTART- -X- -X- O

Switching _ _ O
between _ _ O
generic _ _ O
antiepileptic _ _ O
drugs _ _ O
is _ _ O
a _ _ O
highly _ _ O
debated _ _ O
issue _ _ O
that _ _ O
affects _ _ O
both _ _ O
clinical _ _ O
care _ _ O
and _ _ O
overall _ _ O
health _ _ O
care _ _ O
costs. _ _ O
To _ _ O
evaluate _ _ O
the _ _ O
single-dose _ _ O
pharmacokinetic _ _ O
bioequivalence _ _ O
of _ _ O
3 _ _ O
(1 _ _ O
branded _ _ B-Intervention
and _ _ O
2 _ _ O
generic _ _ B-Control
drugs) _ _ I-Control
on-market, _ _ O
immediate-release _ _ B-Intervention
lamotrigine _ _ I-Intervention
drug _ _ I-Intervention
products. _ _ I-Intervention
The _ _ O
Equivalence _ _ O
Among _ _ O
Antiepileptic _ _ O
Drug _ _ O
Generic _ _ O
and _ _ O
Brand _ _ O
Products _ _ O
in _ _ O
People _ _ O
With _ _ O
Epilepsy _ _ O
(EQUIGEN) _ _ O
single-dose _ _ O
study _ _ O
is _ _ O
a _ _ O
crossover, _ _ O
prospective, _ _ O
sequence-randomized, _ _ O
replicate _ _ O
pharmacokinetic _ _ O
study _ _ O
conducted _ _ O
at _ _ O
5 _ _ O
US _ _ B-Patient
academic _ _ O
epilepsy _ _ O
centers. _ _ O
Fifty _ _ O
adults _ _ B-Patient
(≥18 _ _ I-Patient
years) _ _ I-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
who _ _ I-Patient
were _ _ I-Patient
taking _ _ I-Patient
concomitant _ _ I-Patient
antiepileptic _ _ I-Patient
drugs _ _ I-Patient
and _ _ I-Patient
not _ _ I-Patient
currently _ _ I-Patient
receiving _ _ I-Patient
lamotrigine _ _ I-Patient
were _ _ O
enrolled _ _ O
between _ _ O
July _ _ O
18, _ _ O
2013, _ _ O
and _ _ O
January _ _ O
19, _ _ O
2015. _ _ O
Every _ _ O
participant _ _ O
was _ _ O
randomly _ _ O
assigned _ _ O
to _ _ O
1 _ _ O
of _ _ O
3 _ _ O
equivalent _ _ O
sequences, _ _ O
each _ _ O
comprising _ _ O
6 _ _ O
study _ _ O
periods, _ _ O
during _ _ O
which _ _ O
they _ _ O
had _ _ O
blood _ _ O
draws _ _ O
before _ _ O
and _ _ O
after _ _ O
medication _ _ O
administration. _ _ O
Forty-nine _ _ O
participants _ _ O
were _ _ O
included _ _ O
in _ _ O
intention-to-treat _ _ O
analyses. _ _ O
Participants _ _ O
received _ _ O
a _ _ B-Intervention
single _ _ I-Intervention
25-mg _ _ I-Intervention
dose _ _ I-Intervention
of _ _ I-Intervention
immediate-release _ _ I-Intervention
lamotrigine _ _ I-Intervention
at _ _ O
the _ _ O
start _ _ O
of _ _ O
each _ _ O
period, _ _ O
with _ _ O
the _ _ B-Intervention
branded _ _ I-Intervention
and _ _ O
the _ _ B-Control
2 _ _ I-Control
most _ _ I-Control
disparate _ _ I-Control
generic _ _ I-Control
products _ _ I-Control
each _ _ O
studied _ _ O
twice. _ _ O
Lamotrigine _ _ B-Intervention
was _ _ O
selected _ _ O
as _ _ O
the _ _ O
antiepileptic _ _ O
drug _ _ O
of _ _ O
interest _ _ O
because _ _ O
of _ _ O
its _ _ O
wide _ _ O
use, _ _ O
publications _ _ O
indicating _ _ O
problems _ _ O
with _ _ O
generic _ _ O
switches, _ _ O
and _ _ O
complaints _ _ O
to _ _ O
the _ _ O
US _ _ O
Food _ _ O
and _ _ O
Drug _ _ O
Administration _ _ O
regarding _ _ O
generic _ _ O
products. _ _ O
Both _ _ O
participants _ _ O
and _ _ O
study _ _ O
personnel _ _ O
were _ _ O
blinded _ _ O
to _ _ O
the _ _ O
specific _ _ O
generic _ _ O
products _ _ O
selected. _ _ O
The _ _ O
primary _ _ O
outcome _ _ O
was _ _ O
bioequivalence _ _ O
between _ _ O
products. _ _ O
Maximum _ _ O
plasma _ _ O
concentration _ _ O
(Cmax) _ _ O
and _ _ O
area _ _ O
under _ _ O
the _ _ O
concentration-time _ _ O
curve _ _ O
(AUC) _ _ O
were _ _ O
compared, _ _ O
and _ _ O
average _ _ O
bioequivalence _ _ O
(ABE) _ _ O
was _ _ O
established _ _ O
if _ _ O
the _ _ O
90% _ _ O
CIs _ _ O
of _ _ O
the _ _ O
ratios _ _ O
of _ _ O
the _ _ O
2 _ _ O
products _ _ O
were _ _ O
within _ _ O
equivalence _ _ O
limits _ _ O
(80%-125%). _ _ O
Of _ _ O
the _ _ O
50 _ _ O
randomized _ _ O
participants, _ _ O
49 _ _ O
(98%) _ _ O
received _ _ O
all _ _ O
3 _ _ O
lamotrigine _ _ O
products _ _ O
and _ _ O
completed _ _ O
at _ _ O
least _ _ O
3 _ _ O
pharmacokinetic _ _ O
assessments _ _ O
and _ _ O
46 _ _ O
(92%) _ _ O
completed _ _ O
all _ _ O
6 _ _ O
pharmacokinetic _ _ O
assessments. _ _ O
Among _ _ O
the _ _ O
49 _ _ O
participants, _ _ O
28 _ _ O
(57%) _ _ O
were _ _ O
men _ _ O
and _ _ O
21 _ _ O
(43%) _ _ O
were _ _ O
women, _ _ O
42 _ _ O
(86%) _ _ O
self-identified _ _ O
as _ _ O
white, _ _ O
and _ _ O
46 _ _ O
(16) _ _ O
years _ _ O
was _ _ O
the _ _ O
mean _ _ O
(SD) _ _ O
age. _ _ O
The _ _ B-Outcome
3 _ _ I-Outcome
drug _ _ I-Outcome
products _ _ I-Outcome
were _ _ I-Outcome
considered _ _ I-Outcome
bioequivalent _ _ I-Outcome
because _ _ I-Outcome
the _ _ I-Outcome
90% _ _ I-Outcome
CIs _ _ I-Outcome
were _ _ I-Outcome
within _ _ I-Outcome
equivalence _ _ I-Outcome
limits _ _ I-Outcome
(lowest _ _ I-Outcome
and _ _ I-Outcome
highest _ _ I-Outcome
CI _ _ I-Outcome
limits _ _ I-Outcome
for _ _ I-Outcome
Cmax, _ _ I-Outcome
92.6% _ _ I-Outcome
and _ _ I-Outcome
110.4%; _ _ I-Outcome
for _ _ I-Outcome
AUC0-96, _ _ I-Outcome
96.9% _ _ I-Outcome
and _ _ I-Outcome
101.9%). _ _ I-Outcome
Replicate _ _ O
testing _ _ O
demonstrated _ _ O
no _ _ O
significant _ _ O
differences _ _ O
in _ _ O
within-subject _ _ O
variability _ _ O
across _ _ O
the _ _ O
3 _ _ O
products _ _ O
(likelihood _ _ O
ratios, _ _ O
χ22 _ _ O
for _ _ O
log-transformed _ _ O
variables: _ _ O
AUC0-96, _ _ O
2.58; _ _ O
Cmax, _ _ O
0.64; _ _ O
and _ _ O
AUC0-∞, _ _ O
4.05; _ _ O
P _ _ O
≥ _ _ O
.13) _ _ O
and _ _ O
that _ _ O
the _ _ O
3 _ _ O
products _ _ O
were _ _ O
also _ _ O
bioequivalent _ _ O
according _ _ O
to _ _ O
scaled _ _ O
ABE _ _ O
and _ _ O
individual _ _ O
bioequivalence _ _ O
criteria _ _ O
with _ _ O
no _ _ O
subject _ _ O
× _ _ O
formulation _ _ O
interaction _ _ O
(Cmax, _ _ O
0.00; _ _ O
AUC0-96, _ _ O
0.54; _ _ O
and _ _ O
AUC0-∞, _ _ O
0.36; _ _ O
P _ _ O
≥ _ _ O
.76). _ _ O
This _ _ O
study _ _ O
provides _ _ O
evidence _ _ O
that _ _ O
the _ _ B-Intervention
disparate _ _ I-Intervention
lamotrigine _ _ I-Intervention
products _ _ I-Intervention
studied _ _ O
are _ _ O
bioequivalent _ _ O
when _ _ O
tested _ _ O
in _ _ O
people _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
taking _ _ I-Patient
concomitant _ _ I-Patient
antiepileptic _ _ I-Patient
drugs. _ _ I-Patient
clinicaltrials.gov _ _ O
Identifier: _ _ O
NCT01733394. _ _ O


-DOCSTART- -X- -X- O

There _ _ O
is _ _ O
evidence _ _ O
that _ _ O
everolimus _ _ B-Intervention
(EVE) _ _ I-Intervention
significantly _ _ O
reduces _ _ O
seizure _ _ O
frequency _ _ O
in _ _ O
epilepsy _ _ B-Patient
patients _ _ I-Patient
with _ _ I-Patient
tuberous _ _ I-Patient
sclerosis _ _ I-Patient
complex _ _ I-Patient
(TSC). _ _ O
Given _ _ O
that _ _ O
TSC-related _ _ O
proliferative _ _ O
processes _ _ O
are _ _ O
more _ _ O
dynamic _ _ O
during _ _ O
brain _ _ O
development, _ _ O
seizure _ _ O
outcomes _ _ O
of _ _ O
patients _ _ O
treated _ _ O
with _ _ O
EVE _ _ O
may _ _ O
be _ _ O
age-related _ _ O
and _ _ O
may _ _ O
be _ _ O
less _ _ O
convincing _ _ O
in _ _ O
adult _ _ O
patients. _ _ O
The _ _ O
aim _ _ O
of _ _ O
this _ _ O
study _ _ O
was _ _ O
to _ _ O
assess _ _ O
the _ _ O
effectiveness _ _ O
and _ _ O
the _ _ O
safety _ _ O
profile _ _ O
of _ _ O
EVE _ _ O
in _ _ O
adults _ _ O
in _ _ O
clinical _ _ O
practice. _ _ O
We _ _ O
performed _ _ O
a _ _ O
multicenter _ _ O
retrospective _ _ O
chart _ _ O
review _ _ O
of _ _ O
TSC _ _ B-Patient
subjects _ _ I-Patient
with _ _ I-Patient
active _ _ I-Patient
epilepsy _ _ I-Patient
who _ _ I-Patient
started _ _ I-Patient
EVE _ _ I-Patient
in _ _ I-Patient
adulthood _ _ I-Patient
(≥18 _ _ I-Patient
years _ _ I-Patient
of _ _ I-Patient
age) _ _ I-Patient
at _ _ I-Patient
seven _ _ I-Patient
German _ _ I-Patient
epilepsy _ _ I-Patient
centers. _ _ I-Patient
The _ _ O
primary _ _ O
endpoint _ _ O
was _ _ O
the _ _ O
retention _ _ O
rate _ _ O
after _ _ O
6 _ _ O
months. _ _ O
A _ _ O
total _ _ O
of _ _ O
45 _ _ O
subjects _ _ O
with _ _ O
a _ _ O
mean _ _ O
age _ _ O
of _ _ O
31.6 _ _ O
± _ _ O
11.1 _ _ O
years _ _ O
at _ _ O
EVE _ _ O
start _ _ O
fulfilled _ _ O
the _ _ O
inclusion _ _ O
criteria. _ _ O
Retention _ _ O
rate _ _ O
after _ _ O
6 _ _ O
months _ _ O
was _ _ O
98% _ _ O
(43/44 _ _ O
evaluable _ _ O
subjects). _ _ O
Response _ _ O
rate _ _ O
(seizure _ _ O
reduction _ _ O
≥ _ _ O
50%) _ _ O
was _ _ O
33% _ _ O
(14/43 _ _ O
evaluable _ _ O
subjects; _ _ O
four _ _ O
completely _ _ O
seizure-free). _ _ O
We _ _ O
did _ _ O
not _ _ O
find _ _ O
a _ _ O
significant _ _ O
relationship _ _ O
between _ _ O
epilepsy _ _ O
outcome _ _ O
parameters _ _ O
and _ _ O
patient _ _ O
age _ _ O
at _ _ O
EVE _ _ O
start. _ _ O
Adverse _ _ O
events _ _ O
were _ _ O
reported _ _ O
in _ _ O
19 _ _ O
subjects _ _ O
and _ _ O
were _ _ O
judged _ _ O
to _ _ O
be _ _ O
serious _ _ O
in _ _ O
six _ _ O
patients. _ _ O
Three _ _ O
patients _ _ O
died _ _ O
during _ _ O
the _ _ O
observation _ _ O
period. _ _ O
Evidence _ _ O
suggests _ _ O
that _ _ O
EVE _ _ O
is _ _ O
an _ _ O
effective _ _ O
add-on _ _ O
treatment _ _ O
for _ _ O
epilepsy _ _ O
in _ _ O
adult _ _ O
TSC _ _ O
patients, _ _ O
surprisingly _ _ O
without _ _ O
any _ _ O
age _ _ O
limit _ _ O
to _ _ O
individual _ _ O
benefit. _ _ O
A _ _ O
strong _ _ O
age-dependent _ _ O
effect _ _ O
within _ _ O
the _ _ O
period _ _ O
of _ _ O
adulthood _ _ O
seems _ _ O
unlikely. _ _ O
Even _ _ O
if _ _ O
there _ _ O
was _ _ O
no _ _ O
proof _ _ O
of _ _ O
a _ _ O
causal _ _ O
relationship _ _ O
between _ _ O
deaths _ _ O
and _ _ O
EVE _ _ O
intake, _ _ O
patients _ _ O
with _ _ O
EVE _ _ O
should _ _ O
be _ _ O
carefully _ _ O
monitored, _ _ O
especially _ _ O
for _ _ O
infections _ _ O
and _ _ O
stomatitis. _ _ O


-DOCSTART- -X- -X- O

Epilepsy _ _ O
is _ _ O
a _ _ O
neurological _ _ O
disease _ _ O
that _ _ O
causes _ _ O
recurrent _ _ O
seizures _ _ O
and _ _ O
can _ _ O
have _ _ O
a _ _ O
significant _ _ O
impact _ _ O
on _ _ O
a _ _ O
person's _ _ O
quality _ _ O
of _ _ O
life _ _ O
(QOL). _ _ O
A _ _ B-Intervention
self-management _ _ I-Intervention
intervention _ _ I-Intervention
(SMI) _ _ I-Intervention
can _ _ O
allow _ _ O
adults _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
to _ _ O
modify _ _ O
behaviors _ _ O
in _ _ O
order _ _ O
to _ _ O
manage _ _ O
their _ _ O
seizures _ _ O
and _ _ O
evaluate _ _ O
the _ _ O
impact _ _ O
of _ _ O
medication _ _ O
and _ _ O
treatments _ _ O
on _ _ O
their _ _ O
daily _ _ O
lives. _ _ O
The _ _ O
purpose _ _ O
of _ _ O
this _ _ O
study _ _ O
was _ _ O
to _ _ O
investigate _ _ O
the _ _ O
effects _ _ O
of _ _ O
a _ _ B-Intervention
SMI _ _ I-Intervention
for _ _ O
adults _ _ B-Patient
with _ _ I-Patient
epilepsy. _ _ I-Patient
This _ _ O
was _ _ O
a _ _ O
longitudinal _ _ O
randomized _ _ O
controlled _ _ O
trial. _ _ O
Adults _ _ B-Patient
with _ _ I-Patient
epilepsy _ _ I-Patient
between _ _ I-Patient
the _ _ I-Patient
age _ _ I-Patient
of _ _ I-Patient
20 _ _ I-Patient
and _ _ I-Patient
65 _ _ I-Patient
years _ _ I-Patient
were _ _ I-Patient
recruited _ _ I-Patient
from _ _ I-Patient
a _ _ I-Patient
medical _ _ I-Patient
center _ _ I-Patient
in _ _ I-Patient
northern _ _ I-Patient
Taiwan. _ _ I-Patient
Participants _ _ O
were _ _ O
assigned _ _ O
to _ _ O
an _ _ B-Intervention
intervention _ _ I-Intervention
group _ _ I-Intervention
(IG) _ _ I-Intervention
or _ _ O
control _ _ B-Control
group _ _ I-Control
(CG) _ _ I-Control
through _ _ O
simple _ _ O
randomization. _ _ O
Data _ _ O
regarding _ _ O
demographic _ _ O
and _ _ O
clinical _ _ O
characteristics _ _ O
were _ _ O
collected _ _ O
at _ _ O
baseline _ _ O
(T0). _ _ O
In _ _ O
addition, _ _ O
participants _ _ O
answered _ _ O
nine _ _ O
validated _ _ O
self-report _ _ O
questionnaires, _ _ O
which _ _ O
were _ _ O
used _ _ O
as _ _ O
outcome _ _ O
measures. _ _ O
Following _ _ O
collection _ _ O
of _ _ O
baseline _ _ O
data, _ _ O
the _ _ B-Control
CG _ _ I-Control
received _ _ I-Control
routine _ _ I-Control
monthly _ _ I-Control
counseling _ _ I-Control
over _ _ I-Control
the _ _ I-Control
next _ _ I-Control
3 _ _ I-Control
months. _ _ I-Control
The _ _ B-Intervention
IG _ _ I-Intervention
received _ _ I-Intervention
the _ _ I-Intervention
routine _ _ I-Intervention
monthly _ _ I-Intervention
counseling, _ _ I-Intervention
as _ _ I-Intervention
well _ _ I-Intervention
as _ _ I-Intervention
individual _ _ I-Intervention
face-to-face _ _ I-Intervention
health _ _ I-Intervention
counseling _ _ I-Intervention
on _ _ I-Intervention
self-management _ _ I-Intervention
1 _ _ I-Intervention
h/month _ _ I-Intervention
and _ _ I-Intervention
remote _ _ I-Intervention
counseling _ _ I-Intervention
via _ _ I-Intervention
the _ _ I-Intervention
phone _ _ I-Intervention
or _ _ I-Intervention
computer _ _ I-Intervention
network _ _ I-Intervention
at _ _ I-Intervention
least _ _ I-Intervention
twice _ _ I-Intervention
per _ _ I-Intervention
month. _ _ I-Intervention
After _ _ O
the _ _ O
first _ _ O
month _ _ O
(T1) _ _ O
and _ _ O
at _ _ O
the _ _ O
end _ _ O
of _ _ O
the _ _ O
third _ _ O
(T2) _ _ O
and _ _ O
sixth _ _ O
months _ _ O
(T3) _ _ O
participants _ _ O
answered _ _ O
the _ _ O
nine _ _ O
questionnaires _ _ O
again. _ _ O
Differences _ _ O
in _ _ O
outcomes _ _ O
between _ _ O
the _ _ O
IGs _ _ O
and _ _ O
CGs _ _ B-Control
were _ _ O
analyzed _ _ O
by _ _ O
comparing _ _ O
scores _ _ O
for _ _ O
the _ _ O
nine _ _ O
outcome _ _ O
variables _ _ O
at _ _ O
T0 _ _ O
with _ _ O
scores _ _ O
at _ _ O
T1, _ _ O
T2, _ _ O
and _ _ O
T3 _ _ O
with _ _ O
generalized _ _ O
estimating _ _ O
equations. _ _ O
A _ _ O
total _ _ O
of _ _ O
210 _ _ O
adults _ _ O
agreed _ _ O
to _ _ O
participate _ _ O
in _ _ O
the _ _ O
study; _ _ O
however, _ _ O
only _ _ O
155 _ _ O
participants _ _ O
completed _ _ O
the _ _ O
questionnaires _ _ O
for _ _ O
all _ _ O
three _ _ O
time _ _ O
points: _ _ O
75 _ _ O
in _ _ O
the _ _ B-Control
CG _ _ I-Control
and _ _ O
80 _ _ O
in _ _ O
the _ _ O
IG. _ _ O
The _ _ O
mean _ _ O
age _ _ O
of _ _ O
the _ _ O
155 _ _ O
participants _ _ O
was _ _ O
39.6 _ _ O
years _ _ O
(SD _ _ O
= _ _ O
10.9). _ _ O
There _ _ O
was _ _ O
no _ _ O
significant _ _ O
difference _ _ O
between _ _ O
demographic _ _ O
or _ _ O
clinical _ _ O
variables _ _ O
between _ _ O
the _ _ O
two _ _ O
groups. _ _ O
The _ _ O
only _ _ O
difference _ _ O
in _ _ O
baseline _ _ O
scores _ _ O
(T0) _ _ O
among _ _ O
the _ _ O
nine _ _ O
self-report _ _ O
questionnaires _ _ O
was _ _ O
in _ _ O
epilepsy _ _ O
knowledge, _ _ O
measured _ _ O
with _ _ O
the _ _ O
Epilepsy _ _ O
Knowledge _ _ O
Profile _ _ O
questionnaire, _ _ O
which _ _ O
were _ _ O
significantly _ _ O
higher _ _ O
for _ _ O
the _ _ B-Control
CG _ _ I-Control
(mean _ _ O
= _ _ O
32.28, _ _ O
SD _ _ O
= _ _ O
3.92) _ _ O
than _ _ O
the _ _ O
IG _ _ O
(mean _ _ O
= _ _ O
23.01, _ _ O
SD _ _ O
= _ _ O
2.79) _ _ O
(p _ _ O
< _ _ O
0.001). _ _ O
Generalized _ _ B-Outcome
estimating _ _ I-Outcome
equations _ _ I-Outcome
(GEE) _ _ I-Outcome
analysis _ _ I-Outcome
showed _ _ I-Outcome
scores _ _ I-Outcome
decreased _ _ I-Outcome
significantly _ _ I-Outcome
at _ _ I-Outcome
T3 _ _ I-Outcome
from _ _ I-Outcome
baseline _ _ I-Outcome
for _ _ I-Outcome
the _ _ I-Outcome
CG _ _ I-Outcome
for _ _ I-Outcome
epilepsy _ _ I-Outcome
knowledge _ _ I-Outcome
and _ _ I-Outcome
QOL _ _ I-Outcome
(p _ _ I-Outcome
< _ _ I-Outcome
0.001). _ _ I-Outcome
Improvements _ _ O
in _ _ O
scores _ _ O
for _ _ O
sleep _ _ O
quality, _ _ O
anxiety, _ _ O
depression, _ _ O
self-efficacy, _ _ O
coping, _ _ O
and _ _ O
social _ _ O
support _ _ O
did _ _ O
not _ _ O
differ _ _ O
between _ _ O
groups. _ _ O
Classification _ _ O
of _ _ O
the _ _ O
IG _ _ O
by _ _ O
gender _ _ O
showed _ _ O
a _ _ O
significantly _ _ O
greater _ _ O
increase _ _ O
for _ _ O
males _ _ O
compared _ _ O
with _ _ O
females _ _ O
from _ _ O
baseline _ _ O
to _ _ O
T3 _ _ O
for _ _ O
epilepsy _ _ O
knowledge _ _ O
(p _ _ O
< _ _ O
0.001). _ _ O
If _ _ O
we _ _ O
further _ _ O
classified _ _ O
the _ _ O
IGs _ _ O
by _ _ O
seizure _ _ O
frequency, _ _ O
participants _ _ O
with _ _ O
a _ _ O
seizure _ _ O
frequency _ _ O
of _ _ O
≥1 _ _ O
per _ _ O
year _ _ O
had _ _ O
a _ _ O
more _ _ O
significant _ _ O
increase _ _ O
in _ _ O
epilepsy _ _ O
knowledge _ _ O
and _ _ O
increase _ _ O
in _ _ O
QOL _ _ O
compared _ _ O
with _ _ O
participants _ _ O
with _ _ O
a _ _ O
seizure _ _ O
frequency _ _ O
of _ _ O
<1 _ _ O
per _ _ O
year _ _ O
at _ _ O
T3 _ _ O
compared _ _ O
with _ _ O
T0. _ _ O
The _ _ O
lack _ _ O
of _ _ O
improvement _ _ O
in _ _ O
health-related _ _ O
quality _ _ O
of _ _ O
life _ _ O
(HRQoL) _ _ O
following _ _ O
the _ _ O
SMI _ _ O
may _ _ O
indicate _ _ O
that _ _ O
additional _ _ O
time _ _ O
is _ _ O
required _ _ O
to _ _ O
change _ _ O
behaviors _ _ O
that _ _ O
impact _ _ O
this _ _ O
variable _ _ O
for _ _ O
patients _ _ O
with _ _ O
epilepsy. _ _ O
Additional _ _ O
research _ _ O
should _ _ O
focus _ _ O
on _ _ O
variables _ _ O
associated _ _ O
with _ _ O
medication _ _ O
compliance, _ _ O
epilepsy _ _ O
knowledge, _ _ O
medicine _ _ O
symptom _ _ O
distress, _ _ O
self-efficacy, _ _ O
anxiety, _ _ O
and _ _ O
HRQoL. _ _ O


